MILLENIUM PHARMACEUTICALS, jetzt schägt sie zurück - 500 Beiträge pro Seite

[js200]

11/22/2002 (13:51 ET) VOLUME(+): MLNM Volume 40% > 20-adsv, Stock +4.74% - Knobias
11/22/2002 (13:29 ET) Stockwinners Option Report For November 22 - Internet Wire
11/22/2002 (13:01 ET) ImmunoGen achieves milestone in collaboration with Millennium - Datamonitor
11/22/2002 (13:01 ET) Millennium initiates phase I clinical trial of MLN2704 in patients with metastatic androgen-independent prostate cancer - Datamonitor
11/22/2002 (10:34 ET) MOVER(+): Millennium Higher; Initiated Phase I Trials - Knobias


JS200

[js200]

MLNM - Millennium Pharmaceuticals, Inc. (NASDAQ NM : MLNM)

--------------------------------------------------------------------------------
MOVER(+): Millennium Higher; Initiated Phase I Trials



FRIDAY , NOVEMBER 22, 2002 10:34 AM

Millennium Pharmaceuticals, Inc. (NasdaqNM: MLNM)

- Last Trade: $ 9.95900
- Up: $ 0.45900
- % Change: +4.83158%
- Volume at Publication: 2,254,600
- 20-day Average Volume: 4,354,300

Recent company news:

11/21/02: BZL Biologics LLC. today announced that its development partner, Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) has initiated a phase I clinical trial of MLN2704 (formerly known as MLN591 DM1) in patients with metastatic androgen-independent prostate cancer. MLN2704 employs a novel approach designed to deliver chemotherapy directly to prostate tumor cells while minimizing harm to healthy cells. The primary objectives of the open-label, dose-escalation study are to determine the dose-limiting toxicity, the maximum tolerated dose, and pharmacokinetic properties of MLN2704.

11/21/02: ImmunoGen, Inc. (Nasdaq: IMGN) today announced that the Company earned a $1.0 million milestone payment from Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) with Millennium`s initiation of clinical trials with MLN2704 (formerly known as MLN591DM1). This milestone will be recognized as revenue in ImmunoGen`s quarter ending December 31, 2002, the period in which the milestone payment was earned.

Recent company filings:

10-Q filed on 11/12/02 included the following:

Three months ended: 09/30/02; 09/30/01
Total Revenues: $95,755,000; $82,175,000
Net Income: $(98,879,000); $(25,234,000)

Technical analysis:

- Above 3 of 4 moving averages
- Near-term support price: $ 8.04000
- Near-term resistance price: $ 10.08000

JS200

[js200]

company news

--------------------------------------------------------------------------------

MLNM - Millennium Pharmaceuticals, Inc. (NASDAQ NM : MLNM)

--------------------------------------------------------------------------------
Millennium initiates phase I clinical trial of MLN2704 in patients with metastatic androgen-independent prostate cancer



FRIDAY , NOVEMBER 22, 2002 01:01 PM

Nov 22, 2002 (Datamonitor via COMTEX) -- Millennium Pharmaceuticals has initiated a phase I clinical trial of MLN2704 in patients with metastatic androgen-independent prostate cancer. The primary objectives of this open-label, dose-escalation study are to determine the dose-limiting toxicity, the maximum tolerated dose, and pharmacokinetic properties of MLN2704.

MLN2704 is designed to deliver the maytansanoid chemotherapeutic agent DM1 directly to prostate cancer cells through the MLN591 delivery mechanism, a targeting monoclonal antibody vehicle (T-MAV), that binds specifically to the prostate- specific membrane antigen (PSMA).

The study will be conducted at two clinical sites in the US and based on the dose-escalation scheme, will include approximately 30 patients.

"With the initiation of the MLN2704 phase I clinical trial, we are moving toward our goal of initiating three to four compounds in human clinical trials this year, and we are very excited about the continued growth of the T-MAV program which includes both chemotherapeutic and radiotherapeutic investigational compounds," said Barry Greene, general manager of oncology at Millennium.

"Hormone-refractory prostate cancer remains a significant area of unmet medical need and we are hopeful that the MLN2704 program could potentially be an important development for patients in need of new treatment options," Mr Greene said to the press.

MLN591 is a deimmunized monoclonal antibody that targets prostate-specific membrane antigen or PSMA. Unlike the enzyme PSA which circulates in the blood, PSMA is a protein expressed on the cell surface of virtually all prostate cancer cells and its abundance on the cell surface increases as a tumor metastasizes.



URL: http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon


Copyright (C) 2002 Datamonitor. All rights reserved


-0-


KEYWORD: United States
SUBJECT CODE: All cancer
Pharmaceuticals
Healthcare R&D
Cancer, Prostate

JS200

[js200]

company news

--------------------------------------------------------------------------------

MLNM - Millennium Pharmaceuticals, Inc. (NASDAQ NM : MLNM)

--------------------------------------------------------------------------------
ImmunoGen achieves milestone in collaboration with Millennium



FRIDAY , NOVEMBER 22, 2002 01:01 PM

Nov 22, 2002 (Datamonitor via COMTEX) -- ImmunoGen has earned a $1 million milestone payment from Millennium Pharmaceuticals after the latter`s initiation of clinical trials with MLN2704, a new anticancer candidate. This milestone will be recognized as revenue in ImmunoGen`s quarter ending December 31, 2002, the period in which the milestone payment was earned.

MLN2704 is a Tumor-Activated Prodrug (TAP) product composed of Millennium`s MLN591 antibody and ImmunoGen`s DM1 effector molecule. ImmunoGen`s TAP technology uses tumor-targeting antibodies to deliver a highly potent cell-killing agent specifically to cancer cells.

ImmunoGen`s proprietary DM1 is designed to remain attached to the antibody and inactive while the TAP product is circulating through the bloodstream, yet readily kill cancer cells once the product has reached the tumor. The MLN591 antibody to which the DM1 is attached binds specifically to the prostate -specific membrane antigen (PSMA), which is expressed by virtually all prostate tumors.

The phase I study initiated by Millennium is a dose-escalation study in patients with metastatic androgen-independent prostate cancer, as noted in the press release issued by Millennium.

"We are pleased with the progress Millennium has made in the development of MLN2704. Four DM1-based TAP products have now entered clinical testing - two developed by ImmunoGen and two by companies that licensed our TAP technology for use with their antibodies," commented Dr Mitchel Sayare, ImmunoGen chairman and CEO, in a media release.

In February 2002, ImmunoGen licensed to Millennium the right to use its DM1 TAP technology with antibodies that target PSMA in exchange for an upfront payment, milestone payments, and royalties on product sales. This license derived from a collaboration established between the companies in 2001 that provides Millennium with access to test ImmunoGen`s TAP technology with a restricted number of antigen targets.



URL: http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon


Copyright (C) 2002 Datamonitor. All rights reserved


-0-


KEYWORD: United States
SUBJECT CODE: All cancer
Pharmaceuticals
Healthcare R&D
Healthcare licensing
ImmunoGen, Inc.
Cancer, General

JS200

[js200]

company news

--------------------------------------------------------------------------------

MLNM - Millennium Pharmaceuticals, Inc. (NASDAQ NM : MLNM)

--------------------------------------------------------------------------------
Stockwinners Option Report For November 22

Note To Editors: The Following Is An Investment Opinion Issued By Stockwinners.com

FRIDAY , NOVEMBER 22, 2002 01:29 PM

AUSTIN, TX, Nov. 22, 2002 (INTERNET WIRE via COMTEX) -- Option trading was brisk on Friday, as traders were taking positions on both sides of the ledger. However, most of the action was on the bearish side.

In an early move reported by Stockwinners.com ActiveTraders editors, an investor sold 2,900 contracts of Millennium Pharmaceutical (NASDAQ:MLNM) December $10 call options, expecting shares of the biotechnology firm to head lower in the near future. Elsewhere, the ActiveTraders page reported put selling by a morning trader with an opinion on Texas Instruments (NYSE:TXN). That player sold 8,000 contracts of TXN December $20 puts, expecting the stock to head up.

Back on the bearish side of the ledger, put options on Bristol-Myers Squibb (NYSE:BMY) and Brocade Communications (NASDAQ:BRCD) were active. One morning participant bought 4,000 BMY December $27.50 put contracts, while another purchased 8,000 BRCD December $5 put contracts.

Stockwinners.com offers real-time updates on option and stock activity through its ActiveTraders page and E-Mail alerts. Additional services include real-time quotes, daily stock picks, daily option picks, pre-market/post-market prices, momentum plays and a Rumor Mill. Free two-week on-line trial subscriptions to the STOCKWINNERS.com service are available at www.STOCKWINNERS.com and at 800/946-7143.

Stockwinners.com, Inc. is not a registered broker dealer or a registered investment adviser. No information accessed through the Stockwinners.com, Inc. Web site, or any link contained on the Stockwinners.com, Inc. Web site, constitutes a recommendation by Stockwinners.com, Inc. to buy, sell or hold any security, financial product, or instrument discussed therein. Information accessed through linked sites neither is, nor should be construed as, an offer, or a solicitation of an offer, to buy or sell securities by Stockwinners.com, Inc. Stockwinners.com, Inc. may or may not hold positions in securities being discussed in this news release and/or mentioned on the Stockwinners.com, Inc. Web site. Investors shall be fully responsible for any investment decisions they make, and such decisions will be based solely on their evaluation of their financial circumstances, investment objectives, risk tolerance and liquidity needs. Investors are encouraged to consult with their registered broker and/or investment adviser before making any investment decision.



CONTACT: Faye F. Nia
512-343-6300



Copyright 2002 Internet Wire, All rights reserved.


-0-


SUBJECT CODE: Business/Finance: General:Investment Opinion
Business/Finance: General:Investment Opinion

JS200

[js200]

company news

--------------------------------------------------------------------------------

MLNM - Millennium Pharmaceuticals, Inc. (NASDAQ NM : MLNM)

--------------------------------------------------------------------------------
VOLUME(+): MLNM Volume 40% > 20-adsv, Stock +4.74%



FRIDAY , NOVEMBER 22, 2002 01:51 PM

This is the 2nd VOLUME alert for MLNM in the past 7 calendar days.

Trading for Millennium Pharmaceuticals, Inc. (NASDAQ NM: MLNM) has been heavier than usual in today`s session. By 13:50 ET, the stock had already traded 6,116,600 shares via 8,970 trades. The cumulative volume is 40.47% above than its 20-day average of 4,354,300. Normally the stock experiences around 7,788 individual trades per session.

So far, today`s volume surge has caused a net rise in MLNM`s stock price. At the time of this alert, the stock was trading at $9.950, up $0.450 (+4.74%).

One year ago, the Company`s shares closed at $31.220. The price has declined more than 68 percent since then.

Over the last 10 trading session MLNM has traded in a range between $7.850 and $10.080 and is currently trading 72.55% below its 52-week high of $36.250 set on December 05, 2001 and 39.55% above its 52-week low of $7.130 from October 23, 2002.

In the previous 3 sessions, MLNM trading has displayed a positive trend. Closing results have been as follows:

November 21, 2002 --- closed at $9.500 up $0.730 (+8.32%) on 7,576,000 shares
November 20, 2002 --- closed at $8.770 up $0.160 (+1.86%) on 3,874,000 shares
November 19, 2002 --- closed at $8.610 up $0.450 (+5.51%) on 7,524,000 shares

The Company last released news on November 21, 2002 (yesterday):

"BZL Biologics Announces Initiation of Phase I Clinical Trial of MLN2074 for Advanced Prostate Cancer"

MILLENNIUM PHARMACEUTICALS, INC.
Millennium Pharmaceuticals, Inc., a Delaware corporation, is a biopharmaceutical company. The Company claims its focus is to apply its comprehensive and integrated science and technology platform to discover and accelerate the development and breakthrough drugs and predictive medicine products. The Company primarily focuses its research and development and commercialization activities in four key areas: cardiovascular, oncology, inflammatory and metabolic. The Company views the pursuit of mergers, acquisitions and product in-licensing as important in achieving its business goals. In addition, the Company, whose principal offices are located in Cambridge Massachusetts, is listed on the Nasdaq 100 Index.


JS200

[schakal23]

und was beduetet das ganse auf deutsch
wäre nicht schlecht danke

[MichiZocker]

Wäre net vn euch wenn mir jemand zu teil erklären könnte was das englische auf sich hat aber auch in deutsch.
ich und Schakal bedanken23 sich

[js200]

MACHINELLE ÜBERSETZUNG



Gesellschaftsnachrichten

--------------------------------------------------------------------------------

MLNM, Millennium Pharmaceuticals, Inc. (NASDAQ NM): MLNM,

--------------------------------------------------------------------------------
ImmunoGen erreicht in Zusammenarbeit mit Jahrtausend Meilenstein



FREITAG, 22. NOVEMBER 2002 01:01 PM

22. Nov 2002 Datamonitor über COMTEX, ImmunoGen hat nach der latter`s-Einleitung von klinischen Prozessen mit MLN2704, einem neuem anticancer-Bewerber, eine $1 Million Meilensteinzahlung aus Millennium Pharmaceuticals verdient. Dieser Meilenstein wird in ImmunoGen`s Viertelende 31. Dezember 2002 die Periode, in der die Meilensteinzahlung verdient wurde, als Einnahmen erkannt werden.

MLN2704 ist ein Tumor-aktivierter Prodrug (HAHN) von Millennium`s MLN591-Antikörper und ImmunoGen`s DM1 effector-Molekül zusammengesetztes Produkt. ImmunoGen`s TAP Technologieverwendungen Tumor-zielende Antikörper, um ausdrücklich einen sehr mächtigen Zellen-mörderischen Agenten bei Kerbszellen abzuliefern.

ImmunoGen`s, den gesetzlich geschützter DM1 entworfen wurde, um zu bleiben, befestigte zum Antikörper und inaktiv, während das TAP-Produkt durch den Blutkreislauf zirkuliert, doch bereitwillig töten Sie Kerbszellen, sobald das Produkt den Tumor erreicht hat. Der MLN591-Antikörper, zu dem der DM1 ausdrücklich feste Klemmen zur Prostata ist, bestimmtes Membranenantigen (PSMA), das von praktisch allen Prostatatumoren ausgedrückt wird.

Die Phase, die ich studiere, die bis Millennium initiiert wird, ist ein Dosiseskalation-Studium in Patienten in metastatic Androgen-unabhängiger Prostatakerbs, wie in der Pressenfreilassung bemerkt, gab bis Millennium aus.

"Wir sind zufrieden mit dem Fortschritt, den Millennium in der Entwicklung von MLN2704 gemacht hat. Vier DM1-DM1-based TAP Produkte haben jetzt klinische Erprobung eingegeben - gewordenen von ImmunoGen und zwei entwickelt zwei von Firmen, die unsere TAP-Technologie für die Verwendung als ihre Antikörper" genehmigten, Dr Mitchel Sayare, ImmunoGen-Vorsitzender und DIREKTOR, in einer Medien-Freilassung, äußerten sich.

Im Februar 2002 genehmigte ImmunoGen zu Millennium das Recht, seine DM1 TAP-Technologie mit Antikörpern zu benutzen, die zu Produktverkäufen als Entgelt für eine freimütige Zahlung, Meilensteinzahlungen und Tantiemen auf PSMA abzielen. Diese von einer Zusammenarbeit hergeleitete Lizenz begründete zwischen den Firmen in 2001 dieses stellt Millennium mit Zugang bereit, um ImmunoGen`s TAP Technologie mit einer beschränkten Anzahl von Antigenzielen zu prüfen.



URL: http://www.datamonitor.com
Wiederveröffentlichung oder Neuverteilung, einschließlich durch das Rahmen oder ähnliche Mittel,
wird ausdrücklich ohne vorausgehende geschriebene Zustimmung verboten. Datamonitor wird nicht verantwortlich für Fehler oder Verzögerungen im Inhalt sein, oder für irgendwelche darauf in Vertrauen ergriffene Handlungen


Copyright (C) 2002 Datamonitor. Alle Rechte reserviert

JS200

[ollihat]

Also, ich finde das ziemlich öde, einfach die Company News hier hereinzustellen!
Jeder, der sich für den Wert interessiert, schaut sich das doch ohnehin an. Da genügt dann auch der Hinweis auf die Fundstelle.

[Aeppler]

@OLLIHAT

deine meinung teile ich nicht

ich finde es gut , sich sachlich mit berichten hier im threat auseinanderzusetzen, spart enorm zeit.

js200 u.a. weiter so

gruss @eppler

[dr.gips]

hi aeppler!
was machen deine corvas ?

[puhvogel]

@oliihat: Manchmal ist ist es ganz nützlich Nachrichten hier reinzustellen, da diese gelegentlich im Netz völlig verschwinden.

[Boersenkrieger]

corvas wollt ich auch mal hab dann aber corvis gekauft... läuft auch nicht besser egal

[LMeister7]

Guten Abend,
wenn ich mich richtig erinnere(Kalk) wollte MLNM noch dieses Jahr zukaufen. Hat vielleicht wer irgendwelche Gerüchte aufgeschnappt. Ich möchte gerne vermeiden, dass mich wie bei COR nochmal der Blitz beim Sch... trifft. Ist das Ding evtl. schon eingepreist. Ich denke evtl. in Richtung ILXO(Campath) oder was kommt noch in Frage. Vielleicht hat Meister L. das Ding auch verschoben. Ihr merkt sicher, dass ich nicht ganz auf dem Laufenden bin. Habe noch einen tiefroten Restbestand und weiss nicht so Recht ob die Zeit zum Nachlegen schon reif ist? Was meint Ihr?!
MfG,
LM7

[Boersenkrieger]

Ich sag nur eins.... kaufen kaufen kaufen. MLNM wird die Microsoft der Biotecs. Die Firma wird bestimmt in ein paar Jahren über 2-3 Mrd $ Umsatz machen und in einem erneuten Hype eine Marktkap. von 100 Mrd $ erreichen können...

[Aeppler]

@dr.gips

CVAS ist bei mir Schnee von gestern

bin bei 8.8 in MLNM rein sollte eine gute Anlage sein.

Was ich schade finde, ist die Tatsache, dass viele kleine, bzw unter 1$ notierende Biotechs an deutschen Börsen kaum Umsatz haben, aber was nicht ist, das kann ja noch werden, wenn die Pilz spriessen.

@eppler

[js200]

11/26/2002 (09:06 ET) TheSubway.com Covers ARBA, CMKI, MLNM and CORV - Knobias
11/26/2002 (08:09 ET) TheSUBWAY.com Announces Investment Opinion: Morning Stock Picks! - Business Wire
11/22/2002 (17:08 ET) New 10-Q/A just released for MLNM - Edgar
11/22/2002 (13:51 ET) VOLUME(+): MLNM Volume 40% > 20-adsv, Stock +4.74% - Knobias
11/22/2002 (13:29 ET) Stockwinners Option Report For November 22 - Internet Wire


JS200

[js200]

12/02/2002 (09:46 ET) GAP-UP: Opening Higher ICGE, CMGI, UNWR, ZRAN, MLNM - Knobias
11/26/2002 (09:06 ET) TheSubway.com Covers ARBA, CMKI, MLNM and CORV - Knobias
11/26/2002 (08:09 ET) TheSUBWAY.com Announces Investment Opinion: Morning Stock Picks! - Business Wire
11/22/2002 (17:08 ET) New 10-Q/A just released for MLNM - Edgar
11/22/2002 (13:51 ET) VOLUME(+): MLNM Volume 40% > 20-adsv, Stock +4.74% - Knobias


JS200

[js200]

company news

--------------------------------------------------------------------------------

MLNM - Millennium Pharmaceuticals, Inc. (NASDAQ NM : MLNM)

--------------------------------------------------------------------------------
GAP-UP: Opening Higher ICGE, CMGI, UNWR, ZRAN, MLNM



MONDAY , DECEMBER 02, 2002 09:46 AM

In the first half hour of trading, these five stocks opened significantly higher than their previous close and are temporarily sustaining those gains.

Open +19.04% ***Internet Capital Group Inc (NasdaqNM: ICGE)
--------------------[Investment opinion issued by TheSubway.com today]

Open +17.36% ***CMGI Inc (NasdaqNM: CMGI)
--------------------[Investment opinion issued by TheSubway.com today]

Open +28.54% ***US Unwired Incorporated (NasdaqNM: UNWR)
--------------------[reported Q3 results on 11/15]

Open +11.75% *** Zoran Corporation (NasdaqNM: ZRAN)
--------------------[last news issued on 11/19]

Open +11.39% *** Millennium Pharmaceuticals, Inc. (NasdaqNM: MLNM)
--------------------[last issued news on 11/22]

Each morning between 9:30 ET and 10:00 ET, Knobias will report on selected over-the-counter stocks that have “gapped-up” in early trading. Each of these alerts will contain a maximum of five OTC stocks during the first 30 minutes of trading.

JS200

[js200]

Von Gestern

MLNM
MILLENNIUM PHARMACEUTICALS INC
10.620
-0.300 -2.75%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 11/20/2002 (13) days ago, when the stock price was 8.770. Since then the stock gained 21.09% .

Today the stock closed lower with a lower high and a lower low. The volume is normal. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Long Black Candlestick

Today a Long Black Candlestick formed. Sellers were aggressive and selling pressure was strong. Be careful, this may be a potential turning point!

Stock Quote
Last 10.620
Previous Close 10.920
Change -0.300
% Change -2.75%
Volume 4,951,194
Stock Activity
Open 10.980
Day`s High 11.050
Day`s Low 10.460
52 Week High 35.450
52 Week Low 7.191

Stock Price History
3 Month % Change -5.43
6 Month % Change -22.08
12 Month % Change -66.92
Stock Statistics
50 Day Close MA 8.775
200 Day Close MA 14.059
65 Day Volume MA 4,848,681

JS200

[js200]

company news

--------------------------------------------------------------------------------

MLNM - Millennium Pharmaceuticals, Inc. (NASDAQ NM : MLNM)

--------------------------------------------------------------------------------
atugen accelerates successfully drug discovery programme at ALTANA and receives two milestone payments



WEDNESDAY, DECEMBER 04, 2002 03:02 AM

Dec 04, 2002 (Hugin via COMTEX) -- Berlin. 4th December 2002 - atugen AG today announced that it has received two milestone payments from ALTANA Pharma AG, the international Pharmaceuticals Group of ALTANA AG (NYSE: AAA) as part of a validation alliance for new target molecules associated with cancer and diseases of the immune system, signed in 2001. The milestone payments are related to the validation of the first two targets from ALTANA Pharma AG using atugen`s GeneBloc(R) technology. In particular, atugen developed potent GeneBlocs(R), specific antisense molecules, for the inhibition of gene expression and validated the function in oncology assays. The rapid validation of the two targets, only 6 months after starting the program, enables ALTANA Pharma AG to commence High Throughput Screening to identify therapeutic candidates. No financial details were disclosed. "We are extremely pleased to be able to fulfill the terms of the agreement in record time," Dr Zisi Fotev, VP of Business Development of atugen commented. "We look forward to the developments of the continuing validation of ALTANA`s other targets and a continuing successful relationship with ALTANA." "We are delighted to be working with atugen and pleased to see that our confidence in their abilities has been proved so rapidly," Prof. Dr. Radtke, CSO of ALTANA Pharma AG stated. "Target validation is an important early step in our drug discovery process, at which a gene`s and protein`s participation in a disease is confirmed. This step is then triggering intense drug finding activities." atugen AG is a technology leader in disease pathway elucidation located in Berlin, Germany. Building on successful collaborations with a large number of pharmaceutical and biotechnology partnerships, atugen is positioned to take advantage of the industry`s need to unravel the function of genes and to dissect signal transduction pathways. atugen has already proven its ability by establishing a portfolio of validated targets and compounds inhibiting the PI 3-kinase pathway, which plays an important role in most cancer types, diabetes, wound healing and other indications. The company offers proprietary KnockDown(TM) technologies (antisense molecules i.e. GeneBlocs(R), improved synthetic siRNA, vector expression systems for siRNA and ribozymes) and superior transfection reagents. atugen has entered into a variety of different partnerships with major pharmaceutical and biotechnology companies ranging from target validation services to strategic alliances to discover and validate gene targets for drug discovery. atugen provides or has provided target discovery and validation services to Agouron Pharmaceuticals, Altana Pharma, Arena Pharmaceuticals, AstraZeneca, Axys Pharmaceuticals, Bayer, Boehringer Ingelheim, Kinetek, Millennium Pharmaceuticals, Novo Nordisk, Oxford Glycosciences, Pfizer, Roche Biosciences, Schering AG/Berlex Biosciences, Serono and UCSF. ALTANA AG (NYSE:AAA) is an international pharmaceuticals and chemicals Group with sales of n2.3 billion in 2001 and over 9,000 employees all around the world. It is the strategic management holding company of the ALTANA Group, comprising two operating Divisions, ALTANA Pharma AG and ALTANA Chemie AG. The pharmaceutical division ALTANA Pharma AG is an international Group with around 30 subsidiaries and affiliates in Europe, the Americas, South Africa, Australia and Asia. ALTANA Pharma AG concentrates on therapeutics, imaging (contrast media), in-vitro diagnostics and OTC medication, and focuses on innovative pharmaceutical research (gastroenterology, respiratory, oncology). In 2001, ALTANA Pharma AG achieved sales of n1.6 billion, i.e. up 26% year-on-year. Therapeutics, the most important area of business, is based on prescription drugs for respiratory, cardiovascular and gastrointestinal indications. Pantoprazole, used to treat gastrointestinal disorders, is ALTANA Pharma`s best-selling drug, generating worldwide sales of n1.3 billion in 2001. ALTANA Pharma AG employs around 7,500 people worldwide, of which around 3,000 work in Germany. For further information, contact: atugen Noonan Russo Presence Dr Zisi Fotev Sarah Burl Tel: [phone] Tel: [phone] Fax: [phone] Fax: [phone] Email: [e-mail] Email: [e-mail] Web: www.atugen.com Web: www.nrp-euro.com

Please click on the link to view the pdf version



Copyright (c) 2002, HUGIN AS. All rights reserved.


-0-


SUBJECT CODE: Finance

JS200

[js200]

company news

--------------------------------------------------------------------------------

MLNM - Millennium Pharmaceuticals, Inc. (NASDAQ NM : MLNM)

--------------------------------------------------------------------------------
EquityOutlook.Com: New ratings on Internap Network Services, Millennium Pharmaceuticals, Duke Energy, Boeing, Clear Channel



TUESDAY , DECEMBER 03, 2002 11:27 AM

Dec 03, 2002 (M2 PRESSWIRE via COMTEX) -- following stocks: (Get FREE ratings at http://www.equityoutlook.com/index.htm)

Internap Network Services (NASDAQ:INAP) - Outperform Millennium Pharmaceuticals (NASDAQ:MLNM) - Outperform Duke Energy (NYSEUK) - Outperform Boeing (NYSE:BA) - Outperform Clear Channel (NYSE:CCU) - Underperform

WHAT THESE RATINGS MEAN:

These stocks are rated with a proprietary system of technical analysis. These ratings do not indicate a "long term" view of any company listed. These are ratings that indicate our opinion of a stock`s PRICE movement versu s the SP 500 over the short term. "Mainstream wallstreet" implores traders to "buy and hold." This strategy proves at times to be DISASTROUS. We believe that traders should find entry and exit positions over the short term to take profits or conserve capital.

These ratings reflect our opinion as of the first trading day of the week. These ratings may change based on daily market conditions.

Investors can find more ratings at: www.equityoutlook.com/index.htm

Investors that want a TRULY unbiased stock rating service should visit: http://www.equityoutlook.com/reports.htm

Disclaimer: EquityOutlook.Com (a StockLogix.Com, LLC company) is a registered investment adviser in the State of Louisiana (IARD#118718). No information accessed through the EquityOutlook.Com, or any link contained on the

EquityOutlook.Com Web site, constitutes a recommendation by EquityOutlook.Com to buy, sell or hold any security, financial product, or instrument discussed therein. Information accessed through linked sites neither is, nor should be construed as, an offer, or a solicitation of an offer, to buy or sell securities by EquityOutlook.Com. EquityOutlook.Com does not hold positions in securities being discussed in this news release and/or mentioned on the EquityOutlook.Com Web site. Investors shall be fully responsible for any investment decisions they make, and such decisions will be based solely on their evaluation of their financial circumstances, investment objectives, risk tolerance and liquidity needs. Investors are encouraged to consult with their registered broker and/or investment adviser before making any investment decision.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].



(C)1994-2002 M2 COMMUNICATIONS LTD

JS200

[ollihat]

Nachbörslich SUPER Rally!

[Boersenkrieger]

Na sag ich doch MLNM =

[js200]

Millennium: Siebenmeilenstiefel und Spekulationen Newssuche
WKN / Symbol / Stichwort






Das Biotech-Unternehmen riskiert den Sprung ins Dunkle und wird frühzeitig den Zulassungsantrag für Velcade einreichen. Wegen gleichzeitiger Personalveränderungen wird über die Hintergründe des Schrittes kräftig spekuliert.

Einen Kurssprung von mehr als 20 Prozent hat die Aktie von Millennium Pharmaceuticals nach Schließung der Börsentore vollzogen. Dafür ist Velcade verantwortlich, ein Medikamentenkandidat, der zur Behandlung unterschiedlichster Arten von Krebs entwickelt wird. Für Anfang 2003 hat Millennium überraschend die Einreichung des Zulassungsantrages für die Behandlung von Knochenmarkkrebs (Multiples Myelom) angekündigt.

Der Schritt ist ungewöhnlich, weil Velcade zur Behandlung dieser Indikation erst die zweite Phase der klinischen Tests abgeschlossen hat. Gewöhnlich erfolgt der Zulassungsantrag erst nach erfolgreichem Abschluss der dritten Phase. Millenniums CEO Mark Levin hat gegenüber Analysten auf Treffen mit Verantwortlichen der FDA verwiesen, deren Ergebnis die Gesellschaft dazu bewogen habe, den Schritt zu unternehmen.

Gelingt der Siebenmeilen-Schritt des Medikamenten-Kandidaten und erhält Velcade zudem noch den Status eines Kandidaten, der besonders schnell begutachtet wird, könnte nach Analystenmeinung im Herbst 2003 die Zulassung erfolgen. Levin hat allerdings bisher keine genaueren Angaben darüber gemacht, wie die Gespräche mit der FDA verlaufen sind oder ob die Gesellschaft eine schriftliche Zusicherung hat, die die vorzeitige Einreichung des Zulassungsantrages stützt.

Es wundert nicht, dass über diesen Umstand Spekulationen ins Kraut schießen. Das sich drehende Personalkarussell der Gesellschaft sorgt zudem für Wirbel. Der bisherige CFO von Millennium verlässt das Unternehmen, gleiches gilt für einen der wichtigsten Wissenschaftler. In US-Medien wird ein möglicher Zusammenhang zwischen beiden Ereignissen diskutiert: Dabei steht die Frage im Vordergrund, ob die Abgänger sich gegen den vorzeitigen Zulassungsantrag ausgesprochen haben könnten. Eine andere Lesart wäre, dass Millennium den Abgang von wichtigem Personal mit einer guten Nachricht aufzuwiegen sucht, um dem Aktienkurs vor weiteren Verlusten zu schützen.

Analysten bezeichnen den Schritt als riskant, verweisen aber auf das Potenzial, das sich im Erfolgsfall ergeben könnte. Ed Tenthoff von ThinkEquity Partners äußert sich positiv, weil Velcade statt Ende 2004 ein Jahr früher die Zulassung erhalten könnte.


JS200

[js200]

12/04/2002 (16:46 ET) VOLUME(+): MLNM Volume 89% > 20-adsv, Stock +1.79% - Knobias
12/04/2002 (16:41 ET) New 8-K just released for MLNM - Edgar
12/04/2002 (16:35 ET) New 8-K just released for MLNM - Edgar
12/04/2002 (16:05 ET) Millennium To Host Conference Call And Webcast - PR Newswire
12/04/2002 (16:04 ET) Alnylam Pharmaceuticals Appoints Dr. John Maraganore as President and CEO - PR Newswire


JS200

[js200]

12/05/2002 (10:21 ET) RATING(=): Ryan, Beck & Co Keeps MLNM @ Outperform - Knobias
12/05/2002 (10:12 ET) VOLUME(+): MLNM Volume 6% > 20-adsv, Stock +5.27% - Knobias
12/05/2002 (09:46 ET) GAP-DN: Opening Lower JILL MLNM AVGO AEOS ATCC - Knobias
12/05/2002 (08:37 ET) RATING(=): CIBC Reiterations for Thursday, December 5th - Knobias
12/05/2002 (08:30 ET) PRMKT:Millennium To File NDA w/ FDA; Management Changes - Knobias


JS200

[Slobo]

Folgende These:

COO Kevin Starr verlässt das UNternehmen, weil er bereits weiss, dass VELCADE von der FDA genehmigt wird. Er kennt die Wirkungsweise und den Therapieerfolg.
Das hat er sich zum Ziel gesetzt und geschafft. Den ein Medikament bereits nach der II. Testphase in die FDA zu schicken muss schon sehr viel Gewissheit bedeuten.
Jetzt lässt es sich Starr ganz einfach gut gehen und widmet sich seiner Familie. Eigentlich ein guter Gedanke, denn normalerweise jeder nachvollziehen können sollte.
Finanziell wirde es ihm meiner Ansicht nach dabei nicht schlecht gehen.

Also, ich denke die Geschichte mit VELCADE geht klar und der Ausstieg von Starr ist für mich auch problemlos nachvollziehbar. Kevin Starr hat ja auch deutlich gemacht, dass er das UNternehmen verlässt, um ab jetzt für seine Familie da zu sein. Zudem hat der Boss von Millennium bereits im Vorfeld mit den Leuten der FDA über die Geschichte mit VELCADE gesprochen.

Was denkt ihr ?????????????

[binary]

auf jeden fall was es toll jemanden zu finden der wegen velcade mir heute fast 13 € pro aktie gegeben hat!

[Boersenkrieger]

@binary

aber vergiß das nachkaufen nicht... kurse um die 30-50 € werden bald wieder realität sein

[Boersenkrieger]

mit peanuts-zockereien ist nämlich noch keiner reich geworden.... nicht vergessen

[Slobo]

Warum stürzt Millennium ab? Gibt es irgendeine Horrormeldung??? Ich dachte das neue Medikament gibt Aufschwung!?!?

[Megapol]

Konnte nichts finden

[kurttilly]

Außer dieser Meldung :

TA: Millennium Pharmaceuticals: Mittelfristigen Abwärtstrend gebrochen
09.12.2002 11:55:00


Die Aktie von Millennium Pharmaceuticals (WKN-Deutschland 900625) konnte sich in den letzten tagen deutlich erholen und einen mittelfristigen Abwärtstrend brechen. Nach einer kurzen Konsolidierung sind aus charttechnischer Sicht weiter steigende Kurse zu erwarten.

Quelle: MARKET MAKER

Nach einer mehrwöchigen Seitwärtsbewegung unterhalb einer Unterstützungsliniebei ca. 9,00 Dollar, erholte sich die Aktie von Millennium Pharmaceuticals kontinuierlich und brach dabei einen mittelfristigen Abwärtstrend. Derzeit notiert die Aktie bei 10,81 Dollar und tendiert weiter aufwärts. Die Bollinger-Bänder lassen einen nach oben überdehnten Kurs erkennen. Die nächste Widerstandslinie ist bei 12,25 Dollar zu erkennen. Sie entstand aus einem Zwischenhoch im Abwärtstrend.

Die Umsätze nahmen als die Abwärtstrendlinie gebrochen wurde, kurzzeitig deutlich zu. Das 20 Tage-Momentum kletterte in den letzten Wochen auf derzeit 126 Zähler. Es notiert damit auf einem sehr hohen Niveau im dreistelligen Bereich. Der MACD wechselte vor wenigen Tagen in positives Terrain und kann sich dort mit aktuell +0,6 Zählern behaupten. Der RSI prallte Anfang der Woche von der 70 Prozent-Marke nach unten ab und notiert mit 65,7 Prozent wieder deutlicher in der neutralen Zone.

Ausblick: Aus charttechnischer Sicht ist kurzfristig mit einer Konsolidierung auf dem derzeitigen Kursniveau zu rechnen. Lassen die Oszillatoren anschließend wieder mehr Potenzial nach oben erkennen, ist ein weiterer Kursanstieg denkbar. Mittelfristig sind Kurse von 16,00 Dollar möglich. Anleger können investieren, sobald die Konsolidierung abgeschlossen ist.


-mah

[Megapol]

Übrigens gibt gab es heute einige Blocktrades. Schon am Freitag gab es je einen Trade von 100.000 und 50.000 Stück.

Heute gab es u. a:

17:38:06 9,9200 100.000 Stück
16:20:20 11,3000 75.000 Stück

[Slobo]

Wer kann Englisch??
www.nasdaq.com
MLNM eingeben und dann auf Info-Q.
dort steht eine ellenlange neue Meldung über Millennium drin.

[LMeister7]

Hallo,
folgenden übersetzten Artikel habe ich bei Yahoo gefunden. Schlussfolgern muss jeder selbst. Vorweg der Link zum Artikel:http://www.forbes.com/2002/12/09/cx_mh_1209mlnm.html?partner…

und hier die ziemlich miese Übersetzung:
"Biotechnik
Die Zukunft von Jahrtausend
Matthew Herper, 12.09.02, 10:45 sind ET

NEW YORK, Letzte Woche verkündete Millennium Pharmaceuticals, daß es sein experimentelles Kerbsarzneimittel, Velcade, zu Reglern bei den U.S. einreichen würde. Essen und Drogenverwaltung über Mittelphase-Daten. Heute wurden die Studien, die Millennium so selbstsicher machten, bei einer medizinischen Versammlung in Philadelphia enthüllt.

Einige Analytiker, einschließlich des S.G. Cowen`s Yaron Werber, spekulierten dieses Millennium, nasdaq: MLNM, Nachrichten (Leute), bewarb sich früh mit dem FDA, um seinen Vorratspreis zu fördern. Weitere Zweifel wurden gehoben, als Kevin Starr als Oberhaupt zurücktrat, das Offizier bedient, um mit seiner Familie zu sein. Die heute bei der jährlichen Versammlung der amerikanischen Gesellschaft der Hämatologie präsentierten Daten stellen wenigstens ein starkes Gegenargument zu jenen Sorgen dar.

Mehr auf Mark Levin

Aufgeführt auf besten Bezahlten Direktoren

Mehr auf Millennium Pharmaceuticals

Forbes 500s

In anderen Worten, Millennium spielt wenigstens mit einer guten Hand. Dieses Studium, das von Paul Richardson beim Dana-Farber-Institut geführt wurde, prüfte nur das kränkste Patientenleiden an einem relativ seltenen Krebs, das mehrfachen myeloma gerufen wurde. Diese 202 Leute waren bei der Tür von Tod. Die meisten hatten sechs Behandlungen schon versagt, und 60% hatten durch eine Knochenmarktransplantation gelitten. Ihr Krebs setzte fort zurückzukommen.

In sieben Patienten veranlaßte Velcade ihren Krebs, ganz zu verschwinden, glätten Sie wenn durch neue, unglaublich empfindliche Prüfungen gemessen hat. Ein Dutzend mehr sah, daß ihr Krebs außer für eine Spurmenge verschwindet. 35% von Patienten sahen einen bedeutungsvollen Rückgang in ihrem Blutkerbs und benutzten rigorose klinische Standards. Sie, die den Gruppen mittleres Überleben ausgestreckt werden, timen zu 16 Monaten; im Durchschnitt würde es erwartet werden, nur sechs Monate zu sein.

Aber diese glühenden Ergebnisse haben eine grelle Schwäche: Sie vergleichen Velcade nicht gegen eine übliche Behandlung oder ein Placebo. Das ist, warum Millennium plante, ursprünglich auf ein größeres zu warten, Endphase-Versuch, zu enden, bevor es sich zum FDA ergab. Jahrtausendantwort: Patienten, die auf Velcade reagieren, scheinen, länger als jene zu leben, der nicht macht, deshalb hat die Medizin eine Wirkung.

"Es ist in mehrfachem myeloma gut feststehend, daß Überleben und Antwortraten eine statistische Wechselbeziehung haben", sagt Barry Greene, allgemeiner Manager der Onkologie bei Millennium. "Unsere Antwortrate-Daten zeigen eindeutig einen Überlebensvorteil für Patienten, die auf Velcade reagieren".

Wird diese Strategie mit dem FDA arbeiten? Vielleicht, aber Millennium wird mehr dieses Überlebenstrends zeigen, müssen. Sogar vor heutigen Daten wurde präsentiert, aber, irgendein Gedanke der das Bekommen früher von Velcade vor Regler eher als später war eine gute Idee. Der Vorrat schob sich in die zwei Tage folgenden Millennium`s Ankündigung aufwärts.

Bevor die ASH-Versammlung anfing, Raymond Warrell, Hauptmanager von Genta, nasdaq: GNTA, Nachrichten (Leute), äußerte sich, daß er denkt, ist Velcade einer von den seltenen Fällen, wo schnell ein Arzneimittel zu verfolgen, Sinn macht. "Jahrtausend hat starke Daten", sagte er. Warrell, der Onkologe dafür bei Gedenksloan-Kettering Kerbszentrum in New York war, CEO zu werden, hat in der Vergangenheit gesagt, daß der Antrieb, Drogenzustimmungen zu beschleunigen, außer Kontrolle gerät.

Aber, auch wenn Velcade für Patienten mit mehrfachem myeloma genehmigt wird, der auf anderen Arzneimitteln gescheitert ist, wird Millennium nicht aus den Wäldern sein. Als SG Cowen`s Werber weist darauf hin, mehrfacher myeloma ist eine seltene Krankheit, und der Markt für Velcade wird anfangs werte nur mehrere hundert Millionen von Dollarn sein. Das wird kein Millennium gewinnbringend machen.

Mark Levin, der CEO von Jahrtausend, hat gesagt, daß Velcade schließlich ein blockbuster werden konnte, aber nur, nachdem neue Daten das Benutzen des Arzneimittels in Verbindung mit Chemotherapie für gewöhnlichere Krebse hereingekommen sind. Statt bald gewinnbringend zu werden, setzt er fort, in sehr teure Forschung und Entwicklung zu investieren.

Levin`s logisches Denken erklärt vor mehreren Monaten in einem Interview, geht wie es: Es hat mehrere tausend öffentlich getauschte Biotechnikfirmen gegeben. Nur eine Handvoll, einschließlich des Amgen, nasdaq: AMGN (Nachrichten), Leute und Genentech nyse: DNA, Nachrichten (Leute), hat es geschafft, feste Forschung in doppelte-Ziffer-Wuchs zu verwandeln. Ihren Erfolg gleichzukommen, sagt er, Millennium muß eine ertragbare Pipeline der Arzneimittel bauen.

Jene Ambitionen scheinen vielleicht zu vielen Investoren ein wenig hoch, aber das ein Stück von etwas besitzen will, was Geld verdient, statt sich zu bemühen, der nächste Genentech zu sein. Für das Versprechen alles Velcade gibt es immer noch etwas, was darüber gesagt werden sollte, zu viel auf keine Hand zu wetten, egal wie gut es einmal sieht, haben Sie die ersten wenigen Karten gesehen."
-----------------------------------------------------------

MfG,
LM7

[Phedre]

Hallo
hier die news von heute

1.
Jahrtausendfeier überzeugt hinsichtlich der Krebsdroge
Montag Dezember 9, 2:35 P.M. UND
Durch Victoria Griffith in Boston


Jahrtausendfeierpharmazeutische Produkte stellten solche positive klinische Proberesultate für seine Krebsdroge Velcade bei einer nationalen wissenschaftlichen Sitzung am Montag dar, daß sie vorwärts seine Anwendung für Marktzustimmung bis zum einem vollen Jahr verschoben hatte.
REKLAMEANZEIGE



Die Firma bittet um Abstand von der Nahrung und von der Drogeleitung im ersten Viertel des folgenden Jahres. Wenn es Zustimmung gewinnt, wird Jahrtausendfeier die erste genomicsgruppe zum Bilden des Sprunges von der reinen Technologie zur Drogeentdeckung.

Das Setzen von Velcade auf den Markt wurde vindicate die Fließband"Annäherung" der Gruppe viel-much-touted zur Biotechnologie. Jahrtausendfeier hat lang gehalten, daß das Geheimnis zum Drogeerfolg in den Zahlen liegt: nur indem sie die Führung mit frühem Stadium anfüllen, können Mittel - das Kennen der Anwärter fällt entlang die Weise - eine Firma sie sicherstellen beenden mit einem Produkt.

Die Methode ist weit in der biotechindustrie nachgeahmt worden, aber Sceptics bezweifeln Fähigkeit der Jahrtausendfeier, seinen Fall zu prüfen. Obgleich er zwei Produkte auf dem Markt hat - die Krebsdroge Campath und die Herzkrankheitbehandlung Integrilin - beide kamen durch Erwerb.

Das Potential von Velcade ist hart zu messen. "Höchstverkäufe konnten von $100m zu $1bn überall sein,", sagt Rechnung Tanner, Analytiker mit Leerink Swann. "aber Zustimmung würde es zeigen, daß ist transitioned von einem R&D-Betrieb zu einer kommerziellen Gruppe.",

Jahrtausendfeier sucht, einen Partner, um Velcade global zu vermarkten aber kann alleine gehen es zu Hause. "wir werden der Treiber im US-Markt sein, aber im Fernen Osten und im Europa benötigen wir einen Partner," besagte Hauptgeschäftsführermarkierung Levin. Ein Abkommen sollte innerhalb der folgenden drei Monate verkündet werden.

Gebildet worden 10 Jahren als computer-gestützte Forschungsgruppe, haben Vermögen vor der Jahrtausendfeier ups und niederwirft vom genomicssektor widergespiegelt. Die Firma fing an, R&D zum Produktsektor zu unterstützen. Wenn lukrativ, entschied Herr Levin früh, daß das größte Geld in der Drogeentdeckung sein würde und Jahrtausendfeier zu den Produkten schielt. Schließlich würden andere genomicsfirmen einschließlich der menschlichen Genomwissenschaften, -Incyte und -Celera Klage folgen.

Als Begeisterungover stieg das Der Reihe nach ordnen des menschlichen Genoms an, tat so Anteile der Jahrtausendfeier. Vor zwei Jahren, erreichten sie fast $90. Die Gruppe zog Nutzen aus dem receptiveness der Öffentlichkeit zu den Anteilen der genomicsfirmen, daß es Milliarden Dollar in den Kapitalmärkten aufwarf. Als der Biotechnologieluftblasenstoß, Anteile der Jahrtausendfeier fast 90 Prozent ihres Wertes verschüttete.

Die ebenen Zeiten ließen Jahrtausendfeier mit erheblichen Bargeldniveaus. Während einige Reserven verbraucht worden sind, hat die Gruppe noch fast $1.2bn in seinen Coffers - Geld, das es Velcade vermarkten und mehr Forschung finanzieren muß.

Indem sie mit der FDA auf der Stärke der Versuche der Phase II alleine - die meisten Drogen machen Tests der Phase III bevor Abstand durch - Jahrtausendfeier nimmt eine Gefahr einordnet. ImClone lief in Mühe, als seine Krebsbehandlung Erbitux zurückgewiesen wurde, nachdem eine Phase Anwendung II-gründete.

Aber Jahrtausendfeier ist überzeugt. Sie prüfte das Mittel auf 202 Patienten, die unter mehrfachem myeloma, einen tödlichen Krebs leiden. Thirty-five Prozent reagierten auf die Behandlung und 10 Prozent sahen kompletten Erlaß der Krankheit. Die Gruppe stellt auch verbesserte Survivabilitydaten, etwas zur Verfügung, welche die FDA in solch eine Anwendung sehen mag.

"wir sind überzeugtes Velcade machen uns zu einen globalen biopharmaspieler," sagte Herrn Levin. "es dauert uns eine andere Dekade, um eine der oberen pharmazeutischen Gruppen in der Welt zu werden.",


2.
Velcade Resultiert Positiv, Sagt Jahrtausendfeier

Durch Adam Feuerstein
Älterer Verfasser
12/09/2002 02:03 P.M. EST
Klicken Sie hier für mehr Geschichten durch Adam Feuerstein


Jahrtausendfeierpharmazeutische Produkte ( MLNM :Nasdaq - Nachrichten - Kommentar - Forschung - Analyse) sagten Montag, daß seine experimentelle Krebsdroge Velcade wirkungsvolles prüfte, wenn sie Patienten mit sehr vorgerücktem mehrfachem myeloma behandelte, einen Krebs des Knochenmarks.

Das Cambridge, Mass.-basedbiotechunternehmen berichtete über Endrundenresultate von einer Studie der Phase II von Velcade bei der jährlichen Sitzung der amerikanischen Gesellschaft von Hämatologie. Letzte Woche, Jahrtausendfeier sagte, daß sie beabsichtigt, Marketing- Zustimmung für Velcade von der Nahrung und von der Drogeleitung aufgrund von Resultaten von diesem zu suchen Studie.


Bericht Montages über Velcades positive Wirksamkeit wurde groß erwartet, seit die Firma über Einleitung- Resultate von dieser gleichen Studie im letzten Frühling an der amerikanischen Gesellschaft der klinischen Onkologiesitzung berichtete.

Jahrtausendfeieranteile waren weg von 11% bis $9,98 im neuen Handeln, hauptsächlich weil die Daten keine realen Überraschungen hielten, und in vielen Investoren, die auf den Nachrichten verkauft wurden. Etwas Sicherheitsinteressen auf Velcade, die während der Darstellung Montages hervorgehoben wurden, obgleich nicht neu, waren auch wahrscheinliches Wiegen auf dem Vorrat.

Daten von 193 von 202 Patienten in der Studie zeigten komplette Erlassse in 4% von Patienten, entsprechend einem zwingenden klinischen Maß, das als die Blattkriterien bekannt ist (pronounced BLAH-Tag). Eine anderen 6% von PatientenWAREN in der Lage, fast komplette Erlassse, entsprechend Jahrtausendfeier zu erzielen.

Die gesamte Ansprechgeschwindigkeit in der Studie war 35%, definiert als die Gesamtmenge der kompletten, teilweisen und kleinen Antworten, die Firma, die gesagt wurde und addierte, daß ein unabhängiger Ausschuß der Doktoren alle geduldigen Antworten überprüfte.

Die Patienten, die in dieser Studie eingeschrieben wurden, hatten Fälle mehrfachen myeloma vorgerückt, die weiterkamen, nachdem sie einen Durchschnitt von sechs vorherigen Behandlungregierungen empfangen hatten. Ihre durchschnittliche Lebenserwartung betrug sechs bis neun Monate, auf der Grundlage von historische medizinische Daten. Patienten in der Studie Velcade überlebten ein Durchschnitt von 16,4 Monaten.

"diese Resultate zeigen einen wichtigen Potentialfortschritt in der Behandlung des mehrfachen myeloma an und können neue Hoffnung für erhöhtes Überleben in dieser geduldigen Bevölkerung anbieten,", sagte Dr. Paul Richardson des Krebsinstituts Dana-Farber in Boston, der Hauptforscher der Studie, in einer Aussage

3.

Jahrtausendfeier Pharma: DrogecStudie Zeigt 35%-Ansprechgeschwindigkeit
Montag Dezember 9, 12:39 P.M. UND


PHILADELPHIA (Dow Jones) -- JahrtausendfeierPharmazeutische Produkte, Inc.. besagte Endrundenresultate von der Studie der Phase II seiner Krebsdroge Velcade zeigten an, daß die Droge am Verlangsamen von Entwicklung des zurückgefallenen und refraktären mehrfachen myeloma erfolgreich war, das Knochenmark durch die Überproduktion der weißen Blutzellen in Angriff nimmt.
In einem Pressekommuniqué Montag sagte biopharmaceutical Firma des Cambridges, Mass., daß die Entdeckungen, daß eine Majorität Patienten in der Studie eine Verkleinerung oder Ausgleichung ihrer Krankheitschwierigkeit erfuhr, wenn einige Patienten komplette Erlassse erfahren anzeigten.

Die Resultate wurden Montag bei der 44th jährlichen Sitzung der amerikanischen Gesellschaft von Hämatologie in Philadelphia verkündet.

Die Studie der Multi-centerphase II schloß 202 Patienten mit refraktäres und mehrfaches myeloma Zurückfallens mit ein, das ein erwartetes Überleben von sechs bis neun Monaten hatten und das "sechs vorheriger therapeutischer Regierungen für ihren Krebs berechnet hatte.

Studieren Sie Resultate von den 193 evaluable Patienten zeigte komplette Erlassse in 4% von Patienten, wie durch Bladekriterien und ein zusätzliches 6% von Patienten, die eine Verringerung 100% des M-Proteins, hatten eine Markierung der Tumorbelastung, aber ein positiver immunofixationtest (ein empfindlicher Antikörpertest für Spurenmengen M-Protein) definiert. Die gesamte Ansprechgeschwindigkeit war 35%, definiert als die kombinierte Gesamtmenge der kompletten und teilweisen Erlassse und der minimalen Antworten. Gesamt, erfuhr 59% von Patienten eine Antwort oder erzielte beständige Krankheit.

Letzte Wochenjahrtausendfeier sagte, daß sie eine neue Drogeanwendung bis zum frühem 2003 beim Markt Velcade als Behandlung für zurückgefallenes und refraktäres mehrfaches myeloma einreichen würde.

Früh wurde dieses Jahr, Velcade Schnellschienenstatus durch die Nahrung und die Drogeleitung als bewilligt, das Potential habend, den lebensbedrohenden Zustand zu behandeln. Jahrtausendfeier plant auch, einen Marketing-Ermächtigungsantrag zur europäischen Agentur für die Auswertung der medizinischen Produkte bis zum frühem 2003 zu stellen.

Jahrtausendfeier handelte vor kurzem bei $10 pro Anteil, hinunter $1,19 oder 10,6%, auf Ausgabe von 6,5 Million Anteilen. Tägliche Ausgabe des Durchschnittes ist 5,3 Million Anteile

4.

Neue Daten Von Velcade(TM) (Bortezomib) Für EinspritzungcKammcStudie Zeigen Antworten Bei Patienten Mit Zurückgefallenem Mehrfachem Myeloma An
Montag Dezember 9, 10:38 morgens UND
-- ErgänzungscGipfelcStudie Im Früheren Stadium Der Krankheit --


PHILADELPHIA, PA, Dez. 9/PRNewswire-FirstCall/-- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - Nachrichten ) verkündeten heute abschließende Resultate der KAMM-Studie der Phase II (vorher bekannt als 024) für seine Untersuchungskrebsdroge VELCADE in der Behandlung der Patienten mit mehrfachem myeloma dessen Krebs nach front-line Behandlung zurückgefallen war. Die Studie wertete auch die Antwort zu VELCADE im Verbindung mit dexamethasone bei den Patienten aus, die nicht auf VELCADE alleine reagieren. Die Resultate, heute dargestellt bei der 44th jährlichen Sitzung der amerikanischen Gesellschaft von Hämatologie, von angezeigter gleichbleibender klinischer Tätigkeit von VELCADE bei zwei Behandlungdosen, einschließlich der kompletten Erlassse und eines möglichen Dosiseffektes für klinische Antwort und nachteilige Fälle.
(Foto: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
"diese Daten fügen der auftauchenden Abbildung der klinischen Tätigkeit mit VELCADE," besagter Hauptforscher Sundar Jagannath, MD, von der katholischen medizinischen Mitte Str. Vincents in neuem York, NY hinzu. Er erklärte, daß Forscher häufig zuerst feststellen, wenn eine Krebsdroge bei Patienten mit der vorgerücktesten Krankheit aktiv ist und wer wenige Behandlungwahlen haben. Diese Forschungsannäherung wurde in der GIPFEL-Studie der Phase II demonstriert, früheren heutigen Tag dargestellt, für den abschließende Daten anzeigten, daß die Mehrheit einen Patienten eine Antwort oder eine erzielte beständige Krankheit erfuhr, als behandelt mit VELCADE; diese Patienten waren zurückgefallen und waren trotz des Empfangens der mehrfachen, vorherigen Therapien refraktär. "diese neuen Entdeckungen schlagen vor, daß VELCADE Patienten auch fördern kann, die nach wenigen vorherigen Behandlungen zurückgefallen sind," er sagte.

Studie und Entdeckungen

Die Studie der Multi-centerphase II schloß 54 Patienten mit mehrfachem myeloma mit ein dessen Krankheit nach front-line Therapie zurückgefallen war. Patienten im Versuch hatten einen Mittelpunkt von einer vorherigen Linie Therapie, die Behandlungregierungen der Mehrfachverbindungsstelle umfaßt haben kann unterschiedliche. Gesamt, hatten 98 Prozent vorherige steroid Therapie, die 72-Prozent-vorherigen alkylierenden Vertreter, die 50-Prozent-vorherigen anthracyclines, 48 Prozent vorherige Stammzelleversetzung und 30 Prozent vorherige Thalidomide empfangen. Während des Versuches wurden Patienten randomisiert, um entweder 1,0 mg/m2 oder 1,3 mg/m2 von VELCADE(TM) (bortezomib) für Einspritzungtherapie für bis 24 Wochen (Tage 1, 4, 8 und 11 zu empfangen eines Zyklus 21-day, für bis acht Zyklen). Nach zwei oder vier Zyklen VELCADE alleine, nicht wurden die reagierenden Patienten mit VELCADE plus dexamethasone, eine herkömmliche Therapie behandelt.

Antworten wurden mit Blattkriterien - ein rigoroser Einschätzungsstandard festgesetzt, der verwendet wurde, um Änderungen im Krankheitstatus, einschließlich einer Bestätigung später zu beschreiben sechs Wochen. Eine "komplette Antwort" erforderte ein 100-Prozent-Verschwinden des M-Proteins (eine Markierung der Tumorbelastung); negative immunofixationprüfung; Plasmazellen von weniger als fünf Prozent im Knochenmark; keine Zunahme der Größe oder der Zahl der lytischen Knochenverletzungen; und Verschwinden der weichen Gewebetumoren (plasmacytomas). "teilweise" Erlassse und "minimale" Antworten stellten wenige Grad der Antwort basiert auf den gleichen Kriterien dar. Die Verschlechterung dieser Anzeigen setzte "progressive Krankheit." fest, Wichtig wurden diese Ermittlungen der Antwort von einem unabhängigen Berichtausschuß (IRC) bestätigt.

Studienresultate von der Gruppe der Behandlung 1,3 mg/m2 (n=26) waren, wie folgt: -- komplette Erlassse in vier Prozent Patienten, wie durch Bladekriterien festgestellt. -- die gesamte Ansprechgeschwindigkeit betrug 50 Prozent. Gesamte Antwort wurde als die kombinierte Gesamtmenge der kompletten und teilweisen Erlassse und der minimalen Antworten definiert. -- gesamt, erfuhren 69 Prozent Patienten eine Antwort oder erzielten beständige Krankheit. -- als dexamethasone der Behandlung der Patienten hinzugefügt wurde, die nicht auf 1,3 mg/m2 von VELCADE alleine reagierten, erhöhte die gesamte Ansprechgeschwindigkeit von 50 Prozent bis 62 Prozent. Studienresultate von der Gruppe der Behandlung 1,0 mg/m2 (n=27) waren, wie folgt: -- komplette Erlassse in vier Prozent Patienten, wie durch Bladekriterien definiert und in einem zusätzlichen sieben Prozent, die eine 100-Prozent-Verringerung des M-Proteins aber eines positiven immunofixationtests hatten (ein empfindlicher Antikörpertest für Spurenmengen M-Protein). -- die gesamte Ansprechgeschwindigkeit betrug 33 Prozent. Gesamte Antwort wurde als die kombinierte Gesamtmenge der kompletten und teilweisen Erlassse und der minimalen Antworten definiert. -- gesamt, erfuhren 59 Prozent Patienten eine Antwort oder erzielten beständige Krankheit. -- als dexamethasone der Behandlung der Patienten hinzugefügt wurde, die nicht auf 1,0 mg/m2 von VELCADE alleine reagierten, erhöhte die gesamte Ansprechgeschwindigkeit von 33 Prozent bis 44 Prozent.
Die gesamte mittlere Zeit zur Weiterentwicklung betrug 11 Monate. Das gesamte mittlere Überleben für die kombinierten Behandlunggruppen war nicht bei 8,8 Monaten weiterer Verfolgung erreicht worden.

VELCADE(TM) (bortezomib) für Einspritzung wurde im Allgemeinen gut-zugelassen und nachteilige Fälle waren handlich und vorhersagbar. Die am allgemeinsten berichteten nachteiligen Fälle waren, einschließlich der Übelkeit, sich Diarrhöe gastro-intestinal-in Verbindung stehend, Verstopfung und, sowie Thrombocytopenie, Zusatzneuropathie, Neutropenie, Ermüdung, anorexia, Pyrexia und Anämie erbrechen. Es schien, Unterschiede bezüglich der Frequenz der nachteiligen Fälle zwischen den 1,0 mg/m2 und 1,3 Gruppen der Behandlung mg/m2, besonders im Fall Zusatzneuropathie (18 Prozent gegen 58 Prozent) zu geben, die weiter in den fortwährenden SPITZEN-Versuch der Phase III bei Patienten ausgewertet wird, die eine Dosisverkleinerung wegen der nachteiligen Fälle benötigen.

"während diese Studie nicht statistisch angetrieben wurde, um die Sicherheit und die Wirksamkeit von VELCADE (bortezomib) für Einspritzung bei zwei unterschiedlichen Dosen zu vergleichen, sind wir, daß die Resultate mit denen gleichbleibend sind, die in unseren HauptcGipfel-Versuch der phase II gesehen werden," sagten Barry Greene, Generaldirektor, Onkologie, an der Jahrtausendfeier erfreut.

SPITZE, ein internationaler, der Multi-centerphase III Versuch von VELCADE gegen Hochdosisdexamethasone bei Patienten mit zurückgefallenem oder refraktärem mehrfachem myeloma, fing im Juni 2002 für Patienten an, die ein--drei zu den vorhergehenden Therapien empfangen haben. Phase I und II sind Versuche von VELCADE in den verschiedenen Arten der festen Tumoren unterwegs.

Über mehrfaches myeloma

Mehrfaches myeloma ist ein Krebs des Knochenmarks, in dem weiße Blutzellen die Plasmazellen benannten, normalerweise verantwortlich für die Produktion der Antikörper (Proteine, die Infektion und Krankheit kämpfen), sind overproduced. Die starke Verbreitung dieser anormalen Plasmazellen, bekannt als myelomazellen, verursacht verringerte Produktion der normalen roten und weißen Blutzellen und der normalen Krankheit-Kämpfenantikörper, sowie das Wachstum der Tumoren, die zu den mehrfachen Aufstellungsorten - folglich das Bezeichnungsmehrfachverbindungsstellenmyeloma verbreiten. Die verringerte weiße Blutzellenproduktion beschädigt das immune System, während die myelomatumoren Knochenzerstörung verursachen, die als Schmerz und Brüche verkündet.

Mehrfaches myeloma ist das zweithäufigste allgemeine hämatologische malignancy und obgleich die Krankheit überwiegend ein Krebs vom älteren ist (der Altersdurchschnitt des Angriffes beträgt 65 bis 70 Jahre des Alters), zeigen neue Statistiken zunehmende Ausdehnung und jüngeres Alter des Angriffes an. In den Vereinigten Staaten haben mehr als 40.000 Einzelpersonen mehrfaches myeloma und über 14.000 neuen Fällen von der Krankheit werden jedes year.(1) weltweit dort sind ungefähr 74.000 neue Fälle und über 45.000 Todesfällen wegen des mehrfachen myeloma jedes year.(2) bestimmt

Das JahrtausendfeiercOnkologiecVorrecht

Jahrtausendfeier wird am Ausüben von Onkologie als Kernvorrechtbereich festgelegt und weiht bedeutende Betriebsmittel und Fähigkeiten in den Bereichen der Technologie, wissenschaftliche Sachkenntnis, klinische Entwicklung und strategische geschäftliche Entwicklung ein. Zu diesem Zweck wird Jahrtausendfeier auf Aufnahme von Fremdmitteln seine Sachkenntnis, in den Kinasen, in der proteasome Bahn und im Zielen der monoclonal Antikörper gerichtet, und hat bereits eine tiefe Rohrleitung produziert, die von den mehrfachen Romanzielen bis zu einem in den Handel gebrachten therapeutischen Produkt reicht. Gegenwärtige klinische Programme schließen VELCADE(TM) (bortezomib) für Einspritzung, ein Untersuchungs, das kleine Molekül der Erst-inkategorie mit ein, das entworfen wird, um das proteasome zu hemmen. Unter den vorgerücktesten klinischen Mitteln zusätzlich zu VELCADE sind MLN518, MLN591RL, MLN2704 und MLN576 (XR11576). Campath® (alemtuzumab), ein therapeutisches entwickelt von einer ehemaligen Joint Venture von Millennium und ILEX Oncology, Inc., ist in den Vereinigten Staaten und in einer Anzahl von europäischen Ländern im Handel erhältlich.

Über Jahrtausendfeier

Millennium Pharmaceuticals, Inc., eine führende biopharmaceutical Firma, Co fördert Einspritzung INTEGRILIN® (eptifibatide), eine führende Therapie des Marktes für Patienten mit akutem kranzartigem Syndrom und hat eine robuste klinische Entwicklungsrohrleitung der Produktanwärter. Der die Forschung Firma, die Entwicklung und die Kommerzialisierungtätigkeiten werden in vier Krankheitbereichen fokussiert: Herzgefäß-, Onkologie, Entzündung und metabolisches. Indem sie sein Wissen des menschlichen Genoms, seines führenden Verständnisses der Krankheiteinheiten und seiner industrialisierten Technologieplattform anwendet, entwickelt Jahrtausendfeier Durchbruch personifizierte Medizinprodukte. Hauptsitz gehabt in Cambridge, Masse. Jahrtausendfeier hat auch Service in Südsan Francisco, in Calif. und in Cambridge, Großbritannien.

Dieses Pressekommuniqué enthält "das Vorwärts-Schauen von Aussagen," einschließlich der Aussagen über unser Wachstum und zukünftiges Betriebsergebnis, Entdeckung und Entwicklung der Produkte, möglichen Erwerb, strategischen Bündnisse und geistiges Eigentum. Verschiedene Gefahren können die tatsächlichen Resultate der Firma veranlassen, sich materiell zu unterscheiden und umfassen: nachteilige Resultate unserem Drogeentdeckung und klinische Entwicklungsprozesse; Störung, Patentschutz für unsere Entdeckungen zu erreichen; kommerzielle Beschränkungen erlegten durch die Patente auf, die durch dritte Beteiligte besessen wurden oder gesteuert waren; unsere Abhängigkeit nach den strategischen Bündnispartnern zum sich Entwickeln und In den Handel bringen Produkte und Dienstleistungen basiert auf unserer Arbeit; Schwierigkeiten oder verzögert, wenn sie Genehmigungen durch die zuständige Aufsichtsbehörde erreichen, um Produkte und Dienstleistungen zu vermarkten, resultierend aus unseren Entwicklungsbemühungen; der kommerzielle Erfolg der Einspritzung INTEGRILIN® (eptifibatide); unsere Fähigkeit, die umwandelbaren Anmerkungen auszulöschen angenommen im COR-Erwerb; und die Anforderung für die erhebliche Finanzierung zum Leiten Forschung und Entwicklung und Erweitern von Kommerzialisierungtätigkeiten. Mit für eine weitere Liste und Beschreibung die Gefahren und Ungewißheiten von stellen wir gegenüber, von sehen die Reports, die wir die Aktien und Austauschkommission vorgelegt haben. Wir dementieren jede mögliche Absicht oder Verpflichtung, irgendwelche Vorwärts-schauenden Aussagen zu aktualisieren oder zu verbessern, ob resultierend aus neuen Informationen, zukünftige Fälle oder anders.


mfg
phedre

[Aeppler]

Was du Wolle? Ich nix Achmet!

Meine Güte, ist das ein Gegatze.

Stell lieber den englischen Text rein, dieses Deutsch hilft den meisten warscheinlich noch weniger weiter.

Aber danke für Deine Mühe!

@eppler

[Boersenkrieger]

Naja zum schmunzeln isser ja...
mal sehen was uns "Jahrtausendfeier" noch einbringt

[Boersenkrieger]

und nicht vergessen !!! KAUFEN !!! MLNM =

[JS222]

EquityOutlook.com Announces Stock Evaluation Ratings: New Ratings on Nextel Communications, QUALCOMM, JP Morgan Chase &Co, Comcast Corporation, Millennium Pharmaceuticals
via COMTEX

December 25, 2002

SHREVEPORT, La., Dec 25, 2002 (BUSINESS WIRE) --

EquityOutlook.Com (IARD#118718) - www.equityoutlook.com - evaluates the following stocks: (Get FREE ratings at http://www.equityoutlook.com/index.htm)

Nextel Communications (NASDAQ:NXTL) - Outperform QUALCOMM (NASDAQ:QCOM) - Underperform JP Morgan Chase &Co (NYSE:JPM) - Underperform Comcast Corporation (NASDAQ:CMCSK) - Outperform Millennium Pharmaceuticals (NASDAQ:MLNM) - Underperform WHAT THESE RATINGS MEAN:
These stocks are rated with a proprietary system of technical analysis. These ratings do not indicate a `long term`view of any company listed. These are ratings that indicate our opinion of a stock`s PRICE movement versus the SP 500 over the short term. `Mainstream wallstreet`implores traders to `buy and hold.`This strategy proves at times to be DISASTROUS. We believe that traders should find entry and exit positions over the short term to take profits or conserve capital. These ratings reflect our opinion as of the first trading day of the week. These ratings may change based on daily market conditions.

Investors can find more ratings at: www.equityoutlook.com/index.htm

Investors that want a TRULY unbiased stock rating service should visit: http://www.equityoutlook.com/reports.htm

Disclaimer: EquityOutlook.Com (a StockLogix.Com, LLC company) is a registered investment adviser in the State of Louisiana (IARD#118718). No information accessed through the EquityOutlook.Com, or any link contained on the EquityOutlook.Com Web site, constitutes a recommendation by EquityOutlook.Com to buy, sell or hold any security, financial product, or instrument discussed therein. Information accessed through linked sites neither is, nor should be construed as, an offer, or a solicitation of an offer, to buy or sell securities by EquityOutlook.Com. EquityOutlook.Com does not hold positions in securities being discussed in this news release and/or mentioned on the EquityOutlook.Com Web site. Investors shall be fully responsible for any investment decisions they make, and such decisions will be based solely on their evaluation of their financial circumstances, investment objectives, risk tolerance and liquidity needs. Investors are encouraged to consult with their registered broker and/or investment adviser before making any investment decision.

EquityOutlook.Com Chester T. Kelley, 318/212-0640 TICKERS: NASDAQ:NXTL

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2002 Business Wire. All rights reserved.

JS200

[Phedre]

Hallo
neue news auf englisch.

Millennium Initiates Phase II Clinical Trial with VELCADE™ (bortezomib) for Injection in Patients with Colorectal Cancer
– First phase II Company-sponsored trial in solid tumors –
Cambridge, Mass., (December 30, 2002) - Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the recent initiation of a phase II clinical trial of VELCADE in patients with colorectal cancer. The randomized, open-label study will assess the response rates of patients with refractory metastatic colorectal cancer to treatment with VELCADE alone or VELCADE plus Camptosar® (irinotecan hydrochloride injection). VELCADE is currently in a phase III study in patients with multiple myeloma and a range of phase I and II clinical trials in patients with hematologic and solid tumors.
We have seen encouraging preclinical and early clinical results with bortezomib in solid tumors that have provided the scientific basis to initiate this phase II study," said principal study investigator David P. Ryan, M.D., from Massachusetts General Hospital. These preliminary results have shown that the combination of bortezomib plus irinotecan at full doses was well tolerated and did not appear to exacerbate the most problematic side effects commonly seen with this standard chemotherapy agent.
VELCADE is designed to specifically block proteasomes, which are enzyme complexes in the cell responsible for breaking down a variety of proteins, including many that regulate cell division. In preclinical studies, inhibition of the proteasome has shown to lead to the disruption of cell cycle progression, resulting in cancer cell death (apoptosis). VELCADE is the first and only proteasome inhibitor currently in clinical trials for treating cancer.
The clinical trial is being conducted at approximately 20 sites in North America in up to 175 patients with colorectal cancer whose disease has progressed following treatment with no more than two prior chemotherapeutic regimens. Up to 75 patients will be randomized to a treatment arm of VELCADE™ (bortezomib) for Injection alone and up to 100 patients to a combination arm consisting of VELCADE and Camptosar. The primary endpoint of the study is tumor response.
The initiation of this phase II trial represents not only an important milestone in the development of VELCADE, but further emphasizes our commitment to growing the Millennium oncology franchise, said Barry Greene, general manager, oncology franchise at Millennium. The early data we have seen from our various phase I combination trials hold promise for the further expansion of our solid tumor program and we are continuing to aggressively pursue the development of VELCADE in solid tumors.
Recent VELCADE™ (bortezomib) for Injection News
Millennium presented results from two phase II studies of VELCADE at the recent American Society of Hematology (ASH) meeting. In addition, Millennium recently announced that the Company intends to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Agency for the Evaluation of Medicinal Products (EMEA) for the use of VELCADE to treat relapsed and refractory multiple myeloma by early 2003.
For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at [phone].
About Colorectal Cancer
The American Cancer Society estimates that there will be approximately 148,300 new cases of colorectal cancer in 2002 in the United States. Colorectal cancer is estimated to cause over 56,000 deaths each year. Although primary colorectal cancer is responsive to therapy if diagnosed and treated at an early stage, advanced metastatic colorectal cancer is less responsive to various chemotherapies.
The Millennium Oncology Franchise
Millennium is committed to pursuing oncology as a core franchise area, dedicating significant resources and capabilities in the areas of technology, scientific expertise, clinical development, and strategic business development. To this end, Millennium is focused on leveraging its expertise in kinases, the proteasome pathway, and targeting monoclonal antibodies, and has already produced a deep pipeline that ranges from multiple novel targets to a commercialized therapeutic product. Current clinical programs include VELCADE, an investigational, first-in-class small molecule designed to inhibit the proteasome. Among the most advanced clinical compounds in addition to VELCADE are MLN518, MLN591RL, MLN2704 and MLN576 (XR11576). Campath® (alemtuzumab), a therapeutic developed from a former joint venture of Millennium and ILEX Oncology, Inc., is commercially available in the United States and a number of European countries.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co-promotes INTEGRILIN® (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.
This press release contains "forward-looking statements," including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause Millennium`s actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN® (eptifibatide) Injection; our ability to extinguish the convertible notes assumed in the COR acquisition; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

[die_null]

Millenium, oje ... the last Dreck

[Boersenkrieger]

neee du null,
MLNM ist schon super. nur die anleger sind zu doof das zu merken. aber seit ende der 90er ist börse sowieso nur noch irre.

[Isabartels]

Null kann halt kein Englisch. Da kann man dann natürlich nur dumm labern!

[Boersenkrieger]

genau, war doch eine erwartete nett nachricht... der soll isch lieber zero nennen

Grüße vom Share-warrior

[Boersenkrieger]

Preis-Buchwert 0,79 !!!
Also unter Buchwert fallen eigentlich nur Aktien die in einem Marktbereich tätig sind wo ein deutlicher Rückgang erwartet wird, wo die Finanzlage angespannt ist (MLNM hat 1,8 Mrd $ Cash ), oder Firmen deren Reputation schlecht ist, MLNM hat Koopereationen en masse.... Verstehe das wer will, ich halte das für eine absolute Fehleinschätzung des Marktes. Daß der Markt ja nicht immer recht hat wissen wir ja seit 2000... bzw man muß eben warten bis er recht hat

[JS222]

JP Morgan H&Q 21st Annual Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation
via COMTEX

December 30, 2002

CAMBRIDGE, Mass., Dec 30, 2002 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced today that its presentation to the JP Morgan H&Q 21st Annual Healthcare Conference will be webcast live and may be accessed by visiting the investor relations section the Company`s website, www.millennium.com.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Mark Levin, chairperson and chief executive officer of Millennium, will provide an overview of the company and review corporate goals for 2003. His presentation will be delivered at 10:00 a.m. (Pacific Time) on Monday, January 6, 2003 from the Westin St. Francis Hotel in San Francisco. The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass. Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

Editor`s Note: This release is available on Millennium`s website at www.millennium.com

Contact: Cynthia Clayton, Investor Relations Millennium Pharmaceuticals, Inc. [phone] MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X58194504
SOURCE Millennium Pharmaceuticals, Inc.

Cynthia Clayton, Investor Relations of MillenniumPharmaceuticals, Inc., [phone]/Company News On-Call: http://www.prnewswire.com/gh/cnoc/comp/114562.html/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, 888-776-6555 or 212-782-2840
http://www.millennium.com


JS200

[greenhorn1998]

Hallo zusammen!

Im Biotech-World-Board wird die Möglichkeit diskutiert, dass Millennium vor der Übernahme von Xoma steht. Ein großes Aktienpaket sei bereits gekauft worden, Millennium besitzt wohl eine Option auf weitere Anteile. Was haltet ihr davon?

Gruß, greenhorn

[Phedre]

Hallo!

Genaissance Pharmaceuticals Enters Into HAP(TM) Technology License Agreement With Millennium Pharmaceuticals
Tuesday January 7, 7:01 am ET


NEW HAVEN, Conn., Jan. 7 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has licensed its HAP(TM) Technology to Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) for use in its drug discovery and development programs. Under the terms of the non-exclusive, multi-year agreement, Millennium will pay Genaissance license fees. Genaissance will have certain rights to support Millennium`s DNA biomarker and pharmacogenomic efforts.
"We are pleased to enter into this agreement with Millennium, as they have a track record of using leading edge technology for new product development," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "We look forward to developing a strong relationship with our colleagues at Millennium."

"As a leading biopharmaceutical company, Millennium is committed to personalized medicine, and we believe Genaissance`s technology will allow us to accelerate our work in integrating DNA markers into clinical development and pharmaceutical products," said Geoff Ginsburg, M.D., Ph.D., Vice President of Molecular Medicine, Millennium Pharmaceuticals.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance currently has agreements with six of the top pharmaceutical and biotechnology companies: AstraZeneca, Biogen, Johnson & Johnson PRD, Millennium, Pfizer and Pharmacia. Genaissance is located in Science Park in New Haven, Connecticut.

This press release contains forward-looking statements, including statements about the ability of Genaissance to apply its technologies to the development, marketing and prescribing of drugs. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to in such statements, including, but not limited to, the extent to which genetic markers (haplotypes) are predictive of drug efficacy and safety, the attraction of new business and strategic partners, the adoption of our technologies by the pharmaceutical industry, the timing and success of clinical trials, competition from pharmaceutical, biotechnology and diagnostics companies, the strength of our intellectual property rights and those risks identified in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 7, 2002 and our Quarterly Reports on Form 10-Q for the quarter ended June 30, 2002 and September 30, 2002 filed with the Securities and Exchange Commission on August 14, 2002 and November 14, 2002, respectively. The forward-looking statements contained herein represent the judgment of Genaissance as of the date of this release. Genaissance disclaims any obligation to update any forward-looking statement.

mfg
Phedre

[js200]

@GREENHORN

Meinst du dieses hier


XOMA Receives $7.5 Million From Millennium Under Existing Development Arrangement
23 Dec 2002, 7:01pm ET
E-mail or Print this story
- - - - -

BERKELEY, Calif.--(BUSINESS WIRE)--Dec. 23, 2002--XOMA Ltd.
(Nasdaq:XOMA) announced today that it has issued approximately
1,443,000 shares to Millennium Pharmaceuticals, Inc. for gross
proceeds of approximately $7.5 million, pursuant to their existing
collaboration and investment arrangement announced in November of
2001. Under the investment agreement, Millennium remains committed to
purchase, at XOMA`s option, up to an additional $37.5 million of
XOMA`s common shares over the next 18 months, at then prevailing
market prices.
"We are pleased to have the funding mechanism with Millennium that
provides us with this cash infusion and for up to an additional $37.5
million, should we opt to use it," said Peter B. Davis, XOMA`s Vice
President and Chief Financial Officer. "This gives us a committed
source of cash as we proceed with the Raptiva(TM) approval process and
our other development efforts."
The new shares have been registered with the Securities and
Exchange Commission for re-sale by Millennium under an effective
registration statement on Form S-3. Nothing herein should be deemed to
be an offer to sell or a solicitation of an offer to buy any
securities. Any sales under the aforementioned registration statement
must be accompanied by a prospectus, which can be obtained from
Millennium.

About XOMA

JS200

[Isabartels]

GLOBAL BIOTECH INVESTING

Millennium Pharma kaufen Datum: 07.01.2003


Die Experten des Börsenbriefs "Global Biotech Investing" empfehlen die Millennium Pharma-Aktie mit "kaufen". (WKN 900625) Das Unternehmen habe 18 Wirkstoffe in klinischen Testphasen. Hinzu kämen 20 Produkte, die sich in der vorklinischen Phase, der Basisforschung, befänden. In diesem Jahr werde Millennium Pharma bereits eine Mrd. US-Dollar umsetzen. Allerdings werde für dieses und das kommende Jahr noch ein Verlust ausgewiesen werden, da die Gesellschaft jeden Cent in die Forschung stecke. Klar kalkulierbare Rahmenbedingungen seien die extrem spannende Produktpipeline und die 1,2 Mrd. US-Dollar Cash. Die Empfehlung der Experten der "Global Biotech Investing" für Millennium Pharma lautet "kaufen" unter 8 US-Dollar.




Quelle: AKTIENCHECK.DE AG

[didiprotein]

@isa
Hallo!Ich halte sehr viel von MLNM und glaube auch das sie gute Chancen haben den Sprung zu den ganz großen Biotechs zu schaffen.Auch einen Kauf auf jetzigen Niveau kann ich eigentlich nicht wiedersprechen.Nur was diese teuren Biotech-Briefe schreiben(Biotech-Report und GBI hatte ich selber lange abboniert)kann ich nicht mehr für gut heißen.Seit nunmehr 2 Jahren geben sie immer wieder Kaufempfehlungen mit den gleichen Argumenten.MLNM z.B.wurde auch bei über 30€ zumKauf empfohlen.Einziger Trost ist das sie mittlerweile nicht mehr groß daneben liegen können,mit ihren Empfehlungen.
gruß dp

[Isabartels]

Hallo Didi,
da hast Du nicht ganz unrecht. Aber auf dem jetzigen Niveau(ich habe bei 7,91 Euro massiv gekauft) kann man, wenn man etwas Geduld hat nicht mehr viel falsch machen.
Gruß
Isa

[ReblausfromAustria]

Millennium im Dornröschenschlaf?

Ich beobachte diese Aktie nun schon seit mehr als einem
halben Jahr und frage mich, warum sich dort kaum was tut.
Jetzt notiert sie schon wieder zu einem Wert, der sogar unter den Cash-Beständen liegt.

[didiprotein]

@isa
Hi!Wenn MLNM nicht irgendwelche Leichen im Keller versteckt hat (was ich natürlich nicht glaube)kann man normalerweise mit einem längeren Anlagehorizonzt nichts verkehrt machen.Gäbe es die politischen Spannungen nicht wäre ich in MLNM schon drin(das gleiche gilt auch für MEDX).So warte ich noch ab,werde aber auf jeden Fall noch kaufen.
gruß dp

[js200]

company news

--------------------------------------------------------------------------------

MLNM - Millennium Pharmaceuticals, Inc. (NASDAQ NM : MLNM)

--------------------------------------------------------------------------------
RATING(=): Ryan Beck Keeps AMGN, MLNM @ Outperform



TUESDAY , JANUARY 07, 2003 12:41 PM

Company: Amgen Inc. (NasdaqNM: AMGN)

Brokerage Firm: Ryan, Beck & Co

Rating Action: Reiteration

Rating: Outperform

Target Price: $65

Source: Briefing.com

********************************************************************

Company: Millennium Pharmaceuticals, Inc. (NasdaqNM: MLNM)

Brokerage Firm: Ryan, Beck & Co

Rating Action: Reiteration

Rating: Outperform

Target Price: $23

Source: Briefing.com

JS200

[js200]

01/07/2003 (12:41 ET) RATING(=): Ryan Beck Keeps AMGN, MLNM @ Outperform - Knobias
01/07/2003 (09:28 ET) PREMARKET: GNSC Licensed HAP Tech to MLNM - Knobias
01/07/2003 (07:01 ET) Genaissance Pharmaceuticals Enters Into HAP(TM) Technology License Agreement With Millennium Pharmaceuticals - PR Newswire
01/06/2003 (12:00 ET) Cardiovascular Conference to Feature Latest Drug Discovery & Development Research on February 10-11, 2003 in San Diego, CA. - PR Newswire
01/06/2003 (11:42 ET) MLNM CEO to Speak at JP Morgan Health Conference Today - Knobias


JS200

[Phedre]

Hallo
was meint ihr, wie lange werde die den kurs noch unten halten.
Das is ja nicht zu aushalten.

[sevenclever]

wenn keiner mehr zahlen möchte, dann bleibt der Kurs unten
Angebot und Nachfrage...
Oder sind zu viele SHORT

SettlementDate / ShortInterest
Dec. 13, 2002 / 11,483,512
Nov. 15, 2002 / 11,192,266
Oct. 15, 2002 / 11,844,929
Sep. 13, 2002 / 11,702,346
Aug. 15, 2002 / 12,896,457
Jul. 15, 2002 / 10,073,767
Jun. 14, 2002 / 9,079,770
May 15, 2002 / 9,898,390
Apr. 15, 2002 / 8,886,643

Wer bietet 10 EUR

seven

[js200]

company news

--------------------------------------------------------------------------------

MLNM - Millennium Pharmaceuticals, Inc. (NASDAQ NM : MLNM)

--------------------------------------------------------------------------------
Firms, Managers Respond to Bush Proposal to Drop Taxes on Dividends



WEDNESDAY, JANUARY 08, 2003 03:08 AM

Jan 08, 2003 (The Boston Globe - Knight Ridder/Tribune Business News via COMTEX) -- Within hours of President Bush`s proposal yesterday to eliminate the tax on dividends, corporate America responded: Clear Channel Communications, the nation`s biggest radio broadcaster, announced that it would consider for the first time instituting a dividend if Congress approves the plan.

Hundreds of companies likely would follow suit, and many that already return a portion of their profits to shareholders would undoubtedly increase their dividends. More companies, in short, would be paying bigger dividends in a world without the tax.

There`s no question that would be good news for investors who like dividends, and would like them even more without a federal tax. Less clear is whether a new obsession with dividends would be healthy for the stock market and for the corporations that sell their stock to the public.

"From management`s viewpoint, the impact of all this is a little muddy," said Charles Carlson, editor of the DRIP Investor newsletter, which focuses on dividend reinvestment plans.

"Now you`ve put managers in kind of an interesting bind," he said.

"Are they going to sacrifice investing for the future to give investors the dividends they will now want, just to boost stock prices? Investors will be clamoring for that excess capital."

Not everyone shares that assessment, of course.

Corporate America has long complained about the "double taxation" of dividends, with both companies and shareholders paying taxes on corporate profits.

Likewise, investor groups dislike that capital gains are taxed at a lower rate than are dividends.

Those two factors combined during the bull market of the 1990s to dramatically reduce the number of companies that pay dividends. Even since a slight increase in the number of dividend-paying companies last year, four out of five stocks trading on the major exchanges do not return profits to shareholders that way.

The list of companies in Massachusetts that pay significant dividends reads like a who`s who of the old economy: Athol toolmaker L.S. Starrett, workplace clothing manufacturer Unifirst, shoemaker Stride Rite Corp., and NStar, the electric utility, for example, along with most banks.

The high-tech companies and those in fast-growing industries such as biotechnology -- EMC Corp., Teradyne, Genzyme, Millennium Pharmaceuticals -- traditionally have shunned dividends so they can plow earnings back into new products.

Companies that would have paid dividends in previous decades instead collected large cash holdings totaling billions of dollars. They will be under the most pressure to begin offering a dividend soon, Carlson said.

"Companies such as Cisco Systems can make much less of a compelling case that it needs all that money for growth opportunities when they aren`t growing right now," he said. "Now the double-taxation argument is taken away, too, so why not give investors some of that money back?"

Ed Killen, manager of the Berwyn Income mutual fund, which focuses on dividend-paying stocks, said the proposed change would make life easier for corporate managers.

As it stands now, he said, companies are pressured not to pay a dividend because of the double-taxation argument. That puts pressure on companies to reinvest the money for growth or to buy back shares of stock, when at times it makes more sense to give investors a share of the profits.

Eliminating the dividend tax would give corporate managers another option, he predicted.

"We`re living in a world where we already have overcapacity in many industries," Killen said. "So it doesn`t always make sense for companies to invest in even more capacity. [Eliminating the tax] adds a little bit of reality, a little bit of balance, to the corporate decision-making process."

In his speech to the Economic Club of Chicago yesterday, President Bush focused as much on whether it was right to tax dividends as he did on the fiscal impact.

"It`s fair to tax a company`s profits," he said. "It`s not fair to double-tax by taxing the shareholder on the same profits."

Critics dismiss that argument, and say the plan is simply a giveaway to the richest Americans, who tend to pay the most in investment-related taxes.

But on Wall Street, the proposal was met with immediate approval this week.

As word leaked out about the plan, share prices in the first three trading days of the year skyrocketed, with the major market indexes rising more than 5 percent apiece. Dividend-paying stocks benefited the most from the rally, following a pattern that has become typical over the past 18 months as investors search for stocks with some sort of guaranteed income.

The markets paused yesterday and finished largely unchanged, but Killen predicted that over the long run the elimination of the dividend tax would be a positive influence on stock prices. It could, he said, induce a variety of companies to begin offering dividends, including those in industries such as high tech and biotech.

"More of those companies will start paying dividends, which I think will stimulate demand and put more money into consumer hands," Killen said. "That`s a good thing."

By Scott Bernard Nelson

To see more of The Boston Globe, or to subscribe to the newspaper, go to
http://www.boston.com/globe


(c) 2003, The Boston Globe. Distributed by Knight Ridder/Tribune Business News.

JS200

[js200]

http://www.boston.com/globe/

JS200

[js200]

Vom Freitag

MLNM
MILLENNIUM PHARMACEUTICALS INC
8.670
+0.390 +4.71%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 12/11/2002 (30) days ago, when the stock price was 9.440. Since then the stock fell -8.16% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. The volume is low. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and the buying pressure was strong. Be careful, this may be a potential turning point!

Stock Quote
Last 8.670
Previous Close 8.280
Change +0.390
% Change +4.71%
Volume 3,350,128
Stock Activity
Open 8.260
Day`s High 8.720
Day`s Low 8.100
52 Week High 25.280
52 Week Low 7.191

Stock Price History
3 Month % Change -4.30
6 Month % Change -6.97
12 Month % Change -62.48
Stock Statistics
50 Day Close MA 8.927
200 Day Close MA 12.335
65 Day Volume MA 5,145,067

JS200

[Phedre]

Hallo!


Millennium Pharmac. chancenreich Datum: 13.01.2003


Die Analysten von "TradeCentre.de" halten die Aktie von Millennium Pharmaceuticals für ein chancenreiches Investment. (WKN 900625) Mit einer Marktkapitalisierung von 2,5 Mrd. USD zähle Millennium Pharma bereits zu den Blue-Chips der Branche. Das Unternehmen sei auf Erkrankungen wie Krebs, Asthma und Fettleibigkeit spezialisiert. Zu den bedeutendsten Kooperationspartnern gehörten Firmen wie Roche, Bayer oder American Home Produkts. Millennium habe über 18 Produkte in den klinischen und ca. 20 in den vorklinischen Phasen. Erfolgreiche Zulassungen könne das Unternehmen ebenfalls vorzeigen. Insgesamt seien es fünf, darunter befänden sich "Integrilin" und "Campath". Beide Medikamente würden erfolgreich zur Behandlung von Lymphdrüsenkrebs eingesetzt. "MLN 341" (Velcade) sowie "MLN 518" hätten von der FDA den "fast track"-Status erhalten, welcher eine beschleunigte Entwicklung und Vermarktung ermögliche. "MLN 341" (Velcade) gehöre zur Gruppe der Proteasom-Inhibitoren und befinde sich in den Phasen II und III. Zu der zweit häufigsten Art von Blutkrebs zähle das Multiple Myelom. In den USA würden jährlich mehr als 11.000 Menschen daran sterben. Dieses Jahr wolle das Unternehmen fast 500 Mio. USD an Umsatz generieren. Auf Grund von weiteren Entwicklungskosten würden die Verluste in 2003 auf 300 Mio. USD steigen. Das Erreichen der Gewinnschwelle sei weiter das oberste Ziel, welches Ende 2004 geschafft werden solle. Der Marktabsatz von Integrilin solle 2003 um 20% auf 365 Mio. USD steigen. In den Kassen würden 1,8 Mrd. USD Cash lauern. Alleine der Buchwert liege bei 10,5 USD. Laut den Aussagen des UK General Manager sei Millennium kein Übernahmeziel, da die Firma durch viele weltweite Kooperationen mit Pharmaunternehmen abgesichert sei. Die Aktie befinde sich seit Ende Oktober in einem flachen Aufwärtstrend den sie kontinuierlich fortsetze. Die am Freitag gebildete weiße Kerze bestätige dies. Die Experten von "TradeCentre.de" raten Anlegern eine erste Positionen an Millennium Pharmaceuticals-Aktien auf aktuellem Niveau aufzubauen, wenn die Aktie den Aufwärtstrend bei ca. 8 USD erfolgreich testet. Ein Stopp sei unter dem Tief bei 7 USD zu setzen. Die Aktie habe die Chance bei erfolgreicher Zulassung von Velcade auf 20 USD zu steigen.


mfg
Phedre

[LMeister7]

Hallo,
ich glaube die Jungs aus dem vorherigen Posting sind ein ganz klein wenig zu optimistisch. MLNM selbst sieht den Break erst in 2006. Andere Zahlen was Cash und Buchwert anbelangt habe ich auch schon gesehen. Vielleicht war`n da ja ein paar übermütige Analpraktikanten am Werk?!
http://quotes.freerealtime.com/rt/frt/N?symbol=MLNM&art=C200…
Nichts für ungut, bin selber seit 7,83€ wieder dabei. Konnte nicht wiederstehen.
MfG,
LM7

[js200]

company news

--------------------------------------------------------------------------------

MLNM - Millennium Pharmaceuticals, Inc. (NASDAQ NM : MLNM)

--------------------------------------------------------------------------------
Talking-Points.com: Talking-Points.com announces new investment opinions on Advanced Micro Devices, Inc., Commerce One, Inc., Cable & Wireless PLC, Millennium Pharmaceuticals Inc., NorthWestern Corporation and OM Group, Inc



MONDAY , JANUARY 13, 2003 11:08 AM

Los Angeles, CA., Jan 13, 2003 (M2 PRESSWIRE via COMTEX) -- Talking-Points.com - http://www.talking-points..com/content.html - Announces Investment Opinion on Advanced Micro Devices, Inc. (NYSE:AMD), Commerce One, Inc. (Nasdaq: CMRC), Cable & Wireless PLC (NYSE: CWP), Millennium Pharmaceuticals Inc. (Nasdaq: MLNM), NorthWestern Corporation (NYSE: NOR) and OM Group, Inc. (NYSE: OMG).

(For the complete research reports on these stocks, sign up for the Talking Points Premium Edition at http://www.talking-points.com/signup.html)

Advanced Micro Devices, Inc. (NYSE:AMD) - Buy

Commerce One, Inc. (Nasdaq: CMRC) - Buy

Cable & Wireless PLC (NYSE: CWP) - Strong Buy

Millennium Pharmaceuticals Inc. (Nasdaq: MLNM) - Buy

NorthWestern Corporation (NYSE: NOR) - Strong Buy

OM Group, Inc. (NYSE: OMG) - Buy

WHAT THESE RATINGS MEAN:

These stocks are rated with an unbiased system of technical and fundamental analysis.

These ratings are meant as short-term opinions for active traders. Each week, market newsletter Talking Points releases 3-6 "Fresh Picks" for the week ahead in its Premium Edition publication. Signup for the Premium Edition at http://www.talking-points.com/signup.html.

Disclaimer:

1. We are not brokers, investment advisors, or securities dealers. Our newsletter is provided as our personal opinions and is for informational purposes only.

2. Information on our website may contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.

3. Always research your own investments, and consult your investment advisor before investing.

4. Visit the Securities Exchanges Commission website and read about how to avoid internet scams.

5. Understand that we at Talking-Points.com may buy stock in the companies that we recommend in our newsletter, and may sell those shares after recommending them.

6. Small-cap companies, micro-cap companies, penny stocks and/or thinly traded shares are highly risky and volatile investments. You risk losing some or all of the money you invest.

7. We disclose any and all compensations received from companies profiled or mentioned on the site in accordance with the 1933 Securities Act Section 17 (b).

Our Picks

The stocks profiled on Talking-Points.com are only the opinions of Talking-Points.com and its representatives. These opinions are based on our research, which may be extensive or limited, done on each individual stock.

Our sources include, but are not limited to, online research, company profiles, member suggestions, past performance, magazines, newspapers, analyst suggestions, broker recommendations, contact with the company, company rumors, and other similar information sources. All opinions are based on information that is accessible by the public.

CONTACT: Greg Fry, Publisher, Talking-Points.com Tel: [phone]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].



(C)1994-2003 M2 COMMUNICATIONS LTD


-0-


JS200

[js200]

MLNM
MILLENNIUM PHARMACEUTICALS INC
9.010
+0.340 +3.92%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 12/11/2002 (33) days ago, when the stock price was 9.440. Since then the stock fell -4.56% .

Today the stock closed higher with a higher high and a higher low. The volume is normal. The security price is trending sideways.



Click here to get a full trend analysis of this stock Candlestick Analysis


Today’s Candlestick Patterns:
Spinning Top


Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bears and a potential change or interruption in the current trend!





Stock Quote
Last 9.010
Previous Close 8.670
Change +0.340
% Change +3.92%
Volume 4,276,424
Stock Activity
Open 8.944
Day`s High 9.170
Day`s Low 8.700
52 Week High 25.280
52 Week Low 7.191


Stock Price History
3 Month % Change -7.11
6 Month % Change -14.19
12 Month % Change -58.48
Stock Statistics
50 Day Close MA 8.959
200 Day Close MA 12.269
65 Day Volume MA 5,140,105

JS200

[js200]

01/13/2003 (11:08 ET) Talking-Points.com: Talking-Points.com announces new investment opinions on Advanced Micro Devices, Inc., Commerce One, Inc., Cable & Wireless PLC, Millennium Pharmaceuticals Inc., NorthWestern Corporation and OM Group, Inc - M2 Communications
01/10/2003 (11:06 ET) EquityOutlook.Com: New ratings on Millennium Pharmaceuticals, Circuit Cty Strs Inc, The AES Corporation, Bed Bath & Beyond Inc - M2 Communications
01/10/2003 (09:19 ET) New SC 13G/A just released for MLNM - Edgar
01/08/2003 (03:08 ET) Firms, Managers Respond to Bush Proposal to Drop Taxes on Dividends - Knight Ridder
01/07/2003 (12:41 ET) RATING(=): Ryan Beck Keeps AMGN, MLNM @ Outperform - Knobias

[js200]

Despite Sagging Economy, MIT Sloan `Massachusetts Tech Trek`Draws Record Number of MBAs, Companies
via COMTEX

January 14, 2003

CAMBRIDGE, Mass., Jan 14, 2003 (BUSINESS WIRE) --

More than 110 MBA students from the MIT Sloan School of Management will visit more than 50 companies as part of the fifth annual Massachusetts Tech Trek, held January 15-17. The Trek enables students from MIT Sloan to meet with senior executives from local technology firms to learn about their businesses operations and strategy. Despite a challenging economy and a tough hiring environment, the 2003 Massachusetts Tech Trek has drawn a record number of both students and companies, indicating that even in bad times, companies are interested in hiring qualified people to drive future growth.

Students will visit the offices of a variety of companies in the fields of hardware, software, consumer technology, wireless, communications, and biotechnology. Participating companies include Bose, EMC, Cisco, PTC, Genzyme, and Millennium Pharmaceuticals, as well as emerging companies such as SpeechWorks, edocs, UPromise, and Alkermes. Students will also visit several venture capital firms, including Polaris, YankeeTek, Flagship, and North Bridge.

`We are absolutely thrilled with the number of leading technology and biotechnology companies who agreed to be part of this Trek,`said Chris Lee, MBA `04, who led the organizing team. `Not only did we get great companies, but almost all of them agreed to provide senior executives to meet with us. I think the record number of students participating reflects the high quality of the meetings.`

The Massachusetts Tech Trek is a completely student-run event, organized by the very active MediaTech Club at MIT Sloan. The event is sponsored by Hale and Dorr LLP, Comerica, and the MIT Biomedical Enterprise Program.

`It`s important for students to gain exposure to the people who are actually practicing the critical lessons taught in the classroom,` said Phil Rossetti, senior partner at Hale and Dorr LLP. `We are delighted to be part of this valuable networking and educational experience.`

The company visits will be complemented by a networking event, January 16, 6-9 p.m., at the offices of Atlas Venture and Castile Ventures (media invited- http://www.sloanmediatech.org/massinvite). In addition to the MBAs, executives from the Trek companies will be in attendance, as well as individuals from the Greater Boston technology, life sciences, and venture community.

`By sponsoring the networking function, we give students the opportunity to learn first-hand from senior executives what skills and methods are necessary to survive in this competitive economic environment,`said Parag Shah, senior vice president at Comerica Bank. `The vision of these executives and the stories of their experience provide critical guidance to students planning a career in the Massachusetts technology or life sciences industries.`

The goal of the Tech Trek is not only to introduce students to good companies and fascinating technologies, but to also provide students with an opportunity to obtain gainful employment for both summer internships and full-time employment after graduation.

`As someone who moved to Boston to attend MIT Sloan and plans to work in the Boston technology community after graduation, the Tech Trek provides a great opportunity for me to get a lay of the land and meet some of the key players in the industry,`said Brad Terrell, MBA `04.

For fifty years the MIT Sloan School of Management, based in Cambridge, Mass., has been one of the world`s leading academic sources of innovation in management. The School`s mission is to develop principled, innovative leaders who improve the world and to generate ideas that advance management practice.

Students available for interviews--contact Paul Denning

MIT Sloan School of Management Paul Denning, 617/253-0576 [e-mail] or Justin Steinman, 617/283-8097 MBA Class of 2004 [e-mail]

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.

JS200

[Phedre]

Millenniums Ausblick für 2003

Für 2003 erwartet Millennium den neuesten Angaben zufolge
einen höheren Umsatz, gleichzeitig meldete das
Management aber eine Ausweitung der Verluste, die auf
höhere Forschungs- und Entwicklungskosten zurückzuführen
seien. Die Umsätze für Integrilin werden im
laufenden Geschäftsjahr zwar um 20% auf $65 Millionen
anziehen, dies wird aber nicht ausreichen, die hohen
Ausgabe im Bereich F&E zu kompensieren. Trotz der positiven
Nachricht, die klinischen Versuche voranzutreiben,
um potenzielle Wirkstoffe so schnell wie möglich auf
den Markt zu bringen, gibt es im Ausblick von Millennium
dennoch einen Wermutstropfen. Die hohen Ausgaben
werden nämlich dazu beitragen, dass Millennium den
"Breakeven" vom Jahr 2004 in das Jahr 2006 verlegen
muss. Im Jahr 2005 soll der Umsatz mit Integrilin zwar wie
geplant die $500 Millionendollar-Grenze erreicht haben,
doch dies wird nicht ausreichen, um Millennium in die
Profitabilität zu katapultieren. Deshalb setzt man große
Hoffnungen in das neue Produkte Velcade, dass beim
Multiplen Myelom bereits ermutigende Daten liefern
konnte und sich hoffentlich auch bei anderen Tumoren als
wirksam erweisen kann.
Noch in diesem Quartal will Millennium den Zulassungsantrag
für Velcade auf Basis von Phase II Daten bei der
FDA einreichen. In klinischen Studien der Phase II konnte
sich Velcade bei der Therapie des Multiplen Myeloms als
besonders wirksam erweisen und wird deshalb bereits auf
seine Wirksamkeit bei anderen soliden Tumoren getestet.
Eine Vielzahl von Studien ist bereits auf den Weg gebracht
und weitere sind bereits geplant. Die Investoren
scheinen sich mittlerweile an die steigenden Ausgaben
von Millennium gewöhnt zu haben, der Kurs der Aktie
blieb nach dem Ausblick auf jeden Fall stabil. Die diesjährige
Performance der Aktie wird jedoch stark mit den
weiteren Ergebnissen von Velcade korreliert sein. Sollte
es gelingen, einen starken Vermarktungspartner für das
Produkt zu finden sowie eine Zulassung zur Behandlung
des Multiplen Myeloms in den USA zu erhalten, dürfte
Millennium erst einmal aus dem Schneider sein.
Die Ergebnisse, die Velcade in todkranken Patienten in
einer Phase II Studie erzielen konnte, machen zuversichtlich,
dass die FDA der vorgezogenen Zulassung tatsächlich
zustimmen könnte. Kritisch ist allerdings, dass
Millennium Velcade nicht im Vergleich zur Standardtherapie
getestet hat, es wurde lediglich die Überlebenszeit
unter Velcade mit der unter herkömmlicher Therapie verglichen.
Die dabei ermittelte Steigerung der durchschnittlichen
Überlebensrate von 6 auf 16 Monate ist allerdings
sehr ermutigend, da frühere Therapiestudien gezeigt hatten,
dass beim Multiplen Myelom eine Korrelation zwischen
der Überlebensrate und der Ansprechrate auf ein
Medikament besteht.
Dennoch ist zur Zeit noch Vorsicht geboten wenn es um
ein Investment bei Millennium geht, wer auf Nummer
sicher gehen will, verlässt sich nicht nur auf eine baldige
Therapiemöglichkeit für das Multiple Myelom, sondern
wartet die Studien zur Behandlung anderer bösartiger
Tumoren ab. Sollte Velcade lediglich gegen das Multiple
Myelom zum Einsatz kommen, ist nur ein Umsatzvolumen
von einigen hundert Millionen Dollar zu erwarten, im Falle
einer Wirksamkeit auch bei anderen Tumoren, könnte das
Produkt tatsächlich das von Millennium prognostiziert
Blockbuster-Potenzial besitzen.

mfg
phedre

[Phedre]

Hallo!

Die Experten des Anlegermagazins "Der Aktionär" bewerten die Millennium-Aktie mit "dabei bleiben". (WKN 900625) In der vergangenen Woche habe die Gesellschaft eine Gewinnwarnung für das laufende Geschäftsjahr 2003 veröffentlicht. Millennium rechne zwar mit einem leichten Umsatzanstieg, doch die Kosten für Forschung und Entwicklung seien stärker gestiegen als zunächst prognostiziert. Auf diese Meldung habe der Markt gelassen reagiert. Die Experten von "Der Aktionär" empfehlen bei Millennium dabeizubleiben.

mfg
phedre

[js200]

Millennium Initiates Phase II Clinical Trial With Velcade(TM) (Bortezomib) for Injection fn Patients With Advanced Non-Small Cell Lung Cancer
via CDS

January 15, 2003

Company-Sponsored Trial Will Evaluate VELCADE Alone and in Combination With Taxotere(R) --



CAMBRIDGE, Mass., Jan. 15 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the initiati on of a phase II clinical trial of VELCADE in patients with stage IIIb (locally advanced) or stage IV (metastatic) non-small cell lung cancer (NSCLC). The randomized, open-label study will assess response rates of patients with previously treated NSCLC to treatment with VELCADE alone or VELCADE plus Taxotere (docetaxel). VELCADE is currently being investigated in a phase III study in patients with multiple myeloma and a range of phase I and II clinical trials in patients with hematologic and solid tumors.

`We are excited to be starting this phase II trial with VELCADE because of the significant unmet medical need in NSCLC,`said Robert Belt, M.D., of Oncology and Hematology Associates of Kansas City, MO, the first investigator to enroll and dose a patient in this study. `We are hopeful that the outcome of this trial with VELCADE will provide a new treatment option for patients with NSCLC who have exhausted other therapies.`

VELCADE(R) (bortezomib) for Injection is designed to specifically block proteasomes, which are enzyme complexes in the cell responsible for breaking down a variety of proteins, including many that regulate cell division. In preclinical studies, inhibition of the proteasome has been shown to lead to the disruption of cell cycle progression, resulting in cancer cell death (apoptosis). VELCADE is the first and only proteasome inhibitor currently in clinical trials for treating cancer.

The clinical trial is being conducted at up to 20 sites in North America in approximately 155 patients with stage IIIb or IV, relapsed or refractory NSCLC. Up to 75 patients will be randomized to a treatment arm of VELCADE alone and up to 80 patients to a combination arm consisting of VELCADE and docetaxel. The primary endpoint of the study is tumor response as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.

`The initiation of this trial in patients with NSCLC, our second company- sponsored phase II trial in solid tumors, is based on promising data from preclinical and phase I clinical solid tumor studies with VELCADE,`said Barry Greene, general manager, oncology at Millennium. `Millennium is committed to strategically and expeditiously growing the VELCADE solid tumor program and anticipates reporting activity in up to four tumor types by the end of 2003.`



Recent VELCADE News

Millennium presented results from two phase II studies of VELCADE in multiple myeloma at the recent American Society of Hematology (ASH) meeting. In addition, Millennium recently announced that the Company intends to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Agency for the Evaluation of Medicinal Products (EMEA) for the use of VELCADE to treat relapsed and refractory multiple myeloma in the first quarter of this year. The Company also recently initiated a phase II trial with VELCADE in patients with metastatic colorectal cancer.



For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at [phone].



About Non-Small Cell Lung Cancer

According to the American Cancer Society, lung cancer is the leading cause of cancer death among both men and women in the United States. Approximately 157,200 deaths will be attributed to lung cancer and 171,900 new cases will be diagnosed in 2003. Of those, 80% will be NSCLC. There are three sub-types of NSCLC, including Squamous Cell Carcinoma, Adenocarcinoma, and Large-cell Undifferentiated Carcinoma. The five-year survival rate for all stages of NSCLC combined is 15%. If NSCLC is diagnosed and treated early with surgery before spreading to the lymph nodes or other organs, the average five-year survival rate improves to 50%. However, it is estimated that only 15% of people with lung cancer are diagnosed at an early stage.



The Millennium Oncology Franchise

Millennium is committed to pursuing oncology as a core franchise area, dedicating significant resources and capabilities in the areas of technology, scientific expertise, clinical development, and strategic business development. To this end, Millennium is focused on leveraging its expertise in kinases, the proteasome pathway, and targeting monoclonal antibodies, and has already produced a deep pipeline that ranges from multiple novel targets to a commercialized therapeutic product. Among the Company`s most advanced clinical compounds in addition to VELCADE(R) (bortezomib) for Injection are MLN518, MLN591RL, MLN2704 and MLN576 (XR11576). Campath(R) (alemtuzumab), a therapeutic developed from a former joint venture of Millennium and ILEX Oncology, Inc., is commercially available in the United States and a number of European countries.



About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, the Company is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., the Company also has facilities in South San Francisco, Calif. and Cambridge, UK.



This press release contains `forward-looking statements,`including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause the Company`s actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN(R) (eptifibatide) Injection; our ability to extinguish the convertible notes assumed in the COR acquisition; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Taxotere(R) is a registered trademark of Aventis Pharmaceuticals.

Campath(R) is a registered trademark of ILEX Pharmaceuticals, L.P.



Editors`Note: This release is also available on the Company`s website at: http://www.millennium.com


JS200

[schakal23]

wir kann bitte auf deutsch das mal überzetsen
was mit velcade ist danke

[skaya]

@schakal23
hi, hier eine Übersetzung von altavista.


Jahrtausendfeier leitet Phase II klinischen Versuch mit Velcade(TM) (Bortezomib) für Einspritzung fn Patienten mit vorgerücktem Nicht-Kleinem Zelle Lungenkrebs über CDS ein Januar 15, 2003 Firma-Geförderter Versuch wertet VELCADE alleine und im Verbindung mit Taxotere(R) aus -- CAMBRIDGE, Mass., Jan. 15/PRNewswire-FirstCall/-- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) verkündete heute das initiati an eines Phase II klinischen Versuches von VELCADE bei Patienten mit Stadium IIIb (am Ort vorgerückt) oder Stadium IV (metastatic) nicht-kleinem Zelle Lungenkrebs (NSCLC). Die randomisierte, open-label Studie setzt Ansprechgeschwindigkeiten der Patienten mit vorher behandeltem NSCLC zur Behandlung mit alleincVelcade oder VELCADE plus Taxotere fest (docetaxel). VELCADE wird z.Z. in einer Phase III Studie bei Patienten mit mehrfachem myeloma und einer Strecke Phase I und II klinische Versuche bei Patienten mit den hämatologischen und festen Tumoren nachgeforscht. ` werden wir aufgeregt, diesen Phase II Versuch mit VELCADE wegen der bedeutendes unmet medizinischen Notwendigkeit in NSCLC, `said Robert Riemen, M.D. zu beginnen, der Onkologie-und Hämatologie-Teilnehmer der Kansas Stadt, MO, der erste Forscher, einen Patienten in dieser Studie einzuschreiben und zu dosieren. ` sind wir hoffnungsvoll, daß das Resultat dieses Versuches mit VELCADE eine neue Behandlungwahl für Patienten mit NSCLC versieht, die anderes therapies.` erschöpft haben VELCADE(R) (bortezomib) für Einspritzung wird entworfen, um proteasomes, die Enzymkomplexe in der Zelle, die für sind das Brechen hinunter eine Vielzahl der Proteine verantwortlich ist, einschließlich vieler spezifisch zu blockieren, die Zelle Abteilung regulieren. In den preclinical Studien ist Hemmung vom proteasome gezeigt worden, um zu die Unterbrechung der Zelle Zyklusweiterentwicklung zu führen, und das resultiert im Krebszelle Tod (apoptosis). VELCADE ist das erste und nur das proteasome Hemmnis z.Z. in den klinischen Versuchen für das Behandeln des Krebses. Der klinische Versuch wird an bis 20 Aufstellungsorten in Nordamerika bei ungefähr 155 Patienten mit Stadium IIIb geleitet, oder IV, zurückgefallenes oder refraktäres NSCLC. bis zu 75 Patienten wird zu einem Behandlungarm von VELCADE alleine und bis 80 Patienten zu einem Kombination Arm randomisiert, der aus VELCADE und docetaxel besteht. Der Primärendpunkt der Studie ist Tumorantwort, wie durch die Warteauswertung Kriterien in den festen Richtlinien der Tumoren (RECIST) festgesetzt. ` die Einführung dieses Versuches bei Patienten mit NSCLC, unser zweite Firma geförderter Phase II Versuch in den festen Tumoren, basiert auf vielversprechenden Daten von den preclinical und Phase I klinischen festen Tumorstudien mit VELCADE, `said Barry Greene, Generaldirektor, Onkologie an der Jahrtausendfeier. ` Jahrtausendfeier wird an das VELCADE feste festgelegt Tumorprogramm, strategisch und prompt, wachsend und das Berichten über Tätigkeit in bis vier Tumorarten Ende 2003.` vorwegnimmt Neue VELCADE Nachrichten Jahrtausendfeier stellte Resultate von Zweiphasen-Studien II von VELCADE im mehrfachen myeloma an der neuen amerikanischen Gesellschaft der Sitzung der Hämatologie (ASCHE) dar. Zusätzlich verkündete Jahrtausendfeier vor kurzem, daß die Firma beabsichtigt, einen neuen Droge-Antrag (NDA) mit der VEREINIGTE STAATEN Nahrung zu stellen und Droge-Leitung (FDA) und eine Marketing-Ermächtigung Anwendung (MAA) mit der europäischen Agentur für die Auswertung der medizinischen Produkte (EMEA) für den Gebrauch VELCADE zur Festlichkeit fiel und refraktäres mehrfaches myeloma im ersten Viertel dieses Jahres zurück. Die Firma auch leitet vor kurzem einen Phase II Versuch mit VELCADE bei Patienten mit metastatic colorectal Krebs ein. Zu mehr Information über VELCADE klinische Versuche, können Patienten und Ärzte mit der Jahrtausendfeier-medizinischen Produktinformation Abteilung an [phone] in Verbindung treten.

Grüße
Skaya

[schakal23]

@skaya
danke

ist doch kein schlechte nachricht warum reagiert der kurz
so negativ?

[sevenclever]

schau dir die letzten Tage an.
Wenn du jetzt noch nicht drin bist
sehe ich heute eine gute Chance.

Solltest du welche zu 8.4-8.5 EUR bekommen.
Auf jeden Fall absichern!!!!

!!ACHTUNG!!
Die Amis machen immer zum Wochenende hin Kasse!!!
MLNM ist nicht einfach zu Traden

Bin unter 8 EUR rein. Deshalb mach ich mir
nicht so viele Sorgen.

Das ist keine Verkauf/Kauf Empfehlung
ich bin schon drin

[js200]

StockPickReport.Com: New ratings on Millennium Pharmaceuticals, Clear Channel Comm Inc, Wachovia Corp, Sonicblue Inc, Dow Chemical Co
via COMTEX

January 16, 2003

Jan 16, 2003 (M2 PRESSWIRE via COMTEX) --

`http://www.stockpickreport.com/?src=bw `}http://www.stockpickreport.com/?src=bw ) makes these stock evaluations for the short term:

Millennium Pharmaceuticals (NASDAQ:MLNM) - Outperform {HYPERLINK `http://www.stockpickreport.com/?src=mlnm" target="_blank" rel="nofollow ugc noopener">http://www.stockpickreport.com/?src=mlnm `}http://www.stockpickreport.com/?src=m lnm

Clear Channel Comm Inc (NYSE:CCU) - Outperform {HYPERLINK `http://www.stockpickreport.com/?src=ccu" target="_blank" rel="nofollow ugc noopener">http://www.stockpickreport.com/?src=ccu `}http://www.stockpickreport.com/?src=cc u

Wachovia Corp (NYSE:WB) - Underperform {HYPERLINK `http://www.stockpickreport.com/?src=wb `}http://www.stockpickreport.com/?src=wb

Sonicblue Inc (NASDAQ:SBLU) - Outperform {HYPERLINK `http://www.stockpickreport.com/?src=sblu" target="_blank" rel="nofollow ugc noopener">http://www.stockpickreport.com/?src=sblu `}http://www.stockpickreport.com/?src=s blu

Dow Chemical Co (NYSEOW) - Underperform {HYPERLINK `http://www.stockpickreport.com/?src=dow" target="_blank" rel="nofollow ugc noopener">http://www.stockpickreport.com/?src=dow `}http://www.stockpickreport.com/?src=do w

WHAT THESE RATINGS MEAN: StockPickReport.Com ranks stocks with a proprietary unbiased system of technical analysis.

These ratings do not indicate a `long term`view of any company listed. These are ratings that reflect our opinion of a stock`s PRICE movement versus the SP 500 over the short term. These ratings may change based on daily market conditions.

You can get a FREE trial at: {HYPERLINK `http://www.stockpickreport.com/?src=bw `}http://www.stockpickreport.com/?src=bw

ABOUT STOCKPICKREPORT.COM: StockPickReport.Com is a stock research firm. Our daily commentary has regular, worldwide distribution. We are Registered Investment Advisors.

We do not accept third-party compensation to make stock suggestions. We do not accept advertising. We do not own shares of any stock we rate.

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.

StockPickReport.Com`s goal is to provide stock research FREE from bias or conflicts. You can get your FREE trial to StockPickReport.Com at {HYPERLINK `http://www.stockpickreport.com/?src=bw `}http://www.stockpickreport.com/?src=bw

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2003 M2 COMMUNICATIONS LTD


JS200

[schakal23]

ich habe das gefunden die haben eine menge for dieses jahr




POST OF THE DAY
Millennium Pharmaceuticals
Looking Forward to 2003?
Email this page
Format for printing
Become a Fool!
Reuse/Reprint



Related Links
Archive

Join Us!

TMF Money Advisor




Discussion Boards
Millennium Pharmaceuticals





By Caesium
January 16, 2003

Posts selected for this feature rarely stand alone. They are usually a part of an ongoing thread, and are out of context when presented here. The material should be read in that light. How are these posts selected? Click here to find out and nominate a post yourself!


There has been a spate of drug candidates entering trials in the past 6 weeks, and a financial outlook from the Company putting back profitability until 2006, and I though it might be an opportune time to open a thread and discuss what we expect from Millennium in terms of achievemen, and what we expect from our investment in them this year.

If we start with their pipeline, 2003 promises to be a very busy year.


MLN01 Phase I due to report now – Xoma responsible for taking into Phase II is they do so.
MLN02 - Phase II expected completion in February – Expect to be discontinued
MLN4760 – Phase I trial results due March 2003
Velcade – Breast cancer Phase I trials results due May 2003
MLN518 – Acute Myeloid Leukemia *(Fast track status) Phase I results due May 2003
MLN576 – Solid Tumors Phase I trials results due June 2003
Velcade – Multiple Myeloma expect FDA news around June 2003
Velcade – Leukemia Phase II results due July 2003
Velcade – Hematological malignancies Phase II results due sometime in 2003
Velcade – Solid Tumors Ongoing phase II trial results due sometime in 2003
MLN591RL – Prostate Cancer Phase II results expected end 2003/early 2004
Integrilin – Coronary Heart Bypass graft Phase III trials results due December 2003
With this amount of trial activity coming to the end of each stage in 2003, there is little wonder that profitability is being pushed back. The sheer expense of all of these trials, (and of course we want them all to move onto the next stage), requires a massive outlay of cash from MLMN`s coffers. Expect a large cash drain this year and into next year.


Their Balance sheet is going to look pretty dire, and their cash flow even worse; in all likelihood their stock price will not look pretty this time next year, if people focus only upon the numbers. There will be little in the way of increased revenues to shore up the deteriorating sets of numbers. Integrilin will continue to ramp up sales and will get a boost if the phase III trials currently underway for heart bypass obtain approval, but that will not be reflected until 2004 at least. Some revenue increase will be forthcoming from the expected approval of Velcade for Multiple Myeloma but not much more than $30m, if that, in 2003 accounts. Longer term, with a market size of only 15,000 in the US and approx. 25,000 in Europe, this alone will not become a blockbuster.

Further encouraging news on Velcade trial results will help keep the share price from freefalling, conversely any bad news on Velcade will have a predictable result on the share price.

One piece of news that only Jat4 here on this board has focused upon is the advice from MLNM that they are actively looking for partners for the marketing of their drug portfolio. They already have their (140 or so) sales force for Integrilin, and in the past we have discussed them expanding that as new drugs found their way to approval. Clearly MLNM have changed tack on this issue, at least for now with Velcade.
They have now seen the need to look for marketing partners, presumably as they realize they cannot afford their own sales force when it comes to the sheer numbers required to market potential blockbuster drugs.

Well at least we now know that MLNM, despite their vaunted leadership and expertise cannot buck basic economics, and consequently any profits gained from blockbuster drugs will be shared with their marketing partner, whoever that may be. My hope as a PFE owner as well as MLNM would be Pfizer, who boasts the best sales force in the Pharma industry. I am sure Joseph`s hope is that it will be Abbot; my bridge partners husband also work for Abbot so I guess I wouldn`t mind either. Or it could be Aventis, already a partner in drug development and stronger in Europe(?). Perhaps they might be a better fit. Or it might be someone completely new to MLNM, (although I doubt it).

Whoever they choose will not affect the 2003 performance in any direct way, although it will impact down the road as to how they share the revenues. If any deal is announced in 2003 look to see how favorable it is to each partner. In the past MLNM were lauded for their deal making ability, it will be interesting to see how good a deal they squeeze for themselves now they NEED a deal. Ultimately they will run out of cash if they don`t.

Aside from the above, my own personal musings relate to their lack of respect to you and me as their shareholders. I am far too much committed to them to sell them for such a reason, but I am very disappointed in them nonetheless.

For me, looking through 2003 when we are sat at $8-$9 a share in January, my conclusion is there is far too much upside compared to downside at these price levels. Their pipeline looks tremendous, at least 11 trial results due in 2003, Integrilin continues increasing sales and we should have Velcade on the market by end of 2003, assuming MLNM management`s confidence in receiving FDA approval is not completely misled. As always it is translating that pipeline into revenues that counts, and we will have to wait until 2004 for that to begin to happen.

All in all, another waiting year. But aside from the brush off from them, a year with more anticipation than previous years. This will not be the "break out" year, but we might see the commencement of positions from the big institutions towards the end of the year if we hear nothing but good news. Absent that and we are looking at muddling along at these levels; perhaps a little move back to the $11-$12 mark on the back of Velcade, but nothing much more IMHO.

Comments and critiques are always welcome.

Caesium



--------------------------------------------------------------------------------


Become

[js200]

@SCHAKAL 23

Ich glaube, dass bei MLNM ein 12 Monatsziel von 16-18 Dollar erreicht werden können.

Meine Meinung

Die Pipline liegt gerammelt voll

JS200

[js200]

Von Gestern ( Sieht gut aus!!!!!!!!! )

MLNM
MILLENNIUM PHARMACEUTICALS INC
8.980
+0.130 +1.47%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 1/15/2003 (1) days ago, when the stock price was 8.850. Since then the stock gained 1.47% .

Today the stock closed higher with a lower high and a higher low (sign of decrease in volatility). The volume is normal. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Spinning Top

Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bulls and a potential change or interruption in the current trend!

Stock Quote
Last 8.980
Previous Close 8.850
Change +0.130
% Change +1.47%
Volume 4,324,596
Stock Activity
Open 8.920
Day`s High 9.320
Day`s Low 8.870
52 Week High 25.280
52 Week Low 7.191

Stock Price History
3 Month % Change 16.93
6 Month % Change -19.03
12 Month % Change -56.26
Stock Statistics
50 Day Close MA 9.044
200 Day Close MA 12.082
65 Day Volume MA 5,132,050

JS200

[js200]

01/16/2003 (14:57 ET) S-8: MLNM Registers 14.5M Shares for Incentive Plan - Knobias
01/16/2003 (14:52 ET) New S-8 just released for MLNM - Edgar
01/16/2003 (11:26 ET) StockPickReport.Com: New ratings on Millennium Pharmaceuticals, Clear Channel Comm Inc, Wachovia Corp, Sonicblue Inc, Dow Chemical Co - M2 Communications
01/16/2003 (09:37 ET) RATING(=): Ryan, Beck & Co Keep MLNM @ Outperf, $23 TP - Knobias
01/16/2003 (06:18 ET) Millennium starts phase II trial of Velcade in advanced non-small cell lung cancer patients - Datamonitor


JS200

[js200]

company news

--------------------------------------------------------------------------------

MLNM - Millennium Pharmaceuticals, Inc. (NASDAQ NM : MLNM)

--------------------------------------------------------------------------------
S-8: MLNM Registers 14.5M Shares for Incentive Plan



THURSDAY , JANUARY 16, 2003 02:57 PM

Millennium Pharmaceuticals, Inc. (Nasdaq NM: MLNM) filed an S-8 during Thursday’s session.

The Company is registering 14,554,711 shares of common stock issuable under its 2000 Stock Incentive Plan.

As of November 11, 2002 there were 287,785,551 shares of common stock outstanding.

JS200

[js200]

company news

--------------------------------------------------------------------------------

MLNM - Millennium Pharmaceuticals, Inc. (NASDAQ NM : MLNM)

--------------------------------------------------------------------------------
RATING(=): Ryan, Beck & Co Keep MLNM @ Outperf, $23 TP



THURSDAY , JANUARY 16, 2003 09:37 AM

Company: Millennium Pharmaceuticals, Inc. (NasdaqNM: MLNM)

Analyst Firm: Ryan, Beck & Co

Rating Action: Coverage Reiterated

Rating: Outperform

12-Month Target Price: $23

Source: Briefing.com

JS200

[schakal23]

ich kaufe wen die krieg anfänget oder wen die krieg ängste vorbei sind auf beide seiten denke bin ich gut bedient?
oder

[js200]

EquityOutlook.Com: New ratings on Millennium Pharmaceuticals, Circuit Cty Strs Inc, The AES Corporation, Bed Bath &Beyond Inc
via COMTEX

January 17, 2003

Jan 17, 2003 (M2 PRESSWIRE via COMTEX) --

following stocks: (Get FREE ratings at {HYPERLINK `http://www.equityoutlook.com/index.htm `}http://www.equityoutlook.com/index.htm)

Millennium Pharmaceuticals (NASDAQ:MLNM) - Outperform

Circuit Cty Strs Inc (NYSE:CC) - Outperform

The AES Corporation (NYSE:AES) - Outperform

Bed Bath &Beyond Inc (NASDAQ:BBBY) - Underperform

WHAT THESE RATINGS MEAN: These stocks are rated with a proprietary system of technical analysis. These ratings do not indicate a `long term`view of any company listed. These are ratings that indicate our opinion of a stock`s PRICE movement versus the SP 500 over the short term.

`Mainstream wallstreet`implores traders to `buy and hold.`This strategy proves at times to be DISASTROUS. We believe that traders should find entry and exit positions over the short term to take profits or conserve capital. These ratings reflect our opinion as of the first trading day of the week. These ratings may change based on daily market conditions.

Investors can find more ratings at: {HYPERLINK `http://www.equityoutlook.com/index.htm `}http://www.equityoutlook.com/index.htm Investors that want a TRULY unbiased stock rating service should visit: {HYPERLINK `http://www.equityoutlook.com/reports.htm `}http://www.equityoutlook.com/reports.htm

Disclaimer: EquityOutlook.Com (a StockLogix.Com, LLC company) is a registered investment adviser in the State of Louisiana (IARD#118718). No information accessed through the EquityOutlook.Com, or any link contained on the EquityOutlook.Com Web site, constitutes a recommendation by EquityOutlook.Com to buy, sell or hold any security, financial product, or instrument discussed therein. Information accessed through linked sites neither is, nor should be construed as, an offer, or a solicitation of an offer, to buy or sell securities by EquityOutlook.Com. EquityOutlook.Com does not hold positions in securities being discussed in this news release and/or mentioned on the EquityOutlook.Com Web site. Investors shall be fully responsible for any investment decisions they make, and such decisions will be based solely on their evaluation of their financial circumstances, investment objectives, risk tolerance and liquidity needs. Investors are encouraged to consult with their registered broker and/or investment adviser before making any investment decision.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2003 M2 COMMUNICATIONS LTD

JS200

[BonMala]

ich bin schon seit 8,5 wieder raus.
Irgendwie wollen sie in Deutschland nicht so richtig....

[lukoil007]

wieso nur in deutschland? der kurs will einfach nicht gen norden, bin seit 2 monaten investiert und warte auch auf bessere zeiten.(siehe märz 2002)

[js200]

EquityOutlook.Com: New ratings on Linear Technology Corp, American Internat Group, Millennium Pharmaceuticals, Rite Aid Corp
via COMTEX

January 20, 2003

Jan 20, 2003 (M2 PRESSWIRE via COMTEX) --

following stocks: (Get FREE ratings at {HYPERLINK `http://www.equityoutlook.com/index.htm `}http://www.equityoutlook.com/index.htm)

Linear Technology Corp (NASDAQ:LLTC) - Underperform American Internat Group (NYSE:AIG) - Outperform Millennium Pharmaceuticals (NASDAQ:MLNM) - Outperform Rite Aid Corp (NYSE:RAD) - Underperform

WHAT THESE RATINGS MEAN: These stocks are rated with a proprietary system of technical analysis. These ratings do not indicate a `long term`view of any company listed. These are ratings that indicate our opinion of a stock`s PRICE movement versus the SP 500 over the short term.

`Mainstream wallstreet`implores traders to `buy and hold.`This strategy proves at times to be DISASTROUS. We believe that traders should find entry and exit positions over the short term to take profits or conserve capital. These ratings may change based on daily market conditions.

Investors can find more ratings at: {HYPERLINK `http://www.equityoutlook.com/index.htm `}http://www.equityoutlook.com/index.htm Investors that want a TRULY unbiased stock rating service should visit: {HYPERLINK `http://www.equityoutlook.com/reports.htm `}http://www.equityoutlook.com/reports.htm

Disclaimer: EquityOutlook.Com (a StockLogix.Com, LLC company) is a registered investment adviser in the State of Louisiana (IARD#118718). No information accessed through the EquityOutlook.Com, or any link contained on the EquityOutlook.Com Web site, constitutes a recommendation by EquityOutlook.Com to buy, sell or hold any security, financial product, or instrument discussed therein. Information accessed through linked sites neither is, nor should be construed as, an offer, or a solicitation of an offer, to buy or sell securities by EquityOutlook.Com. EquityOutlook.Com does not hold positions in securities being discussed in this news release and/or mentioned on the EquityOutlook.Com Web site. Investors shall be fully responsible for any investment decisions they make, and such decisions will be based solely on their evaluation of their financial circumstances, investment objectives, risk tolerance and liquidity needs. Investors are encouraged to consult with their registered broker and/or investment adviser before making any investment decision.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2003 M2 COMMUNICATIONS LTD

JS200

[js200]

Millennium Submits New Drug Application for VELCADE(TM) (Bortezomib) for Injection
via COMTEX

January 22, 2003

CAMBRIDGE, Mass., Jan 22, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that it has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for approval to market VELCADE as a treatment for relapsed and refractory multiple myeloma. In June 2002, VELCADE was granted fast-track status by the FDA as having the potential to treat a serious, life- threatening condition and address an unmet medical need. The NDA was submitted under the provisions of Subpart H - Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses.

The NDA filing for VELCADE is based primarily on the results of the Company`s phase II SUMMIT clinical trial, a multi-center study which included 202 patients with relapsed and refractory multiple myeloma. The results of this trial were presented in full at the December 2002 meeting of the American Society for Hematology.

`The submission of this NDA represents a significant milestone for Millennium and an important step toward fulfilling our mission of making novel treatment options available to patients with significant unmet medical needs,` said Robert Tepper, M.D., president, research and development at Millennium. `Since the initial VELCADE patient dosing just over four years ago, we have been committed to the thorough and expeditious clinical development of VELCADE and are proud that this strategy has resulted in an accelerated filing.`

Orphan Product Designation

VELCADE(TM) (bortezomib) for Injection has also received Orphan Product Designation from the FDA for multiple myeloma. Orphan Product Designation is granted for treatments that may provide significant benefit to patients with serious life-threatening diseases that have a prevalence of no more than 200,000 patients in the U.S. Upon FDA approval of the product, Orphan Product Designation provides seven-year marketing exclusivity in the U.S.

Recent VELCADE News

Millennium recently initiated two phase II trials with VELCADE; one in patients with metastatic colorectal cancer and another in patients with advanced non-small cell lung cancer. In addition, the Company has an ongoing international, multi-center, phase III (APEX) trial of VELCADE in patients with multiple myeloma as well as several phase I/II trials in patients with various hematologic and solid tumors. The Company also plans to initiate additional phase I/II studies later this year.

VELCADE is designed to specifically block the proteasome, which is an enzyme complex in cells responsible for breaking down a variety of proteins, including many that regulate cell division. In preclinical studies, inhibition of the proteasome has been shown to lead to the disruption of cell cycle progression, resulting in cancer cell death (apoptosis). VELCADE is the first and only proteasome inhibitor currently being evaluated in clinical trials for the treatment of cancer.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at [phone].

About Multiple Myeloma

Multiple myeloma is a cancer of the bone marrow in which white blood cells called plasma cells, normally responsible for the production of antibodies (proteins that fight infection and disease), are overproduced. The proliferation of these abnormal plasma cells, known as myeloma cells, causes decreased production of normal red and white blood cells, and of normal disease-fighting antibodies, as well as the growth of tumors that spread to multiple sites - hence the term multiple myeloma. The decreased white blood cell production damages the immune system while the myeloma tumors cause bone destruction that manifests as pain and fractures.

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and younger age of onset. In the United States, more than 40,000 individuals have multiple myeloma and over 14,000 new cases of the disease are diagnosed each year. Worldwide there are approximately 74,000 new cases and more than 45,000 deaths due to multiple myeloma each year.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, the Company is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., the Company also has facilities in South San Francisco, Calif. and Cambridge, UK.

This press release contains `forward-looking statements,`including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause our actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN(R) (eptifibatide) Injection; our ability to extinguish the convertible notes assumed in the COR acquisition; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editors`Note: This release is also available on the Company`s website at: www.millennium.com

Contacts: Steve Sylven (media) Gina Price Nugent (investor) [phone] [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Steve Sylven (media), [phone], or Gina Price Nugent (investor), [phone], both for Millennium Pharmaceuticals, Inc. /Company News On-Call: http://www.prnewswire.com/comp/114562.html

http://www.millennium.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

Millennium to Webcast Conference Call on Year End and Fourth Quarter 2002 Financial Results On January 28, 2003
via COMTEX

January 22, 2003

CAMBRIDGE, Mass., Jan 22, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) will hold a live webcast of its conference call at 5:00 p.m. EST on Tuesday, January 28, 2003. Mark Levin, chairperson and chief executive officer will host the call. He will discuss the Company`s year-end and fourth quarter results for 2003, as well as provide an overview of the Company`s business strategy and goals for 2003. Millennium will announce its financial results for this period in a press release to be issued after market close on Tuesday, January 28, 2003.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The press release and the live webcast can be accessed by visiting the Company`s website, www.millennium.com, under the `Investor Relations`tab. Following the webcast, an archived version of the call will be available at the same address until February 11, 2003.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

Editor`s Note: This release is also available on the Company`s website at: http://www.millennium.com

Contact: Cynthia Clayton Millennium Pharmaceuticals, Inc. [phone]

SOURCE Millennium Pharmaceuticals, Inc.,

Cynthia Clayton of Millennium Pharmaceuticals, Inc., [phone]/Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, 888-776-6555 or 212-782-2840/Company News On-Call: http://www.prnewswire.com/comp/114562.html
http://www.millennium.com


JS200

[schakal23]

wir kann dazu was sagen?






By Adam Feuerstein
Senior Writer
01/28/2003 05:50 PM EST
Click here for more stories by Adam Feuerstein


Losses narrowed at Millennium Pharmaceuticals (MLNM:Nasdaq - news - commentary - research - analysis) in the fourth quarter, although revenue came in a bit lighter than expectations.

The Cambridge, Mass.-based company reported a fourth-quarter net loss, based on generally accepted accounting principles, of $79.7 million, or 28 cents per share, compared to a net loss of $67 million, or 30 cents per share, in the year-ago quarter.


Excluding certain charges, Millennium lost $66.9 million, or 23 cents per share, in the fourth quarter. The results beat Wall Street`s consensus expectation by 4 cents per share, according to Thomson Financial/First Call.

Total revenue for the quarter was $96.8 million, lighter than the $104 million expected by Wall Street analysts.

Breaking it down, fourth-quarter total sales of the drug Integrilin rose 21% to $81.1 million, of which Millennium records $47.9 million as revenue from a co-marketing agreement with Schering-Plough. For the year, Integrilin sales grew 32% to $303.7 million, matching the company`s previous guidance.

So-called strategic-alliance revenue -- money paid to Millennium by drug development partners -- totaled $49 million in the fourth quarter and $193 million for the year. Millennium previously warned that 2002 strategic-alliance revenue would come up short of the previous guidance of $250 million, forcing the company to post a wider 2002 net loss.

Millennium was able to exceed expectations in the fourth quarter, in part, by recording $37.5 million in realized gains from its investment portfolio.

For the year, Millennium said its pro forma net loss grew to $256.3 million, or 92 cents per share, compared to a pro forma net loss of $124.9 million, or 57 cents per share, in 2001.

Looking forward, Millennium reiterated the 2003 outlook given at the recent J.P. Morgan H&Q health care conference earlier this month. The highlights: Total revenue for 2003 to be in the range of $450 million to $475 million. Integrilin sales are forecast to grow 20% to $365 million. The company is forecasting a pro forma net loss in 2003 in the range of $290 million to $320 million, excluding anticipating restructuring charges of $60 million to $80 million.

Based on 288 million shares outstanding, that net loss works out to a range of $1.01 to $1.11 per share. Analysts are currently looking for Millennium to lose $1.04 per share in 2003.

Millennium shares closed Tuesday up 4% to $8.35.

[filuta]

wäre es möglich in deutsch? danke Ambra

[skaya]

@filuta
hi, hier die Übersetzung von altavista
abel Fish Translation, Auf Deutsch:

EST hier für mehr Geschichten durch Adam Feuerstein Verluste verengten
an den Jahrtausendfeier-pharmazeutischen Produkten (MLNM:Nasdaq -
Nachrichten - Kommentar - Forschung - Analyse) im 4. Viertel, obgleich
Einkommen in ein Spitze Feuerzeug als Erwartungen kam. Das
Cambridge, meldete Mass.-based Firma einen Reinverlust des 4. vor
Viertels, basiert auf im Allgemeinen geltenden Bilanzierungsgrundsätzen,
von $79,7 Million oder 28 Cents pro Anteil, verglichen mit einem
Reinverlust von $67 Million oder 30 Cents pro Anteil, am Jahr Viertel.
Ausschließlich bestimmter Aufladungen verlor Jahrtausendfeier $66,9
Million oder 23 Cents pro Anteil, am 4. Viertel. Die Resultate schlugen
Wand Street`s Übereinstimmung Erwartung durch 4 Cents pro Anteil,
entsprechend Thomson Financial/First Anruf. Gesamteinkommen für das
Viertel war $96,8 Million, Feuerzeug als die $104 Million, die von den Wall
Street Analytikern erwartet wurden. Es unten brechend, stiegen
Gesamtverkäufe des 4. Viertels der Droge Integrilin 21% bis $81,1 Million,
von denen Jahrtausendfeier $47,9 Million als Einkommen von einer
Co-Marketing Vereinbarung mit Schering-Pflug notiert. Für das Jahr
wuchsen Integrilin Verkäufe 32% bis $303,7 Million und brachten die
company`s vorhergehende Anleitung zusammen. Sogenanntes
Strategischbündnis Einkommen -- Geld zahlte zur Jahrtausendfeier durch
Drogeentwicklung Partner -- zusammengezählt $49 Million im 4. Viertel
und $193 Million für das Jahr. Jahrtausendfeier warnte vorher, daß
Strategischbündnis Einkommen 2002 herauf Kurzschluß der
vorhergehenden Anleitung von $250 Million kommen würde und die Firma
zwingen würde, einen Reinverlust breitere 2002 bekanntzugeben.
JahrtausendfeierWAR in der Lage, Erwartungen im 4. Viertel, im Teil zu
übersteigen, indem sie $37,5 Million in verwirklichten Gewinnen von
seinem Portefeuille von Anlagepapieren notierte. Für das Jahr die
Jahrtausendfeier, die entwickelte sich sein besagt ist, Proforma Reinverlust
zu $256,3 Million oder 92 Cents pro den Anteil, verglichen mit einem
Proforma Reinverlust von $124,9 Million oder 57 Cents pro Anteil, 2001.
Vorwärts schauend, reiterierte Jahrtausendfeier die Aussicht 2003, die früh
bei der neuen J.P. Morgan H&Q Gesundheitspflegekonferenz dieser Monat
gegeben wurde. Die Höhepunkte: Gesamteinkommen, damit 2003 in der
Strecke $450 Million bis $475 Million ist. Integrilin Verkäufe werden
prognostiziert, um 20% bis $365 Million zu wachsen. Die Firma
prognostiziert einen Proforma Reinverlust 2003 in der Strecke $290 Million
bis $320 Million, ausschließlich des Vorwegnehmens der
umstrukturierenden Aufladungen von $60 Million bis $80 Million. Gegründet
auf 288 Million ausgegebenen Aktien, arbeitet dieser Reinverlust zu einer
Strecke $1,01 bis $1,11 pro Anteil aus. Analytiker suchen z.Z. nach
Jahrtausendfeier, um $1,04 pro Anteil 2003 zu verlieren. Jahrtausendfeier
teilt geschlossenen Dienstag herauf 4% bis $8,35.

Grüße
Skaya

[js200]

Research and Markets: Millennium Pharmaceuticals Inc
via COMTEX

January 30, 2003

Jan 30, 2003 (M2 PRESSWIRE via COMTEX) --

This company profile for Millennium Pharmaceuticals Inc is taken directly from the BiotechWatch database.

The BiotechWatch database is a continuously updated interactive database that follows such parameters as products under development, status of clinical trials, cash on hand, burn rate, and upcoming clinical milestones for over 5000 products from more than 600 biotech and medical device companies.

This user-friendly Millennium Pharmaceuticals Inc company profile tracks products in clinical development, cash on hand, clinical trial status, milestones, corporate alliances, and current stock prices and fundamentals.

This information is of particular interest to those investing in the biotechnology sector, industry professionals, and fund managers.

Each profile includes the following -

Company fundamentals: Stock price 52 week high and low price Shares outstanding Cash on hand Years of cash Market capitalization Daily trading volume

Derived statistics: Market cap / cash on hand Market cap less cash on hand Price less cash value per share Cash value per share (cash / shares out) Price / 52 week range 52 week high / price 52 week low / price 52 week high less price Price less 52 week low

Company Information: Clinical trial phases (for each product in development) Total number of products Total number of clinical trials Medical specialties Diseases and conditions treated Expected development milestones

A Note on Biotech Company Profiles:

Valuations of most biotech companies are determined by the perceived value of their technology, the success of their clinical trials, the breadth of the clinical market being addressed, their likely competitors, the strength of the strategic partnerships they have forged, the depth of their research and clinical pipelines, and their current financing.

These company profiles allow you to carefully monitor these parameters across the biotechnology sector. They allow investors and industry professionals to make the most informed decisions possible.

The profiles can be used as a basic research tool to access information such as cash-on-hand, milestones, trading volume, and products under development for a specific disease or medical indication. These latter parameters provide information regarding potential competitors and/or partners in specific development areas. As the timeliness of this information is of paramount importance, the BiotechWatch staff updates all clinical trial information daily and financial information such as stock price, market cap, shares outstanding, 52 week high and low and their derivative values are updated every 5 minutes.

For a complete index of this report click on http://www.researchandmarkets.com/reports/10489" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/10489

Report Pricing:

Electronic EUR 54 (US$ 50).

ORDERING INFORMATION - FIVE EASY WAYS TO PLACE YOUR ORDER:

ORDER ONLINE: To order this report please click on http://www.researchandmarkets.com/reports/10489" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/10489 ORDER VIA EMAIL: mailto:[e-mail] ORDER VIA FAX-BACK FORM: Click on http://www.researchandmarkets.com/reports/10489" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/10489 Fax to [phone] ORDER VIA POST: Click on http://www.researchandmarkets.com/reports/10489" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/10489 Mail to Research and Markets Ltd., Guinness Centre, Taylors Lane, Dublin 8, Ireland ORDER VIA PHONE: Telephone: [phone]

About Research and Markets Ltd.

Research and Markets Ltd. are Europe`s largest resource for market research. R&M distribute thousands of major research publications from the world`s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or [e-mail]

CONTACT: Holly Swift, Public Relations Manager, Research, Research and Markets Ltd. e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2003 M2 COMMUNICATIONS LTD


JS200

[schakal23]

die breschen weiter ein ist jetst das tiefst ?
ich glaube die marchieren weiter nach unten alle haben schiss von velcade das dier nicht durch kommt
aber wen doch??????????????in baar monate sind wir schlauer

[Hurricanfighterplane4]

Wie wäre es mal mit einem gepflegten Deutschkurs?

[schakal23]

Ein tüte voll bitte

[57er]

Gewinn je Aktie

in Mio. EUR 2004(e) 2003(e) 2002

Umsatz 557,07 456,68 359,65
EbitDa -297,13 -348,99 -330,25
EBIT -320,21 -378,85 -334,83
Gewinn je Aktie in USD -- -- --
KGV -- -- --
Dividende je Aktie in USD -- -- 0,00
Dividendenrendite -- -- 0,00%
Cashflow je Aktie in USD -- -- 1,21
Nettovermögen je Aktie in USD 7,61 8,68 10,38 aktueller Kurs: 7,40 $

[57er]

dazu mal im Vergleich

Thyssen Krupp

Gewinnentwicklung

in Mio. EUR 2004(e) 2003(e) 2002

Umsatz 39.741,80 37.946,75 36.697,95
EbitDa 3.250,35 2.910,39 2.664,00
EBIT 1.480,00 1.236,39 763,00
Gewinn je Aktie in EUR 1,39 1,04 0,48
KGV 7,41 9,90 21,46
Dividende je Aktie in EUR 0,60 0,50 0,40
Dividendenrendite 5,72% 4,77% 3,81%
Cashflow je Aktie in EUR 4,88 4,13 4,31
Nettovermögen je Aktie in EUR 18,05 17,40 16,70
Nettoverschuldung in EUR 4.828,83 5.140,09 4.742,00 (neg. Prognose =
Nettogeldbestand

[Phedre]

Hei
neues Kursziel ? € !!!!!!!!!!!!
sieht nicht gut aus
wer weiss was


mfg
phedre

[ass3000]

Hallo,

Weiß jemand was bei MLNM los ist, das ist doch nicht normal wie die verschleudert werden.Hängt das vielleicht mit der Zulassung von dem Medikament Velcade zusammen?
Da wissen wieder einige Leute mehr wie wir Dummen.

[Robin7]

Ich nehme an, da sind jetzt die Shortseller drin. Die Aktie fällt jeden Tag wie ein Stein. Neues Alle-Time-Low.

[Prunus1]

Da wird wohl mal wieder der langfristige Abwärtstrend getestet.

[MP1902]

@Robin7, bis All-Time-Low ist´s schon noch ein Stück

Denke auch an den Test der des unteren Bergrenzung des langfristigen Abwärtstrends. Müsste dann so bei ca. 4,80$ sein. Mal sehen obs so weit kommt, wäre ein guter Einstiegskurs, denke ich.

[enna2]

Ich denke auch das es eher doch mit Velcade zusammenhängt.
Da wissen einige mehr,und schmeißen Ihre Stücke jetzt fast schon zu Schleuderpreisen raus...

[Prunus1]

Wenn`s so weiter geht testen wir den heute noch

[schakal23]

@an all
kann bitte jemand schnell sagen was das bedeutet?


vwd/PRN: Millennium seeks European regulatory approval for Bortezomib (VELCADE(TM)) 3.5mg powder for solution for injection
Mitteilung übermittelt von PR Newswire. Für den Inhalt ist allein das berichtende Unternehmen verantwortlich.

Cambridge, Massachusetts, February 4 /PRNewswire/ -- - The Company continues to move forward with rapid, global development

Millennium Pharmaceuticals, Inc. today announced that it has submitted a complete Marketing Authorisation Application (MAA) to the European Agency for the Evaluation of Medicinal Products (EMEA) for the approval of bortezomib (VELCADE) as a treatment for relapsed and refractory multiple myeloma. This application was submitted approximately one week after the Company filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the same indication.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The submission is based primarily on the results of the phase II SUMMIT clinical trial, a multi-centre study which included 202 patients with relapsed and refractory multiple myeloma. The key findings from the study showed that 35 percent of evaluable patients experienced a response and nearly one out of 10 experienced a complete remission. The data from this trial were presented in full at the December 2002 meeting of the American Society for Hematology. Overall, more than 600 patients treated with bortezomib (VELCADE) were included in this submission. Both the U.S. and European filings come just over four years after the Company initiated clinical studies in multiple myeloma.

"The submission of this application in Europe is a significant step for Millennium toward our global mission of making novel treatment options available to patients with significant unmet medical needs," said Barry Greene, vice president and general manager, oncology franchise at Millennium. "Since initial verification of promising response with bortezomib (VELCADE) in multiple myeloma, we have been committed to its thorough and expeditious clinical development."

- Recent Bortezomib (VELCADE) News

Millennium recently initiated two phase II trials with bortezomib (VELCADE); one in patients with metastatic colorectal cancer and another in patients with advanced non-small cell lung cancer. In addition, the Company has an ongoing international, multi-centre, phase III (APEX) trial of bortezomib (VELCADE) in patients with multiple myeloma as well as several other phase I/II trials in patients with various hematologic and solid tumours. The Company also plans to initiate additional phase I/II studies in other cancers later this year.

Bortezomib (VELCADE) was designed specifically to block the proteasome, an enzyme complex in cells responsible for breaking down a variety of proteins, including many that regulate cell division. In preclinical studies, inhibition of the proteasome has been shown to lead to the disruption of cell cycle progression, resulting in the death of cancer cells (apoptosis). Bortezomib (VELCADE) is the first and only proteasome inhibitor currently being evaluated in clinical trials for the treatment of cancer.

For more information about bortezomib (VELCADE) clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at [phone].

- About Multiple Myeloma

Multiple myeloma is a cancer of the bone marrow in which white blood cells called plasma cells, normally responsible for the production of antibodies (proteins that fight infection and disease), are overproduced. The proliferation of these abnormal plasma cells, known as myeloma cells, causes decreased production of normal red and white blood cells, and of normal disease-fighting antibodies, as well as the growth of tumors that spread to multiple sites - hence the term multiple myeloma. The decreased white blood cell production damages the immune system while the myeloma tumors cause bone destruction that manifests as pain and fractures.

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and younger age of onset. Every year, there are almost 19,000 new cases and over 14,000 deaths from multiple myeloma in the European Union. Worldwide there are approximately 74,000 new cases and more than 45,000 deaths due to multiple myeloma each year.

- Millennium`s Oncology Franchise

Millennium is committed to pursuing oncology as a core franchise area, dedicating significant resources and capabilities in the areas of technology, scientific expertise, clinical development, and strategic business development. To this end, Millennium is focused on leveraging its expertise in kinases, the proteasome pathway, and targeting monoclonal antibodies, and has already produced a deep pipeline that ranges from multiple novel targets to a commercialized therapeutic product. Among the Company`s most advanced clinical compounds in addition to bortezomib (VELCADE) are MLN518, MLN591RL, MLN2704 and MLN576 (XR11576). Alemtuzumab (U.S. brand name Campath(R), EU brand name MabCampath(R)), a therapeutic developed from a former joint venture of Millennium and ILEX Oncology, Inc., is commercially available in the United States and a number of European countries.

- About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialisation activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, the Company is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., the Company also has facilities in South San Francisco, Calif. and Cambridge, UK.

This press release contains "forward-looking statements," including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause the Company`s actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN(R) (eptifibatide) Injection; our ability to extinguish the convertible notes assumed in the COR acquisition; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CAMPATH(R) and MabCampath(R), are registered trademarks of ILEX Pharmaceuticals, L.P

Editors` Note: This release is also available on the Company`s website at: http://www.millennium.com/

Contacts: Kelly Lindenboom (media) Cynthia Clayton (investor) [phone] [phone]

Millennium Pharmaceuticals, Inc.
Kelly Lindenboom (media), [phone], or Cynthia Clayton (investor), [phone], both for Millennium Pharmaceuticals, Inc./ Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO AP Archive: http://photoarchive.ap.org/ PRN Photo Desk, 888-776-6555 or 212-782-2840/ Company News On-Call: http://www.prnewswire.com/comp/114562.html/ Web site: http://www.millennium.com/

5. Februar 2003, 00:02


Druckversion | Nachricht weiterleiten


Sport

21.05. Radsport: Cipollini gewinnt neunte Giro-Etappe
21.05. Fußball: Le Guen wird neuer Trainer in Lyon
21.05. WM: Sieben Bundesliga-Profis in Kroatiens Kader
21.05. Fußball: Liverpool muss für Ziege nicht nachzahlen
21.05. Fußball: FCK verpflichtet Kongolesen Lembi
21

[schakal23]

hab schon trotzdem was meint ihr dazu

vwd/PRN: Millennium sucht europäische vorschriftsmäßige Zustimmung nach Bortezomib (VELCADE(TM)) 3.5mg Pulver für Lösung für Einspritzung
Mitteilung übermittelt von PR Newswire. Für-Höhle Inhalt ist allein das berichtende Unternehmen verantwortlich.

Cambridge, Massachusetts, 4. Februar / PRNewswire /, The Company setzt fort, mit schneller, globaler Entwicklung vorzurücken

Millennium Pharmaceuticals, Inc. verkündete heute, daß es zur europäischen Agentur für die Einschätzung von Medicinal Products (EMEA) für die Zustimmung zu bortezomib (VELCADE) als eine Behandlung einen vollständigen Marketing Authorisation Antrag (MAA) eingereicht hat, für fiel und widerspenstiger mehrfacher myeloma zurück. Dieser Antrag wurde ungefähr eine Woche eingereicht, nachdem die Gesellschaft einen Neuen Drogenantrag (NDA) mit den U.S. eingereicht hatte. Essen und Drogenverwaltung (FDA) für das gleiche Anzeichen.

, Foto: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO,

Die Unterwerfung wird hauptsächlich klinischer Versuch IIEN GIPFEL auf den Ergebnissen der Phase basiert, ein Multizentrum-Studium, das 202 Patienten damit einschloß, fiel und widerspenstiger mehrfacher myeloma zurück. Der Haupttatbestand vom Studium zeigten, daß 35 Prozent der evaluable-Patienten erfuhren, erfuhren eine Antwort und beinahe einer aus 10 einen vollständigen Erlaß. Die Daten von diesem Versuch wurden vollständig Versammlung der amerikanischen Gesellschaft für Hematology beim Dezember 2002 präsentiert. Insgesamt wurden mehr als 600 Patienten, die mit bortezomib (VELCADE) behandelt wurden, in dieser Unterwerfung eingeschlossen. Beiden AMERIKANISCHE und europäische Feilspäne kommen nur über vier Jahre, nachdem die Gesellschaft klinische Studien in mehrfachem myeloma initiiert hatte.

"Die Unterwerfung dieses Antrages in Europa ist für Millennium ein bedeutungsvoller Schritt zu unserer globalen Mission, neuartige Behandlungsmöglichkeiten medizinische Bedürfnisse" zu Patienten verfügbar mit bedeutungsvollem unmet zu machen, sagte Barry Greene, Vizepräsident und allgemeiner Manager, Onkologieprivileg für Millennium. "Seit anfänglicher Nachprüfung, Antwort mit bortezomib (VELCADE) in mehrfachem myeloma zu versprechen, sind wir zu seiner gründlichen und schnellen klinischen Entwicklung verpflichtet worden."

, Letzter Bortezomib (VELCADE) Nachrichten

Jahrtausend initiierte vor kurzem IIE Prozesse mit bortezomib (VELCADE) zwei Phase; einer in Patienten mit metastatic colorectal-Krebs und noch einem in Patienten mit vorangebrachtem nicht-kleinem Zelllungenkerbs. Außerdem hat die Gesellschaft ein andauerndes internationales Multizentrum, Phase III (SPITZE) Versuch von bortezomib (VELCADE) in Patienten mit mehrfachen myeloma sowie mehreren anderen Phaseni/II-Versuchen in Patienten mit verschiedenen hematologic und festen Tumoren. Die Gesellschaft plant auch, später dieses Jahr zusätzliche Phaseni/II-Studien in anderen Krebsen zu initiieren.

Bortezomib (VELCADE) wurde entworfen, um den proteasome ausdrücklich zu blockieren, ein Enzymkomplex in Zellen verantwortlich dafür, eine Vielfalt der Proteine zu zerlegen, einschließlich vielen dieses regulieren Sie Zellteilung. In preclinical-Studien Hemmung des proteasome ist gezeigt worden, um zur Störung der Zellzyklusfortbewegung zu führen und wird in den Tod der Kerbszellen (apoptosis) resultiert. Bortezomib (VELCADE) ist das erste und einzige proteasome-Schutzmittel, das gegenwärtig in klinischen Versuchen für die Behandlung des Krebses eingeschätzt wird.

Für mehr Informationen über bortezomib (VELCADE) können klinische Versuche, Patienten und Ärzte dem Jahrtausend bei +1 ((510)) 740-1273 Medizinische Produktinformationsabteilung verständigen.

, Über Mehrfachem Myeloma

Mehrfacher myeloma ist ein Krebs der Knochenmark, in dem weiße Blutzellen Plasmazellen genannt, normalerweise verantwortlich für die Produktion der Antikörper (Proteine, die Infektion und Krankheit bekämpfen,), wird überproduziert. Die Vermehrung dieser abnormalen Plasmazellen, die als myeloma-Zellen bekannt wird, Ursachen verminderten Produktion der Normale rote und weiße Blutzellen, und von normalen Krankheit-kämpfenden Antikörpern, sowie der Wuchs von Tumoren, die sich zu mehrfachen Stellen ausbreiteten, also der Begriff mehrfacher myeloma. Die reduzierte weiße Blutzellproduktion beschädigt das immune System, während die myeloma-Tumoren verursachen, beinen Sie Zerstörung aus, die als Schmerz und Brüche zeigt.

Mehrfacher myeloma ist die zweite gewöhnlichste hematologic-Bösartigkeit und obwohl die Krankheit vorwiegend ein Krebs der Alten ist, ist das durchschnittliche Alter des Einbruches 65 bis 70 Jahre volljährig, letzte Statistiken weisen auf sowohl zunehmendes Vorkommen als auch jüngeres Alter des Einbruches hin. Jedes Jahr gibt es fast 19,000 neue Fälle und über 14,000 Toden von mehrfachem myeloma in der European Union. Weltweit gibt es wegen mehrfachen myeloma jedes Jahr ungefähr 74,000 neue Fälle und mehr als 45,000 Tode.

, Das Onkologieprivileg von Jahrtausend

Jahrtausend wird zu verfolgender Onkologie als ein Kernprivileggebiet begangen und widmet bedeutungsvolle Ressourcen und Fähigkeiten in den Gebieten von Technologie, wissenschaftlichem Sachverstand, klinischer Entwicklung und strategischer Geschäftsentwicklung. Zu diesem Ende wird Millennium seinen Sachverstand in kinases, den proteasome-Pfad, und das Abzielen auf monoclonal-Antikörper auf leveraging gerichtet, und hat schon eine tiefe Pipeline produziert, die sich von mehrfachen Romanzielen zu einem kommerzialisierten therapeutischen Produkt bewegt. Unter den am meisten vorangebrachten klinischen Verbindungen der Gesellschaft zusätzlich zu bortezomib (VELCADE) ist MLN518, MLN591RL, MLN2704 und MLN576 (XR11576). Alemtuzumab (AMERIKANISCHER Markenname Campath(R), EU Markenname MabCampath(R,), ein therapeutisches entwickelte von einem ehemaligen gemeinsamen Unterfangen von Jahrtausend und ILEX Oncology, Inc., ist in den Vereinigten Staaten und einer Anzahl europäischer Länder kommerziell verfügbar.

, Über Millennium

Millennium Pharmaceuticals, Inc., eine führende biopharmaceutical-Gesellschaft, Mit, fördert INTEGRILIN(R, ((eptifibatide)) Injection, ein Markt-führendes kardiovaskuläres Produkt, und hat eine robuste klinische Entwicklungspipeline der Produktbewerber. Die Forschung der Gesellschaft, Entwicklung und commercialisation-Aktivitäten werden in vier Krankheitsvierteln fokussiert: kardiovaskulär, Onkologie, Aufflammen und Stoffwechsel. Die Gesellschaft entwickelt Medizinprodukten eine persönliche Note gegebenen Durchbruch, indem er sein Wissen vom menschlichen genome, seinem Verständnis für Krankheitsmechanismen und seiner industrialisierten Technologieplattform anwendet. Headquartered in Cambridge zieht sich zusammen., die Gesellschaft hat auch Einrichtungen in Südsan Francisco, Calif. und Cambridge, VEREINIGTES KÖNIGREICH.

Diese Pressenfreilassung enthält "zukunftsweisende Aussagen", einschließlich Aussagen über unseren Wuchs und Zukunft, die Ergebnisse, Entdeckung und Entwicklung von Produkten, potentiellen Erwerben, strategischen Bündnissen und geistigem Eigentum bedient. Verschiedene Risikos veranlassen vielleicht die eigentlichen Ergebnisse der Gesellschaft, sich wesentlich zu unterscheiden, einschließlich: ungünstige Ergebnisse in unserer Drogenentdeckung und klinische Entwicklung marschiert; Mißerfolg, patentgeschützten Schutz für unsere Entdeckungen zu erhalten,; kommerzielle Einschränkungen drängten sich durch Patente auf, die besessen werden oder von dritten Parteien kontrolliert werden,; unsere Abhängigkeit von strategischen Bündnispartnern, um Produkte und Dienste auf unsere Arbeit basierend zu entwickeln und zu kommerzialisieren,; Schwierigkeiten oder Verzögerungen darin, vorschriftsmäßige Zustimmungen zu erhalten, um Produkte und Dienste zu vermarkten, die von unseren Entwicklungsanstrengungen resultieren,; der kommerzielle Erfolg von INTEGRILIN(R, (eptifibatide), Injection,; unsere Fähigkeit, die umwandelbaren Notizen auszulöschen, nahm im COR-Erwerb an; und die Anforderung an beträchtlicher Finanzierung, um Forschung und Entwicklung zu führen und Kommerzialisierungsaktivitäten zu erweitern. Für eine weitere Liste und eine Beschreibung von den Risikos und den Ungewißheiten, denen wir gegenüberstehen, sehen Sie die Berichte, die wir mit den Sicherheiten und Tauschkommission eingereicht haben. Wir streiten irgendeine Absicht oder eine Pflicht ab zu aktualisieren oder revidieren alle zukunftsweisende Aussagen, ob als ein Ergebnis neuer Informationen, künftige Ereignisse oder ansonsten.

CAMPATH(R und MabCampath(R, ist eingeschriebene Warenzeichen des ILEX Pharmaceuticals, L.P,

Die Notiz von Redakteuren: Diese Freilassung ist auf website der Gesellschaft dabei auch verfügbar: http://www.millennium.com /

[schakal23]

das ganse minus heute hat das vieleicht mit diesem neuer midekament zutun REVIMID

[fromToronto]

.

....Scheint eine Erholung einzusetzen!

Sind ja auch genügend Stücke in USA abgegeben worden.




.

[Shenzhou]

interesanter Intradayverlauf:





Shenzhou

[sevenclever]

was ist da interessant?
hab gestern ausserbörslich gekauft - MLNM ist wie ein Stein gefallen!!!
Bei 5.3 USD hab ich zugeschlagen Gut, es ging noch
a bisserl Tiefer...

Da waren(sind) einige SHORT, sowas geht
nicht für alle gut...(hihi)
Hab sie schon mal zu 6.9 USD eingebucht.

seven abwartend

[sevenclever]

ups 6.3 USD...
da war der abschicken-Butten mal wieder schneller...

[schakal23]

ich habe heute welche zu 5.9 gekauft und warte erstmal
weiter dan werde ich meine zweite position kaufen viel glück an alle und die daumen drücken für velcade

[Phedre]

Hallo

Die Analysten vom Investmenthaus Ryan, Beck & Co stufen die Aktie von Millennium Pharmaceuticals (WKN 900625) unverändert mit „outperform“ ein. Das Unternehmen habe in Europa einen Zulassungsantrag für Velcade gestellt.

Wenn Velcade díe Zulassung bekommt (USA,Europa...)werden die Shorties bluten.



mfg
Phedre

[sukashi]

sehe enormes potential für millennium:
kurs schon weit zurückgekommen-
zulassung für velcade in aussicht.
strong by
sukashi

[puhvogel]

Wenn ich mir den Kurs so anschaue, würde ich mich nicht über eine baldige kräftige Kapitalerhöhung wundern. Nur so als Tip.

[Robin7]

Für was sollte es eine Kapitalerhöhung geben bei weit über einer Milliarde Cash?

[puhvogel]

Vielleicht wollen die was kaufen, das Geschäft langfristig sichern oder oder oder.
CVTX ENZN alles schon gehabt, trotz voller Kassen.
SGP sammelt momentan auch Milliarden $ ein, und die haben es sicher nicht so nötig.

Nur so eine Vermutung von mir.

[js200]

StockPickReport.Com: New ratings on Costco Wholesale Corp, Millennium Pharmaceuticals, Dupont E I Nemours &Co, Barrick Gold Corp, Accenture Ltd
via COMTEX

February 7, 2003

Feb 07, 2003 (M2 PRESSWIRE via COMTEX) --

`http://www.stockpickreport.com/?src=bw `}http://www.stockpickreport.com/?src=bw ) makes these stock evaluations for the short term:

Costco Wholesale Corp (NASDAQ:COST) - Underperform {HYPERLINK `http://www.stockpickreport.com/?src=cost" target="_blank" rel="nofollow ugc noopener">http://www.stockpickreport.com/?src=cost `}http://www.stockpickreport.com/?src=c ost

Millennium Pharmaceuticals (NASDAQ:MLNM) - Outperform {HYPERLINK `http://www.stockpickreport.com/?src=mlnm" target="_blank" rel="nofollow ugc noopener">http://www.stockpickreport.com/?src=mlnm `}http://www.stockpickreport.com/?src=m lnm

Dupont E I Nemours &Co (NYSED) - Outperform {HYPERLINK `http://www.stockpickreport.com/?src=dd `}http://www.stockpickreport.com/?src=dd

Barrick Gold Corp (NYSE:ABX) - Underperform {HYPERLINK `http://www.stockpickreport.com/?src=abx" target="_blank" rel="nofollow ugc noopener">http://www.stockpickreport.com/?src=abx `}http://www.stockpickreport.com/?src=ab x

Accenture Ltd (NYSE:ACN) - Outperform {HYPERLINK `http://www.stockpickreport.com/?src=acn" target="_blank" rel="nofollow ugc noopener">http://www.stockpickreport.com/?src=acn `}http://www.stockpickreport.com/?src=ac n

WHAT THESE RATINGS MEAN: StockPickReport.Com ranks stocks with a proprietary unbiased system of technical analysis.

These ratings do not indicate a `long term`view of any company listed. These are ratings that reflect our opinion of a stock`s PRICE movement versus the SP 500 over the short term. These ratings may change based on daily market conditions.

You can get a FREE trial at: {HYPERLINK `http://www.stockpickreport.com/?src=bw `}http://www.stockpickreport.com/?src=bw

ABOUT STOCKPICKREPORT.COM: StockPickReport.Com is a stock research firm. Our daily commentary has regular, worldwide distribution. We are Registered Investment Advisors.

We do not accept third-party compensation to make stock suggestions. We do not accept advertising. We do not own shares of any stock we rate.

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.

StockPickReport.Com`s goal is to provide stock research FREE from bias or conflicts. You can get your FREE trial to StockPickReport.Com at {HYPERLINK `http://www.stockpickreport.com/?src=bw `}http://www.stockpickreport.com/?src=bw

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2003 M2 COMMUNICATIONS LTD

JS200

[schakal23]

Update Millennium Chemicals Inc.: Neutral
10.02.2003 15:05:23
In ihrer Analyse vom Freitag, 7. Februar 2003 stufen die Analysten von UBS Warburg die Aktie des Unternehmens Millennium Chemicals Inc. von "Buy" auf "Neutral" zurück. Ein Kursziel geben die Analysten nicht an.

-red-


????????????????????

[schakal23]

12.02.2003
Millennium meiden
Der Aktionär

Die Experten des Anlegermagazins "Der Aktionär" empfehlen die Millennium-Aktie (WKN 900625) vorerst zu meiden.

Dem Wert hätten die in der Vorwoche vorgelegten Zahlen für das 4. Quartal nicht die notwendigen Impulse verliehen. Die Marktteilnehmer hätten sich im Gegenteil enttäuscht gezeigt und regelrecht auf die Aktie eingeprügelt.

Ein neues Jahrestief sei bei 6,24 US-Dollar erreicht worden. Das Papier sei unter den Stop gefallen.

Die Empfehlung der Experten von "Der Aktionär" für Millennium lautet vorerst "meiden".

[christian_58]

Guten Morgen,

die vom Aktionär die spinnen doch. Noch vor 2 Wochen empfehlen Sie die Aktie unbedingt zu kaufen.
Ich sehe MLNM als Langfristinvest. Entweder sie packens oder eben nicht. Ich schau mir den Kurs 2005 mal wieder näher an.
Übrigens, spätestens nach dem Verkaufsdruck nach diesen Zahlen, dürften alle Zocker aus der Aktie raus sein. Also wer verkauft eine Millennium unter 5US Dollar?
Also - Kopf hoch - 2005 schaun wir weiter!

Ciao

[Robin7]

Ist doch eigentlich ein gutes Zeichen, wenn Deppen die Millennium bei 100 Dollar mit Kursziel 300 Dollar empfohlen haben, jett bei 6 Dollar zum Verkauf raten.

[dr.gips]

der förtsch ist mir schon seit einiger zeit seeeehr suspekt!!

[js200]

02/12/2003 (08:54 ET) New SC 13G just released for MLNM - Edgar
02/11/2003 (11:42 ET) RATING(=): Ryan, Beck & Co Keep MLNM @ Outperf, $14 TP - Knobias
02/11/2003 (08:51 ET) New 4 just released for MLNM - Edgar
02/10/2003 (11:52 ET) EquityOutlook.Com: New ratings on Millennium Pharmaceuticals, Pmc-sierra Inc, Abbott Laboratories, American Electric Power Company - M2 Communications
02/07/2003 (11:31 ET) StockPickReport.Com: New ratings on Costco Wholesale Corp, Millennium Pharmaceuticals, Dupont E I Nemours & Co, Barrick Gold Corp, Accenture Ltd - M2 Communications

JS200

[Ce758]

was meint ihr zum Kursverlauf?
sieht nach Bodenbildung aus,
das Drama scheint langsam ein Ende zu finden.
Bei den geringen Umsätzen kann das Pendel leicht in die Gegenrichtung ausschlagen, wenn die Leerverkäufer erstmal brennen...

[schakal23]

Cambridge, Massachusetts, February 19 /PRNewswire/ -- Millennium Pharmaceuticals, Inc announced today that its presentation to the Bio CEO & Investor Conference 2003 will be webcast live and may be accessed by visiting the investor relations section the Company``s website, http://www.millennium.com/.

(Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO)

Millennium senior management will provide an overview of the Company. The presentation will be delivered at 11:00 a.m. (EST) on Wednesday, February 26, 2003 from the Waldorf Astoria in New York City. The presentation will be archived for 30 days.

About Millennium

Millennium

[skaya]

hi, eine düstere Prognose:
MILLENNIUM PHARMA - Mittelfristig : 5,5 $ Kursziel

19.02. 13:26
Millennium Pharma (MLNM)

Kursstand : 6,97 $

Wochenchart mit Tageschartausschnitt.

Seit Ende 2000 bewegt sich diese Momentumaktie aus dem Amex Biotech Index (BTK) in einem übergeordneten Abwärtstrendkanal, der sich seit Mitte 2002 zunehmend zu verschärfen beginnt.

Die Unterkante des ursprünglichen Abwärtstrendkanals ist nach unten durch. Die wichtige charttechnische Unterstützung bei 7 $ wurde unterschritten.

Kurzfristig ist maximal nochmals eine Kurserholung bis 7,7 $ möglich, wobei eine solche Erholung auf sehr zittrigen Beinen stehen würde. Der BTK hat nämlich seine Ausbruchbewegung aus der großen mittelfristigen symmetrischen Dreiecksformation nach unten begonnen.

Mittelfristig erwarten wir ein übergeordneten charttechnisches Kursziel von 5,5 $ für die Millennium Pharma Aktie. Bodenbildungstendenzen können wir aus charttechnischer Sicht nicht erkennen!

Grüße
Skaya

Quelle: Biotech-Experte

[sevenclever]

@skaya

glaubst du das selber oder schreibst du das weil du es irgendwo gefunden hast

seven der schon dick im Plus liegt

ANALYSTENGESCHWAFEL macht euch doch slebst ein Bild
Die Blindschleichenschwätzer...

[js200]

Lehman Brothers Sixth Annual Global Healthcare Conference To Webcast Millennium Pharmaceuticals Presentation [INLINE]
via CDS

February 24, 2003

CAMBRIDGE, Mass., Feb. 24 /PRNewswire-FirstCall/-- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced today that its presentation to the Lehman Brothers Sixth Annual Global Healthcare Conference will be webcast live and may be accessed by visiting the investor relations section of the Company`s website, http://www.millennium.com.

(Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Millennium senior management will provide an overview of the Company. The presentation will be delivered at 4:15 p.m. (EST) on Monday, March 3, 2003 from the Loews Miami Beach Hotel in Miami Beach, Florida. The presentation

will be archived for 30 days.



About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass. Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.



Editor`s Note: This release is available on Millennium`s website at http://www.millennium.com



Contact:

Cynthia Clayton, Investor Relations

Millennium Pharmaceuticals, Inc.


JS200

[Phedre]

Hallo an alle!

Emea Accepts Marketing Authorization Application For Bortezomib (VELCADE™ 3.5MG Powder for Solution for Injection
– Clinical development of bortezomib (VELCADE) one of the fastest; well under the industry average of seven years –
Cambridge, Mass., February 25, 2003 - Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced today that the Agency for the Evaluation of Medicinal Products (EMEA) has accepted for review the Company`s Marketing Authorization Application (MAA) for bortezomib (VELCADE) for the treatment of relapsed and refractory multiple myeloma.
This announcement comes approximately three weeks after the Company submitted marketing applications in both the European Union (EU) and the United States. Bortezomib (VELCADE) received fast track status from the U.S. Food and Drug Administration (FDA) in June 2002, and Millennium filed the New Drug Application (NDA) under the provision of Subpart H Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses on January 21, 2003. The MAA was submitted to the EMEA a week later.
"We are very pleased that the EMEA has accepted this MAA for review," said Barry Greene, general manager, oncology at Millennium. "Having taken just over four years to go from the dosing of the first patient to the recent global filings, bortezomib (VELCADE) represents one of the industry`s fastest clinically developed drug candidates. We look forward to continuing to work closely with the global regulatory authorities to help get this important medicine to multiple myeloma patients."
The global filings for bortezomib (VELCADE) in the EU and the U.S. were based primarily upon the results of the phase II SUMMIT trial, a multi-center study of 202 patients with relapsed and refractory multiple myeloma which were presented in full at the December 2002 meeting of the American Society of Hematology (ASH). The key findings from the study showed that the overall response rate among evaluable patients was 35 percent and that even among this critically ill group of patients, nearly one out of 10 experienced a complete remission. The most commonly reported adverse events were gastrointestinal-related, including nausea, diarrhea, constipation, and vomiting, as well as thrombocytopenia, peripheral neuropathy, neutropenia, fatigue, anorexia, pyrexia and anemia. The data were submitted in the common technical document (CTD) format, which allowed for nearly simultaneous filings in the EU and the U.S.
About Bortezomib (VELCADE) and Proteasome Inhibition
Bortezomib (VELCADE) represents a completely new approach to treating multiple myeloma which is also being investigated in many other cancers. The rapid development of this product is based on the Company`s profound understanding of cancer and disease pathways and the effect proteasome inhibition has on those pathways. Cancer is characterized by uncontrolled cell proliferation; bortezomib (VELCADE), the first and currently only proteasome inhibitor to be studied in cancer patients, blocks the proteasome and interferes with the chemical messengers that are associated with unregulated cancer cell growth and survival. For patients, this means bortezomib (VELCADE) may help slow and even halt the progression of the disease, potentially helping cancer patients live longer.
Millennium recently initiated two phase II trials with bortezomib (VELCADE); one in patients with metastatic colorectal cancer and another in patients with advanced non-small cell lung cancer. In addition, the Company has an ongoing international, multi-center, phase III (APEX) trial of bortezomib (VELCADE) in patients with relapsed or refractory multiple myeloma as well as several phase I/II trials in patients with various hematologic and solid tumors. The Company also plans to initiate additional phase I and II studies later this year. For more information about bortezomib (VELCADE) clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at [phone].
About Multiple Myeloma
Multiple myeloma is a cancer of the bone marrow in which white blood cells called plasma cells, normally responsible for the production of antibodies (proteins that fight infection and disease), are overproduced. The proliferation of these abnormal plasma cells, known as myeloma cells, causes decreased production of normal red and white blood cells, and of normal disease-fighting antibodies, as well as the growth of tumors that spread to multiple sites - hence the term multiple myeloma. The decreased white blood cell production damages the immune system while the myeloma tumors cause bone destruction that manifests as pain and fractures.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co-promotes INTEGRILIN® (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass. Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.
This press release contains "forward-looking statements," including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause the Company`s actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN® (eptifibatide) Injection; our ability to extinguish the convertible notes assumed in the COR acquisition; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

mfg phedre

[filuta]

Hallo, wäre schön wenn es jemand In Kürze in deutsch sagen könnte. Heißt das ganze wenigstens was gutes?Danke Ambra

[Phedre]

Hallo

Millennium Pharma Grants CEO 200,000 Stock Options
Friday February 28, 3:21 pm ET


WASHINGTON (Dow Jones)--Millennium Pharmaceuticals Inc. Chairman and Chief Executive Mark Levin received a grant of 200,000 stock options this week, according to a regulatory filing Friday.
The options, granted Wednesday, have a term of 10 years and an exercise price of $6.88 a share. The options grant vests over four years in equal monthly installments beginning March 26, the filing said.

ADVERTISEMENT


Shares of Millennium recently traded at $7.09, up 12 cents, or 1.6%.

The filing didn`t include the reason for the grant. Many companies are reporting the equity components of their executives` 2002 pay earlier this year because of new rules that require the disclosure of equity transactions by company insiders within 48 hours. Companies typically disclose executive compensation in annual proxies.

According to the company`s most recent proxy, filed last March, Levin received a salary of $406,000, a bonus of $365,800 and 375,000 stock options.

In a separate filing with the Securities and Exchange Commission (News - Websites) on Friday, the Cambridge, Mass., pharmaceutical developer said it granted 93,800 options to its vice chairman, Vaughn Kailian, and 28,100 options to its general counsel, John Douglas III.

Und hier nochmal auf ditsch !

Jahrtausendfeier Pharma Bewilligt Aktienoptionen CEOS 200.000
Freitag Februar 28, 3:21 P.M. UND


WASHINGTON (Dow Jones) -- JahrtausendfeierPharmazeutische Produkte Inc.. Markierung Levin des Vorsitzenden und des Hauptgeschäftsführers empfing eine Bewilligung von 200.000 Aktienoptionen diese Woche, entsprechend einer regelnden Archivierung Freitag.
Die Wahlen, Mittwoch bewilligt, haben eine Bezeichnung von 10 Jahren und von Übungspreis von $6,88 pro Anteil. Die Wahlbewilligung bekleidet über vier Jahren in den gleichen Monatsratenzahlungen, die März 26 anfangen, die gesagte Archivierung.


Anteile der Jahrtausendfeier handelten vor kurzem bei $7,09, herauf 12 Cents oder 1,6%.

Die Archivierung umfaßte nicht den Grund für die Bewilligung. Viele Firmen berichten über den Billigkeitsbestandteilen der Bezahlung ihrer Hauptleiter 2002 früh dieses Jahr wegen der neuen Richtlinien, die die Freigabe der Billigkeitsverhandlungen durch Firmaeingeweihte innerhalb 48 Stunden erfordern. Firmen geben gewöhnlich Executivausgleich in den jährlichen Proxies frei.

Entsprechend dem neuesten Proxy der Firma eingeordnet letzter März, Levin empfing ein Gehalt von $406.000, eine Prämie von $365.800 und 375.000 Aktienoptionen.

In unterschiedlich Archivierung mit Sicherheiten und Austausch Kommission ( Nachrichten - Websites ) auf Freitag, Cambridge, Mass., sagte pharmazeutischer Entwickler, daß er 93.800 Wahlen seinem Vorsitzenden bewilligte, Vaughn Kailian und 28.100 Wahlen zu seinen allgemeinen Beratern, John Douglas III.

mfg
phedre

[thomtrader]

@:#136

[js200]

TransForm Discovers New Crystal Forms of HIV Protease Inhibitor Ritonavir; Article Published in PNAS Demonstrates TransForm`s Expertise in Crystal Form Discovery
via CDS

March 4, 2003

TransForm Pharmaceuticals Inc., today announced significant research findings that identify new crystal forms of the HIV protease inhibitor, Ritonavir (Norvir(R)). The work appears in the March 2003 edition of the Proceedings of the National Academy of Sciences (PNAS). Using their novel technology, TransForm`s scientists identified several new forms of the well-known drug substance, one of which was a previously unknown polymorph, along with identifying novel, reproducible methods of preparing both the known and novel forms. A summary of the work was presented at the American Chemical Society ProSpectives meeting in February 2003 in Tampa, FL and later this month will be presented in a poster at the American Chemical Society National Meeting in New Orleans, LA. `This study has further demonstrated the power of TransForm`s technology in efficiently resolving a well-publicized problem with the HIV protease inhibitor, Ritonavir,`stated Edward Scolnick, M.D., President Emeritus, Merck Research Labs. `This example illustrates the importance of selecting the best product form the first time around. These findings provide new insights into the science of crystallizing compounds, and provide more opportunity for developing even better drugs or for improving marketed products.`Ritonavir, an important drug used to treat HIV, garnered much attention in 1998 when a previously unknown, but thermodynamically more stable, polymorph of the drug unexpectedly appeared two years after its launch. This new form had less than 50% of the solubility of the original form, which could not be recovered despite considerable

efforts. As a result, the drug failed the dissolution specifications approved by the FDA, and had to be withdrawn from the market pending reformulation of the newly discovered polymorph. In their study of the compound, TransForm`s scientists identified five forms of Ritonavir, including reported Forms I and II, and the discovery of three new forms, Forms III, IV and V. The scientists found these forms by performing over 2,000 crystallization experiments, utilizing multiple, and sometimes combined, crystallization methods over a six week period using CrystalMax(TM), TransForm`s proprietary high-throughput crystallization system. CrystalMax(TM) includes proprietary experimental design and execution software, robotic dispensing and handling, high-throughput micro-analysis, and advanced data analysis and mining capabilities. Further details are discussed in the paper titled `Elucidation of Crystal Form Diversity of the HIV Protease Inhibitor Ritonavir by High-Throughput Crystallization`by Sherry L. Morissette, Stephen Soukasene, Douglas Levinson, Michael J. Cima, and Orn Almarsson, PNAS March 4, vol. 100, No. 5, pages 2180-2184. The work also appears on line at www.pnas.org/cgi/doi/10.1073/pnas.0437744100. The application of CrystalMax(TM) represents a significant example of the importance of combining a deep understanding of chemistry with high throughput technology that enables reliable screening of polymorphs to select the most suitable solid form of a drug candidate for development. TransForm`s ability to quickly and comprehensively identify the diversity of solid forms of a drug or drug candidate can have significant advantages in managing the product life cycle and in strengthening intellectual property protection. `TransForm`s high-throughput technology empowers its scientists to push the envelope in crystallization, and to explore a much broader experimental space than was previously possible,`stated Michael Zaworotko, Ph.D., Professor and Chair, Department of Chemistry, University of South Florida in Tampa, Florida. `High-throughput screening is a significant complement to good chemistry. As the TransForm Ritonavir study demonstrates, the risk of failing to invest appropriately in this area can be significant and unforeseen, while the benefits can be considerable.`About TransForm TransForm is reinventing the pharmaceutical industry`s approach to form and formulation, with a novel set of high-throughput, automated platform technologies, powered by state-of-the-art informatics and a scientific and managerial team with deep experience in pharmaceuticals. It uses these capabilities to optimize drug form and/or formulations, and increase the clinical and commercial value of pharmaceutical products, across the entire pharmaceutical value chain. In research and development, TransForm is working with partners such as Alza Corporation and Lilly, to help them make better candidate selection decisions, and reduces attrition and development time and cost. For later stage and marketed products, TransForm can help partners enhance product life cycle management by rapidly discovering novel forms and/or formulations to potentially improve bioavailability, broaden intellectual property protection and enable new dosage forms and/or combination products. TransForm is also using these capabilities to develop its own proprietary product portfolio. TransForm, founded in late 1999 with initial technology from Millennium Pharmaceuticals (NASDAQ:MLNM), is a privately held company located in Lexington, Massachusetts. For more information, please visit our website at www.transformpharma.com.



CONTACT: TransForm Pharmaceuticals, Inc.
Barbara Carter, 781/674-7834
or
Noonan/Russo Presence
Robert Stanislaro, 212/845-4268


JS200

[schakal23]

sieht nicht gutaus


BUSINESS NEWS March 8, 2003



TEXT-S&P cuts Millennium Chemicals corp credit rating
2003-03-07 16:32:43 EST

(The following statement was released by the rating agency)

NEW YORK, March 7 - Standard & Poor`s Ratings Services said today that it has lowered its corporate credit rating on Millennium Chemicals Inc. to non-investment-grade `BB+` from `BBB-`, citing the company`s subpar financial profile, and the persistent operating pressures that continue to limit prospects for improvement to the financial profile this year. The current outlook is negative.

Red Bank-N.J.-based Millennium, with about $1.6 billion of annual sales and approximately $1.2 billion of outstanding debt (excluding adjustments to capitalize operating leases), is primarily engaged in the production of commodity chemicals.

"The downgrade reflects renewed concerns that substantially higher raw material costs and lingering economic uncertainties are likely to limit Millennium`s ability to generate the free cash flow necessary to substantially improve the company`s financial profile," said Standard & Poor`s credit analyst Kyle Loughlin. The financial profile has been stretched by adverse business conditions during the past couple of years, which has forestalled Millennium`s efforts to reduce its sizeable debt burden. Standard & Poor`s said that it also recognizes that adverse business conditions in the petrochemical industry, including recent escalation in raw materials costs, are likely to limit cash distributions from 29.5%-owned Equistar Chemicals LP this year.

Standard & Poor`s said that its ratings on Millennium reflect the company`s average business risk profile and aggressive debt burden, mitigated somewhat by financial policies that strongly prioritize debt reduction as business conditions improve. Positive momentum in titanium dioxide (TIO2, a white pigment used in coatings, plastics, and paper production), and meaningful sources of untapped liquidity, in the form of bank facilities and the ownership stake in Equistar Chemicals, remain positive factors. Complete ratings information is available to subscribers of RatingsDirect, Standard & Poor`s Web-based credit analysis system, at www.ratingsdirect.com. All ratings affected by this rating action can be found on Standard & Poor`s public Web site at www.standardandpoors.com; under Fixed Income in the left navigation bar, select Credit Ratings Action

[Phedre]

Hallo

Millennium Chemicals Inc. WKN:903002

OK

mfg
phedre

[Phedre]

Hallo

Nadine Wong von Zacks Investment Research empfiehlt in ihrem "BioTech Stock Report", der Aktie von Millennium Pharmaceuticals Augenmerk zu schenken. (WKN 900625) Bisher sei die Entwicklung des neuen Krebsmedikamentes von Millennium, Velcade, gut unterwegs und mehr und mehr Anleger interessierten sich für die Sache. Zugleich fragten sich die Anleger, welches Medikament bei der Behandlung multipler Myelome schneller zum Zug kommen werde, das Medikament Velcade von Millennium oder das Medikament Thalomid von Celgene oder Revimid. Thalomid werde zur Zeit bereits von Ärzten unter der Hand für die Behandlung multipler Myelome verschrieben, obwohl das Medikament noch nicht zur Krebsbehandlung zugelassen sei. Millennium habe mittlerweile ein neues Ansuchen um Zulassung eingebracht und versuche, bei der Behandlung wiederkehrender Mylome zugelassen zu werden. Die europäischen Behörden hätten inzwischen ein ähnliches Ansuchen angenommen. In den USA werde sich an Hand der Ergebnisse einer Studie der Phase II, die im letzten Dezember veröffentlicht worden sei, entscheiden, ob das Ansuchen entgegen genommen werde. Wenn alles gut gehe, könnte das Medikament bereits in der 2. Jahreshälfte des Jahres 2003 auf den Markt kommen, mindestens um 12 - 18 Monate früher, als wenn man mit der Zulassung bis zur Phase III warten würde. Die Hürden für eine solche vorgezogene Zulassung seien allerdings hoch. Zwar scheine die Wirkung überzeugend, die entscheidende Frage werde aber sein, ob die genannte Studie ausreichend geplant und durchgeführt worden sei. Sollten die amerikanischen Behörden das Ansuchen entgegen nehmen, sei dies bereits eine erste Vorentscheidung in diese Richtung. Etwa Mitte März sollte dies klar sein. Da es zur Zeit nur wenige Möglichkeiten gebe, wiederkehrende Myelome zu behandeln, sei es sehr interessant, wie die Sache weitergehen werde. Millennium könnte jedenfalls mit Sicherheit ein weiteres Medikament gut gebrauchen. Nadine Wong von Zacks Investment Research empfiehlt daher, die Aktie von Millennium Pharmaceuticals gut im Auge zu behalten.

mfg phedre

[ass3000]

@schakal 23

Hallo,

Die Abstufung durch S&P betrifft Millenium Chemicals und
nicht Millennium Pharmaceuticals. Also was sieht hier nicht gut aus?

[schakal23]

oh Gott bin ich erleichtert. Ich hab das ganz übersehen.

danke!

[sukashi]

was seid ihr doch für träumer....

[js200]

03/07/2003 (16:44 ET) New 10-K just released for MLNM - Edgar
03/05/2003 (06:03 ET) Nadine Wong Profiles the Following Stocks: Millennium and Celgene - Business Wire
03/05/2003 (06:00 ET) Nadine Wong Profiles the Following Stocks: Millennium and Celgene - Business Wire
03/03/2003 (16:36 ET) New 4 just released for MLNM - Edgar
03/03/2003 (16:17 ET) New 4/A just released for MLNM - Edgar

JS200

[js200]

Nadine Wong Profiles the Following Stocks: Millennium and Celgene

Wednesday, March 05, 2003 06:03 ET

CHICAGO, Mar 5, 2003 (BUSINESS WIRE) -- Multiple myeloma is one of those disorders where patients have few treatment options. That`s just the kind of news that Nadine Wong and savvy investors are looking for in the biotech space. Learn about a company with an innovative new treatment that could be good medicine for your portfolio. Get her takes on Millennium (NASDAQ:MLNM) and Celgene (NASDAQ:CELG). Click here for the full story exclusively on Zacks.com: http://featuredexpert2bw.zacks.com/

Here are the highlights from the Featured Expert column:

Millennium`s (NASDAQ:MLNM) developmental timeline for Velcade, its novel cancer drug, is on track and investors are gravitating to its story. At the same time, investors are wondering which drug has the advantage in treating patients with multiple myeloma. Will it be Millennium`s Velcade or Celgene`s (NASDAQ:CELG) Thalomid or Revimid?

Currently, Thalomid is prescribed off-label by physicians to treat multiple myeloma, even though Thalomid has not been approved by the Food and Drug Administration (FDA) to treat multiple myeloma or any other cancers.

Millennium filed a new drug application (NDA) with the FDA seeking accelerated approval for Velcade in relapsed/refractory multiple myeloma. The U.S. submission is based on data from the recently completed Phase II study (the SUMMIT trial) which was presented at the last American Society of Hematology (ASH) meeting in December. Assuming the six-month priority review goes well, Velcade could be on the market in the second half of 2003, at least 12 to 18 months sooner than if the company were to rely on its ongoing Phase III trial for approval.

Millennium`s strategy of filing a NDA based on a surrogate end point (tumor response rates measured by drops in paraprotein) in a Phase II trial is aggressive. Although approval is certainly possible, the hurdles are high. The efficacy results seem convincing at face value, but critical issues for approval will be whether the SUMMIT trial was adequately designed and conducted. The FDA`s decision will be known within 60 days of the NDA submission; that is, by mid-March.

Given relapsed/refractory multiple myeloma patients have few treatment options, it will be interesting to see how the story unfolds. Millennium could definitely use another drug on the market.

Learn more about the drugs and treatments that will have an impact on the future, and possibly your investment universe, though the technical analysis and stock suggestions of Nadine Wong by clicking: http://featuredexpert3bw.zacks.com/

About Zacks Featured Experts

To be a successful investor you need professional advice. Experts who know what they`re talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.

Recommendations from Featured Experts Highlighted in FREE Investment Newsletter

The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://www.freeprofit1bw.zacks.com

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1981 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://www.freeprofitbw.zacks.com

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.


CONTACT: Zacks.com
Terry Batey, 312/630-9880 x 307
[e-mail]
www.Zacks.com



(c) 2003 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.


-0-


KEYWORD: ILLINOIS
SUBJECT CODE: E-COMMERCE
INTERNET
BANKING
SOURCE:
Zacks.com


JS200

[LMeister7]

Hallo,
frohe Kunde: http://biz.yahoo.com/prnews/030310/nem039_1.html
MfG,
LM7

[skaya]

prima, dass ist der erste Schritt zur Zulassung.
Grüße
Skaya

[js200]

FDA Accepts for Review NDA Filing and Grants Priority Review for VELCADE(TM) (bortezomib) for Injection
via COMTEX

March 10, 2003

CAMBRIDGE, Mass., Mar 10, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that the U.S. Food and Drug Administration (FDA) accepted for review and granted Priority Review designation of the Company`s New Drug Application (NDA) for VELCADE for the treatment of relapsed and refractory multiple myeloma. Priority Review is granted by the FDA to an NDA for a new treatment that addresses an unmet medical need. The FDA expedites the approval process for such an NDA by reducing the target review period for the application from 10 months to six months. Acceptance of the filing means that FDA has made a threshold determination that the NDA is sufficiently complete to permit a substantive review.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

`We believe that the acceptance of our NDA for review is another step in our ongoing commitment of working to get this important medicine to multiple myeloma patients,`said Barry Greene, general manager, oncology at Millennium. `The Agency`s decision to grant the application Priority Review status underscores the potential therapeutic benefit of VELCADE and represents a significant step toward the Company`s global mission of developing novel treatments in areas of significant unmet medical need.`

The acceptance of this filing comes approximately six weeks after the Company filed marketing applications in both the U.S. and the European Union (EU). VELCADE was granted fast track status by the FDA in June 2002, and Millennium filed the NDA under the provisions of Subpart H Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses on January 21, 2003. The Agency for the Evaluation of Medicinal Products (EMEA) accepted the Marketing Authorization Application (MAA) for review on February 24, 2003.

The NDA submission was based primarily upon the results of the phase II SUMMIT trial, a multi-center study of 202 patents with relapsed and refractory multiple myeloma which were presented in full at the December 2002 meeting of the American Society of Hematology (ASH). The data were submitted electronically as well as in the common technical document (CTD) format, which allowed for nearly simultaneous filings in the U.S. and the EU.

About VELCADE(TM) (bortezomib) for Injection and Proteasome Inhibition

VELCADE and proteasome inhibition represent a completely new approach to treating multiple myeloma. The Company is also investigating VELCADE in many other cancers. The rapid development of this product is based on the Company`s deep understanding of cancer and disease pathways and the effect proteasome inhibition has on those pathways. Cancer is characterized by uncontrolled cell proliferation; VELCADE, the first and currently only proteasome inhibitor to be studied in cancer patients, blocks the proteasome and interferes with chemical messengers that are associated with unregulated cancer cell growth and survival. For patients, this means VELCADE may help slow and even halt the progression of the disease, potentially helping cancer patients live longer.

Millennium is conducting an international, multi-center, phase III APEX trial of VELCADE in patients with relapsed or refractory multiple myeloma as well as two phase II trials with VELCADE, one in patients with metastatic colorectal cancer and another in patients with advanced non-small cell lung cancer. In addition, the Company also has several ongoing phase I and II trials in patients with various hematologic and solid tumors and plans to initiate additional phase I and II studies later this year. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at [phone].

About Multiple Myeloma

Multiple myeloma is a cancer of the bone marrow in which white blood cells called plasma cells, normally responsible for the production of antibodies (proteins that fight infection and disease), are overproduced. The proliferation of these abnormal plasma cells, known as myeloma cells, causes decreased production of normal red and white blood cells, and of normal disease-fighting antibodies, as well as the growth of tumors that spread to multiple sites - hence the term multiple myeloma. The decreased white blood cell production damages the immune system while the myeloma tumors cause bone destruction that manifests as pain and fractures.

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and younger age of onset. In the United States, more than 40,000 individuals have multiple myeloma and over 14,000 new cases of the disease are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths due to multiple myeloma each year.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four areas: cardiovascular disease, oncology and inflammatory and metabolic diseases. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, the Company is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., the Company also has facilities in South San Francisco, Calif. and Cambridge, UK.

This press release contains `forward-looking statements,`including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause the Company`s actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN; our ability to extinguish the convertible notes assumed in the COR acquisition; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editors`Note: This release is also available on the Company`s website at: www.millennium.com.

Contacts: Kelly Lindenboom (media) Gina Price Nugent (investor) [phone] [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Kelly Lindenboom (media), [phone], or Gina Price Nugent(investor), [phone] both of Millennium Pharmaceuticals, Inc./Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, 888-776-6555 or 212-782-2840/Company News On-Call: http://www.prnewswire.com/comp/114562.html
http://www.millennium.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

03/10/2003 (11:46 ET) VOLUME(+): MLNM Volume 31% > 20-adsv, Stock +10.71% - Knobias
03/10/2003 (11:38 ET) New 4 just released for MLNM - Edgar
03/10/2003 (11:13 ET) MLNM Higher; FDA Grants Priority Review for VELCADE - Knobias
03/10/2003 (11:03 ET) FDA Accepts for Review NDA Filing and Grants Priority Review for VELCADE(TM) (bortezomib) for Injection - PR Newswire
03/07/2003 (16:44 ET) New 10-K just released for MLNM - Edgar

JS200

[js200]

Von Gestern

MLNM
MILLENNIUM PHARMACEUTICALS INC
7.410
+0.410 +5.86%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 1/28/2003 (41) days ago, when the stock price was 8.350. Since then the stock fell -11.26% .

Today the stock closed higher with a higher high and a higher low. The volume is extremely high. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 7.410
Previous Close 7.000
Change +0.410
% Change +5.86%
Volume 14,747,197
Stock Activity
Open 6.970
Day`s High 8.080
Day`s Low 6.800
52 Week High 25.280
52 Week Low 6.430


Stock Price History
3 Month % Change -25.23
6 Month % Change -36.18
12 Month % Change -69.91
Stock Statistics
50 Day Close MA 7.600
200 Day Close MA 9.954
65 Day Volume MA 4,855,586

JS200

[js200]

StockPickReport.Com: New ratings on Millennium Pharmaceuticals, Freddie Mac, United Technologies, Cephalon, &Cray
via COMTEX

March 11, 2003

Mar 11, 2003 (M2 PRESSWIRE via COMTEX) --

http://www.stockpickreport.com/?src=bw ) makes these short- term stock recommendations:

Millennium Pharmaceuticals (NASDAQ:MLNM) - SELL - http://pr.stockpickreport.com/MLNM.htm Freddie Mac (NYSE:FRE) - BUY - http://pr.stockpickreport.com/FRE.htm United Technoligies (NYSE:UTX) - SELL - http://pr.stockpickreport.com/UTX.htm Cephalon (NASDAQ:CEPH) - SELL - http://pr.stockpickreport.com/CEPH.htm Cray (NASDAQ:CRAY) - SELL - http://pr.stockpickreport.com/CRAY.htm

Millennium Pharmaceuticals (NASDAQ:MLNM) StockPickReport.Com Rating: SELL (-5) http://pr.stockpickreport.com/MLNM.htm

Millennium Pharmaceuticals is a biopharmaceutical company that applies its comprehensive and integrated science and technology platform to discover and accelerate the development of drugs and predictive medicine products.

MLNM`s end-of-day price moved under recent trendlines throughout the most-recent couple of weeks as indicated by a short-term average of the 3-week closing-price moving average. At the same time, our researchers find that MLNM`s daily average volume continues to slip below recent levels. Finally, we forecast the stock will sustain the current trade momentum with lower prices possible, as predicted by MLNM`s recent short-term stochastic reading.

In our opinion, StockPickReport.Com research indicates a `short-sell` strategy (buying puts, selling calls, short-selling, or outright selling of MLNM) at current levels is the logical move at this time.

Freddie Mac (NYSE:FRE) StockPickReport.Com Rating: BUY (5) http://pr.stockpickreport.com/FRE.htm

Freddie Mac purchases single-family and multi-family residential mortgages and mortgage-related securities, which it finances primarily by issuing mortgage passthrough securities and debt instruments in the capital markets.

We see that FRE`s volume still continues to move to the upside. Also, our technical analysts think the stock should persist with the current market momentum with an upward bias, as indicated by FRE`s recent near-term stochastic mark. Finally, traders may want to note that the stock`s end-of-day price trended sideways over the previous couple of trading sessions as indicated by a one-week average of its three-week average.

In our opinion, StockPickReport.Com research indicates a `long` strategy (selling puts, buying calls, closing short positions, or outright buying FRE) at current levels offers traders a nice chance for a profitable trade.

United Technoligies (NYSE:UTX) StockPickReport.Com Rating: SELL (-2) http://pr.stockpickreport.com/UTX.htm

United Technologies provides a broad range of high-technology products and support services to the building systems and aerospace industries.

The stock`s closing-price average made a leg-up since last week. Also, the stock`s average near- term share volume continues to move down. Finally, our researchers anticipate UTX will most likely set about a reversal of course as predicted by UTX`s recent short-term stochastic analysis.

In our opinion, StockPickReport.Com research indicates a `short-sell` strategy (buying puts, selling calls, short-selling, or outright selling of UTX) at current levels is the logical move at this time.

Cephalon (NASDAQ:CEPH) StockPickReport.Com Rating: SELL (-2) http://pr.stockpickreport.com/CEPH.htm

Cephalon discovers, develops and markets products to treat neurological disorders and cancers.

Technical analysis finds that CEPH`s multi-week moving-average of volume fell during the previous week. Moreover, our analysts forecast the stock will see a break of tone in conjunction with the most current near-term stochastic indicator. In conclusion, the stock`s end-of-day price average decreased to weaker levels over the last week or so; with that in mind, our researchers think that this is positive data in regard to traders who bought puts recently.

In our opinion, StockPickReport.Com research indicates a `short-sell` strategy (buying puts, selling calls, short-selling, or outright selling of CEPH) at current levels is the logical move at this time.

Cray (NASDAQ:CRAY) StockPickReport.Com Rating: SELL (-6) http://pr.stockpickreport.com/CRAY.htm

Cray Inc., formerly Tera Computer Company, designs, builds, sells and services high-performance computer systems, known as supercomputers.

CRAY`s price slipped below recent levels during the most-recent few sessions as evidenced by it`s weekly moving average of it`s longer-term end-of-day average. And, CRAY investors could find it valuable to note that the stock`s daily average shares-traded increased over the week-ago period.

Subsequently, our analysts anticipate CRAY will maintain the recent market action with lower prices possible, in accordance with CRAY`s new short-term stochastic indicator.

In our opinion, StockPickReport.Com research indicates a `short-sell` strategy (buying puts, selling calls, short-selling, or outright selling of CRAY) at current levels is the logical move at this time.

WHAT THESE RATINGS MEAN: StockPickReport.Com ranks stocks with a proprietary unbiased system of technical analysis. These ratings do not indicate a `long term`view of any company listed. These are ratings that reflect our opinion of a stock`s potential price movement over the next five to ten trading sessions. The stock ratings range from +10 (which indicates our view that a stock has a great chance to move higher) to - 10 (which indicates our belief that a stock has a great chance to move lower).

These ratings may change based on daily market conditions.

ABOUT STOCKPICKREPORT.COM:

StockPickReport.Com is a stock research firm. Our daily commentary has regular, worldwide distribution. We are Registered Investment Advisors. We do not accept third-party compensation to make stock suggestions. We do not own shares of any stock we rate.

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.

StockPickReport.Com`s goal is to provide stock research FREE from bias or conflicts. You can get your FREE trial to StockPickReport.Com at http://www.stockpickreport.com/?src=bw

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2003 M2 COMMUNICATIONS LTD

JS200

[Megapol]

11.03. 16:35
MILLENNIUM Pharma steigt auch heute an

Auch heute steigt die Aktie von Millennium Pharma weiter an und gehört damit zu den aktuell größten Kursgewinnern im Nasdaq 100.

Der Kurs konnte sich nach dem Ausbruch aus einer relativen SKS-Formation im Bereich des Supports um 7 Dollar stabilisieren und bricht aus der Konsolidierung der Vortage unter erhöhtem Volumen nach oben aus.
Aktuell wird der Widerstand in Form der Nackenlinie der SKS-Formation sowie der langfristige _Downtrend erreicht.

Weiteren Widerstand bilden das Niveau um 8,9 und 10,3 Dollar.





Quelle: (©GodmodeTrader - http://www.godmode-trader.de)

[Megapol]

11.03. 16:36
Institutionelle bei Millennium Pharma

Im Folgenden steht an erster Stelle der Name des institutionellen Shareholders bzw. Fonds, an zweiter Stelle das gehaltene Aktienpaket und an dritter Stelle die Änderung des Aktienpakets. Die Daten beziehen sich auf das vierte Quartal 2002.




Quelle: (©GodmodeTrader - http://www.godmode-trader.de)

[js200]

Schaeffer`s Option Activity Watch Features DIS, AIG, MLNM
via COMTEX

March 11, 2003

CINCINNATI, Mar 11, 2003 /PRNewswire via COMTEX/ --

Today`s Schaeffer`s Option Activity Watch features Walt Disney (NYSE: DIS), American International Group (NYSE: AIG), and Millennium Pharmaceuticals (Nasdaq: MLNM). The Option Activity Watch is a report that takes a closer look at three equities appearing in our most unusual option activity report from the previous day. The Option Activity Watch is published on www.SchaeffersResearch.com -- the home of Bernie Schaeffer and Schaeffer`s Investment Research. For additional information about this report or to have it delivered to you free via email every day click on the following link: http://www.schaeffersresearch.com/addinfo" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/addinfo .

(Photo: http://www.newscom.com/cgi-bin/prnh/20020725/SCHAEFFERLOGO )

Schaeffer`s Option Activity Watch:

There are a number of sentiment tools we use here at Schaeffer`s every day to help with our overall Expectational Analysis(R) for an individual stock. One of those is a screen that filters stocks with unusually high call or put volume from the previous day`s trading. This morning, I searched for yesterday`s unusual call activity and came up with the following list.

Click the following link to see the list of stocks with unusually high call volume: http://www.schaeffersresearch.com/wire?ID=7256" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7256 .

1. One of the stocks that caught my eye was Walt Disney (NYSE: DIS). Yesterday`s call volume of 5,845 contracts compares to its average daily volume for the past month of just 1,626. Diving deeper into the data, we see that yesterday`s volume caused the stock`s Schaeffer`s put/call open interest ratio (SOIR) to drop from 0.56 to 0.51. On the surface, this move may seem insignificant. However, it represents a decline in the SOIR percentile rank from 41 to 27 percent. (In other words, the current SOIR reading is lower than about 73 percent of those taken during the past year.) Additional signs of optimism can be seen in the steadily declining number of DIS shares sold short and in the number of Wall Street analysts who are bullish on the stock. According to Zacks, 22 of the 24 who follow DIS rate it a `hold`or better. Meanwhile, the company is stuck in minefield of fundamental concerns that range from sagging consumer confidence and heightened threats of terrorism to the possibility of a war with Iraq. Add to that the continued resistance of DIS`s declining 10-month moving average, and these high expectations could unwind in the form of more selling to push the shares lower.

Click the following link to see the Monthly Chart of DIS since August 2001 with 10-Month Moving Average: http://www.schaeffersresearch.com/wire?ID=7256" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7256 .

2. Another name on the list is American International Group (NYSE: AIG), which saw call volume of 18,704 contracts yesterday that was nearly three times its average daily volume. Most of this activity occurred at AIG`s out- of-the-money April and May 50 strikes, which increased by 2,763 and 2,538 contracts, respectively. This activity pushed the stock`s SOIR to 0.66 -- its lowest reading of the past year. AIG`s technical picture is horrible, with the stock trading to a new annual low today following a recent rejection at the 50 level. What`s more, a recent article in The Wall Street Journal raised the question of whether property-casualty insurers would be able to collect enough premium from terrorism insurance sales to mitigate losses from potential attacks.

Click the following link to see the Weekly Chart of AIG since March 2001: http://www.schaeffersresearch.com/wire?ID=7256" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7256 .

3. Call volume was also heavy on Millennium Pharmaceuticals (Nasdaq: MLNM) yesterday. Overall, more than 5,220 contracts traded hands -- a sharp increase from the stock`s daily average. This helps bring MLNM`s SOIR to 0.35, which represents nearly three calls for every put in the front three months of options. Yesterday`s big story was that the FDA has granted priority review to MLNM`s application for its new bone marrow cancer treatment, Velcade. This could explain the addition of 1,547 calls at the stock`s (then) out-of-the-money April 7.50 strike. In fact, today finds the shares trading just above this level following yesterday`s sharp rally and subsequent pullback. However, our research shows MLNM could be poised for future declines. A test of its current SOIR shows that there are 95 occasions during the past three years when this reading has fallen between 0.30 and 0.40. For those 95 occurrences, the stock declined by an average of 6.28 percent during the next 15 days. Those who are long the April 7.50 call better hope this bit of history doesn`t repeat itself.

Click the following link to see the Daily Chart of MLNM since December 2002: http://www.schaeffersresearch.com/wire?ID=7256" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7256 .

The best way to take advantage of the timely commentaries from SchaeffersResearch.com is to sign up to receive their e-newsletters -- Opening View, Midday Report, Market Recap and Monday Morning Outlook. Click here to have the Schaeffer`s commentaries delivered to you free via email every day: http://www.schaeffersresearch.com/addinfo" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/addinfo .

About Schaeffer`s Investment Research ( www.SchaeffersResearch.com )

Schaeffer`s Investment Research, founded by Bernie Schaeffer in 1981, is a financial information and trading resources company. It publishes Bernie Schaeffer`s Option Advisor, the nation`s leading options subscription newsletter. The firm`s contrarian approach focuses on stocks with technical and fundamental trends that run counter to investor expectations. The firm`s website, www.schaeffersresearch.com, is recognized as one of the leading information sources for stock and options traders and was cited as the top options website by both Forbes and Barron`s. Click here for more details about Schaeffer`s trading methodology: www.schaeffersresearch.com/method .

Contact: Tom Godich of Schaeffer`s, [phone], [e-mail] .

SOURCE Schaeffer`s Investment Research

Tom Godich of Schaeffer`s, [phone], [e-mail] /Photo: http://www.newscom.com/cgi-bin/prnh/20020725/SCHAEFFERLOGO AP Archive: http://photoarchive.ap.org PRN Photo Desk, [phone] or [phone]

http://www.schaeffersresearch.com

Copyright (C) 2003 PR Newswire. All rights reserved.

Print story

Current Quote

NDC: MLNM
Biotech/Medical

Last: 7.610
Change: 0.200
Volume: 4,880,100
Day High: 7.760
Day Low: 7.440



First Alert News
Get real-time MLNM release alerts by entering your email address below.

JS200

[js200]

Von gestern

MLNM
MILLENNIUM PHARMACEUTICALS INC
7.390
-0.020 -0.27%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 1/28/2003 (42) days ago, when the stock price was 8.350. Since then the stock fell -11.50% .

Today the stock closed lower, close to its low (sign of weakness) with a lower high and a higher low (sign of decrease in volatility). The volume is high. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Short Black Candlestick

Today a Short Black Candlestick formed. There was a limited price change that may represent consolidation

Stock Quote
Last 7.390
Previous Close 7.410
Change -0.020
% Change -0.27%
Volume 7,561,844
Stock Activity
Open 7.440
Day`s High 7.760
Day`s Low 7.380
52 Week High 25.280
52 Week Low 6.430

Stock Price History
3 Month % Change -21.72
6 Month % Change -35.74
12 Month % Change -70.00
Stock Statistics
50 Day Close MA 7.577
200 Day Close MA 9.902
65 Day Volume MA 4,846,950

JS200

[Brettvormkopp]

Meine Prognose : Das Präparat Velcade wird ein Blockbuster
und Millennium wird ein Highflyer in 2003.
Das Präparat wird von einigen Leuten dringend
benötigt. Ich kenne selber ...
Ich wüßte auch nicht mehr, wo bei 2 Milliarden Cash
bei dem Kurswert das Risiko besteht.
Wenn ich mal Medigene mit 45 Mios in Cash anschaue -
ne Lachnummer dagegen
Rein !!!

[js200]

SG Cowen 23rd Annual Healthcare Conference to Webcast Millennium Pharmaceuticals Presentations [INLINE]
via CDS

March 13, 2003

CAMBRIDGE, Mass., March 13 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced today that its presentations at the SG Cowen 23rd Annual Healthcare Conference will be webcast live and may be accessed by visiting the investor relations section of the Company`s website, http://www.millennium.com.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Millennium senior management will provide an overview of the Company and progress against 2003 goals. The first presentation will be delivered at 8:00 a.m. (EST), to be followed by a 9:00 a.m. presentation, on Thursday, March 20, 2003 from the Marriott Copley Place Hotel in Boston. The presentations will be archived for 30 days.



About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass. Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.



Editor`s Note: This release is available on Millennium`s website at http://www.millennium.com



Contact:

Cynthia Clayton, Investor Relations

Millennium Pharmaceuticals, Inc.


JS200

[schakal23]

Kurzzusammenfassung:
Analyst: UBS Warburg
Rating: Buy Kurs: n/A
KGV: Kursziel: n/A
Update: upgrade WKN: 903002
Update Millennium Chemicals Inc.: Buy
13.03.2003 13:08:50
In ihrer Analyse vom Mittwoch, 12. März 2003 stufen die Analysten von UBS Warburg die Aktie des Unternehmens Millennium Chemicals Inc. von "Neutral" auf "Buy" herauf. Ein Kursziel geben die Analysten nicht an.

[skaya]

hi schakal,
Du hast MLNM wieder mit Millennium Chemicals vewechselt

Grüße
Skaya

[js200]

StayinFront to Provide Rapid Deployment of CRM Solution for Leading Biopharmaceutical Company
via COMTEX

March 18, 2003

FAIRFIELD, NJ, Mar. 18, 2003 (INTERNET WIRE via COMTEX) --

StayinFront, a leading global provider of enterprise-wide customer relationship management (CRM) applications, decision support tools and eBusiness systems, today announced it has been selected by Millennium Pharmaceuticals Inc. (NASDAQ: MLNM) to provide a multi-channel CRM system for use by that company`s field sales force, managers and home office personnel to integrate with marketing and medical departments.

Millennium will implement Visual Elk(TM), StayinFront`s enterprise-wide solution for managing and integrating all points of customer interaction. A campaign management module will be used by the field sales force to schedule and track events. The StayinFront system is a single source solution, which gives organizations the option to take on some service components themselves.

Thomas R. Buckley, chief executive officer of StayinFront, said, `StayinFront`s technically superior products offer an exact fit to business processes and the ability to rapidly change when needed. We provide a solid value proposition and a responsive partnership for implementation as well as for long-term goals. Our considerable knowledge and experience in life sciences and the unique architecture of our products has allowed us to successfully build our customer base in this market.`

About Visual Elk(TM)

Visual Elk is designed to provide a single CRM platform that can manage and integrate all points of customer interaction including sales, marketing, customer support applications and the Web. Visual Elk is a highly configurable, cost-effective, enterprise-wide solution. The unique Object-Oriented data models utilized in Visual Elk allow an exact fit CRM system to be configured for use with an existing business structure without costly and time-consuming programming code. The system can be seamlessly delivered through multiple applications simultaneously; across a network, via the Web or through a remote, disconnected field force, giving maximum flexibility to the corporation as technology and business needs change.

About Panorama(TM)

Panorama is a powerful data analysis and decision support tool specifically designed for non-technical users. Through the use of intuitive Drag, Drop and Drill technology, Panorama can be used to quickly and easily analyze sales, marketing and financial information from any ODBC database. Panorama can be delivered as a Windows(R) application or through a browser, via the Web.

About StayinFront, Inc.

StayinFront, Inc. is a leading global provider of enterprise-wide customer relationship management (CRM) applications, decision support tools and eBusiness systems. StayinFront`s family of products includes Visual Elk, the company`s flagship CRM software; Panorama, a powerful stand-alone or integrated data analysis and decision support tool; Web Works, an eBusiness configuration technology; Pocket Elk, a fully-featured CRM system for the Microsoft Pocket PC platform based devices; and Industry Add-ins and Solution Add-ins for specific business management needs.

StayinFront offers a rapidly configured and implemented solution to manage and integrate all points of customer interaction including sales, marketing, customer support applications and the Web. Among the analysts following our company and products is Dale Hagemeyer of Gartner Group, Inc.

Headquartered in Fairfield, New Jersey, StayinFront has offices in Illinois, Maine, the United Kingdom, Belgium, Australia, Singapore and New Zealand. A worldwide network of Implementation Partners installs and supports StayinFront systems around the globe. The company can be contacted via the Web at www.stayinfront.com.

Note to editors: Visual Elk, Panorama, Pocket Elk, Web Works, Active Elk and StayinFront are trademarks of StayinFront, Inc. All other trademarks are owned by their respective companies.

Sam Barclay StayinFront 973-461-4800 Jeanne Achille The Devon Group 732-542-2000 Ext. 11

Copyright 2003 Internet Wire, All rights reserved.

JS200

[schakal23]

das ist diese verdamte such maschine sory

[js200]

Von Gestern

MLNM
MILLENNIUM PHARMACEUTICALS INC
8.830
+0.590 +7.16%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 3/13/2003 (5) days ago, when the stock price was 8.250. Since then the stock gained 7.03% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. The volume is normal. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 8.830
Previous Close 8.240
Change +0.590
% Change +7.16%
Volume 5,050,237
Stock Activity
Open 8.300
Day`s High 8.880
Day`s Low 8.200
52 Week High 25.280
52 Week Low 6.430

Stock Price History
3 Month % Change 0.11
6 Month % Change -10.45
12 Month % Change -65.07
Stock Statistics
50 Day Close MA 7.579
200 Day Close MA 9.701
65 Day Volume MA 4,354,027

JS200

[js200]

More Assistance Now Available for Massachusetts Citizens Without Prescription Drug Coverage
via COMTEX

March 19, 2003

BOSTON, Mar 19, 2003 /PRNewswire via COMTEX/ --

The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced the Massachusetts launch of www.helpingpatients.org, an online database of patient assistance programs (PAPs) designed to help thousands of state residents who lack adequate prescription drug coverage.

The database, created and funded by the pharmaceutical industry, provides patients with immediate access to information on more than 1,400 medicines offered through more than 140 industry and 185 government and privately sponsored patient assistance programs. Of the 48 PhRMA-member companies offering direct assistance on the new website, many have significant Massachusetts operations, including AstraZeneca, Biogen, Genzyme Corp., Merck and Co., Millennium Pharmaceuticals, Novartis, Pfizer, Serono Inc. and Wyeth Pharmaceuticals.

`The launch of this site is indicative of the commitment that pharmaceutical companies are making to help people in Massachusetts get better access to prescription drugs,`said Mark Grayson, a PhRMA spokesperson. `This level of assistance is particularly important because of the general belt- tightening in state programs. The initiative also serves to strengthen the long-term, industry-wide effort to ensure that patients have the medications they desperately need,`he said.

Designed to help low-income individuals who are uninsured or underinsured, PAPs provide access to medications for millions of people, including seniors covered solely by Medicare, which currently lacks a prescription drug benefit.

A recent survey conducted by PhRMA indicated that company-sponsored patient assistance programs provided prescription services to more than 5 million Americans in 2002. In Massachusetts, during the course of the past four years, nearly 100,000 patients have been directly aided by assistance programs. The estimated wholesale value of medicines distributed through company patient assistance programs totals $1.5 billion.

To make it simple for Massachusetts residents or their physicians to find a patient assistance program that offers the specific medications they need, www.helpingpatients.org enables patients to fill out an online form and receive a listing of programs for which they may be qualified. PhRMA also publishes a printed version of the Directory of Prescription Drug Patient Assistance Programs, which lists programs, the companies that offer them, available medicines, basic eligibility requirements and contact persons.

The pharmaceutical industry has a long tradition of providing prescription drug medicines free of charge to patients who might not otherwise be able to afford them. `While patient assistance programs are invaluable for ensuring that the neediest patients have access to medicines, they cannot be expected to solve the larger national problem of access to medical care, including prescription drugs,`said Grayson of PhRMA. `The pharmaceutical industry will continue to work cooperatively with those seeking public and private sector solutions to chronic health system challenges,`he added.

Massachusetts residents can download a free copy of the directory at www.helpingpatients.org, or at PhRMA`s web site www.phrma.org.

CONTACT: Andrew D. Nannis Joe M. Grillo PhRMA Nicolazzo &Associates [phone] [phone] [e-mail] [e-mail]

SOURCE The Pharmaceutical Research and Manufacturers of America (PhRMA)

Andrew D. Nannis of PhRMA, [phone], [e-mail]; or Joe M. Grillo for Nicolazzo &Associates, [phone], [e-mail]

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

StayinFront: StayinFront to provide rapid deployment of CRM solution for leading biopharmaceutical company
via COMTEX

March 20, 2003

Mar 20, 2003 (M2 PRESSWIRE via COMTEX) --

StayinFront, a leading global provider of enterprise-wide customer relationship management (CRM) applications, decision support tools and eBusiness systems, announced it has been selected by Millennium Pharmaceuticals Inc. to provide a multi-channel CRM system for use by its field sales force, managers and home office personnel to integrate with marketing and medical departments.

Millennium will implement Visual Elk(tm), StayinFront`s enterprise-wide solution for managing and integrating all points of customer interaction. A campaign management module will be used by the field sales force to schedule and track events. The StayinFront system is a single source solution, which gives organisations the option to take on some service components themselves.

Thomas R. Buckley, CEO of StayinFront, said, `StayinFront`s technically superior products offer an exact fit to business processes and the ability to rapidly change when needed. We provide a solid value proposition and a responsive partnership for implementation as well as for long-term goals. Our considerable knowledge and experience in life sciences and the unique architecture of our products has allowed us to successfully build our customer base in this market.`

About Millennium Pharmaceuticals, Inc.

Millennium researches and develops breakthrough treatments for serious diseases. Its main approach is to provide patients with `personalised medicine`, where the individual patient receives the most effective medicines for his/her condition.

Millennium is built on a solid foundation of talented people, ground-breaking business relationships, an unparalleled science and discovery platform, and a strong clinical and commercial presence. These factors have enabled Millennium, in less than 10 years, to grow from a bold young startup company into a leading pharmaceutical company, with two products brought to the market and more due to be launched.

About Visual Elk(tm)

Visual Elk is designed to provide a single CRM platform that can manage and integrate all points of customer interaction including sales, marketing, customer support applications and the Web. Visual Elk is a highly configurable, cost-effective, enterprise-wide solution. The unique Object-Oriented data models utilized in Visual Elk allow an exact fit CRM system to be configured for use with an existing business structure without costly and time-consuming programming code. The system can be seamlessly delivered through multiple applications simultaneously; across a network, via the Web or through a remote, disconnected field force, giving maximum flexibility to the corporation as technology and business needs change.

About Panorama(tm)

Panorama is a powerful data analysis and decision support tool specifically designed for non-technical users. Through the use of intuitive Drag, Drop and Drill technology, Panorama can be used to quickly and easily analyze sales, marketing and financial information from any ODBC database. Panorama can be delivered as a Windows application or through a browser, via the Web.

About StayinFront, Inc.

StayinFront, Inc. is a leading global provider of enterprise-wide customer relationship management (CRM) applications, decision support tools and eBusiness systems. StayinFront`s family of products includes Visual Elk, the company`s flagship CRM software; Panorama, a powerful stand-alone or integrated data analysis and decision support tool; Web Works, an eBusiness configuration technology; Pocket Elk, a fully-featured CRM system for the Microsoft Pocket PC platform based devices; and Industry Add-ins and Solution Add-ins for specific business management needs.

StayinFront offers a rapidly configured and implemented solution to manage and integrate all points of customer interaction including sales, marketing, customer support applications and the Web. Among the analysts following our company and products is Dale Hagemeyer of Gartner Group, Inc.

Headquartered in Fairfield, New Jersey, StayinFront has offices in Illinois, Maine, the United Kingdom, Belgium, Australia, Singapore and New Zealand. A worldwide network of Implementation Partners installs and supports StayinFront systems around the globe. The company can be contacted via the Web at www.stayinfront.com.

Note to editors:

Visual Elk, Panorama, Pocket Elk, Web Works, Active Elk and StayinFront are trademarks of StayinFront, Inc. All other trademarks are owned by their respective companies.

CONTACT: Nigel Huxtable, StayinFront Tel: [phone] e-mail: [e-mail] Natalie Johnson/Nicola Welch, MCC International Ltd Tel: [phone] Fax: [phone] e-mail: [e-mail] e-mail: [e-mail] WWW: http://www.mccint.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2003 M2 COMMUNICATIONS LTD

JS200

[js200]

Banc of America Securities Healthcare Conference 2003 to Webcast Millennium Pharmaceuticals Presentation
via COMTEX

March 20, 2003

CAMBRIDGE, Mass., Mar 20, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced today that its presentation at the Banc of America Securities Healthcare Conference 2003 will be webcast live and may be accessed by visiting the investor relations section of the Company`s website, www.millennium.com.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Millennium senior management will provide an overview of the Company and progress against 2003 goals. The presentation will be delivered at 9:45 a.m. (PST) on Thursday, March 27, 2003 from the Four Seasons Hotel in Las Vegas. The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass. Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

Editor`s Note: This release is available on Millennium`s website at www.millennium.com

Contact: Cynthia Clayton, Investor Relations Millennium Pharmaceuticals, Inc. [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Cynthia Clayton, Investor Relations for MillenniumPharmaceuticals, Inc., [phone]/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, 888-776-6555 or 212-782-2840/Company News On-Call: http://www.prnewswire.com/comp/114562.html
http://www.millennium.com


JS200

[js200]

StockPickReport.Com Announces Stock Evaluation Ratings for Oracle, Hewlett-Packard, Millennium Pharmaceuticals, JP Morgan and Johnson & Johnson

Friday , March 28, 2003 18:06 ET

SHREVEPORT, La., Mar 28, 2003 (BUSINESS WIRE) -- StockPickReport.Com (IARD#119079 - http://www.stockpickreport.com/?src=bw)" target="_blank" rel="nofollow ugc noopener">http://www.stockpickreport.com/?src=bw) makes these short-term stock recommendations:

Oracle (NASDAQ:ORCL) - SELL - http://pr.stockpickreport.com/ORCL.htm

Hewlett-Packard (NYSE:HPQ) - SELL - http://pr.stockpickreport.com/HPQ.htm

Millennium Pharmaceuticals (NASDAQ:MLNM) - SELL - http://pr.stockpickreport.com/MLNM.htm

JP Morgan (NYSE:JPM) - BUY - http://pr.stockpickreport.com/JPM.htm

Johnson & Johnson (NYSE:JNJ) - SELL - http://pr.stockpickreport.com/JNJ.htm

--------------------------------- Oracle (NASDAQ:ORCL) StockPickReport.Com Rating: SELL http://pr.stockpickreport.com/ORCL.htm

Oracle Corporation develops, manufactures, and markets enterprise software that helps customers manage and grow businesses and manage their operations.

Our researchers think the stock will persist with the current trade trend with lower prices possible, as predicted by the stock`s newest near-term stochastic analysis. At the same time, the stock`s end-of- day price 3-week rate-of-change climbed to elevated territory since last week . Our data finds that the stock`s multi-week average of shares-traded fell during the last seven-day period.

In our opinion, StockPickReport.Com research indicates a "short-sell" strategy (buying puts, selling calls, short-selling, or outright selling of ORCL) at current levels is the logical move at this time.

For clarification on how we rate ORCL a SELL, please visit: http://pr.stockpickreport.com/ORCL.htm

Hewlett-Packard (NYSE:HPQ) StockPickReport.Com Rating: SELL http://pr.stockpickreport.com/HPQ.htm

HP is a leading provider of products, technologies, solutions and services to consumers and business. The company`s offerings span IT infrastructure, personal computing and access devices, global services, and imaging and printing.

Our researchers anticipate the stock will stay with the recent trade direction in a likely decline lower, as indicated by the most recent short-term stochastic reading. Furthermore, the stock`s price slipped below recent levels during the last couple of weeks as indicated by it`s 1-week average of the 15-day closing-price moving average. Finally, the daily shares traded for the stock rose greater than prior levels over the most recent couple of weeks.

In our opinion, StockPickReport.Com research indicates a "short-sell" strategy (buying puts, selling calls, short-selling, or outright selling of HPQ) at current levels is the logical move at this time.

For clarification on how we rate HPQ a SELL, please visit: http://pr.stockpickreport.com/HPQ.htm.

Millennium Pharmaceuticals (NASDAQ:MLNM) StockPickReport.Com Rating: SELL http://pr.stockpickreport.com/MLNM.htm

Millennium Pharmaceuticals is a biopharmaceutical company that applies its comprehensive and integrated science and technology platform to discover and accelerate the development of drugs and predictive medicine products.

The short-term shares traded for MLNM moved beyond previous moving averages over the last number of sessions. Lastly, the stock`s closing-price moving average descended to lower territory over the last week or so. In our opinion, StockPickReport.Com research indicates a "short-sell" strategy (buying puts, selling calls, short-selling, or outright selling of MLNM) at current levels is the logical move at this time.

For clarification on how we rate MLNM a SELL, please visit: http://pr.stockpickreport.com/MLNM.htm.

JP Morgan (NYSE:JPM) StockPickReport.Com Rating: BUY http://pr.stockpickreport.com/JPM.htm

JP Morgan Chase & Co is a leading wholesale financial services firm.

JPM`s volume continues to move to the upside. Also, we anticipate the stock will most likely set about a transformation in course as predicted by JPM`s most current near-term stochastic mark. The stock`s end-of-day price average rose to higher territory over the last few sessions.

In our opinion, StockPickReport.Com research indicates a "long" strategy (selling puts, buying calls, closing short positions, or outright buying JPM) at current levels may not be advisable. The stock is close to a change in direction, we think.

For clarification on how we rate JPM a BUY, please visit: http://pr.stockpickreport.com/JPM.htm.

Johnson & Johnson (NYSE:JNJ) StockPickReport.Com Rating: SELL http://pr.stockpickreport.com/JNJ.htm

Johnson & Johnson, employing approximately 108,300 people worldwide, is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world.

Our researchers anticipate the stock should march lower in accordance with the most current short-term stochastic chart. Incidentally, JNJ`s price slipped into lower territory during the recent few market sessions as indicated by a near-term average of it`s longer-term closing- price average. JNJ`s short-term share volume continues to decrease.

In our opinion, StockPickReport.Com research indicates a "short-sell" strategy (buying puts, selling calls, short-selling, or outright selling of JNJ) at current levels is the logical move at this time.

For clarification on how we rate JNJ a SELL, please visit: http://pr.stockpickreport.com/JNJ.htm.

WHAT THESE RATINGS MEAN:

StockPickReport.Com ranks stocks with a proprietary unbiased system of technical analysis. These ratings do not indicate a "long term" view of any company listed. These are ratings that reflect our opinion of a stock`s potential price movement over the next five to ten trading sessions. The stock ratings range from +10 (which indicates our view that a stock has a great chance to move higher) to - 10 (which indicates our belief that a stock has a great chance to move lower). These ratings may change based on daily market conditions.

ABOUT STOCKPICKREPORT.COM:

StockPickReport.Com is a stock research firm. Our daily commentary has regular, worldwide distribution. We are Registered Investment Advisors. We do not accept third-party compensation to make stock suggestions. We do not own shares of any stock we rate. Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited. StockPickReport.Com`s goal is to provide stock research FREE from bias or conflicts. You can get your FREE trial to StockPickReport.Com at http://www.stockpickreport.com/?src=bw


CONTACT: StockPickReport.Com, Shreveport
Dewey Burchett, 318/219-2368
[e-mail]
http://www.stockpickreport.com/index.htm

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.



Copyright (C) 2003 Business Wire. All rights reserved.


-0-


KEYWORD: LOUISIANA
INDUSTRY KEYWORD: COMPUTERS/ELECTRONICS
BANKING
PHARMACEUTICAL
MEDICAL
DEVICES
INVESTMENT
OPINION
SOURCE:
StockPickReport.Com

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


03/28/2003 (18:06 ET) StockPickReport.Com Announces Stock Evaluation Ratings for Oracle, Hewlett-Packard, Millennium Pharmaceuticals, JP Morgan and Johnson & Johnson - Business Wire



03/27/2003 (10:02 ET) CONF: MLNM To Present At BOA Healthcare Conference @ 12:45 ET - Knobias



03/26/2003 (06:41 ET) MEDIA: Today`s Wall Street Journal Mentions MLNM - Knobias



03/20/2003 (16:01 ET) Banc of America Securities Healthcare Conference 2003 to Webcast Millennium Pharmaceuticals Presentation - PR Newswire



03/20/2003 (11:12 ET) StayinFront: StayinFront to provide rapid deployment of CRM solution for leading biopharmaceutical company - M2 Communications



03/20/2003 (09:29 ET) Hemispherx Biopharma to Present at the Strategic Research Institutes First `SiRNA` Conference - PR Newswire



03/20/2003 (07:02 ET) CONF: MLNM To Present At SG Cowen Health Care Conference @ 09:00 ET - Knobias



03/20/2003 (07:02 ET) CONF: MLNM To Present At SG Cowen Health Care Conference @ 08:00 ET - Knobias



03/19/2003 (09:15 ET) More Assistance Now Available for Massachusetts Citizens Without Prescription Drug Coverage - PR Newswire



03/18/2003 (13:54 ET) StayinFront to Provide Rapid Deployment of CRM Solution for Leading Biopharmaceutical Company - Internet Wire



03/18/2003 (13:38 ET) DEF 14A: MLNM Vote; Directors; Stock Purchase Plan - Knobias



03/18/2003 (12:05 ET) New DEF 14A just released for MLNM - Edgar



03/13/2003 (16:01 ET) SG Cowen 23rd Annual Healthcare Conference to Webcast Millennium Pharmaceuticals Presentations - PR Newswire



03/12/2003 (16:59 ET) New SC 13D just released for MLNM - Edgar



03/11/2003 (12:15 ET) Schaeffer`s Option Activity Watch Features DIS, AIG, MLNM - PR Newswire



03/11/2003 (11:53 ET) FDA grants priority review for Millenium`s Velcade - Datamonitor



03/11/2003 (09:29 ET) MORNING UPDATE: Man Securities Issues Alerts for MLNM, TER, HNZ, KR, And XOMA - PR Newswire



03/11/2003 (08:51 ET) RATING(=): Ryan Beck Reiterates MLNM Rating @ Outperform - Knobias



03/11/2003 (04:51 ET) StockPickReport.Com: New ratings on Millennium Pharmaceuticals, Freddie Mac, United Technologies, Cephalon, & Cray - M2 Communications



03/10/2003 (11:46 ET) VOLUME(+): MLNM Volume 31% > 20-adsv, Stock +10.71% - Knobias



03/10/2003 (11:38 ET) New 4 just released for MLNM - Edgar



03/10/2003 (11:13 ET) MLNM Higher; FDA Grants Priority Review for VELCADE - Knobias



03/10/2003 (11:03 ET) FDA Accepts for Review NDA Filing and Grants Priority Review for VELCADE(TM) (bortezomib) for Injection - PR Newswire



03/07/2003 (16:44 ET) New 10-K just released for MLNM - Edgar



03/05/2003 (06:03 ET) Nadine Wong Profiles the Following Stocks: Millennium and Celgene - Business Wire


JS200

[js200]

Millennium Commences Required Cash Offers for Convertible Notes
via COMTEX

March 31, 2003

CAMBRIDGE, Mass., Mar 31, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced its required cash offers to the holders of its outstanding 4.50% Convertible Senior Notes due June 15, 2006 and 5.00% Convertible Subordinated Notes due March 1, 2007.

(Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Millennium assumed the convertible notes in connection with its merger with COR Therapeutics, Inc. on February 12, 2002. The offers are being made in accordance with the terms of the notes, under which the noteholders have the right to exchange the notes for cash on April 29, 2003. These cash amounts equal 109.5% and 108.5% of the principal amount of the 4.50% notes and the 5.00% notes, respectively, plus, in each case, interest accrued and unpaid through April 28, 2003. The offers and withdrawal rights expire at 9:00 a.m., Eastern Time, on Tuesday, April 29, 2003.

Millennium is actively considering amending the terms of some or all of the notes to provide additional rights to holders of the notes, although there can be no assurance that Millennium will amend any notes. If Millennium decides to amend the terms of the notes, it will make a public announcement of that fact by issuing a press release no later than April 22, 2003.

This press release is neither an offer to purchase nor a solicitation of an offer to sell securities. The offers are made only through the Notice of Put Right and Offer to Purchase and the related Letter of Transmittal for the applicable class of notes, which are being mailed to noteholders today. Additional copies of these documents may be obtained by contacting Gina Price Nugent at Millennium or the Paying Agent for the offers, U.S. Bank, N.A., at [phone].

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass. Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

Important additional information will be filed with the SEC

Millennium plans to file today with the SEC Schedule TOs in connection with its tender offer for each of the 4.50% notes and the 5.00% notes. The Schedule TOs, including the related Notice of Put Right and Offer to Purchase, will contain important information about Millennium, the notes, the tender offer and related matters. Investors and security holders are urged to read the Schedule TOs carefully when they become available.

Investors and security holders may obtain free copies of each of the Schedule TOs and other documents filed with the SEC by Millennium through the web site maintained by the SEC at www.sec.gov. In addition, investors and security holders may obtain free copies of each of the Schedules TOs from Millennium by contacting Gina Price Nugent, or from the Paying Agent by contacting Frank Leslie of U.S. Bank, N.A. at [phone].

Editors`Note: This release is also available on the Company`s website at: www.millennium.com

Contacts: Cynthia Clayton (investor) [phone] Adriana Jenkins (media) [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Cynthia Clayton (investor), [phone], or Adriana Jenkins(media), [phone], both of Millennium Pharmaceuticals, Inc./Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, 888-776-6555 or 212-782-2840/Company News On-Call: http://www.prnewswire.com/comp/114562.html
http://www.millennium.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[schakal23]

01.04. 19:10
MILLENNIUM Pharma - Konsolidierung des Ausbruchs
(©GodmodeTrader - http://www.godmode-trader.de)



Maßgebend ist auch bei der Aktie von Millennium Pharma (MLNM) aktuell der übergeordnete Downtrend seit 2000.
Der Kurs konnte nach dem temporären Bruch des Supports bei 7,0 Dollar aus einem langfristig gebildeten Bullkeil erneut nach oben ausbrechen und konsolidiert derzeit den Anstieg aus.
Im Hoch ist der Kurs am Widerstand um 8,9 Dollar gescheitert. Einen wichtigen langfristigen Widerstand bildet vor allem der Bereich um 10,3 Dollar.
Unterstützung findet der Kurs neben der Nackenlinie einer SKS-Formation auf dem gebrochenen längerfristigen Downtrend.

Tageschart (Eine Kerze = ein Tag)



Wochenchart (Eine Kerze = eine Woche)

[filuta]

Was ist mit dieser Seite los? Man kann keine Texte lesen? Es werden keine Seiten gezeigt?
Danke für Hilfe. Ambra

[schakal23]

was meinst du da mit ich sehe alles









--------------------------------------------------------------------------------

03.04. 21:02
MILLENNIUM Pharma - Ausbruch läuft

--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)
Die Aktie von Millennium Pharma (MLNM) konnte sich auf dem Support bei 7 Dollar stabilisieren und brach anschließend aus dem langfristig gebildeten Bullkeil nach oben aus.
Die nach dem anstieg gebildete kurzfristige Bullflag wurde an den Vortagen trendbestätigend nach oben aufgelöst.

Heute wird der Widerstand bei 8,9 Dollar wieder deutlicher nach oben durchbrochen. Wichtige Widerstände finden sich bei 10,3 Dollar und vor allem am langfristig übergeordneten Downtrend. Dieser bleibt als maßgebend anzusehen.

Tageschart (Eine Kerze = ein Tag)




Wochenchart (Eine Kerze = eine Woche)

[filuta]

Wieso kann ich keine Seite aufmachen und die Beiträge lesen? Bei mir erscheint nur die Startseite. Danke für Hinweise. [e-mail]. ambra

[JS222]

04/07/2003 (12:20 ET) StockPickReport.com Announces Stock Evaluation Ratings on Siebel Systems, Altera, Mercury Interactive, Millennium Pharmaceuticals and Bed Bath & Beyond - Business Wire
04/07/2003 (08:41 ET) Mica Capital Partners, LLC Announces Investment Opinion: EquityCast.com Market Performance & News Alert - Business Wire
04/03/2003 (11:11 ET) StockPickReport.com Announces Stock Evaluation Ratings for Exxon-Mobil, Wal-Mart, Sanmina-SCI, Millennium Pharmaceuticals, King Pharmaceuticals Inc. - Business Wire
04/02/2003 (15:55 ET) Thomson Financial Clients Win 28 Out of 30 Awards at the Investor Relations Magazine US Awards 2003 - PR Newswire
04/02/2003 (08:45 ET) RATING(=): Ryan Beck Reiterates MLNM Rating @ Outperform - Knobias

JS200

[JS222]

Von Gestern

MLNM
MILLENNIUM PHARMACEUTICALS INC
9.260
+0.260 +2.89%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 4/3/2003 (5) days ago, when the stock price was 9.370. Since then the stock fell -1.17% .

Today the stock closed higher with a lower high and a higher low (sign of decrease in volatility). The volume is low. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
White Candlestick

Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.

Stock Quote
Last 9.260
Previous Close 9.000
Change +0.260
% Change +2.89%
Volume 2,819,196
Stock Activity
Open 9.010
Day`s High 9.431
Day`s Low 8.970
52 Week High 23.120
52 Week Low 6.430

Stock Price History
3 Month % Change 15.32
6 Month % Change 2.89
12 Month % Change -54.25
Stock Statistics
50 Day Close MA 7.643
200 Day Close MA 9.440
65 Day Volume MA 4,416,772

JS200

[JS222]

04/09/2003 (12:14 ET) Millennium Initiates Phase I Clinical Trial of MLN1202 - PR Newswire
04/09/2003 (07:20 ET) TABLE: Unconfirmed Earnings Expected Tuesday, Apr 15 - Knobias
04/07/2003 (12:20 ET) StockPickReport.com Announces Stock Evaluation Ratings on Siebel Systems, Altera, Mercury Interactive, Millennium Pharmaceuticals and Bed Bath & Beyond - Business Wire
04/07/2003 (08:41 ET) Mica Capital Partners, LLC Announces Investment Opinion: EquityCast.com Market Performance & News Alert - Business Wire
04/03/2003 (11:11 ET) StockPickReport.com Announces Stock Evaluation Ratings for Exxon-Mobil, Wal-Mart, Sanmina-SCI, Millennium Pharmaceuticals, King Pharmaceuticals Inc. - Business Wire

JS200

[JS222]

Millennium Initiates Phase I Clinical Trial of MLN1202

--Initiation of trial meets key company goal --

Wednesday, April 09, 2003 12:14 ET

CAMBRIDGE, Mass., Dec 16, 2002 /PRNewswire-FirstCall via Comtex/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the initiation of a phase I clinical trial of MLN1202. MLN1202, a novel humanized monoclonal antibody that blocks the chemokine receptor known as CCR2, is being developed as a potential treatment for patients with rheumatoid arthritis and possibly other inflammatory diseases. The primary objectives of this double-blind, placebo-controlled, single dose-escalation study are to evaluate the tolerability, pharmacokinetic and pharmacodynamic properties of MLN1202. The study will be conducted in Europe and will include approximately 48 healthy volunteers.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO" target="_blank" rel="nofollow ugc noopener">http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"MLN1202 represents the third new molecular entity to enter clinical development this year, meeting an important company goal," said Steve Gilman, Ph.D. general manager, inflammation franchise at Millennium. "Rheumatoid arthritis remains a significant area of unmet medical need and we are hopeful that MLN1202`s novel mechanism of action may provide patients with an additional therapeutic option."

The CCR2 receptor is found on the surface of monocytes and some T cells and binds hormone-like "chemokines" known as monocyte chemoattractant proteins (MCPs). Using the CCR2 receptor, MCPs signal monocytes and T cells to migrate to sites of injury as part of the inflammatory process. MLN1202 is designed to specifically block the MCP-CCR2 chemokine pathway and prevent infiltration of immune cells into inflammatory sites, such as arthritic joints.

A number of published preclinical studies suggest that CCR2 plays an important role in the inflammatory response and that antagonism of CCR2 could potentially be an effective therapeutic approach in a variety of inflammatory and autoimmune indications, including rheumatoid arthritis, multiple sclerosis, atherosclerosis, restenosis and fibrosis.

For more information about MLN1202 clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at [phone].

About Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic, progressive inflammatory disease of the articular (rotating) joints that results in significant pain, stiffness and swelling and leads to degradation of the joint tissue. RA can cause permanent damage and deformities to joints, resulting in loss of function and ultimately leading to joint replacement surgery in some cases. In addition, some RA patients develop extra-articular manifestations such as rheumatoid nodules, interstitial lung disease and vasculitis.

According to the Arthritis Foundation, RA affects 2.1 million Americans and is about 3 times more common in women than men. The disease has a significant socioeconomic impact with medical costs and indirect expenses due to lost wages for RA estimated to be over $3 billion per year. In addition, mortality rates for people with RA are double those of the general population.

The cause of RA is not known. However, it is believed that RA is an autoimmune disease where the body`s natural immune system attacks healthy joint tissue causing inflammation and subsequent joint damage.

The Millennium Inflammation Franchise

Millennium`s inflammation franchise includes a number of novel molecular targets and compounds in various stages of development, from discovery research to advanced clinical trials. These programs include small molecules and monoclonal antibodies to potentially treat patients with a broad spectrum of chronic inflammatory diseases. Millennium and Aventis Pharmaceuticals, Inc. formed an alliance in June 2000 focused on identifying drug targets and developing new therapies for inflammatory diseases. Scientists are collaborating on discovery, development and commercialization of small molecule drugs and other product candidates for the treatment of rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD), multiple sclerosis, and inflammatory bowel disease. The companies are sharing inflammation discovery pipeline assets, jointly developing new technologies and sharing costs equally.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass. Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

This press release contains "forward-looking statements," including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause Millennium`s actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN(R) (eptifibatide) Injection; our ability to extinguish the convertible notes assumed in the COR acquisition; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editor`s Note: This release is available on Millennium`s Web site at www.millennium.com.


Contacts:
Millennium Pharmaceuticals, Inc.
Steve Sylven (media)
[phone]

Gina Price Nugent (investor)
[phone]

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X16271261


SOURCE Millennium Pharmaceuticals, Inc.


Photo : NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOG



CONTACT: Steve Sylven (media), [phone], or Gina Price Nugent
(investor), [phone], both of Millennium Pharmaceuticals, Inc.
/Company News On-Call: http://www.prnewswire.com/comp/114562.htm" target="_blank" rel="nofollow ugc noopener">http://www.prnewswire.com/comp/114562.htm

URL: http://www.prnewswire.com
http://www.millennium.com

JS200

[JS222]

http://www.knobias.com/news.htm?ticker=MLNM&eid=3.1.3e42ce3e…

JS200

[JS222]

Millennium to Webcast Conference Call on First Quarter 2003 Financial Results on April 15, 2003
via COMTEX

April 9, 2003

CAMBRIDGE, Mass., Apr 9, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) will hold a live webcast of its conference call at 5:00 p.m. EDT on Tuesday, April 15, 2003. Mark Levin, chairperson and chief executive officer will host the call. He will discuss the Company`s first quarter results for 2003, as well as provide an overview of the Company and progress against 2003 goals. Millennium will announce its financial results for this period in a press release to be issued after market close on Tuesday, April 15, 2003.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The press release and the live webcast can be accessed by visiting the Company`s website, www.millennium.com, under the Investor section, by using the `Investor Overview`tab. Following the webcast, an archived version of the call will be available at the same address until April 29, 2003.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

Editor`s Note: This release is also available on the Company`s website at: http://www.millennium.com

Contact: Cynthia Clayton Millennium Pharmaceuticals, Inc. [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Cynthia Clayton of Millennium Pharmaceuticals, Inc.,[phone]/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, 888-776-6555 or 212-782-2840/Company News On-Call: http://www.prnewswire.com/comp/114562.html
http://www.millennium.com

Copyright (C) 2003 PR Newswire. All rights reserved.


JS200

[JS222]

Von Gestern

MLNM
MILLENNIUM PHARMACEUTICALS INC
8.900
-0.360 -3.89%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 4/3/2003 (6) days ago, when the stock price was 9.370. Since then the stock fell -5.02% .

Today the stock closed lower, close to its low (sign of weakness) with a higher high and a lower low (sign of increase in volatility). The volume is low. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Long Black Candlestick
Bearish Engulfing Pattern

Today a Long Black Candlestick formed. Sellers were aggressive and selling pressure was strong. Be careful, this may be a potential turning point!

The last two candlesticks formed a Bearish Engulfing Pattern. This is a bearish formation that marks a potential change in trend, and indicates that the bears have sized control from bulls.

Stock Quote
Last 8.900
Previous Close 9.260
Change -0.360
% Change -3.89%
Volume 3,299,901
Stock Activity
Open 9.450
Day`s High 9.540
Day`s Low 8.880
52 Week High 23.120
52 Week Low 6.430

Stock Price History
3 Month % Change 7.49
6 Month % Change 6.08
12 Month % Change -53.79
Stock Statistics
50 Day Close MA 7.654
200 Day Close MA 9.424
65 Day Volume MA 4,376,987

JS200

[JS222]

Von Gestern

MLNM
MILLENNIUM PHARMACEUTICALS INC
8.920
+0.020 +0.22%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 4/3/2003 (7) days ago, when the stock price was 9.370. Since then the stock fell -4.80% .

Today the stock closed higher with a lower high and a lower low. The volume is extremely low. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Spinning Top

Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bulls and a potential change or interruption in the current trend!

Stock Quote
Last 8.920
Previous Close 8.900
Change +0.020
% Change +0.22%
Volume 2,153,621
Stock Activity
Open 8.870
Day`s High 9.010
Day`s Low 8.630
52 Week High 23.120
52 Week Low 6.430

Stock Price History
3 Month % Change 2.88
6 Month % Change -1.55
12 Month % Change -55.91
Stock Statistics
50 Day Close MA 7.671
200 Day Close MA 9.413
65 Day Volume MA 4,345,012

JS200

[js200]

Groundbreaking Research Identifies Molecular Pathway Underlying Key Infection-Fighting Mechanism
via COMTEX

April 14, 2003

CAMBRIDGE, Mass., Apr 14, 2003 /PRNewswire-FirstCall via COMTEX/ --

Researchers at the University of Massachusetts Medical School (Worcester), Harvard University and Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the discovery of a new pathway underlying the body`s innate immune response, which provides immediate, first-line defense against organisms such as viruses. The research, published in the online edition of Nature Immunology, represents an important advance in understanding how the immune system responds rapidly to infection before more specific responses - such as antibody production - are activated. The new discovery may also provide important insights into inflammatory processes and, possibly, into cancer cell proliferation.

The new pathway features two proteins known as I kappa B kinase epsilon and TANK-binding kinase-1. These proteins were shown to provide essential signals that lead to increased production of interferon and other proteins which stimulate defensive responses.

`The significance of this discovery goes beyond the innate immune response,`said Tom Maniatis, Ph.D., department of molecular and cellular biology, Harvard University. `There are many similarities between this and inflammatory responses, as well as an important connection to the NF kappa B pathway.`

The new research establishes an activation pathway for the body`s innate immune response, a non-specific defensive response that is activated against infectious agents such as viruses and bacteria. The similarities between this response and inflammatory processes suggest that the new pathway could potentially be relevant for these processes as well. The connection with the NF kappa B pathway is also significant because of the central role that NF kappa B plays, not just in the innate immune response, but also in inflammation and cancer cell proliferation.

`We now understand more clearly how the body coordinates responses that are important in fighting infections and inflammation,`said Katherine Fitzgerald, Ph.D., assistant professor at the University of Massachusetts Medical School.

`Some of the most advanced medical research today involves understanding the pathways of disease,`said Robert I. Tepper, M.D., president of research and development at Millennium. `This provides new avenues of research that will hopefully one day lead to new ways of treating infectious disease as well as inflammation and possibly even cancer.`

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass. Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

This press release contains `forward-looking statements,`including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause our actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN; our ability to extinguish the convertible notes assumed in the COR acquisition; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editor`s Note: This release is available on Media section of Millennium website at www.millennium.com

Contact: Adriana Jenkins (media) Gina Price Nugent (investors) [phone] [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Adriana Jenkins (media), [phone], or Gina Price Nugent (investors), [phone], both for Millennium /Company News On-Call: http://www.prnewswire.com/gh/cnoc/comp/114562.html

http://www.millennium.com


JS200

[Iguana]

eine bitte - MLMN meldet diese woche quartalszahlen.
falls jemand den genauen termin und zeitpunkt kennt (vor börseneröffnung oder danach), wäre es nett die info kurz hier reinzustellen. danke!

gruß, iguana

[js200]

@IGUNA

Stand im **179**

Millennium to Webcast Conference Call on First Quarter 2003 Financial Results on April 15, 2003
via COMTEX

April 9, 2003

CAMBRIDGE, Mass., Apr 9, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) will hold a live webcast of its conference call at 5:00 p.m. EDT on Tuesday, April 15, 2003. Mark Levin, chairperson and chief executive officer will host the call. He will discuss the Company`s first quarter results for 2003, as well as provide an overview of the Company and progress against 2003 goals. Millennium will announce its financial results for this period in a press release to be issued after market close on Tuesday, April 15, 2003.

JS200

[js200]

Von Gestern

MLNM
MILLENNIUM PHARMACEUTICALS INC
9.100
+0.320 +3.64%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 4/3/2003 (11) days ago, when the stock price was 9.370. Since then the stock fell -2.88% .

Today the stock closed higher with a higher high and a higher low. The volume is low. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Spinning Top

Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bulls and a potential change or interruption in the current trend!

Stock Quote
Last 9.100
Previous Close 8.780
Change +0.320
% Change +3.64%
Volume 2,569,276
Stock Activity
Open 9.020
Day`s High 9.234
Day`s Low 8.890
52 Week High 23.120
52 Week Low 6.430

Stock Price History
3 Month % Change -1.09
6 Month % Change -6.19
12 Month % Change -60.02
Stock Statistics
50 Day Close MA 7.727
200 Day Close MA 9.382
65 Day Volume MA 4,290,837

JS200

[js200]

Millennium Reports First Quarter 2003 Financial Results
via COMTEX

April 15, 2003

CAMBRIDGE, Mass., Apr 15, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported consolidated financial results for the quarter ended March 31, 2003.

Revenue for the quarter ended March 31, 2003 was $81.7 million, compared to $68.6 million for the same period in 2002. Co-promotion revenue, based on worldwide sales of INTEGRILIN(R) (eptifibatide) Injection, was $50.9 million for the quarter ended March 31, 2003, compared to $22.1 million for the same period in 2002, which included only six and one half weeks of sales. Worldwide sales of INTEGRILIN for the quarter ended March 31, 2003 were $89.0 million, as provided to Millennium by Schering-Plough Corporation, representing an increase of 31 percent from the same period last year.

Strategic alliance revenue for the quarter ended March 31, 2003 was $30.8 million, compared to $46.5 million for the same period in 2002. The Company`s revenue mix reflects increased co-promotion revenue and lower collaborative revenues as a result of discovery-focused and technology partnerships coming to their expected conclusions.

Research and development (R&D) expenses for the quarter ended March 31, 2003 were $126.8 million, compared to $101.3 million for the same period in 2002. This increase reflects the Company`s continued investment in its clinical programs, primarily VELCADE(TM) (bortezomib) for Injection and INTEGRILIN.

Selling, general and administrative (SG&A) expenses for the quarter ended March 31, 2003 were $35.4 million, compared to $37.2 million for the same period in 2002. SG&A expenses reflect a balance between managing G&A expense and increasing the resources devoted to the Company`s commercial organization as Millennium prepares for the launch of VELCADE, pending approval by the U.S. Food and Drug Administration (FDA).

Other income (expense) for the quarter ended March 31, 2003 was ($0.8) million, compared to $21.4 million for the same period in 2002. The decrease in other income reflects a lower average level of invested funds during the quarter and the low interest yields currently available.

For the quarter ended March 31, 2003, net loss on a GAAP basis was $137.9 million or $0.47 per share compared to $303.9 million or $1.20 per share for the same period in 2002. Included in the quarter ended March 31, 2003 is a $28.2 million restructuring charge relating to the write-down of certain intangible assets and facilities and personnel costs associated with the discontinuation of discovery efforts. Included in the quarter ended March 31, 2002 is a $242.0 million in-process R&D charge recorded in connection with the COR merger.

Pro forma net loss for the quarter ended March 31, 2003 was $100.0 million or $0.34 per share, compared to $56.3 million or $0.22 per share for the same period in 2002. The increase in pro forma net loss is a result of increased R&D expense and decreased investment income and collaborative revenue.

Millennium reports pro forma net loss which excludes certain non- operational and restructuring charges, non-cash and specified other charges that management generally does not consider in evaluating the Company`s ongoing operations. These results are provided as a complement to results provided in accordance with accounting principles generally accepted in the United States (known as `GAAP`). Management believes this pro forma measure helps indicate underlying trends in the Company`s business, and uses this pro forma measure to establish budgets and operational goals that are communicated internally and externally, to manage the Company`s business and to evaluate its performance. A reconciliation of pro forma to GAAP is included in the attached condensed consolidated financial statements.

As of March 31, 2003, Millennium had approximately $1.7 billion in cash, cash equivalents and marketable securities, and $683.3 million in principal amount of convertible debt. On March 31, 2003, Millennium commenced required cash offers to the holders of approximately $600.0 million in principal amount of convertible debt it assumed in the merger with COR. The Company is actively considering amending the terms of some or all of these notes to provide additional rights to holders of the notes, although there can be no assurance that Millennium will amend any notes. If Millennium decides to amend the terms of the notes, it will make a public announcement of that fact by issuing a press release no later than April 22, 2003.

`This is a particularly exciting time for us as we prepare for the launch of VELCADE(TM) (bortezomib) for Injection, pending FDA approval,`said Kenneth Bate, chief financial officer. `We are expanding our commercial organization with the addition of an oncology sales force in the U.S. and are looking forward to making this drug available to clinicians and to patients. While we will devote considerable resources to the launch of VELCADE in 2003, we will also continue to manage expenses company-wide, bringing them in line with anticipated revenue.`

COMPANY HIGHLIGHTS

Products and Pipeline

INTEGRILIN(R) (eptifibatide) Injection, an intravenous GP IIb-IIIa inhibitor, is co-promoted and co-developed by Millennium and Schering-Plough. Both parties share the revenue and expenses related to U.S. product sales and Schering-Plough pays Millennium royalties on sales outside of the U.S. Based on recent third party audit reports for February 2003, INTEGRILIN continues to be the market leader both in patient share and dollar share with approximately 64 percent and 50 percent, respectively, of the U.S. market.

Results from CRUSADE were presented at the recent America College of Cardiology (ACC) meeting, including data demonstrating a statistically significant 44 percent decrease in hospital mortality in patients with high- risk acute coronary syndrome who received a GP IIb-IIIa inhibitor within the first 24 hours of arriving at the hospital. Other data presented showed that these patients who were cared for by a cardiologist, rather than a non- cardiologist, were more likely to be treated with guideline-recommended therapies, including GP IIb-IIIa inhibitors, resulting in decreased mortality rate.

`Our market research reveals that the CRUSADE results are of significant interest to clinical cardiologists and will likely impact their decision to prescribe INTEGRILIN,`said Vaughn Kailian, vice chairperson. `In order to assure broad awareness of the CRUSADE results among clinical cardiologists, we will be expanding our sales force to encourage use of INTEGRILIN at time of diagnosis of high-risk patients with acute coronary syndrome.`

CRUSADE is a quality improvement initiative by Duke Clinical Research Institute with funding and support from Millennium and Schering-Plough to increase adherence to the ACC/American Heart Association guidelines for the early and aggressive treatment of acute coronary syndrome in high-risk patients. CRUSADE is providing critical information about the care these patients receive, and how it could be improved. As of the end of March 2003, data was collected from over 47,000 cases.

VELCADE(TM) (bortezomib) for Injection, the Company`s novel proteasome inhibitor which is being evaluated in clinical studies for the treatment of several types of cancer, met significant regulatory milestones in the U.S. and Europe this quarter. The FDA, which had already granted VELCADE Orphan Drug Designation, accepted for review and granted Priority Review designation to the Company`s New Drug Application for the treatment of relapsed and refractory multiple myeloma. The European Agency for the Evaluation of Medicinal Products accepted for review the Company`s Marketing Authorisation Application for VELCADE. Millennium is also conducting an international, multi-center phase III APEX trial of VELCADE in patients with either relapsed or refractory multiple myeloma. Efforts are ongoing to develop this compound for other hematologic and solid tumors as well. There are over 30 clinical trials ongoing with VELCADE in a variety of other cancers, including Millennium-sponsored phase II clinical trials in patients with non-small cell lung cancer and colorectal cancer, a broad variety of investigator-initiated trials, and trials sponsored by the National Cancer Institute.

About INTEGRILIN(R) (eptifibatide) Injection

INTEGRILIN is indicated for the treatment of patients with acute coronary syndrome (UA/NQMI), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI) and for the treatment of patients undergoing PCI, including those undergoing intracoronary stenting.

INTEGRILIN is contraindicated in patients with: a history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days; severe hypertension (systolic blood pressure > 200 mm Hg or diastolic blood pressure > 110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within preceding six weeks; history of stroke within 30 days, or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb-IIIa inhibitor; dependency on renal dialysis; or known hypersensitivity to any component of the product.

Bleeding is the most common complication encountered during INTEGRILIN therapy. The majority of excess major bleeding events were localized at the femoral artery access site. Oropharyngeal, genitourinary, gastrointestinal, and retroperitoneal bleeding were also seen more commonly with INTEGRILIN compared to placebo. Please consult Full Prescribing Information which can be accessed at www.millennium.com/integrilin.html.

INTEGRILIN is co-promoted and co-developed by Millennium Pharmaceuticals and Schering-Plough Corporation.

Note: Millennium will host a conference call at 5:00 p.m. EDT on April 15, 2003. The live webcast can be accessed at www.millennium.com under the Investor Overview page of the Investors section and will be archived until April 29, 2003. This press release can be found under the Media section of the website.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four areas: cardiovascular disease, oncology and inflammatory and metabolic diseases. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, the Company is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., the Company also has facilities in South San Francisco, Calif. and Cambridge, UK.

This press release contains `forward-looking statements,`including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause our actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN; our ability to extinguish the convertible notes assumed in the COR acquisition; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This press release also contains financial measures which are not generally GAAP and should not be construed as superior to GAAP financial measures. Information regarding our use of non-GAAP financial measures and information about comparable GAAP financial measures is available in the Investor Relations section by using the `Investor Overview`tab of our website, www.millennium.com.

Note: Prior year comparisons include six and one half weeks of financial results for COR Therapeutics, Inc., which was merged with Millennium on February 12, 2002.

Millennium Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (in thousands, except per share amounts) Three Months Ended March 31, 2003 2002 (Note 1) (unaudited) REVENUES: Revenue under strategic alliances $30,834 $46,457 Co-promotion revenue 50,881 22,142 Total revenues 81,715 68,599 COSTS AND EXPENSES: Research and development 126,810 101,312 Selling, general and administrative 35,383 37,241 Cost of co-promotion revenue 18,696 7,728 Total costs and expenses 180,889 146,281 OTHER INCOME (EXPENSE): Investment income 9,607 28,157 Interest expense (10,417) (6,793) Total other income (expense) (810) 21,364 PRO FORMA NET LOSS (Note 2) $(99,984) $(56,318) Acquired in-process research and development - (242,000) Amortization of intangibles (9,676) (5,543) Restructuring charges (Note 3) (28,195) - NET LOSS $(137,855) $(303,861) PRO FORMA NET LOSS PER SHARE $(0.34) $(0.22) BASIC AND DILUTED NET LOSS PER SHARE $(0.47) $(1.20) Weighted average shares, basic and diluted 292,944 253,901 Note 1: On February 12, 2002 Millennium acquired COR Therapeutics, Inc. (`COR`). The transaction was recorded as a purchase for accounting purposes and the condensed consolidated statements of operations data include COR`s operating results from the date of acquisition. Note 2: Acquired in-process research and development, amortization of intangibles, and restructuring charges are deducted in accordance with generally accepted accounting principles in the United States (`GAAP`) to arrive at GAAP reported net loss for the periods presented in 2003 and 2002, respectively. Note 3: Restructuring charges primarily include the write-down of certain intangible assets, and facilities and personnel costs associated with the discontinuation of certain discovery efforts and reallocation of resources to enhance commercial capabilities. Millennium adopted Statement of Financial Accounting Standards (`SFAS`) No. 146 `Accounting for Costs Associated with Exit of Disposal Activities`(`SFAS No. 146`) as of December 1, 2002. Condensed Consolidated Balance Sheets (in thousands) March 31, December 31, 2003 2002 (unaudited) Cash, cash equivalents and marketable securities $1,651,851 $1,759,063 Other current assets 195,858 179,678 Property and equipment, net 305,298 310,325 Restricted cash and other assets 57,772 64,224 Goodwill and intangible assets, net 1,661,254 1,684,317 Total assets $3,872,033 $3,997,607 Current liabilities $921,938 $949,547 Deferred revenue 3,113 1,704 Capital lease obligations, net 58,809 61,338 Long term debt 83,325 83,325 Stockholders`equity 2,804,848 2,901,693 Total liabilities and stockholders`equity $3,872,033 $3,997,607 Contacts: Clare Midgley (investor) Cynthia Clayton (investor) [phone] [phone] Gina Price Nugent (investor) Adriana Jenkins (media) [phone] [phone]
SOURCE Millennium Pharmaceuticals, Inc.

Clare Midgley (investor), [phone], or Gina Price Nugent(investor), [phone], or Cynthia Clayton (investor), [phone],or Adriana Jenkins (media), [phone], all of Millennium/Company News On-Call: http://www.prnewswire.com/comp/114562.html
http://www.millennium.com


JS200

[schakal23]

Millennium Pharmaceuticals unter Erwartungen Alle Nachrichten

15.04. / 23:4



Druckversion


Das Biopharmazieunternehmen Millennium Pharmaceuticals meldet für das abgelaufene erste Quartal einen Verlust von $100 Millionen oder 34 Cents je Aktie nach einem „pro forma“ Verlust von $56.3 Millionen oder 22 Cents im Vorjahr. Analysten rechneten mit einem Verlust je Aktie von 30 Cents. Der Umsatz, der mit der anteiligen Bewerbung von Medikamenten generiert wurde, wuchs im Jahresvergleich von $22.1 auf $22.1 Millionen. Der durch strategische Allianzen erlöste Umsatz fiel jedoch von $46.5 auf $30.8 Millionen. Die F&E (Forschung & Entwicklung) Ausgaben wuchsen von $101.3 auf $126.8 Millionen. Ende des ersten Quartals hatte Millennium Cash, bargleiche Mittel und kurzfristig liquidierbare Vermögensgegenstände in Höhe von $1.7 Milliarden.

© BörseGo


sch.........

[liasis]

16.04. 15:24
Millennium Pharma wird abgestuft

--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)
UBS Warburg stuft Millennium Pharma nach den Quartalszahlen (siehe BoerseGo.de "Biotech-News") von Buy auf Neutral mit Kursziel $10 ab.

[js200]

Millennium Confirms Terms of Convertible Notes
via COMTEX

April 21, 2003

CAMBRIDGE, Mass., Apr 21, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that it is no longer actively considering amending the terms of its 4.50% Convertible Senior Notes due June 15, 2006 or 5.00% Convertible Subordinated Notes due March 1, 2007.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The Company had previously indicated that it was considering amending the notes to provide noteholders with additional rights, but is no longer pursuing this option. On March 31, 2003 Millennium, as required by the terms of the notes, commenced cash offers to purchase the notes for cash on April 29, 2003 at a price equal to 109.5% of the principal amount of the 4.50% notes and 108.5% of the 5.00% notes, plus, in each case, interest accrued and unpaid through April 28, 2003.

Millennium assumed the approximately $600 million in principal amount of notes in connection with its merger with COR Therapeutics, Inc. on February 12, 2002.

The tender offers and the related withdrawal rights for both the 4.50% and 5.00% notes expire at 9:00 a.m., Eastern Time, on Tuesday, April 29, 2003.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass. Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

Important additional information has been filed with the SEC

Millennium has filed with the SEC Schedule TOs in connection with its tender offers for the notes. The Schedule TOs, including the related Notices of Put Right and Offers to Purchase, contain important information about Millennium, the notes, the tender offers and related matters. Investors and security holders are urged to read the Schedule TOs carefully.

Investors and security holders may obtain free copies of the Schedule TOs and other documents filed with the SEC by Millennium through the web site maintained by the SEC at www.sec.gov. In addition, investors and security holders may obtain free copies of the Schedule TOs from Millennium by contacting Gina Price Nugent, or from the Paying Agent by contacting Frank Leslie of U.S. Bank, N.A. at [phone].

This press release is neither an offer to purchase nor a solicitation of an offer to sell securities.

Editors`Note: This press release is also available under the Media section of the Company`s website at: www.millennium.com.

Contacts: Gina Price Nugent (investor) [phone] Rob Kloppenburg (media) [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Gina Price Nugent (investor), [phone], or RobKloppenburg (media), [phone], both of Millennium/Company News On-Call: http://www.prnewswire.com/gh/cnoc/comp/114562.html/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, 888-776-6555 or 212-782-2840
http://www.millennium.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

CIBC World Markets Annual Biotechnology &Specialty Pharmaceuticals Conference to Webcast Millennium Pharmaceuticals Presentation
via COMTEX

April 23, 2003

CAMBRIDGE, Mass., Apr 23, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced today that its presentation at the CIBC World Markets Annual Biotechnology &Specialty Pharmaceuticals Conference will be webcast live and may be accessed by visiting the Investor Overview page of the Investors section of the Company`s website, www.millennium.com.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Millennium senior management will provide an overview of the Company and progress against 2003 goals. The presentation will be delivered at 11:30 a.m. EDT on Wednesday, April 30, 2003 from the Millennium Broadway Hotel in New York City. The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

Editors`Note: This press release is also available under the Media section of the Company`s website at: www.millennium.com.

Contact: Cynthia Clayton, Investor Relations Millennium Pharmaceuticals, Inc. [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Cynthia Clayton, Investor Relations of MillenniumPharmaceuticals, Inc., [phone]/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, 888-776-6555 or 212-782-2840/Company News On-Call: http://www.prnewswire.com/comp/114562.html
http://www.millennium.com


JS200

[js200]

SECTOR(HCR): Biotechs Lead Sector, Bolstered by ENMD

Wednesday, April 23, 2003 11:21 ET

The Biotechnology industry, up 6.22 points or 1.85% is providing positive gains for the Healthcare Index, which is currently up 1.74 points or 0.70%.

The main leader is EntreMed, Inc. (ENMD), up 40.36%, which is continuing its gains from yesterday after it said its lead cancer drug was shown in a preclinical trial to be more potent than comparable treatments already on the market. ENMD closed up 154% yesterday.

Covance Inc. (CVD), which is up 4.26%, is scheduled to release Q1 earnings after the market closes today. Consensus estimates are Revenue: $238.01 million, EPS: $0.28 per share compared with previous Q1 Revenue of $218.28 million and previous Q1 EPS of $0.19 per share.

On the downside, Albany Molecular Research (AMRI), currently lower by 19.39%, announced that it will report Q1 results before the opening of the market on Tuesday, May 6, 2003. In addition, the company lowered its Q1 and 2003 earnings estimates as a result of reduced research and development spending by pharmaceutical and biotechnology companies.

Public Companies Associated with this story:
ABGENIX INC (NASDAQ NM: ABGX) APPLERA CORPORATION (NYSE: ABI) AFFYMETRIX INC (NASDAQ NM: AFFX)
ALKERMES INC (NASDAQ NM: ALKS) ALEXION PHARMACEUTICALS, INC. (NASDAQ NM: ALXN) AMGEN INC. (NASDAQ NM: AMGN)
AMYLIN PHARMACEUTICALS INC (NASDAQ NM: AMLN) ALBANY MOLECULAR RESEARCH INC (NASDAQ NM: AMRI) BIOGEN, INC. (NASDAQ NM: BGEN)
BIO TECH GENERAL CP (NASDAQ NM: BTGC) CUBIST PHARMACEUTICALS, INC. (NASDAQ NM: CBST) CELL GENESYS INC (NASDAQ NM: CEGE)
CELGENE CORPORATION (NASDAQ NM: CELG) CHIRON CORPORATION (NASDAQ NM: CHIR) APPLERA CORPORATION (NYSE: CRA)
CURAGEN CORPORATION (NASDAQ NM: CRGN) CHARLES RIVER LABORATORIES INTERNAT (NYSE: CRL) CELL THERAPEUTICS INC (NASDAQ NM: CTIC)
COVANCE INC. (NYSE: CVD) CV THERAPEUTICS INC (NASDAQ NM: CVTX) QUEST DIAGNOSTICS INCORPORATED (NYSE: DGX)
DELTA AND PINE LAND COMPANY (NYSE: DLP) GENENTECH INC (NYSE: DNA) ENTREMED, INC. (NASDAQ NM: ENMD)
ENZO BIOCHEM, INC. (NYSE: ENZ) ENZON PHARMACEUTICALS INC (NASDAQ NM: ENZN) GENZYME CORPORATION (NASDAQ NM: GENZ)
GILEAD SCIENCES INC (NASDAQ NM: GILD) GENE LOGIC INC (NASDAQ NM: GLGC) HUMAN GENOME SCIENCES, INC. (NASDAQ NM: HGSI)
ICOS CORPORATION (NASDAQ NM: ICOS) IDEC PHARMACEUTICALS CORPORATION (NASDAQ NM: IDPH) IDEXX LABORATORIES INC (NASDAQ NM: IDXX)
IMMUNOMEDICS INC (NASDAQ NM: IMMU) INCYTE CORPORATION (NASDAQ NM: INCY) INTERMUNE INC (NASDAQ NM: ITMN)
INVITROGEN CORPORATION (NASDAQ NM: IVGN) LEXICON GENETICS, INCORPORATED (NASDAQ NM: LEXG) LIGAND PHARMACEUTICALS INC (NASDAQ NM: LGND)
LABORATORY CORP OF AMERICA HOLDINGS (NYSE: LH) MAXYGEN INCORPORATED (NASDAQ NM: MAXY) MOLECULAR DEVICES CORPORATION (NASDAQ NM: MDCC)
MEDIMMUNE INC (NASDAQ NM: MEDI) MEDAREX INC (NASDAQ NM: MEDX) MILLENNIUM PHARMACEUTICALS, INC. (NASDAQ NM: MLNM)
MONSANTO COMPANY (NYSE: MON) MYRIAD GENETICS INC (NASDAQ NM: MYGN) NABI PHARMACEUTICALS (NASDAQ NM: NABI)
NEUROCRINE BIOSCIENCES INC (NASDAQ NM: NBIX) OSI PHARMACEUTICALS INC (NASDAQ NM: OSIP) PHARMACOPEIA, INC. (NASDAQ NM: PCOP)
PROTEIN DESIGN LABS INC (NASDAQ NM: PDLI) PHARMACEUTICAL PRODUCT DEVELOPMENT (NASDAQ NM: PPDI) PAREXEL INTERNATIONAL CORPORATION (NASDAQ NM: PRXL)
QUINTILES TRANSNATIONAL CORP (NASDAQ NM: QTRN) REGENERON PHARMACEUTICALS INC (NASDAQ NM: REGN) IMS HEALTH INC (NYSE: RX)
SCIOS INC (NASDAQ NM: SCIO) TECHNE CORPORATION (NASDAQ NM: TECH) THERAGENICS CORPORATION (NYSE: TGX)
TRANSKARYOTIC THERAPIES INC (NASDAQ NM: TKTX) TRIMERIS INC (NASDAQ NM: TRMS) UNITED THERAPEUTICS CORPORATION (NASDAQ NM: UTHR)
VERTEX PHARMACEUTICALS INCORPORATED (NASDAQ NM: VRTX) XOMA LTD (NASDAQ NM: XOMA)

JS200

[peter.b]

Kräftig aufwärts ging es am Vortag mit der Aktie von Biotech-Unternehmen Millennium Pharmaceuticals. Die Gesellschaft hat die abschließende Zahlung von 40 Mio. Dollar durch den Pharmakonzern Aventis bekannt gegeben, womit sich das gesamte Volumen der Kooperation auf 160 Mio. Dollar beläuft

[js200]

http://www.investtech.com/nasdaq/ana/mlnm.htm

JS200

[js200]

Millennium Pharmaceuticals to Webcast 2003 Annual Meeting of Stockholders

Thursday , April 24, 2003 16:03 ET

CAMBRIDGE, Mass., Apr 24, 2003 /PRNewswire-FirstCall via COMTEX/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced today that its annual meeting of stockholders will be webcast live and may be accessed by visiting the Investor Overview page of the Investors section of the Company`s website, www.millennium.com.

(Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Millennium senior management will provide an overview of the Company and progress against 2003 goals. The presentation will be delivered at 10:00 a.m. EDT on Wednesday, April 30, 2003 from the Hotel@MIT in Cambridge, Mass. The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

Editors` Note: This press release is also available under the Media section of the Company`s website at: www.millennium.com.


Contact:
Cynthia Clayton, Investor Relations
Millennium Pharmaceuticals, Inc.
[phone]


SOURCE Millennium Pharmaceuticals, Inc


CONTACT: Cynthia Clayton, Investor Relations of Millennium
Pharmaceuticals, Inc., [phone]
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
/Company News On-Call: http://www.prnewswire.com/comp/114562.html" target="_blank" rel="nofollow ugc noopener">http://www.prnewswire.com/comp/114562.html

URL: http://www.millennium.com
http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


KEYWORD: Massachusetts
INDUSTRY KEYWORD: HEA
MTC
BIO
SUBJECT CODE: CCA


STOCK SYMBOLS: [(mlnm)]

JS200

[js200]

Nadine Wong Highlights the Following Stock: Millennium Pharmaceuticals
via COMTEX

April 29, 2003

CHICAGO, Apr 29, 2003 (BUSINESS WIRE) --

Nadine Wong says the biotech industry is emerging from a cyclical trough, so investors looking to strike while the drugs are hot should consider one of her recommendations that could be a major presence for a very long time. Get her take on Millennium (NASDAQ:MLNM). Click here for the full story exclusively on Zacks.com: http://featuredexpert2bw.zacks.com/

Here are the highlights from the Featured Expert column:

Now that the uncertainties about the war in Iraq are largely determined, Wall Street is again focusing on fundamentals - earnings and the U.S. economy. While concern over quarterly earnings has weighed down many companies, the biotechnology industry is looking better.

For Millennium (NASDAQ:MLNM), the story is Velcade, a promising developmental compound currently in Phase III clinical trials for the treatment of multiple myeloma. Velcade`s developmental path will determine Millennium`s success. Management remains confident that it will find a partner for Velcade in the second quarter to market the compound. Millennium anticipates Velcade will receive FDA approval by mid-2003, and is hoping Velcade can be launched later this year.

Millennium is a momentum stock, fueled by anticipation. Nadine Wong thinks the Velcade story is a good one, and thinks the odds are in favor for FDA approval this year.

Keep tabs on the progress of Millennium and the entire biotechnology space by using Nadine Wong`s detailed analysis by clicking: http://featuredexpert3bw.zacks.com/

About Zacks Featured Experts

To be a successful investor you need professional advice. Experts who know what they`re talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.

Recommendations from Featured Experts Highlighted in FREE Investment Newsletter

The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, `Profit from the Pros`. Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to `Profit from the Pros`at: http://www.freeprofit1bw.zacks.com

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1981 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to `Profit from the Pros`weekly e-mail newsletter. For your free newsletter, visit http://www.freeprofitbw.zacks.com

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

SOURCE: Zacks.com

Zacks.com Terry Batey, 312/630-9880 x 307 [e-mail] www.Zacks.com

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.

JS200

[js200]

2003 Deutsche Bank Securities Health Care Conference to Webcast Millennium Pharmaceuticals Presentation
via COMTEX

April 29, 2003

CAMBRIDGE, Mass., Apr 29, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced today that its presentation at the 2003 Deutsche Bank Securities Health Care Conference will be webcast live and may be accessed by visiting the Investor Overview page of the Investors section of the Company`s website, www.millennium.com.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Millennium senior management will provide an overview of the Company and progress against 2003 goals. The presentation will be delivered at 3:00 p.m. EDT on Tuesday, May 6, 2003 from the Waterfront Marriott Hotel in Baltimore, MD. The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

Editors`Note: This press release is also available under the Media section of the Company`s website at: www.millennium.com.

Contact: Cynthia Clayton, Investor Relations Millennium Pharmaceuticals, Inc. [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Cynthia Clayton, Investor Relations of MillenniumPharmaceuticals, Inc., [phone]/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, 888-776-6555 or 212-782-2840/Company News On-Call: http://www.prnewswire.com/comp/114562.html
http://www.millennium.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

Millennium Announces Completion of Cash Offers For 4.50% and 5.00% Convertible Notes
via COMTEX

April 29, 2003

CAMBRIDGE, Mass., Apr 29, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that it has completed the cash offers to the holders of its outstanding 4.50% Convertible Senior Notes due June 15, 2006 and 5.00% Convertible Subordinated Notes due March 1, 2007.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

As of the expiration of the cash offers, today at 9:00 a.m., $294,100,000 in principal amount of the 4.50% notes and $283,724,000 in principal amount of the 5.00% notes were tendered. Millennium has accepted for payment all of those notes, resulting in total payments in the amount of approximately $637 million, which includes accrued interest of $7 million and a $52 million premium payment which the Company had previously recorded as a charge in the second quarter of 2002. In addition, the Company will record a net $10 million charge in the second quarter of 2003 which includes $12 million related to unamortized debt issuance costs due to this portion of the debt being paid off before the notes are due, and $2 million of income related to the premium on the untendered notes. The untendered $22,126,000 -- $5,890,000 in 4.50% notes and $16,246,000 in 5.00 % notes -- will remain as obligations of the Company and due June 15, 2006 and March 1, 2007 respectively.

Millennium assumed the 4.50% and the 5.00% notes in connection with its merger with COR Therapeutics, Inc. on February 12, 2002. On March 14, 2002, Millennium, as required by the terms of the notes, commenced cash repurchase offers to the noteholders in amounts equal to 100% of the principal amounts of the notes plus interest accrued and unpaid through April 28, 2002. On April 22, 2002, Millennium amended the notes to permit noteholders to exchange these notes for cash on April 29, 2003 at a price of $1,095 per $1,000 of principal amount of the 4.50% notes and $1,085 per $1,000 of principal amount of the 5.00% notes. On March 31, 2003 Millennium, as required by the terms of the notes, commenced cash offers to purchase the notes today.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass. Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

This press release contains `forward-looking statements,`including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause our actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editors`Note: This press release is also available under the Media section of the Company`s website at: www.millennium.com.

Contact: Gina Price Nugent (Investor) Rob Kloppenburg (Media) [phone] [phone] Cynthia Clayton (Investor) [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Gina Price Nugent (Investor), [phone], or CynthiaClayton (Investor), [phone], or Rob Kloppenburg (Media),[phone], both of Millennium/Company News On-Call: http://www.prnewswire.com/gh/cnoc/comp/114562.html/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, 888-776-6555 or 212-782-2840
http://www.millennium.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[schakal23]

hi hat jemand was neues gelesen? warum dies anstieg
hat das mit velcade zu tun ich habe bis jetst nicht verkauft was meint ihr?

[js200]

Merck, Schering Plough, XOMA, Celltech R&D, and Protein Sciences Corporation To Present Actual Case Studies at IBC`S 5th Scaling-Up From Bench to Clinic Meeting
via COMTEX

May 2, 2003

WESTBOROUGH, Mass., May 2, 2003 /PRNewswire via COMTEX/ --

IBC`s 5th International Scaling- Up From Bench To Clinic &Beyond meeting will take place in Durham, NC on August 4-6, 2003, with an expected attendance of over 200 delegates. The event will focus on the advances in bioprocessing strategies for successful commercialization. New to this year`s program are numerous industry case studies and updates from companies such as Abbott Bioresearch Center, Amgen, Inc., Baxter Bioscience, Celltech R&D, Dowpharma, Goodwin Biotechnology, ICOS Corporation, Lorantis, LTD, Merck &Co., Millennium Pharmaceuticals, Protein Sciences Corporation, Protherics, LTD, Schering Plough, United Therapeutics, XOMA, LLC, and many more.

Scaling-Up From Bench To Clinic &Beyond also features facility site visits to two leading-edge organizations, Diosynth Biotechnology and Wyeth Vaccines. At Diosynth Biotechnology, delegates will discover what occurs inside a contract manufacturing plant first hand and what to look for when selecting your manufacturer. At Wyeth Vaccines, delegates will have the opportunity to see how they are addressing the manufacturing needs in this era of scarcity of capacity.

This timely and well-respected conference addresses the major questions on the minds at biopharmaceutical companies:

-- How do you create successful biopharmaceutical manufacturing processes? -- What does it take to hasten speed of development while scaling-up the pharmaceutical supply for manufacturing? -- How can your organization survive the changes in capacity? -- What steps should be taken to advance your process development and increase continuity? -- How do you integrate rapid cell line development, process development and manufacturing for product? -- What are the best practices for managing the purification process in product development? -- How do you ensure your company meets and exceeds quality and regulatory requirements in a cost and time-effective manner?
For more information on attending Scaling-Up From Bench To Clinic & Beyond, visit http://www.lifesciencesinfo.com/scalingup; call 508-616-5550 or e-mail [e-mail].

SOURCE IBC Life Sciences

Abby Votto for IBC Life Sciences, [e-mail]

http://www.ibcusa.com

Copyright (C) 2003 PR Newswire. All rights reserved.

Print story

Current Quote

NSD: MLNM
Biotech/Medical

Last: 12.210
Change: 0.600
Volume: 6,498,800
Day High: 12.250
Day Low: 11.470



First Alert News
Get real-time MLNM release alerts by entering your email address below.

JS200

[js200]

05/02/2003 (12:38 ET) New 4 just released for MLNM - Edgar
05/02/2003 (12:28 ET) New 4 just released for MLNM - Edgar
05/02/2003 (12:17 ET) New 4 just released for MLNM - Edgar
05/02/2003 (12:05 ET) New 4 just released for MLNM - Edgar
05/02/2003 (11:53 ET) New 4 just released for MLNM - Edgar

JS200

[schakal23]

danke aber diese verdammte englisch ich habe keine vernüftige überzetser trodstem danke

[js200]

Von Gestern
MLNM
MILLENNIUM PHARMACEUTICALS INC
12.210
+0.600 +5.17%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 4/3/2003 (29) days ago, when the stock price was 9.370. Since then the stock gained 30.31% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. The volume is high. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 12.210
Previous Close 11.610
Change +0.600
% Change +5.17%
Volume 6,459,122
Stock Activity
Open 11.500
Day`s High 12.250
Day`s Low 11.470
52 Week High 19.000
52 Week Low 6.430

Stock Price History
3 Month % Change 75.43
6 Month % Change 58.37
12 Month % Change -34.91
Stock Statistics
50 Day Close MA 8.647
200 Day Close MA 9.345
65 Day Volume MA 4,569,187

JS200

[js200]

http://www.investtech.com/nasdaq/ana/mlnm.htm

JS200

[schakal23]

hi
stimmt das mlnm wird verkauft?
ich habe besuch aus usa ein arzt und ihr meint ihr habe das im radio gehört vor 5tage? weiss jemand was

[js200]

Last Trade: 12.450 Change: 0.240 (+1.966%)
Previous Close: 12.210 Volume: 8,201,900
Bid: 12.410 Ask: 12.490
Today`s Open: 12.210 # of Trades: 13,016

JS200

[js200]

Robert W. Baird 2003 Growth Stock Conference to Webcast Millennium Pharmaceuticals Presentation
via COMTEX

May 6, 2003

CAMBRIDGE, Mass., May 6, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced today that its presentation at the Robert W. Baird 2003 Growth Stock Conference will be webcast live and may be accessed by visiting the Investors section of the Company`s website, www.millennium.com.

Millennium senior management will provide an overview of the Company and progress against 2003 goals. The presentation will be delivered at 10:30 a.m. CDT on Tuesday, May 13, 2003 from the Four Seasons Hotel in Chicago, IL. The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

Editors`Note: This press release is also available under the Media section of the Company`s website at: www.millennium.com.

Contact: Cynthia Clayton, Investor Relations Millennium Pharmaceuticals, Inc. [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Cynthia Clayton, Investor Relations of Millennium Pharmaceuticals, Inc., [phone] /Company News On-Call: http://www.prnewswire.com/comp/114562.html

http://www.millennium.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

MORNING UPDATE: Man Securities Issues Alerts for WMT, MLNM, BSX, UVN, And PCLE
via COMTEX

May 9, 2003

CHICAGO, May 9, 2003 /PRNewswire via COMTEX/ --

Man Securities issues the following Morning Update at 8:30 AM EDT with new PriceWatch Alerts for key stocks.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/MANSECLOGO )

Before the open ... PriceWatch Alerts for WMT, MLNM, BSX, UVN, and PCLE, Put/Call Alert, FuturesWatch, Today`s Economic Calendar, and the Quote Of The Day.

QUOTE OF THE DAY `It is a bit of a tired rally right now.` -- Brian Pears, head stock trader, Victory Capital Management New PriceWatch Alerts for WMT, MLNM, BSX, UVN, and PCLE ... PRICEWATCH ALERTS - HIGH RETURN COVERED CALL OPTIONS -- Wal-Mart Stores Inc. (NYSE: WMT) Last Price 55.01 - SEP 55 CALL OPTION@ $3.30 -> 6.4 % Return assigned* -- Millennium Pharmaceuticals Inc. (Nasdaq: MLNM) Last Price 11.81 - AUG 10 CALL OPTION@ $2.65 -> 9.2 % Return assigned* -- Boston Scientific Corp. (NYSE: BSX) Last Price 46.11 - JUN 45 CALL OPTION@ $4.50 -> 8.1 % Return assigned* -- Univision Communications Inc. (NYSE: UVN) Last Price 29.15 - SEP 30 CALL OPTION@ $2.70 -> 13.4 % Return assigned* -- Pinnacle Systems Inc. (Nasdaq: PCLE) Last Price 9.69 - JUL 10 CALL OPTION@ $0.85 -> 13.1 % Return assigned*
*For our report, `5 Dividend Paying Stocks With Double Digit Returns`, go to: www.InvestorsObserver.com/5div

** Will Cisco`s stock price go up or down in the next 60 days? And why? Is it time to sell or buy the stock? What did we uncover about the company? And... How will it affect the stock price? To get a copy of our Cisco Special Report, go to: www.InvestorsObserver.com/csco1

NOTE: All stocks and options shown are examples only. These are not recommendations to buy or sell any security.

MARKET OVERVIEW

Overseas markets seem in a holding pattern, failing to wander too far from the flat line. Currently nine of the 15 markets that we follow are holding positive numbers with a cumulative average return of plus 0.264 percent. Manufacturing production in the United Kingdom continued to slow in March. In a report released this morning, Industrial production declined by 0.4 percent on the month and was lower by 1.0 percent on a year-over-year basis. Expectations were for a minus 0.3 percent and minus 0.4 percent, respectively.

The market will have to put in a reflective session as there will be little earnings or economic data today. With the environment offering little in the way of positive economic and an absence of key earnings reports, I would anticipate a down session today (but remember nobody can know for certain the market`s intentions).

Be prepared for the investing week ahead with Bernie Schaeffer`s FREE Monday Morning Outlook. For more details and to sign up, go to: http://www.schaeffersresearch.com/redirect.asp?CODE=GJ01A3&P…

PUT/CALL ALERT

Equity option activity on the CBOE yesterday had 380,852 put contracts trade compared to 451,613 call contracts. The resultant 0.843 put/call ratio has accelerated the 21-day moving average`s ascent, currently up to 0.666. The CBOE Market Volatility Index (VIX - 23.69) actually declined by 0.08 percent (in the face of a 1.06 percent decline in the OEX. Remember that the VIX is calculated using options on the OEX. One would expect a decline in the OEX to elicit a rise in the VIX. The Nasdaq 100 Trust Volatility Index (QQV - 27.78) added 0.54 percent.

FUTURES WATCH

The futures markets are higher this morning after two days of consolidation. There was some comment from Intel that it expects their industry to pick up some momentum, which is fueling the NASDAQ futures to once again take the lead and maybe turn the direction of this market back to the upside. The leadership for the NASDAQ has been one of the key factors that have been missing for the past couple of days. The European markets were stronger overnight, which is also contributing to this change in direction. I`m looking for the S&P futures to pick up some momentum above the 92500 level. The markets were without any late volume yesterday, which seemed to stall the market for most of the afternoon. This has been the case on Friday`s and I don`t see that changing today. The movement should come early with a sharp fall off in participation late in the session.

*For a free Trader`s Resource CD click the following link or paste it into your browser address bar: http://www.manfutures.com/mucd.html

TODAY`S ECONOMIC CALENDAR 11:20 a.m.: Chicago Fed President Moskow participates in `Private and Public Sector Responses to Government Issues`panel at Chicago Fed conference in Chicago.

Man Financial Inc is one of the world`s major futures and options brokers and has been recognized as a leading option order execution firm for individuals and institutions. Member CBOE/NASD/SIPC (CRD#6731). For more information and a free CD with educational tools to help you invest smarter, see http://www.mansecurities.com/mu.html." target="_blank" rel="nofollow ugc noopener">http://www.mansecurities.com/mu.html.

This Morning Update was prepared with data and information provided by:

InvestorsObserver.com - Better Strategies for Making Money -> For Investors With a Sense of Humor. Only $1 for your first month plus seven free bonuses worth over $420, see: www.investorsobserver.com/bm

Schaeffer`s Investment Research - Sign up for your FREE e-weekly, Monday Morning Outlook, Bernie Schaeffer`s look ahead at the markets. Sign Up Now http://www.schaeffersresearch.com/redirect.asp?CODE=GJ01A3&P…

All stocks and options shown are examples only. These are not recommendations to buy or sell any security and they do not represent in any way a positive or negative outlook for any security. Potential returns do not take into account your trade size, brokerage commissions or taxes which will affect actual investment returns. Stocks and options involve risk and are not suitable for all investors and investing in options carries substantial risk. Prior to buying or selling options, a person must receive a copy of Characteristics and Risks of Standardized Options available from Sharon at 800-837-6212 or at http://www.cboe.com/Resources/Intro.asp. Privacy policy available upon request.

SOURCE Man Securities

Michael Lavelle of Man Securities, [phone] /Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020214/MANSECLOGO AP Archive: http://photoarchive.ap.org PRN Photo Desk, [phone] or [phone]

http://www.mansecurities.com/mu.html

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

StockDiagnostics.com Reiterates Millennium Pharmaceuticals`
via CDS

May 9, 2003

OPS Rating of `8`



StockDiagnostics.com announced that it has reiterated its OPS Rating of `8`for Millennium Pharmaceuticals Inc (NASDAQ:MLNM). Millennium Pharmaceuticals has had an OPS Rating of `8`for ten consecutive quarters.



StockDiagnostics.com`s maintaining of the OPS RatingTM is based on Millennium Pharmaceuticals`recently filed Cash Flow Statements for its quarter ended March 31, 2003. The company`s computed OPS TM (Operational-cashflow Per Share) for the quarter was $-0.36 per share as compared to $-0.34 per share for the comparable year earlier quarter. OPS for the most recent 12 months ended March 31, 2003 was $-1.26 per share as compared to $-0.84 per share for the 12 months ended March 31, 2002. OPS for Millennium Pharmaceuticals`trailing twelve months reached a five year low.



The shares of Millennium Pharmaceuticals were recently trading at $11.81.



About OPS RatingsTM -- StockDiagnostics.com monitors a public company`s Operational cash flow Per Share (`OPS`) and assigns it an `OPS Rating`, which measures the long term risk associated with a company`s ability to remain in business. A company`s `OPS`logically falls into a mathematical sequence that ranks it into one of eight distinctive `risk`categories. Each of the categories is based on a company`s operating cash flow for each of its last 4 quarters and its cumulative operating cash flow for its most recent 12 months. OPS Ratings are upgraded, downgraded or reiterated each time a company files a quarterly report and at any time that its financial statements are amended. Statistical research on OPS Ratings is available at http://www.StockDiagnostics.com/marketnews." target="_blank" rel="nofollow ugc noopener">http://www.StockDiagnostics.com/marketnews.



About StockDiagnostics.com -- StockDiagnostics.com has a proprietary data refinery that automates the process of collecting, sorting and organizing large amounts of securities pricing and financial data into comparative financial ratios. These ratios are used to identify Financial Statement anomalies and securities pricing variances to monitor changes in the performance of public companies. Go to http://www.StockDiagnostics.com/marketnews for a description of StockDiagnostics.com`s patent-pending technical applications, such as OPS, OPS Ratings, The EPS Syndrome and more. Full details are available at http://www.StockDiagnostics.com/marketnews." target="_blank" rel="nofollow ugc noopener">http://www.StockDiagnostics.com/marketnews.




Print story

Current Quote

NSD: MLNM
Biotech/Medical

Last: 12.080
Change: 0.270
Volume: 3,615,400
Day High: 12.150
Day Low: 11.810



First Alert News
Get real-time MLNM release alerts by entering your email address below.

JS200

[js200]

Millennium to Webcast Conference Call on Recent FDA Approval of Velcade(TM) (bortezomib) for Injection on May 14, 2003
via COMTEX

May 13, 2003

CAMBRIDGE, Mass., May 13, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) will hold a live webcast of its conference call at 8:30 a.m. EDT on Wednesday, May 14, 2003. Mark Levin, chairperson and chief executive officer will host the call. He will discuss the Company`s recent news regarding approval of VELCADE.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The live webcast can be accessed by visiting the Investor section of the Company`s website, www.millennium.com. Following the webcast, an archived version of the call will be available at the same address until May 16, 2003.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

Editor`s Note: This press release is also available under the Media section of the Company`s website at: www.millennium.com

Contact: Cynthia Clayton Millennium Pharmaceuticals, Inc. [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Cynthia Clayton of Millennium Pharmaceuticals, Inc., [phone]/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, 888-776-6555 or 212-782-2840/Company News On-Call: http://www.prnewswire.com/comp/114562.html
http://www.millennium.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

FDA Approves VELCADE(TM) (bortezomib) for Injection for the
via CDS

May 13, 2003

Treatment of Relapsed and Refractory Multiple Myeloma



Millennium Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administrati on (FDA) to market VELCADE for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. The effectiveness of VELCADE is based on response rates. There are no controlled trials demonstrating a clinical benefit such as an improvemen t in survival. VELCADE, the first of a new class of medicines called proteasome inhibitors, is the first treatment in more than a decade to be approved for patients with multiple myeloma - a cancer of the blood.

`The FDA approval of VELCADE represents a major advance in our fight

against multiple myeloma,`said Kenneth Anderson, M.D., from Dana-Farber Cancer Institute in Boston, Mass. `With its new and unique mechanism of action of inhibiting the proteasome, VELCADE is different from traditional chemotherapies and represents a new treatment option for patients.`

`Millennium was established with the goal of using innovative science to develop novel products that would address the unmet medical needs of patients,`said Mark Levin, chief executive officer and chairperson of Millennium. `Our success in bringing VELCADE to patients so rapidly reflects the high level of collaboration among many partners, both internally and externally. Moving forward, Millennium will continue its mission of developing breakthrough products that make a difference in patients`lives.`

VELCADE and proteasome inhibition represent a completely new approach to treating multiple myeloma. The development of this product is based on the Company`s deep understanding of cancer disease pathways and the effect of proteasome inhibition on those pathways. The proteasome is an enzyme complex that exists in all cells and plays an important role in degrading proteins that control the cell cycle and cellular processes. By blocking the proteasome, VELCADE disrupts numerous biologic pathways, including those related to the growth and survival of cancer cells.

Priority Review

VELCADE(TM) (bortezomib) for Injection was granted Priority Review by the FDA on March 10, 2003 and was approved approximately two months later. In addition, it has been just four and a half years from the first human dose to FDA approval, an indication of the importance of VELCADE and proteasome inhibition. As a result of the accelerated approval process and the close collaboration between Millennium, the FDA, the National Cancer Institute and other academic and medical institutions, the development and approval of VELCADE is among the most rapid for a cancer treatment. As part of this accelerated approval, Millennium will be completing preclinical and phase IV clinical studies, including a study of previously untreated multiple myeloma patients.

`Today, the thousands of people living with multiple myeloma in the United States have been given a new treatment option,`said Kathy Giusti, president, Multiple Myeloma Research Foundation (MMRF), and a myeloma patient. `The MMRF has been committed to helping accelerate the search for a cure for multiple myeloma and we are proud to have been able to work with Millennium in bringing this important new therapy to patients.`

`VELCADE is the kind of cutting-edge treatment for which we have been advocating, and provides a new treatment option for the thousands of patients with this disease,`said Susie Novis, president, International Myeloma Foundation (IMF). `The approval of VELCADE represents a major milestone in our quest to see new treatments made available to patients with multiple myeloma.`

Clinical Results

The FDA approval of VELCADE is based primarily upon the results of a major multicenter phase II open-label, single-arm (SUMMIT) trial, which included 202 patients with relapsed and refractory multiple myeloma receiving at least two prior therapies (median of six). Patients had advanced disease, with 91 percent refractory to their most recent therapy prior to study entry. Response rates were independent of the number or type of previous therapies.

Key findings for the 188 patients evaluable for response showed:

-- Overall, the response rate for complete and partial responders was 27.7 percent (criteria per Blade, et al(1)) (95 percent CI; 21, 35);

-- Significantly, 17.6 percent - or almost one out of every five patients - experienced a clinical remission(2) (SWOG criteria) (95 percent CI; 12, 24);

-- The median survival for all patients was 16 months (range was less than one to greater than 18 months);

-- The median duration of response for complete and partial responders was 12 months (95 percent CI; 224 days; NE); and -- Side effects were generally predictable and manageable.



Important Safety Information About VELCADE

VELCADE(TM) (bortezomib) for Injection is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol.

In 228 patients who were treated with VELCADE in two phase II studies of multiple myeloma, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise and weakness) (65 percent), nausea (64 percent), diarrhea (51 percent), appetite decreased (including anorexia) (43 percent), constipation (43 percent), thrombocytopenia (43 percent), peripheral neuropathy (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (37 percent), pyrexia (36 percent), vomiting (36 percent), and anemia (32 percent). Fourteen percent of patients experienced at least one episode of grade four toxicity, with the most common toxicity being thrombocytopenia (three percent) and neutropenia (three percent). Please see accompanying full Prescribing Information at http://www.millennium.com/products/package.pdf.

About Multiple Myeloma

Multiple myeloma (also known as myeloma or plasma cell myeloma) is a cancer of the blood in which malignant plasma cells are overproduced in the bone marrow. Plasma cells are white blood cells that help produce antibodies called immunoglobulins that fight infection and disease. However, most patients with multiple myeloma have cells that produce a form of immunoglobulin called paraprotein (or M protein) that does not benefit the body. In addition, the malignant plasma cells replace normal plasma cells and other white blood cells important to the immune system. Multiple myeloma cells can also attach to other tissues of the body, such as bone, and produce tumors. The cause of the disease is unknown.

Multiple myeloma is the second most common cancer of the blood, representing approximately one percent of all cancers and two percent of all cancer deaths. It is estimated that approximately 45,000 Americans have multiple myeloma with about 15,000 new cases diagnosed each year. Only about 30 percent of multiple myeloma patients survive longer than five years with the disease. Although the disease is predominantly a cancer of the elderly (the average age at diagnosis is 70 years of age) recent statistics indicate both increased incidence and younger age of onset.

Ongoing Clinical Trials

Millennium is conducting an international, multicenter phase III APEX trial of VELCADE in patients with either relapsed or refractory multiple myeloma as well as two phase II trials with VELCADE, one in patients with metastatic colorectal cancer and another in patients with advanced non-small cell lung cancer. In addition, the Company also has several ongoing phase I and II trials in patients with various hematologic and solid tumors and plans to initiate additional phase I and II studies later this year. For more information about VELCADE clinical trials, patients and physicians can contact the Medical Information Line at (866) VELCADE.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four areas: cardiovascular disease, oncology and inflammatory and metabolic diseases. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, the Company is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., the Company also has facilities in South San Francisco, Calif. and Cambridge, UK.

This press release contains `forward-looking statements,`including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause the Company`s actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN(R) (eptifibatide) Injection and VELCADE(TM) (bortezomib) for Injection; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editors`Note: This press release is also available under the Media section of the Company`s website at: www.millennium.com.

(1) The criteria defined by Blade, et al are an assessment standard used to describe changes in disease status, including a confirmation 6 weeks later. The criteria incorporate a full clinical analysis of disease response, specifically, a `complete response`required 100 percent disappearance of the original myeloma protein from the blood and urine on at least two determinations at least six weeks apart by immunofixation; less than five percent plasma cells in the bone marrow; no increase in size or number of lytic bone lesions; and disappearance of soft tissue tumors (plasmacytomas). `Partial response`required )/=50 percent reduction in serum myeloma protein and )/=90 percent reduction of urine myeloma protein on at least two occasions for a minimum of six weeks, stable bone disease and calcium

(2) SWOG clinical remission criteria were a 75 percent reduction in serum myeloma protein and/or a 90 percent reduction in urine protein on at least two occasions for a minimum of at least six weeks, stable bone disease and calcium.



CONTACT: TEL: [phone] Media, Kelly Lindenboom

TEL: [phone] Adriana Jenkins

TEL: [phone] Investors, Gina Nugent

TEL: [phone] Cynthia Clayton


JS200

[js200]

FDA Approves VELCADE(TM) (bortezomib) for Injection for the Treatment of Relapsed and Refractory Multiple Myeloma
via COMTEX

May 13, 2003

CAMBRIDGE, Mass., May 13, 2003 (Canada NewsWire via COMTEX) --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today received approval from the U.S. Food and Drug Administration (FDA) to market VELCADE for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. The effectiveness of VELCADE is based on response rates. There are no controlled trials demonstrating a clinical benefit such as an improvement in survival. VELCADE, the first of a new class of medicines called proteasome inhibitors, is the first treatment in more than a decade to be approved for patients with multiple myeloma - a cancer of the blood.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

`The FDA approval of VELCADE represents a major advance in our fight against multiple myeloma,`said Kenneth Anderson, M.D., from Dana-Farber Cancer Institute in Boston, Mass. `With its new and unique mechanism of action of inhibiting the proteasome, VELCADE is different from traditional chemotherapies and represents a new treatment option for patients.`

`Millennium was established with the goal of using innovative science to develop novel products that would address the unmet medical needs of patients,`said Mark Levin, chief executive officer and chairperson of Millennium. `Our success in bringing VELCADE to patients so rapidly reflects the high level of collaboration among many partners, both internally and externally. Moving forward, Millennium will continue its mission of developing breakthrough products that make a difference in patients`lives.`

VELCADE and proteasome inhibition represent a completely new approach to treating multiple myeloma. The development of this product is based on the Company`s deep understanding of cancer disease pathways and the effect of proteasome inhibition on those pathways. The proteasome is an enzyme complex that exists in all cells and plays an important role in degrading proteins that control the cell cycle and cellular processes. By blocking the proteasome, VELCADE disrupts numerous biologic pathways, including those related to the growth and survival of cancer cells.

Priority Review

VELCADE(TM) (bortezomib) for Injection was granted Priority Review by the FDA on March 10, 2003 and was approved approximately two months later. In addition, it has been just four and a half years from the first human dose to FDA approval, an indication of the importance of VELCADE and proteasome inhibition. As a result of the accelerated approval process and the close collaboration between Millennium, the FDA, the National Cancer Institute and other academic and medical institutions, the development and approval of VELCADE is among the most rapid for a cancer treatment. As part of this accelerated approval, Millennium will be completing preclinical and phase IV clinical studies, including a study of previously untreated multiple myeloma patients.

`Today, the thousands of people living with multiple myeloma in the United States have been given a new treatment option,`said Kathy Giusti, president, Multiple Myeloma Research Foundation (MMRF), and a myeloma patient. `The MMRF has been committed to helping accelerate the search for a cure for multiple myeloma and we are proud to have been able to work with Millennium in bringing this important new therapy to patients.`

`VELCADE is the kind of cutting-edge treatment for which we have been advocating, and provides a new treatment option for the thousands of patients with this disease,`said Susie Novis, president, International Myeloma Foundation (IMF). `The approval of VELCADE represents a major milestone in our quest to see new treatments made available to patients with multiple myeloma.`

Clinical Results

The FDA approval of VELCADE is based primarily upon the results of a major multicenter phase II open-label, single-arm (SUMMIT) trial, which included 202 patients with relapsed and refractory multiple myeloma receiving at least two prior therapies (median of six). Patients had advanced disease, with 91 percent refractory to their most recent therapy prior to study entry. Response rates were independent of the number or type of previous therapies.

Key findings for the 188 patients evaluable for response showed: -- Overall, the response rate for complete and partial responders was 27.7 percent (criteria per Blade, et al(1)) (95 percent CI; 21, 35); -- Significantly, 17.6 percent - or almost one out of every five patients - experienced a clinical remission(2) (SWOG criteria) (95 percent CI; 12, 24); -- The median survival for all patients was 16 months (range was less than one to greater than 18 months); -- The median duration of response for complete and partial responders was 12 months (95 percent CI; 224 days; NE); and -- Side effects were generally predictable and manageable.
Important Safety Information About VELCADE

VELCADE(TM) (bortezomib) for Injection is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol.

In 228 patients who were treated with VELCADE in two phase II studies of multiple myeloma, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise and weakness) (65 percent), nausea (64 percent), diarrhea (51 percent), appetite decreased (including anorexia) (43 percent), constipation (43 percent), thrombocytopenia (43 percent), peripheral neuropathy (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (37 percent), pyrexia (36 percent), vomiting (36 percent), and anemia (32 percent). Fourteen percent of patients experienced at least one episode of grade four toxicity, with the most common toxicity being thrombocytopenia (three percent) and neutropenia (three percent).

Please see accompanying full Prescribing Information at http://www.millennium.com/products/package.pdf." target="_blank" rel="nofollow ugc noopener">http://www.millennium.com/products/package.pdf.

About Multiple Myeloma

Multiple myeloma (also known as myeloma or plasma cell myeloma) is a cancer of the blood in which malignant plasma cells are overproduced in the bone marrow. Plasma cells are white blood cells that help produce antibodies called immunoglobulins that fight infection and disease. However, most patients with multiple myeloma have cells that produce a form of immunoglobulin called paraprotein (or M protein) that does not benefit the body. In addition, the malignant plasma cells replace normal plasma cells and other white blood cells important to the immune system. Multiple myeloma cells can also attach to other tissues of the body, such as bone, and produce tumors. The cause of the disease is unknown.

Multiple myeloma is the second most common cancer of the blood, representing approximately one percent of all cancers and two percent of all cancer deaths. It is estimated that approximately 45,000 Americans have multiple myeloma with about 15,000 new cases diagnosed each year. Only about 30 percent of multiple myeloma patients survive longer than five years with the disease. Although the disease is predominantly a cancer of the elderly (the average age at diagnosis is 70 years of age) recent statistics indicate both increased incidence and younger age of onset.

Ongoing Clinical Trials

Millennium is conducting an international, multicenter phase III APEX trial of VELCADE in patients with either relapsed or refractory multiple myeloma as well as two phase II trials with VELCADE, one in patients with metastatic colorectal cancer and another in patients with advanced non-small cell lung cancer. In addition, the Company also has several ongoing phase I and II trials in patients with various hematologic and solid tumors and plans to initiate additional phase I and II studies later this year. For more information about VELCADE clinical trials, patients and physicians can contact the Medical Information Line at (866) VELCADE.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four areas: cardiovascular disease, oncology and inflammatory and metabolic diseases. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, the Company is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., the Company also has facilities in South San Francisco, Calif. and Cambridge, UK.

This press release contains `forward-looking statements,`including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause the Company`s actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN(R) (eptifibatide) Injection and VELCADE(TM) (bortezomib) for Injection; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editors`Note: This press release is also available under the Media section of the Company`s website at: www.millennium.com.

(1) The criteria defined by Blade, et al are an assessment standard used to describe changes in disease status, including a confirmation 6 weeks later. The criteria incorporate a full clinical analysis of disease response, specifically, a `complete response`required 100 percent disappearance of the original myeloma protein from the blood and urine on at least two determinations at least six weeks apart by immunofixation; less than five percent plasma cells in the bone marrow; no increase in size or number of lytic bone lesions; and disappearance of soft tissue tumors (plasmacytomas). `Partial response`required >/=50 percent reduction in serum myeloma protein and >/=90 percent reduction of urine myeloma protein on at least two occasions for a minimum of six weeks, stable bone disease and calcium
(2) SWOG clinical remission criteria were a 75 percent reduction in serum myeloma protein and/or a 90 percent reduction in urine protein on at least two occasions for a minimum of at least six weeks, stable bone disease and calcium.
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO AP Archive: http://photoarchive.ap.org PRN Photo Desk, 888-776-6555 or 212-782-2840/ /Company News On-Call: http://www.prnewswire.com/comp/114562.html/ /Web site: http://www.millennium.com/
VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=26541

For further information: Media, Kelly Lindenboom, [phone], or Adriana Jenkins, [phone], or Investors, Gina Nugent, [phone], or Cynthia Clayton, [phone], all of Millennium Pharmaceuticals

News release via Canada NewsWire, Toronto 416-863-9350

Copyright (C) 2003 CNW, All rights reserved

Print story

Current Quote

NSD: MLNM
Biotech/Medical

Last: 12.490
Change: -0.160
Volume: 3,635,100
Day High: 12.840
Day Low: 12.470



First Alert News
Get real-time MLNM release alerts by entering your email address below.

JS200

[Pipifax]

Bin in beiden Aktien investiert.

Interessant, wie ähnlich die Entwicklung in den letzten Monaten verlief:

http://http://finance.yahoo.com/q?d=c&c=blsi&t=3m&s=mlnm&l=o…[/URL]

Auch wenn es spekulativ ist, Biotechs sind mir allemal lieber als Goldaktien, denn Gold kann keine Kranken heilen.

[Pipifax]

Sorry.
http://finance.yahoo.com/q?d=c&c=blsi&t=3m&s=mlnm&l=on&z=m&q…

[Pipifax]

http://finance.yahoo.com/q?s=MLNM&d=c&k=c1&c=blsi&a=v&p=s&t=…

[js200]

Schaeffer`s Midday Options Update Features ANF, MLNM, and GP
via COMTEX

May 14, 2003

CINCINNATI, May 14, 2003 /PRNewswire via COMTEX/ --

Today`s Schaeffer`s Midday Options Update features Abercrombie &Fitch (NYSE: ANF), Millennium Pharmaceuticals (Nasdaq: MLNM) and Georgia-Pacific (NYSE: GP). The Midday Options Update contains a brief commentary on the day`s most notable activity and a table listing the most active calls and puts for the day. The Midday Options Update is published every day at www.SchaeffersResearch.com - the home of Bernie Schaeffer and Schaeffer`s Investment Research. For additional information about this report or to have it delivered to you free via email every day click on the following link: http://www.schaeffersresearch.com/addinfo" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/addinfo .

(Logo: http://www.newscom.com/cgi-bin/prnh/20020725/SCHAEFFERLOGO )

Schaeffer`s Midday Options Update

Today`s weak retail results sapped any strength the bulls were able to muster at the open. Sales for April declined 0.1 percent compared to the expected increase of 0.4 percent. This follows March`s sharp rise of 2.1 percent. Last month`s number looks even worse if you take out automobile sales, resulting in a decline of 0.9 percent - the largest drop since September 2001. How much longer can automakers afford to give their cars away at zero percent interest, no money down, and no payments for 45 years? Sooner or later, the makeup wears off and the `true beauty`of this number begins to show through.

It`s Wednesday, and that means the weekly sentiment data is here. Investors Intelligence saw its percentage of bulls dip slightly lower, from 55.8 to 54.4 percent. But the notable change occurred in the bearish camp, where the percentage fell from 24.4 to 23.9 percent. This represents the lowest level of bears since January 18, 2002. Our Quantitative Analysis department looks at these two numbers in a ratio format (bullish percentage divided by bearish percentage). Going back to January 2000, the research shows that previous readings of this ratio above 2.0 have resulted in sharp declines for the S&P 100 Index (OEX - 475.07), which fell by about six percent over the next two months. This week`s data has that ratio sitting at 2.2.

In other news, shares of Abercrombie &Fitch (NYSE: ANF) are trading sharply lower today following last night`s first-quarter earnings report. Although the retailer met Wall Street`s estimate of 26 cents per share, it predicted lower-than-expected second-quarter results. On the plus side, Millennium Pharmaceuticals (Nasdaq: MLNM) is up more than 13 percent after the FDA approved its Velcade drug for the treatment of myeloma, a rare type of blood cancer.

At 1:30 p.m. eastern time, the Dow Jones Industrial Average (DJIA - 8648.8) is lower by 0.35 percent and the S&P 500 Index (SPX - 939.16) is off 0.33 percent. The Nasdaq Composite (COMP - 1532.1) is down 0.49 percent. At 1:32 p.m. in the options pits, 1,286,947 calls had traded compared to 865,620 puts for a composite put/call ratio across all five exchanges of 0.67. The CBOE put/call ratio for equity options weighs in at 0.73.

Sentiment is nearing an optimistic extreme on Georgia-Pacific (NYSE: GP). Call activity has snowballed in recent weeks, causing the stock`s average daily call volume to vault from 400 to 2,320 contracts during the past month. This has pushed GP`s Schaeffer`s put/call open interest ratio (SOIR) from a reading of 1.07 on April 22 to its current level of just 0.33. And the swing in the SOIR`s percentile rank is just as dramatic. The April 22 reading was higher than 97 percent of all readings taken during the past year, while the current SOIR is lower than nearly 99 percent of those from the past year. Most of this call activity is focused on the stock`s June 20 strike. This out-of-the-money option is home to more than 12,800 contracts and represents a tough level of potential resistance the shares must overcome. (The 20 level also coincided with a major rejection from late November - see the chart below.) As a further sign of this building optimism, the number of GP shares sold short continues to trend lower. Short interest has declined by 38 percent during the past year and recently fell to its lowest level since July 2000.

All of these high expectations are going to be hard to meet. Sure, the stock rallied nicely earlier this month after the company said it was `encouraged`by recent efforts in the U.S. Senate to promote asbestos litigation reform. But that rally occurred on steadily declining volume and appears to be petering out now. (Strong volume is often a sign that a rally has legs, while weak volume tends to indicate just the opposite.) Besides, the New York Times article that highlighted the Senate`s involvement (and caused all the ruckus in GP) was later called into question by the law firm representing asbestos victims. A lawyer from the firm called the story `premature`and `misleading.`

One thing is for sure: GP`s bottom line has definitely been impacted by the recent spate of asbestos lawsuits. Last month, the company posted a first-quarter loss of 11 cents per share and admitted that its asbestos litigation problems remain `very volatile,`which may cause `upward pressure` on costs later this year.

Look for lower prices from this relative-strength underperformer as the recent rally flames out. Selling should resume once the bulls begin to realize the error of their ways.

Click the following link to see the Daily Chart of GP since October 2002: http://www.schaeffersresearch.com/wire?ID=7693" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7693 .

About Schaeffer`s Investment Research ( www.SchaeffersResearch.com )

Schaeffer`s Investment Research, founded by Bernie Schaeffer in 1981, is a financial information and trading resources company. It publishes Bernie Schaeffer`s Option Advisor, the nation`s leading options subscription newsletter. The firm`s contrarian approach focuses on stocks with technical and fundamental trends that run counter to investor expectations. The firm`s website, www.schaeffersresearch.com, is recognized as one of the leading information sources for stock and options traders and was cited as the top options website by both Forbes and Barron`s. Click here for more details about Schaeffer`s trading methodology: www.schaeffersresearch.com/method .

Contact: Tom Godich at Schaeffer`s, Phone: [phone]; Email: [e-mail]

SOURCE Schaeffer`s Investment Research

Tom Godich of Schaeffer`s, [phone], [e-mail] /Photo: http://www.newscom.com/cgi-bin/prnh/20020725/SCHAEFFERLOGO AP Archive: http://photoarchive.ap.org PRN Photo Desk, [phone] or [phone]

http://www.schaeffersresearch.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

RATING(=): Morgan Stanley Reiterates MLNM Rating @ Underweight

Wednesday, May 14, 2003 13:08 ET

Issuer: Millennium Pharmaceuticals, Inc. (NasdaqNM: MLNM)
Analyst Firm: Morgan Stanley Dean Witter & Co.

Ratings Action: REITERATION
Current Rating: Underweight

This rating information was reported by Briefing.com.

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


05/14/2003 (14:38 ET) New 3 just released for MLNM - Edgar



05/14/2003 (14:02 ET) Schaeffer`s Midday Options Update Features ANF, MLNM, and GP - PR Newswire



05/14/2003 (13:11 ET) Millennium To Ship Velcade, FDA Reports On Xoliar and Other Biotechnology and Drug Industry News - Financial News USA



05/14/2003 (13:08 ET) RATING(=): Morgan Stanley Reiterates MLNM Rating @ Underweight - Knobias



05/14/2003 (12:01 ET) Wall Street Journal: FDA gives early approval to promising cancer drug - World Media Abstract (US)



05/14/2003 (11:26 ET) RATING(=): S&P Reiterates MLNM Rating @ 4 STARS (Accum) - Knobias



05/14/2003 (09:52 ET) VOLUME(+): MLNM Volume 38% > 20-adsv, Stock +15.45% - Knobias



05/14/2003 (09:45 ET) GAP(+): Opening Higher XLND, PROX, MLNM, RMOO, JCOM - Knobias



05/14/2003 (09:30 ET) FDA approves Velcade for relapsed and refractory multiple myeloma - Datamonitor



05/14/2003 (09:13 ET) MLNM Gets FDA Ok to Market Velcade for Multiple Myeloma - Knobias



05/14/2003 (07:24 ET) MEDIA: Today`s New York Times Mentions MLNM - Knobias



05/14/2003 (06:43 ET) MEDIA: Today`s Wall Street Journal Mentions MLNM - Knobias



05/14/2003 (03:17 ET) Cambridge, Mass., Biotech Firm Wins FDA Approval for Cancer-Fighting Drug - Knight Ridder



05/13/2003 (19:18 ET) Millennium to Webcast Conference Call on Recent FDA Approval of Velcade(TM) (bortezomib) for Injection on May 14, 2003 - PR Newswire



05/13/2003 (18:46 ET) FDA Approves VELCADE(TM) (bortezomib) for Injection for the Treatment of Relapsed and Refractory Multiple Myeloma - Canada NewsWire



05/13/2003 (18:35 ET) FDA Approves VELCADE(TM) (bortezomib) for Injection for the Treatment of Relapsed and Refractory Multiple Myeloma - PR Newswire



05/13/2003 (08:32 ET) CONF: MLNM To Present At Baird Growth Stock Conference @ 11:30 ET - Knobias



05/09/2003 (09:47 ET) MORNING UPDATE: Man Securities Issues Alerts for WMT, MLNM, BSX, UVN, And PCLE - PR Newswire



05/06/2003 (17:19 ET) New 10-Q just released for MLNM - Edgar



05/06/2003 (16:01 ET) Robert W. Baird 2003 Growth Stock Conference to Webcast Millennium Pharmaceuticals Presentation - PR Newswire



05/06/2003 (14:24 ET) SECTOR(HCR): Biotechs Remain Red for Most of Day - Knobias



05/06/2003 (12:02 ET) CONF: MLNM To Present At Deutsche Health Care Conference @ 15:00 ET - Knobias



05/05/2003 (16:26 ET) VOLUME(+): MLNM Volume 85% > 20-adsv, Stock +1.97% - Knobias



05/02/2003 (12:38 ET) New 4 just released for MLNM - Edgar



05/02/2003 (12:28 ET) New 4 just released for MLNM - Edgar


JS200

[js200]

Fast Hundert % seit Tread-eröffnung, toll gelaufen

JS200

[js200]

Es gibt noch Platz für viel MEHR

http://www.investtech.com/nasdaq/ana/mlnm.htm

JS200

[js200]

MEDIA: Today`s Wall Street Journal Mentions MLNM

Thursday , May 15, 2003 06:04 ET

The following article appears in today`s Wall Street Journal(tm) discussing Millennium Pharmaceuticals Inc.:

"Abreast Of The Market: Galen Holdings Gains Wed"

(NasdaqNM: MLNM) last traded at $14.39, up $1.90 (15.21%), on 32,866,100 shares.

OTHER STOCK(S) MENTIONED:
-- Applied Materials Inc. (NasdaqNM: AMAT)
-- Computer Sciences Corp. (NYSE: CSC)
-- Dreyer`s Grand Ice Cream Inc. (NasdaqNM: DRYR)
-- EMC Corp. (NYSE: EMC)
-- Galen Holdings PLC (NasdaqNM: GALN)
-- Motorola Inc. (NYSE: MOT)
-- Network Appliance Inc. (NasdaqNM: NTAP)
-- Novellus Systems Inc. (NasdaqNM: NVLS)
-- Tenet Healthcare Corp. (NYSE: THC)
-- Tiffany & Co. (NYSE: TIF)
-- Williams Cos. (NYSE: WMB)

JS200

[js200]

Schaeffer`s Option Activity Watch Features TGT, MLNM, and IBM [INLINE]
via CDS

May 15, 2003

Today`s Schaeffer`s Option Activity Watch features Target (NYSE: TGT), Millennium Pharmaceuticals (Nasdaq: ML NM), and IBM (NYSE: IBM). The Option Activity Watch is a report that takes a

closer look at three equities appearing in our most unusual option activity report from the previous day. The Option Activity Watch is published on http://www.SchaeffersResearch.com" target="_blank" rel="nofollow ugc noopener">http://www.SchaeffersResearch.com -- the home of Bernie Schaeffer and Schaef fer`s Investment Research. For additional information about this report or to have it delivered to you free via email every day click on the following link: http://www.schaeffersresearch.com/addinfo" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/addinfo .

(Logo: http://www.newscom.com/cgi-bin/prnh/20020725/SCHAEFFERLOGO )



Schaeffer`s Option Activity Watch:



1. A reader named Steve asked me to revisit Target (NYSE: TGT) since highlighting its bullish case on April 25. Beth Gaston wrote about the stock yesterday ahead of earnings, and much of what she had to say still holds true. Since then, the company has posted first-quarter earnings that missed Wall Street`s view by a penny per share. Is that bad? Well, it`s not good. But be careful about heading for the exits just yet.

Keep in mind this is a company that saw an 11.3-percent increase in sales during a month when most other retailers couldn`t give their products away. Revenue rose 7.6 percent for the quarter and net income was up 1.2 percent. The stock is down about five percent today, but so far has been held in check by its rising 20-day moving average. This trendline provided key support on a number of occasions during TGT`s rally from mid-March -- a rally that has carried the shares about 30-percent higher. And perhaps the most attractive thing about this stock is the rampant pessimism from some investors. Its Schaeffer`s put/call open interest ratio (SOIR) spiked from 0.76 to 0.93 overnight, with the current reading higher than 97 percent of those taken during the past year. And short interest is still outrageously high at 16.2 million shares. If TGT breaks below its 20-day trendline, I would start to worry. Until then, keep an eye on the 37 region. A clear move above here could be a sign that we`re looking at a long-term uptrend.

Click the following link to see Beth Gaston`s observation from yesterday: http://www.schaeffersresearch.com/wire?ID=7692" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7692 .

Click the following link to see the Daily Chart of TGT since March 2003 with 20-Day Moving Average: http://www.schaeffersresearch.com/wire?ID=7700" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7700 .



2. Millennium Pharmaceuticals (Nasdaq: MLNM) reported huge news yesterd ay and its shares reacted accordingly. The company received FDA approval for its Velcade treatment of myeloma, a rare blood cancer. The stock gapped higher and added more than 15 percent. Now that the celebration is over, it`s time for MLNM to face some hard truths. Most of these are centered on the 15 level. It`s the site of a previous rejection from August and also coincides with the stock`s declining 20-month moving average. This long-term trendline has capped all of MLNM`s monthly closes for the past two years. What about options? Forget the May series, which expires tomorrow. Instead look at the June 15 strike. This is the site of peak call open interest (6,136 contracts) and an area of potential options-related resistance. At first glance, sentiment toward the shares may seem pessimistic. After all, MLNM`s current SOIR is higher than 80 percent of all those taken during the past year. But the absolute reading of this ratio is 0.47, which means that calls more than double puts in the front three months of options. That`s hardly `pessimistic.`In fact, the stock`s June 15 call was yesterday`s most active option, with open interest jumping from 1,566 to 6,136 contracts. The combination of technical resistance, a nice rally, and all this fascination with 15-strike calls could mean that MLNM is poised to retrace some of its recent gains.

Click the following link to see the Weekly Chart of MLNM since December 2001: http://www.schaeffersresearch.com/wire?ID=7700" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7700 .

Click the following link to see the Monthly Chart of MLNM since January 2001 with 20-Month Moving Average: http://www.schaeffersresearch.com/wire?ID=7700" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7700 .



3. IBM`s (NYSE: IBM) CEO is cautiously optimistic about the computer industry`s direction. I wonder how he feels about his stock trading above 90 anytime soon? This is an area of previous support-turned-resistance that goes back more than two years. It also represents a 50-percent correction of IBM`s long-term slide from 126 (in January 2002) to 54 (in October 2002). Want another reason to hate 90? How about 14,018 reasons? That`s how many calls reside at this strike in the June series, and there are another 33,000 in July. Puts dominate on the stock, with an SOIR of 1.13 that`s higher than 80 percent of all those taken during the past year. And I think the put players may be on to something. Wall Street can`t get enough of the shares, which should always raise a red flag in your mind. Zacks reports that all of the 16 analysts following IBM rate it a `hold`or better. As further proof of this, Big Blue was lauded for its first-quarter earnings report last month despite

the fact that a major financial weekly questioned how the company arrived at some of its revenue and earnings numbers. Bottom line? Expect continued trouble at the 90 mark and, until the shares prove they can overtake this level, I would look elsewhere for bullish ideas.

Click the following link to see the Monthly Chart of IBM since October 2001: http://www.schaeffersresearch.com/wire?ID=7700" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7700 .



The best way to take advantage of the timely commentaries from SchaeffersResearch.com is to sign up to receive their e-newsletters -- Opening View, Midday Report, Market Recap and Monday Morning Outlook. Click here to have the Schaeffer`s commentaries delivered to you free via email every day: http://www.schaeffersresearch.com/addinfo" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/addinfo .



About Schaeffer`s Investment Research ( http://www.SchaeffersResearch.c om )

Schaeffer`s Investment Research, founded by Bernie Schaeffer in 1981, is a financial information and trading resources company. It publishes Bernie Schaeffer`s Option Advisor, the nation`s leading options subscription newsletter. The firm`s contrarian approach focuses on stocks with technical and fundamental trends that run counter to investor expectations. The firm`s website, http://www.schaeffersresearch.com, is recognized as one of the lea ding information sources for stock and options traders and was cited as the top options website by both Forbes and Barron`s. Click here for more details about Schaeffer`s trading methodology: http://www.schaeffersresearch.com/me thod .



Contact: Tom Godich at Schaeffer`s, Phone: [phone]; Email: [e-mail]

JS200

[js200]

Lynx Announces Initiation of Gene Expression Analysis Collaboration
via COMTEX

May 15, 2003

HAYWARD, Calif., May 15, 2003 /PRNewswire-FirstCall via COMTEX/ --

Lynx Therapeutics, Inc. (Nasdaq: LYNX) announced today an agreement with Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) to study gene expression in specific blood cell populations. The agreement features the application of Lynx`s Massively Parallel Signature Sequencing, or MPSS(TM), technology to two areas of study. Initially, MPSS(TM) will be used to identify cell specific gene markers for a certain blood cell type. The results from this study could provide important advances in the identification of genes responsible for the formation of certain specialized cells.

In an additional study, MPSS(TM) will be applied to evaluate gene expression patterns from RNA in peripheral blood monocytes (PBMCs) in response to treatments with specific compounds. These data could provide information on treatment-related gene expression potentially leading to a greater understanding of drug efficacy and safety.

`We consider MPSS(TM) to be the ultimate tool for gene expression studies because it provides quantitative data for virtually all genes in a sample,` said Kevin Corcoran, President and Chief Executive Officer at Lynx. `We believe that MPSS(TM) offers a virtually unlimited dynamic range that provides statistically robust data for low abundance transcripts as well as the most highly expressed genes and yields comprehensive quantitative profiles of gene expression in cells or tissues of interest and produces bankable, digital data.`

`These are particularly exciting projects as we believe they will confirm the value of comprehensive expression profiling in medicinal chemistry studies and provide further evidence of the value of MPSS(TM) in drug target discovery in target-poor disease areas,`said Dr. Tom Vasicek, Vice President of Business Development at Lynx. `We look forward to working with the Millennium scientists who have extensive experience with expression profiling technologies in drug discovery and development.`

About Lynx

Lynx is a leader in the development and application of novel genomics analysis solutions that provide comprehensive and quantitative digital gene expression information important to modern systems biology research in the pharmaceutical, biotechnology and agricultural industries. These solutions are based on Megaclone(TM) and MPSS(TM), Lynx`s unique and proprietary cloning and sequencing technologies. For more information, visit Lynx`s web site at www.lynxgen.com.

This press release contains `forward-looking`statements, including statements related to the identification of differentially expressed genes, the potential success of collaboration arrangements, the addition of new collaborations and agreements and Lynx`s performance of its genomics discovery services for current and future customers and collaborators. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as `believes,` `anticipates,``plans,``predicts,``expects,``envisions,``hopes,` `estimates,``intends,``will,``continue,``may,``potential,``should,` `confident,``could`and similar expressions are intended to identify forward- looking statements. There are a number of important factors that could cause the results of Lynx to differ materially from those indicated by these forward-looking statements, including, among others, risks detailed from time to time in Lynx`s SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2002. Lynx does not undertake any obligation to update forward-looking statements.

SOURCE Lynx Therapeutics, Inc.

Kevin Corcoran or Edward C. Albini both of Lynx Therapeutics, Inc., [phone]

http://www.lynxgen.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

Kosan Appoints Dr. Charles Homcy to Board of Directors
via COMTEX

May 15, 2003

HAYWARD, Calif., May 15, 2003 /PRNewswire-FirstCall via COMTEX/ --

Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that Charles Homcy, M.D. has been appointed to the company`s Board of Directors and will serve as a member of the newly created Strategic Advisory Committee of the Board of Directors. Dr. Homcy currently serves as a senior advisor and member of the Board of Directors at Millennium Pharmaceuticals, Inc., where he held the position of President of Research and Development until 2002. In addition, Dr. Homcy is a Clinical Professor of Medicine at the University of California, San Francisco, School of Medicine and an attending physician at the San Francisco VA Medical Center.

Prior to joining Millennium Pharmaceuticals, Dr. Homcy served as Executive Vice President of Research and Development and board member at COR Therapeutics. Before his work at COR, he held several executive research and development positions at American Cyanamid-Lederle Laboratories and served as a board member to Immunex Corporation. Dr. Homcy has been an attending physician at The Presbyterian Hospital, College of Physicians and Surgeons, at Columbia University, and at Massachusetts General Hospital, and an Associate Professor of Medicine at Harvard Medical School.

`The addition of Dr. Homcy to the Board of Directors reflects Kosan`s commitment to achieving the highest level of scientific and operational excellence,`said Daniel V. Santi, M.D., Ph.D., Kosan`s Chairman and Chief Executive Officer. `Charles Homcy`s knowledge and experience will be of immense benefit to Kosan as we enter into an advanced phase as a biotechnology business.`

Kosan Biosciences Incorporated is a biotechnology company that has proprietary genetic engineering technologies to develop drug candidates from polyketides, a rich source of pharmaceuticals. Kosan is currently focused on the creation of new polyketides and the improvement of existing drugs for the treatment of cancer and infectious disease.

SOURCE Kosan Biosciences Incorporated

Michael S. Ostrach, President &COO of Kosan Biosciences, [phone]; or investors, Stephanie Diaz, [phone], or media, Tim Brons, [phone], both of Vida, LLC, for Kosan Biosciences

http://www.kosan.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[HalfLife11]

@js200 - Vielen Dank dass Du immer soviel Informationen zu Millennium weitergibst - da mein Schulenglisch leider nicht so gut ist würde ich Dich bitten eine kleine Übersetzung an das Textende zu stellen. Sind die Nachrichten nun schlecht oder gut? Vielen Dank.

[LMeister7]

Hallo,
ich möchte auch was beitragen und stelle deshalb einen Link zur Pipeline rein: http://www.millennium.com/rd/pipeline/index.asp
MfG,
LM7

[js200]

Millennium Ships VELCADE(TM) (bortezomib) for Injection Within Six Days of FDA Approval
via COMTEX

May 20, 2003

CAMBRIDGE, Mass., May 20, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that shipments of its novel cancer product VELCADE were sent to wholesalers and medical centers within a week of receiving approval from the U.S. Food and Drug Administration (FDA) on May 13, 2003. The Company expects that physicians and patients throughout the United States will have access to VELCADE today.

(LOGO: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

VELCADE was granted Priority Review by the FDA on March 10, 2003 and was approved approximately two months later. The approval occurred just four and a half years from the first human dose, among the most rapid for a cancer treatment. The rapid development of VELCADE was the result of the FDA`s accelerated approval process and the close collaboration between Millennium, the FDA, the National Cancer Institute, patient advocacy groups and other academic and medical institutions. For additional information about VELCADE, physicians and patients can call 1-866-VELCADE.

`Throughout the development of VELCADE, it has been an important goal for Millennium to get this medication to the patients who need it as quickly as possible,`said Kenneth Bate, chief financial officer at Millennium. `Our ability to make this product available so rapidly reflects this commitment and the collaboration between Millennium and our many partners.`

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, markets VELCADE(TM) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.

This press release contains `forward-looking statements,`including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause the Company`s actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN(R) (eptifibatide) Injection and VELCADE(TM) (bortezomib) for Injection; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editors`Note: This press release is also available under the Media section of the Company`s website at: www.millennium.com.

Contacts: Kelly Lindenboom (media) Gina Nugent (investor) [phone] [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Kelly Lindenboom (media), [phone]; or Gina Nugent(investor), [phone], both for Millennium Pharmaceuticals, Inc./Company News On-Call: http://www.prnewswire.com/comp/114562.html/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, 888-776-6555 or 212-782-2840
http://www.millennium.com

Copyright (C) 2003 PR Newswire. All rights reserved.


JS200

[js200]

Jahrtausendschiffe VELCADE(TM, (bortezomib), für Einspritzung in sechs Tage FDA Approval,
über COMTEX

20. Mai 2003

CAMBRIDGE zieht sich zusammen., 20. Mai 2003 / PRNewswire-FirstCall über COMTEX /--

Millennium Pharmaceuticals, Inc., Nasdaq: MLNM, heute verkündete, daß Sendungen seines neuartigen KerbsproduktesvELCADE zu Großhändlern und medizinischen Zentren für eine Woche vom Erhalten von Zustimmung von den U.S. geschickt wurden. Essen und Drogenverwaltung (FDA) am 13. Mai 2003. Die Gesellschaft erwartet, daß Ärzte und Patienten überall in den Vereinigten Staaten heute Zugang zu VELCADE haben werden.

, LOGO: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO,

VELCADE wurde am 10. März 2003 Vorrangiger Überblick vom FDA gewährt und wurde zwei Monate später ungefähr genehmigt. Die Zustimmung kam nur vier und ein halbe Jahre von der ersten menschlichen Dosis, unter der Schnellsten für eine Kerbsbehandlung, vor. Die schnelle Entwicklung von VELCADE war das Ergebnis vom beschleunigtem Zustimmungsprozeß des FDA und der nahen Zusammenarbeit zwischen Jahrtausend, dem FDA, dem National Cancer Institute, geduldigen Interessengruppen und anderem Akademiker und medizinischen Institutionen. Für zusätzliche Informationen über VELCADE können Ärzte und Patienten 1-866-VELCADE rufen.

`Überall in der Entwicklung von VELCADE ist es ein wichtiges Ziel für Millennium gewesen den Patienten, die es so schnell wie möglich brauchen, dieses Medikament zu bringen, sagte Kenneth Bate `, Oberhaupt finanzieller Offizier bei Millennium. `Unsere Fähigkeit, dieses Produkt verfügbar zu machen, reflektiert dieses Engagement und die Zusammenarbeit zwischen Jahrtausend und unseren vielen Partnern so schnell.`

Über Jahrtausend

Millennium Pharmaceuticals, Inc., eine führende biopharmaceutical-Gesellschaft, Mit, fördert INTEGRILIN(R, ((eptifibatide)) Injection, ein Markt-führendes kardiovaskuläres Produkt, Märkte VELCADE(TM, ((bortezomib)) für Injection, ein neuartiges Kerbsprodukt, und hat eine robuste klinische Entwicklungspipeline der Produktbewerber. Die Forschung der Gesellschaft, Entwicklung und Kommerzialisierungsaktivitäten werden in vier Krankheitsvierteln fokussiert: kardiovaskulär, Onkologie, Aufflammen und Stoffwechsel. Millennium entwickelt Medizinprodukten eine persönliche Note gegebenen Durchbruch, indem es sein Wissen vom menschlichen genome, seinem Verständnis für Krankheitsmechanismen und seiner industrialisierten Technologieplattform anwendet. Headquartered in Cambridge zieht sich zusammen., Millennium hat auch Einrichtungen in Südsan Francisco, Calif. und Cambridge, VEREINIGTES KÖNIGREICH.

Diese Pressenfreilassung enthält `zukunftsweisende Aussagen, `einschließlich Aussagen über unseren Wuchs und Zukunft, die Ergebnisse, Entdeckung und Entwicklung von Produkten, potentiellen Erwerben, strategischen Bündnissen und geistigem Eigentum bedient. Verschiedene Risikos veranlassen vielleicht die eigentlichen Ergebnisse der Gesellschaft, sich wesentlich zu unterscheiden, einschließlich: ungünstige Ergebnisse in unserer Drogenentdeckung und klinische Entwicklung marschiert; Mißerfolg, patentgeschützten Schutz für unsere Entdeckungen zu erhalten,; kommerzielle Einschränkungen drängten sich durch Patente auf, die besessen werden oder von dritten Parteien kontrolliert werden,; unsere Abhängigkeit von strategischen Bündnispartnern, um Produkte und Dienste auf unsere Arbeit basierend zu entwickeln und zu kommerzialisieren,; Schwierigkeiten oder Verzögerungen darin, vorschriftsmäßige Zustimmungen zu erhalten, um Produkte und Dienste zu vermarkten, die von unseren Entwicklungsanstrengungen resultieren,; der kommerzielle Erfolg von INTEGRILIN(R, (eptifibatide) (Einspritzung) und VELCADE(TM ((bortezomib), für Injection,); und die Anforderung an beträchtlicher Finanzierung, um Forschung und Entwicklung zu führen und Kommerzialisierungsaktivitäten zu erweitern. Für eine weitere Liste und eine Beschreibung von den Risikos und den Ungewißheiten, denen wir gegenüberstehen, sehen Sie die Berichte, die wir mit den Sicherheiten und Tauschkommission eingereicht haben. Wir streiten irgendeine Absicht oder eine Pflicht ab zu aktualisieren oder revidieren alle zukunftsweisende Aussagen, ob als ein Ergebnis neuer Informationen, künftige Ereignisse oder ansonsten.

Editors`Note: Diese Pressenfreilassung ist unter dem Medien-Teil von website der Gesellschaft dabei auch verfügbar: www.millennium.com.

Kontakte: Kelly Lindenboom (Medien) Gina Nugent (Investor) ((617)) 679-7405 ((617)) 551-3611

SOURCE Millennium Pharmaceuticals, Inc.

Kelly Lindenboom (Medien), [phone],; oder Gina Nugent(investor, [phone], beide für Millennium Pharmaceuticals, Inc. / Gesellschaft News Auf-Anruf: http://www.prnewswire.com/comp/114562.html/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP-Arch… http://photoarchive.ap.orgPRN Fotoschreibtisch, 888-776-6555 oder 212-782-2840,
http://www.millennium.com

Copyright (C) 2003 PR Newswire. Alle Rechte reserviert.

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


05/19/2003 (10:32 ET) SECTOR(HCR): Biotechs Fairing Well Today, Led by DNA - Knobias



05/19/2003 (09:46 ET) New 4 just released for MLNM - Edgar



05/19/2003 (06:02 ET) Price Headley Highlights: Cisco, iShares GS Networking Index, Dell, S&P/Value, DJ Small Cap Value, NASDAQ Biotech, DJ Healthcare, and Millennium - Business Wire



05/16/2003 (16:49 ET) New 8-K just released for MLNM - Edgar



05/15/2003 (16:37 ET) New SC 13D/A just released for MLNM - Edgar



05/15/2003 (12:04 ET) Schaeffer`s Option Activity Watch Features TGT, MLNM, and IBM - PR Newswire



05/15/2003 (10:33 ET) Techs Report Resilient Earnings: PWEB, ADI, BEAS, BRCD, CA - Financial News USA



05/15/2003 (08:01 ET) Lynx Announces Initiation of Gene Expression Analysis Collaboration - PR Newswire



05/15/2003 (07:30 ET) Kosan Appoints Dr. Charles Homcy to Board of Directors - PR Newswire



05/15/2003 (06:04 ET) MEDIA: Today`s Wall Street Journal Mentions MLNM - Knobias



05/14/2003 (14:38 ET) New 3 just released for MLNM - Edgar



05/14/2003 (14:02 ET) Schaeffer`s Midday Options Update Features ANF, MLNM, and GP - PR Newswire



05/14/2003 (13:11 ET) Millennium To Ship Velcade, FDA Reports On Xoliar and Other Biotechnology and Drug Industry News - Financial News USA



05/14/2003 (13:08 ET) RATING(=): Morgan Stanley Reiterates MLNM Rating @ Underweight - Knobias



05/14/2003 (12:01 ET) Wall Street Journal: FDA gives early approval to promising cancer drug - World Media Abstract (US)



05/14/2003 (11:26 ET) RATING(=): S&P Reiterates MLNM Rating @ 4 STARS (Accum) - Knobias



05/14/2003 (09:52 ET) VOLUME(+): MLNM Volume 38% > 20-adsv, Stock +15.45% - Knobias



05/14/2003 (09:45 ET) GAP(+): Opening Higher XLND, PROX, MLNM, RMOO, JCOM - Knobias



05/14/2003 (09:30 ET) FDA approves Velcade for relapsed and refractory multiple myeloma - Datamonitor



05/14/2003 (09:13 ET) MLNM Gets FDA Ok to Market Velcade for Multiple Myeloma - Knobias



05/14/2003 (07:24 ET) MEDIA: Today`s New York Times Mentions MLNM - Knobias



05/14/2003 (06:43 ET) MEDIA: Today`s Wall Street Journal Mentions MLNM - Knobias



05/14/2003 (03:17 ET) Cambridge, Mass., Biotech Firm Wins FDA Approval for Cancer-Fighting Drug - Knight Ridder



05/13/2003 (19:18 ET) Millennium to Webcast Conference Call on Recent FDA Approval of Velcade(TM) (bortezomib) for Injection on May 14, 2003 - PR Newswire



05/13/2003 (18:46 ET) FDA Approves VELCADE(TM) (bortezomib) for Injection for the Treatment of Relapsed and Refractory Multiple Myeloma - Canada NewsWire

JS200

[js200]

In Phase II Study, Millennium Investigational Drug MLN02 Produced Significant Improvement in Ulcerative Colitis Remission Rates as Compared to Placebo [INLINE]
via CDS

May 21, 2003

Novel Monoclonal Antibody Was Well Tolerated In Ulcerative Colitis And Crohn`s Disease Studies --



CAMBRIDGE, Mass., May 21 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the results of a phase II trial of its investigational drug MLN02 in patients with ulcerative colitis, which showed statistically significant improvements in the clinical remission rates of patients treated with MLN02 compared to placebo, the trial`s primary endpoint. The results from this study, as well as a phase II study of MLN02 in patients with Crohn`s disease, were presented this week at Digestive Disease Week, the largest international gathering of physicians and researchers in gastroenterology, in Orlando, Fla. In both studies, MLN02 appeared to be well tolerated.

(LOGO: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

`For the many ulcerative colitis patients who do not benefit from the current standard of care, the remaining treatment options, steroids and immnunosupressants, can be difficult to tolerate,`said Brian Feagan, M.D., Professor of Medicine at University of Western Ontario and a leading expert in inflammatory bowel disease. `In this study, MLN02, a novel, humanized monoclonal antibody, produced statistically significant improvements in remission rates as compared to placebo, suggesting that it may potentially offer patients an alternative treatment for this painful and debilitating disease.`

MLN02 is an investigational, novel monoclonal antibody that binds to alpha 4 beta 7, a T-cell integrin (a cell surface protein). It has been shown to prevent the migration of T-cells to the gut in laboratory studies. Increased T-cell trafficking is believed to play a role in the pathogenesis of inflammatory bowel disease (IBD), including conditions such as ulcerative colitis and Crohn`s disease.



Study Results Show Statistical Improvement Across All Endpoints

In the double-blind, multi-center trial, a total of 181 patients with mild to moderately active ulcerative colitis were randomized to receive either a 0.5 mg/kg dose of MLN02, a 2.0 mg/kg dose of MLN02 or placebo at days one and 29. On day 43 of the study, remission rates for the two MLN02 dose groups (0.5 mg/kg and 2.0 mg/kg) were 33 percent and 34 percent, compared to 15 percent for patients in the placebo group (p = 0.03). Clinical remission, the primary efficacy measure, was defined as a score of zero or one on the Ulcerative Colitis Clinical Score (UCCS) and a score of zero or one on the Modified Baron Score (MBS), and no blood in a patient`s stool at the study`s conclusion.



Other results from the trial included:

-- Twenty-nine percent of patients (0.5 mg/kg) and 14 percent of patients

(2.0 mg/kg) in the treatment groups had an MBS of zero, compared to

eight percent of those who received placebo (p=0.01). A modified Baron

score of zero implies the presence of normal epithelium when observed

during an endoscopy.

-- The proportion of patients who experienced an improvement of three or

more points on the UCCS from baseline was 66 percent of patients (0.5

mg/kg) and 57 percent (2.0 mg/kg) in the treatment groups, compared to

33 percent of those who received placebo (p=0.001).

-- Serious adverse events were mainly related to exacerbations of

underlying ulcerative colitis and occurred in eight percent of patients

in the two treatment groups, compared to five percent in the placebo

group. An infusion reaction occurred in one MLN02 treated patient who

developed mild angioedema.



`This successful phase II trial represents a significant advance in our development of MLN02 and an important step in the evolution of the inflammation franchise at Millennium,`said Steve Gilman, general manager of

inflammation at Millennium. `We are excited that, in conjunction with our collaborator, Genentech, we may one day be able to provide a new treatment option for patients with inflammatory bowel disease.`



Results from a separate phase II study of MLN02 in patients with mild to moderate Crohn`s disease, which were initially announced last fall, were also presented at the meeting. In this study of 185 patients, those treated with the higher dose (2.0 mg/kg) of MLN02 showed a statistically significant improvement in remission rates compared to placebo, although the study did not achieve its primary endpoint (a decrease of greater than 70 points on the Crohn`s Disease Activity Index). There was a trend toward dose response in the study, and no patients in the trial discontinued due to adverse events.

MLN02 is being developed in collaboration with Genentech, Inc., which holds exclusive worldwide commercialization rights. Millennium and Genentech are currently assessing data from the phase II trials in patients with ulcerative colitis and Crohn`s disease to determine the appropriate next steps for the development and potential commercialization of MLN02.



Inflammatory Bowel Disease

IBD encompasses a group of chronic disorders, including Crohn`s disease and ulcerative colitis, that produce inflammation and ulceration in the intestines. In both disorders, a damaging inflammatory response involving the recruitment and activation of leukocytes results in tissue destruction. Ulcerative colitis causes bleeding and inflammation of the mucosal lining of the colon and rectum, while Crohn`s disease is an inflammation that extends deeper into all layers of the intestinal wall and frequently involves both the small and large intestine. Current drug therapy for serious cases involves several types of therapy, such as steroids and immunosuppressants that broadly suppress the immune response and as a result, carry a risk of infection and adverse side effects.

The Crohn`s and Colitis Foundation estimates that up to one million Americans have IBD, with roughly half of that number for each disease. The specific cause of IBD is unknown.



Genentech Collaboration

In December 1997, Millennium began a collaboration with Genentech, Inc. to develop and commercialize MLN02 for the treatment of IBD. Under the terms of the agreement, Genentech receives exclusive worldwide rights to market MLN02. Millennium is responsible for developing MLN02 through successful phase II clinical trials after which Genentech would be responsible for completing the development of the product. Millennium has the option to take a royalty based on sales or to share in the phase III development costs in return for a share of profits on U.S. sales while continuing to receive royalties on non-U.S. sales. Millennium also receives development milestone payments from Genentech. Millennium and Genentech retain separate rights to develop small molecule therapeutics for the treatment of IBD.



The Millennium Inflammation Franchise

The Millennium inflammation franchise has a number of novel molecular targets and compounds in various stages of development, from discovery research to advanced clinical trials. These development programs include small molecules and monoclonal antibodies to potentially treat a broad spectrum of chronic inflammatory diseases. MLN02 represents the first in a series of programs aimed at preventing leukocyte activation and migration to inflamed tissues for the treatment of a variety of inflammatory conditions.

Millennium and Aventis Pharmaceuticals, Inc. formed an alliance in June 2000 focused on identifying drug targets and developing new therapies for inflammatory diseases. The companies are sharing inflammation discovery pipeline assets and sharing costs.



About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, markets VELCADE(TM) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass., Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.



This press release contains `forward-looking statements,`including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause the Company`s actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN(R) (eptifibatide) Injection and VELCADE(TM) (bortezomib) for Injection; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Editors`Note: This press release is also available under the Media section of the Company`s website at: http://www.millennium.com.



Contacts:

Todd Cooper (media) Gina Nugent (investor)

[phone] [phone]

Kelly Lindenboom (media)

[phone]

JS200

[js200]

.
http://www.investtech.com/nasdaq/ana/mlnm.htm

JS200

[mountainbiker]

So, Leute jetzt gehts los !

[HalfLife11]

Schau mal wie es bei Medarex, Celgene und Humen Genome losgeht 14% - Naja ich bleib meiner Millennium treu.

[js200]

MORNING UPDATE: Man Securities Issues Alerts for BRCM, WMT, MLNM, APOL, And NFLX [INLINE]
via CDS

May 27, 2003

Man Securities issues the following Morning Update at 8:30 AM EDT with new PriceWatch Alerts for key stocks.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/MANSECLOGO )



Before the open ... PriceWatch Alerts for BRCM, WMT, MLNM, APOL, and NFLX, Put/Call Alert, FuturesWatch, Today`s Economic Calendar, and the Quote Of The Day.



QUOTE OF THE DAY

`The euro has reached a record high and that`s clearly an achievement. But if we calm down a bit, we see the euro has been gradually rising for the past two years. This could be the beginning of the end of euro-buying.`

-- Kikuko Takeda, manager of currency research, Bank of Tokyo-Mitsubishi



New PriceWatch Alerts for BRCM, WMT, MLNM, APOL, and NFLX...



PRICEWATCH ALERTS - HIGH RETURN COVERED CALL OPTIONS

-- Broadcom Corp. (Nasdaq: BRCM) Last Price 22.03 - JUL 20.00 CALL OPTION@ $3.00 -) 5.1 % Return assigned*

-- Wal-Mart Stores Inc. (NYSE: WMT) Last Price 52.00 - SEP 50.00 CALL OPTION@ $4.10 -) 4.4 % Return assigned*

-- Millennium Pharmaceuticals Inc. (Nasdaq: MLNM) Last Price 14.26 - JUL 12.50 CALL OPTION@ $2.35 -) 5.0 % Return assigned*

-- Apollo Group Inc. (Nasdaq: APOL) Last Price 52.40 - AUG 50.00 CALL OPTION@ $4.80 -) 5.0 % Return assigned*

-- Netflix Inc. (Nasdaq: NFLX) Last Price 22.12 - JUL 17.5 CALL OPTION@ $5.40 -) 4.7 % Return assigned*




* For our report, `5 Dividend Paying Stocks With Double Digit Returns`, go to: http://www.InvestorsObserver.com/5div



** For a FREE subscription to The Wall Street Journal, Financial Times, or Investors Business Daily go to http://www.InvestorsObserver.com/freenews



NOTE: All stocks and options shown are examples only. These are not recommendations to buy or sell any security.



MARKET OVERVIEW

Overseas markets are performing quite pitifully as none of the 15 markets that we track could post positive figures. The cumulative average return on the group stands at minus 1.124 percent. While the U.S. honored its fallen heroes, the balance of the world carried on with business as usual. A little positive news out of Germany failed to overcome the persistent rise in the euro. The West German Ifo business sentiment survey was expected to decline to 86.5 in May from 86.6 in April. This would have made sense in light of the recent flow of negative economic data out of the country, but the survey surprised with a stronger than expected 87.6 reading. The Ifo Institute, which compiles the index, said business conditions improved in the retail and wholesale sector, but also improved in the industrial sector. Construction slumped further in this May report. The latest numbers would seem to suggest that chances for a moderate upturn in economic conditions in the second half of the year are better than recent economic data would suggest. Breaking the headline number down into its components, Current Conditions slipped slightly to 78.3 from the 78.6 of April. The Expectations Index advanced to 97.2 from the 94.9 of April.

All of today`s data will come through at 10:00 a.m. April Existing Home Sales are expected to have risen by 3.1 percent, recouping from March`s 5.6 percent decline. April New Home Sales are seen taking a breather from March`s surprise 7.3 percent surge. Analysts expect a 2.2 percent decline. If you are holding some homebuilders, a disappointment to the downside could spark a round of `profit taking`but a major impact on the market would seem remote. As an FYI, the PHLX Housing Sector Infixed (HGX - 264.55) added 1.27 percent on Friday and is rapidly approaching its all-time high of 276.54. The HGX has surged some 33 percent from its March 14 nadir around 199 and has hurdled the 260 level which attempted to stymie that advance. Finally the Conference Board Consumer Confidence Index for May is seen at 84.0, improving from April`s 81.0. The April figure surged from the 61.4 released in March, as anxieties over the war in Iraq subsided.



Be prepared for the investing week ahead with Bernie Schaeffer`s FREE Monday Morning Outlook. For more details and to sign up, go to: http://www.schaeffersresearch.com/redirect.asp?CODE=GJ01A3&P…



PUT/CALL ALERT

Equity option activity on the CBOE yesterday had 196,412 put contracts trade compared to 330,919 call contracts. The resultant 0.594 single day put/call ratio has once again twisted the 21-day moving average lower to 0.677. This indicator has failed to offer any clue to the direction of the market for quite some time as it has been basically moving sideways, failing to yield to one direction or another. The CBOE Market Volatility Index (VIX - 21.38) slipped by 1.11 percent and the Nasdaq 100 Trust Volatility Index (QQV - 24.37) dropped by 3.94 percent and established yet another all-time low of 24.13 in the process. Once again, these fear gauges seem to mock the sentimentician, consolidating along historically low levels and failing to yield a severe market decline.



FUTURES WATCH

The futures markets are under pressure this morning as the dollar continues to weaken against the euro. The European markets are lower as well which is helping to pressure the markets. Last week`s trading just ran out of gas as it failed to take out the 95330 high from Early December in the S&P futures while the NASDAQ showed weakness to the S&P futures. The S&P futures

must hole the 92300 level or face some downside follow through to the 9100 level. The 9100 level in the S&P futures is the key level for the week. A close below that level would indicate a pause in the rally and some renewed downside follow through as profit taking will take over. Traders will be watching for the release of the Consumer Confidence number as well as the New Home Sales and Existing Home sales all due out at 9:00 Chicago time. The Consumer Confidence is expected to be 84, a bit higher from the 81 number from the last report.



*For a free Trader`s Resource CD click the following link or paste it into your browser address bar: http://www.manfutures.com/mucd.html



TODAY`S ECONOMIC CALENDAR

10:00 a.m.: April Existing Home Sales (last minus 5.6 percent)

10:00 a.m.: April New Home Sales (last plus 7.3 percent)

10:00 a.m.: May Conference Board Consumer Confidence Index (last 81.0)



Man Financial Inc is one of the world`s major futures and options brokers

and has been recognized as a leading option order execution firm for individuals and institutions. Member CBOE/NASD/SIPC (CRD#6731). For more information and a free CD with educational tools to help you invest smarter, see http://www.mansecurities.com/mu.html .



This Morning Update was prepared with data and information provided by:



InvestorsObserver.com -- Better Strategies for Making Money -) For Investors With a Sense of Humor. Only $1 for your first month plus seven free bonuses worth over $420, see: http://www.investorsobserver.com/bm



Schaeffer`s Investment Research -- Sign up for your FREE e-weekly, Monday Morning Outlook, Bernie Schaeffer`s look ahead at the markets. Sign Up Now http://www.schaeffersresearch.com/redirect.asp?CODE=GJ01A3&P…



All stocks and options shown are examples only. These are not recommendations to buy or sell any security and they do not represent in any way a positive or negative outlook for any security. Potential returns do not take into account your trade size, brokerage commissions or taxes which will affect actual investment returns. Stocks and options involve risk and are not suitable for all investors and investing in options carries substantial risk. Prior to buying or selling options, a person must receive a copy of Characteristics and Risks of Standardized Options available from Sharon at 800-837-6212 or at http://www.cboe.com/Resources/Intro.asp . Privacy polic y available upon request.




Print story

Current Quote

NSD: MLNM
Biotech/Medical

Last: 15.430
Change: 1.170
Volume: 6,623,600
Day High: 15.570
Day Low: 14.140



First Alert News
Get real-time MLNM release alerts by entering your email address below.

JS200

[js200]

Millennium Pharmaceuticals Announces Webcast of American Society of Clinical Oncology Investor Event [INLINE]
via CDS

May 27, 2003

CAMBRIDGE, Mass., May 27 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced today that its investor event at the annual American Society of Clinical Oncology meeting will be webcast live via the investors section of its website at http://www.millennium.com.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Millennium senior management and a clinical investigator will provide an overview of the Company`s oncology franchise, including an update on data from the Company`s oncology development pipeline. The presentations will be delivered beginning at 7:30 p.m. (CDT) on Monday, June 2, 2003, from the Park Hyatt Chicago. The webcast will be archived for seven days.



About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, markets VELCADE(TM) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine

products. Headquartered in Cambridge, Mass., Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.



Editors`Note: This press release is also available under the Media section of the Company`s website at: http://www.millennium.com.



Contact:

Cynthia Clayton, Investor Relations

Millennium Pharmaceuticals, Inc.


JS200

[mountainbiker]

Drecks Amis !

[JS222]

Schaeffer`s Option Activity Watch Features MU, MLNM, and MSFT [INLINE]
via CDS

May 29, 2003

Today`s Schaeffer`s Option Activity Watch features Micron Technology (NYSE: MU), Millennium Pharmaceuticals (Nasdaq: MLNM), and Microsoft (Nasdaq: MSFT). The Option Activity Watch is a report that takes a closer look at three equities appearing in our most unusual option activity report from the previous day. The Option Activity Watch is published on http://www.SchaeffersResearch.com" target="_blank" rel="nofollow ugc noopener">http://www.SchaeffersResearch.com -- the home of Berni e Schaeffer and Schaeffer`s Investment Research. For additional information about this report or to have it delivered to you free via email every day click on the following link: http://www.schaeffersresearch.com/addinfo" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/addinfo .

(Logo: http://www.newscom.com/cgi-bin/prnh/20020725/SCHAEFFERLOGO )



Schaeffer`s Option Activity Watch:



1. A reader named Tim recently asked for my opinion on Micron Technology (NYSE: MU). So here we go. Everyone`s getting all excited about the `recovery`in semiconductor spending. This is one reason why stocks like MU have rallied sharply higher in recent months. In fact, it`s hard to argue with the 68-percent increase the shares have managed off their February bottom. These high hopes are also being reflected in the options pits, where investors are flocking to calls. This activity has sent MU`s Schaeffer`s put/call open interest ratio (SOIR) into a nosedive, falling from 0.58 to 0.28 since early May. The current reading is lower than about 85 percent of those taken during the past year. Our research shows that MU tends to rally by an average of 9.81 percent on previous occasions when its SOIR has been this low.

In early April, a major financial weekly called a bottom in the stock and suggested that it could see a lot of upside going forward. Such articles usually sound alarm bells around here because of their potential contrarian implications. But is that the case for MU? I`m not so sure. Remember: `the trend is your friend,`and this stock`s trend seems to be higher. Besides, there are still signs of skepticism. Short interest increased 17 percent in May to a new all-time high. These shorts represent potential buyers that could be forced to drive MU higher if it continues to perform well. One note of caution: pay close attention to the 11.50-12.00 area. This coincides with the equity`s declining 10-month moving average and is also the site of previous short-term support. MU needs to overtake these marks in order to maintain its strength. A rejection here could spell trouble.

Click the following link to see the Daily Chart of MU since September 2002: http://www.schaeffersresearch.com/wire?ID=778" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7786" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=778" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7786 .

Click the following link to see the Monthly Chart of MU since March 2001 with 10-Month Moving Average: http://www.schaeffersresearch.com/wire?ID=778" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=778 6 .



2. Biotech stocks are certainly `hot`right now, and Millennium Pharmaceuticals (Nasdaq: MLNM) is no exception. The shares have more than doubled in the past two months and are currently challenging potential resistance at the 15 level. Last week, the company reported favorable phase II trial results for its MLN02 drug to treat ulcerative colitis. But one of the most attractive things about this stock is the number of investors who continue to bet against it. This group added 1,900 contracts to MLNM`s August 12.50 put yesterday, which has helped push its SOIR into the 98th percentile of all readings from the past year. On previous occasions when its percentile rank was this high, MLNM has gone on to add about 10 percent during the next 20 days. Short interest is at its highest point since January 2002 -- another sign of extremely low expectations that could ultimately prove wrong. Just be careful of that 15 level. It`s the site of MLNM`s 20-month trendline and also coincides with peak call open interest in the June series.

Click the following link to see the Monthly Chart of MLNM since November 2001 with 20-Month Moving Average: http://www.schaeffersresearch.com/wire?ID=778" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7786" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=778" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7786 .



3. It`s time to reiterate my concerns on Microsoft (Nasdaq: MSFT) from May 19. Since highlighting the mix of optimistic sentiment and technical troubles facing this stock, investors have maintained a steady pace of call activity even as MSFT continues its course lower. Today finds the security`s SOIR at 0.52 after some heavy additions at the June 25 call overnight. The current SOIR is lower than 95 percent of those from the past year. At the same time, MSFT faces a mountain of potential options-related resistance at 25. It`s home to more than 111,000 calls in the June series and another 74,300 contracts in July. The declining trendline I mentioned earlier still resides overhead at 26. And here`s the question pressing on everyone`s mind: if Bill Gates and Steve Ballmer are selling shares like there`s no tomorrow, why shouldn`t I? Earlier this week, it was reported that Ballmer (MSFT`s second- largest shareholder behind you know who) unloaded 39.3 million shares. The executive called it `a personal financial matter.`I call it a good idea.

Click the following link to see the Daily Chart of MSFT since February 2003 with 10-Day Moving Average: http://www.schaeffersresearch.com/wire?ID=778" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7786" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=778" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7786 .



The best way to take advantage of the timely commentaries from SchaeffersResearch.com is to sign up to receive their e-newsletters -- Opening View, Midday Report, Market Recap and Monday Morning Outlook. Click here to have the Schaeffer`s commentaries delivered to you free via email every day: http://www.schaeffersresearch.com/addinfo" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/addinfo .



About Schaeffer`s Investment Research ( http://www.SchaeffersResearch.c om )

Schaeffer`s Investment Research, founded by Bernie Schaeffer in 1981, is a financial information and trading resources company. It publishes Bernie Schaeffer`s Option Advisor, the nation`s leading options subscription newsletter. The firm`s contrarian approach focuses on stocks with technical and fundamental trends that run counter to investor expectations. The firm`s website, http://www.schaeffersresearch.com , is recognized as one of the le ading information sources for stock and options traders and was cited as the top options website by both Forbes and Barron`s. Click here for more details about Schaeffer`s trading methodology: http://www.schaeffersresearch.com/me thod .



Contact: Tom Godich at Schaeffer`s, Phone: [phone]; Email: [e-mail] .




Print story

Current Quote

NSD: MLNM
Biotech/Medical

Last: 14.500
Change: -0.570
Volume: 5,829,600
Day High: N/A
Day Low: 14.430



First Alert News
Get real-time MLNM release alerts by entering your email address below.

JS200

[JS222]

Schaeffer`s Midday Options Update Features F, UTX, IMCLE, MLNM, KLAC
via COMTEX

May 30, 2003

CINCINNATI, May 30, 2003 /PRNewswire via COMTEX/ --

Today`s Schaeffer`s Midday Options Update features Ford Motor (NYSE: F), United Technologies (NYSE: UTX), ImClone Systems (Nasdaq: IMCLE), Millenium Pharmaceuticals (Nasdaq: MLNM), and KLA- Tencor (Nasdaq: KLAC). The Midday Options Update contains a brief commentary on the day`s most notable activity and a table listing the most active calls and puts for the day. The Midday Options Update is published every day at www.SchaeffersResearch.com - the home of Bernie Schaeffer and Schaeffer`s Investment Research. For additional information about this report or to have it delivered to you free via email every day click on the following link: http://www.schaeffersresearch.com/addinfo" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/addinfo .

(Logo: http://www.newscom.com/cgi-bin/prnh/20020725/SCHAEFFERLOGO )

Schaeffer`s Midday Options Update

Today`s dollop of economic data lit a fire under stocks. The market is surging higher following news that the Chicago Purchasing Managers`Index (PMI) jumped to 52.2 percent in May from last month`s reading of 47.6 percent. Most analysts were expecting only a slight move higher to 49.0 percent. Today`s PMI report represents a glimmer of hope for the troubled manufacturing sector. It could also be a sign of things to come for next week`s release of the Institute for Supply Management national factory report. A number of blue chips are rallying on the news, including Ford Motor (NYSE: F) and United Technologies (NYSE: UTX).

Not to be left behind, the University of Michigan Consumer Sentiment Index is also grabbing some headlines today. May`s reading climbed to 92.1 from April`s 86. Although this represents a significant month-over-month improvement, the final reading for May came in below the mid-month reading of 93.6 and the expected 93.0.

Biotechnology stocks are hot again today ahead of this weekend`s American Society of Clinical Oncology meeting. Shares of ImClone Systems (Nasdaq: IMCLE) are about 21 percent higher as investors anticipate good news about the company`s Erbitux cancer drug. Millennium Pharmaceuticals (Nasdaq: MLNM) is another company scheduled to present at the conference, and its shares are currently up about five percent.

At 1:55 p.m. eastern time, the Dow Jones Industrial Average (DJIA - 8831.8) is up 1.38 percent and the S&P 500 Index (SPX - 960.57) is up 1.15 percent. The Nasdaq Composite (COMP - 1589.3) is higher by 0.90 percent. At 1:57 p.m. in the options pits, 1,435,002 calls had traded compared to 948,030 puts for a composite put/call ratio across all five exchanges of 0.66. The CBOE put/call ratio for equity options weighs in at 0.56.

KLA-Tencor (Nasdaq: KLAC) has added about 13 percent since I first mentioned the stock on May 16, and there are some signs that it may have further room to run. Investors continue to add puts even as the equity stomps higher - a sign of growing pessimism that could have bullish implications from a contrarian point of view. Open interest at KLAC`s out-of-the-money June 40 put has climbed from 13,800 to more than 16,000 contracts during the past four days. Today finds the June 45 put active, with volume of 3,729 contracts changing hands. Open interest at this strike has also been on the rise - jumping from 1,800 to nearly 3,000 contracts. This type of activity has the stock`s Schaeffer`s put/call open interest ratio (SOIR) at a reading of 1.59, with puts outnumbering calls in the short-term expiration cycle. The current SOIR reading is higher than 97 percent of those taken during the past year. And although it dipped slightly lower in May, short interest remains high at 24.4 million shares.

Meanwhile, KLAC continues to enjoy the strong price action that`s swept over many semiconductor names in recent weeks. The stock`s most recent pullback was caught by its rising 10-week moving average. The move off this trendline has vaulted KLAC above previous resistance at 45. Not only is this the site of a sharp rejection from late November, it`s also home to the heaviest concentration of calls in the June series (10,409 contracts). As many of you know, once a stock breaks above these areas of potential options- related resistance, it often continues its course higher. As a further sign of this strength, KLAC is poised to notch its first monthly close above its 20-month trendline since May 2002.

Be careful of potential resistance near 47.87. This represents a 50- percent correction of the stock`s decline from March to October 2002. Potential support still lies below at 40 (the site of peak June put open interest and KLAC`s 10-week trendline). Overall, the combination of technical strength and rampant pessimism could add up to more gains before investors start their journey back to reality.

Click the following link to see the Weekly Chart of KLAC since March 2002 with 10-Week Moving Average: http://www.schaeffersresearch.com/wire?ID=7798" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7798 .

About Schaeffer`s Investment Research ( www.SchaeffersResearch.com )

Schaeffer`s Investment Research, founded by Bernie Schaeffer in 1981, is a financial information and trading resources company. It publishes Bernie Schaeffer`s Option Advisor, the nation`s leading options subscription newsletter. The firm`s contrarian approach focuses on stocks with technical and fundamental trends that run counter to investor expectations. The firm`s website, www.schaeffersresearch.com, is recognized as one of the leading information sources for stock and options traders and was cited as the top options website by both Forbes and Barron`s. Click here for more details about Schaeffer`s trading methodology: www.schaeffersresearch.com/method .

Contact: Tom Godich at Schaeffer`s, Phone: [phone]; Email: [e-mail]

SOURCE Schaeffer`s Investment Research

Tom Godich at Schaeffer`s, Phone: [phone]; Email: [e-mail] /Photo: http://www.newscom.com/cgi-bin/prnh/20020725/SCHAEFFERLOGO AP Archive: http://photoarchive.ap.org PRN Photo Desk, [phone] or [phone]

http://www.schaeffersresearch.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

Schaeffer`s `Herd` on the Street Features AMR Corp., Millennium Pharmaceuticals, and TiVo: AMR, MLNM, TIVO

Monday , June 02, 2003 14:19 ET

CINCINNATI, Jun 2, 2003 /PRNewswire via COMTEX/ -- Today`s Schaeffer`s `Herd` on the Street features AMR Corp. (NYSE: AMR), Millennium Pharmaceuticals (Nasdaq: MLNM), and TiVo (Nasdaq: TIVO). `Herd` on the Street contains commentary and charts on stocks that are generating a notable amount of interest on Internet message boards. `Herd` on the Street is published every day at www.SchaeffersResearch.com -- the home of Bernie Schaeffer and Schaeffer`s Investment Research. For additional information about this report or to have it delivered to you free via email every day click on the following link: http://www.schaeffersresearch.com/addinfo" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/addinfo .


(Logo: http://www.newscom.com/cgi-bin/prnh/20020725/SCHAEFFERLOGO )

Schaeffer`s `Herd` on the Street:


AMR Corp.

AMR Corp. (NYSE: AMR), the parent of American Airlines, enjoyed an upgrade this morning from Goldman Sachs Group. The brokerage firm boosted its rating on the shares to an "outperform" from an "in-line" and said that business travel should increase. AMR shares have enjoyed a solid uptrend since late March and have rallied over 10 percent today on the vote of confidence from Goldman. The equity`s 20-day moving average has provided excellent support throughout the past few months, containing slight pullbacks in mid-April and mid-May. On the sentiment front, Schaeffer`s put/call open interest ratio (SOIR) for AMR stands at 0.72, in the top 11 percent of all annual readings of this indicator. The SOIR may be shifting in the very near term, however, as speculators are active today on the out-of-the-money June and July 7.5 calls.

Click the following link to see the Daily Chart of AMR Since March 2003 With 10-Day and 20-Day Moving Averages: http://www.schaeffersresearch.com/wire?ID=7806" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7806 .

Millennium Pharmaceuticals

Millennium Pharmaceuticals (Nasdaq: MLNM) has rallied over five percent today to notch a new annual high. The stock is also one of the most-active names trading on the Nasdaq Composite today. Earlier this morning, the firm said its oncology drug, Velcade, was showing promising anti-tumor activity in clinical trials, both standing alone and being used alongside other treatments. In separate news, Abbott Laboratories said it pared its stake in MLNM to 4.9 percent from 5.22 percent by selling over 700,000 shares. Since early March, the shares have been rallying consistently, nearly tripling in value. The options crowd remains skeptical, however, as Schaeffer`s put/call open interest ratio (SOIR) for MLNM stands in the top 11 percent of all yearly readings at 0.52. The site of heaviest call open interest in the front-quarter`s series is the in-the-money June 15 strike, home to over 15,000 contracts.

Click the following link to see the Daily Chart of MLNM Since March 2003 With 10-Day and 20-Day Moving Averages: http://www.schaeffersresearch.com/wire?ID=7806" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7806 .

TiVo

The L.A. Times reported this morning that digital recording service provider TiVo (Nasdaq: TIVO) has developed a tool to measure viewing patterns of television audiences. TIVO plans to sell its findings from these studies but will protect the anonymity of its viewers. TIVO has risen sharply over the last several sessions, overcoming its December peak and moving within striking distance of double-digit territory. Short sellers are expecting a setback in the shares, as suggested by the nearly six million TIVO shares sold short, for a short-interest ratio of 8.6 times. If these bearish speculators become forced to cover their positions, it could add fuel to the security`s rally. Schaeffer`s put/call open interest ratio (SOIR) for TIVO weighs in at 0.13, in the 44th percentile of all annual readings. Since April 2001, there have been 57 examples of TIVO SOIR percentile rankings between 40 and 50 percent. Historically, solid outperformance has resulted from such a signal. For example, TIVO shares have climbed 9.95 percent in the 15 trading days following an SOIR number in the 40th-50th percentiles. On any given 15-day period, TIVO has risen an average of 4.05 percent.

Click the following link to see the Daily Chart of TIVO Since November 2002 With 10-Day and 20-Day Moving Averages: http://www.schaeffersresearch.com/wire?ID=7806" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=7806 .

For more information on SOIR, short interest, and Expectational Analysis(R), please visit Schaeffer`s Daily Sentiment Complete . ( http://www.schaeffersresearch.com/services/sds/index.asp" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/services/sds/index.asp )

The best way to take advantage of the timely Schaeffer commentaries is to sign up to receive their free e-newsletters -- Opening View, Midday Report, Market Recap and Monday Morning Outlook. Click here to have the Schaeffer`s commentaries delivered to you free via email every day: http://www.schaeffersresearch.com/addinfo" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/addinfo .

About Schaeffer`s Investment Research ( www.SchaeffersResearch.com ):

Schaeffer`s Investment Research, founded by Bernie Schaeffer in 1981, is a financial information and trading resources company. It publishes Bernie Schaeffer`s Option Advisor, the nation`s leading options subscription newsletter. The firm`s contrarian approach focuses on stocks with technical and fundamental trends that run counter to investor expectations. The firm`s website, www.schaeffersresearch.com , is recognized as one of the leading information sources for stock and options traders and was cited as the top options website by both Forbes and Barron`s. Click here for more details about Schaeffer`s trading methodology: www.schaeffersresearch.com/method .

Contact: Tom Godich at Schaeffer`s, Phone: [phone]; Email: [e-mail]

SOURCE Schaeffer`s Investment Research


CONTACT: Tom Godich of Schaeffer`s, [phone],
[e-mail]
/Photo: http://www.newscom.com/cgi-bin/prnh/20020725/SCHAEFFERLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, [phone] or [phone]

URL: http://www.schaeffersresearch.com
http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


ProviderSequenceNumber: 2744

KEYWORD: Ohio
INDUSTRY KEYWORD: FIN
PUB
SUBJECT CODE: INO


STOCK SYMBOLS: [(amr)] [(mlnm)] [(tivo)]

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


06/02/2003 (14:19 ET) Schaeffer`s `Herd` on the Street Features AMR Corp., Millennium Pharmaceuticals, and TiVo: AMR, MLNM, TIVO - PR Newswire



06/02/2003 (11:41 ET) New 4 just released for MLNM - Edgar



06/02/2003 (11:36 ET) New 4 just released for MLNM - Edgar



06/02/2003 (11:30 ET) New 4 just released for MLNM - Edgar



06/02/2003 (11:24 ET) New 4 just released for MLNM - Edgar



06/02/2003 (11:17 ET) New 4 just released for MLNM - Edgar



06/02/2003 (11:08 ET) New 4 just released for MLNM - Edgar



06/02/2003 (10:59 ET) New 4 just released for MLNM - Edgar



06/02/2003 (10:50 ET) New 4 just released for MLNM - Edgar



06/02/2003 (10:31 ET) New 4 just released for MLNM - Edgar



06/02/2003 (09:50 ET) 52W HIGH: New 52-Wk High for MLNM @ $17.500 up12.54% - Knobias



06/02/2003 (09:02 ET) Millennium Announces Preliminary Phase I and Phase II Findings of VELCADE(TM) (Bortezomib) For Injection in Studies of Non-Hodgkin`s Lymphoma and Solid Tumors - PR Newswire



06/02/2003 (07:55 ET) DJ. Hot Stocks To Watch: MLNM WMB ACET SLE - OsterDowJones Select



05/30/2003 (15:51 ET) New SC 13D/A just released for MLNM - Edgar



05/30/2003 (14:50 ET) Schaeffer`s Midday Options Update Features F, UTX, IMCLE, MLNM, KLAC - PR Newswire



05/29/2003 (12:24 ET) Schaeffer`s Option Activity Watch Features MU, MLNM, and MSFT - PR Newswire



05/28/2003 (13:34 ET) MLNM: Short Interest UP 2.2% to 15.3M in May 2003 - Knobias



05/27/2003 (16:01 ET) Millennium Pharmaceuticals Announces Webcast of American Society of Clinical Oncology Investor Event - PR Newswire



05/27/2003 (10:07 ET) MORNING UPDATE: Man Securities Issues Alerts for BRCM, WMT, MLNM, APOL, And NFLX - PR Newswire



05/22/2003 (12:15 ET) RATING(1): JMP Sec Initiates MLNM Rating @ Mkt Perform - Knobias



05/22/2003 (08:37 ET) MLNM Trial on MLN02 Showed Significant Improvements - Knobias



05/21/2003 (16:18 ET) In Phase II Study, Millennium Investigational Drug MLN02 Produced Significant Improvement in Ulcerative Colitis Remission Rates as Compared to Placebo - PR Newswire



05/21/2003 (09:20 ET) SECTOR(HCR): Morgan Stanley Cuts Biotech Sector - Knobias



05/20/2003 (13:55 ET) Millennium Ships VELCADE(TM) (bortezomib) for Injection Within Six Days of FDA Approval - PR Newswire



05/19/2003 (10:32 ET) SECTOR(HCR): Biotechs Fairing Well Today, Led by DNA - Knobias

JS200

[inter123]

stammt vom heutigen Tag (5.6.2003)
Nadine Wong`s Favorite Recommendation
----------------------------------------------------------------

MILLENIUM PHARMACEUTICALS (NASDAQ: MLNM)

On May 14, 2003, the FDA gave marketing approval on Velcade for
the treatment of relapsed and refractory multiple myeloma and
Millennium has begun the launch of the drug. The next step for
the company is to sign a large developmental and
commercialization partner. Millennium said this would happen at
the end of the second quarter of 2003.

The partner would likely be the sole marketer of Velcade in
Japan, but would be included in a joint venture in Europe.
Furthermore, the deal could include upfront payments of at least
$100 million, significant milestone fees of $250-500 million,
and reimbursement for future development activities in solid
tumor indications. In the U.S., Millennium would lead the sales
effort for the multiple myeloma market and retain all revenue.

The U.S. sales estimates are $22 million for 2003 and $74
million sales for 2004. Millennium would probably receive a 25%
royalty outside the U.S. Needless to say, we are ecstatic for
Velcade and foresee this event as a turning point for the
company. It`s the first genomic company to succeed in getting a
drug to the market. Separately, management stated that enrollment
in the ongoing Phase III APEX trial (comparing Velcade as a
single agent with high-dose dexamethasone, a commonly used
therapy for this disease) is on track and expects completion by
year-end 2003. Data could be released by mid-2004. This
randomized trial may form the basis for a full approval in late
2004/2005 for multiple myeloma.

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


06/05/2003 (19:12 ET) Millennium to Lay Off 600 Employees - Associated Press Online



06/05/2003 (15:17 ET) Millennium to Lay Off 600, Shut 2 Plants - Associated Press Online



06/05/2003 (12:18 ET) SECTOR(HCR): Biotechs Up, Led by MLNM, PDLI, DNA - Knobias



06/05/2003 (09:30 ET) Millennium Announces Restructuring - PR Newswire



06/05/2003 (06:10 ET) Millennium releases preliminary data for Velcade in non-Hodgkin`s lymphoma and solid tumors - Datamonitor



06/04/2003 (16:01 ET) Goldman Sachs Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation - PR Newswire



06/04/2003 (09:00 ET) Biotechnology Executives to Gather in Cambridge to View Leading Companies and Products from Downunder - Business Wire



06/03/2003 (11:06 ET) Stock Market Ratings by StockPickReport.com for Merck, Millennium Pharmaceuticals, Alcoa - Business Wire



06/03/2003 (09:01 ET) Millennium Announces Promising Early Study Results With VELCADE(TM) (bortezomib) For Injection Combined With Doxil in Patients With Advanced Multiple Myeloma - PR Newswire



06/03/2003 (08:17 ET) MLNM CEO Appears on CNBC`s "Squawk Box" Today - Knobias



06/03/2003 (06:00 ET) Paul Tracy Highlights the Following Stocks: Amgen, IDEC Pharma, Gilead Sciences, Millennium Pharma, and Omnicom Group - Business Wire



06/02/2003 (14:19 ET) Schaeffer`s `Herd` on the Street Features AMR Corp., Millennium Pharmaceuticals, and TiVo: AMR, MLNM, TIVO - PR Newswire



06/02/2003 (11:41 ET) New 4 just released for MLNM - Edgar



06/02/2003 (11:36 ET) New 4 just released for MLNM - Edgar



06/02/2003 (11:30 ET) New 4 just released for MLNM - Edgar



06/02/2003 (11:24 ET) New 4 just released for MLNM - Edgar



06/02/2003 (11:17 ET) New 4 just released for MLNM - Edgar



06/02/2003 (11:08 ET) New 4 just released for MLNM - Edgar



06/02/2003 (10:59 ET) New 4 just released for MLNM - Edgar



06/02/2003 (10:50 ET) New 4 just released for MLNM - Edgar



06/02/2003 (10:31 ET) New 4 just released for MLNM - Edgar



06/02/2003 (09:50 ET) 52W HIGH: New 52-Wk High for MLNM @ $17.500 up12.54% - Knobias



06/02/2003 (09:02 ET) Millennium Announces Preliminary Phase I and Phase II Findings of VELCADE(TM) (Bortezomib) For Injection in Studies of Non-Hodgkin`s Lymphoma and Solid Tumors - PR Newswire



06/02/2003 (07:55 ET) DJ. Hot Stocks To Watch: MLNM WMB ACET SLE - OsterDowJones Select



05/30/2003 (15:51 ET) New SC 13D/A just released for MLNM - Edgar

JS200

[js200]

http://www.investtech.com/nasdaq/ana/mlnm.htm

JS200

[schakal23]

06.06.2003
Millennium Pharmac. "outperform"
Robert W. Baird

Die Analysten vom Investmenthaus Robert W. Baird stufen Aktie von Millennium Pharmaceuticals (ISIN US5999021034/ WKN 900625) unverändert mit „outperform“ ein und sehen das Kursziel bei 20 US-Dollar.

Millennium habe die bereits erwarteten Restrukturierungsmaßnahmen bekannt gegeben. Die gesenkten Forschungsaufwendungen würden Raum für die Entwicklungsbemühungen zur Ausweitung der Velcade-Indikation für Körpertumore schaffen.

Das Unternehmen wolle 600 Mitarbeiter einsparen und die R&D-Aktivitäten an einem Ort bündeln. Bei Vorlage der Q2-Zahlen am 22. Juli wolle das Unternehmen einen neuen Finanzausblick präsentieren. Der Abbau von Angestellten könnte nach Ansicht der Analysten alleine zu jährlichen Einsparungen von 120 Mio. US-Dollar führen. Die R&D-Aufwendungen dürften sich ab 2004 auf jährlich 100 Mio. US-Dollar belaufen.

Insgesamt erachte man die genannten Schritte als sehr positive Nachrichten für das Unternehmen. Die neusten Ankündigungen sowie die Erwartungen in Velcade würden Anlass geben die Aktie zum Kauf zu empfehlen.

Vor diesem Hintergrund bewerten die Analysten von Robert W. Baird die Aktie von Millennium Pharmaceuticals weiterhin mit dem Votum „outperform“.

[schakal23]

was ist los seid baar tage geht mächtig nach unten??
inseider verkäufe kommt schlechte nachricht?

[Montha]

Warum wird MLNM so durchgereicht die letzten Tage ?

[bernimaus]

nicht fragen - kaufen kaufen kaufen! solche tage wie heute kommen nicht so häufig. für mill. gibts ganz klar nur eine richtung, und die zeigt nach norden. zeigt mir einen zweiten chart, der so sauber läuft, und dann weißt du, wo der kurs nächste woche steht.

denkt an bernimaus seine worte!

[js200]

XOMA Initiates Phase I Clinical Trial of MLN2201, an Inhibitor of Vascular Inflammation
via COMTEX

June 19, 2003

BERKELEY, Calif., Jun 19, 2003 (BUSINESS WIRE) --

XOMA Ltd. (Nasdaq:XOMA) announced today the initiation of a phase I clinical trial of MLN2201 (formerly known as MLN01), a humanized monoclonal antibody being developed for conditions related to inflammation of the heart and blood vessels. MLN2201 is one of two products currently under development as part of an ongoing collaboration with Millennium Pharmaceuticals, Inc. (Nasdaq:MLNM).

The phase I study is an open-label, dose-escalating clinical trial designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MLN2201 in healthy volunteers. Participants will receive a single intravenous infusion of MLN2201 followed by a monitoring and evaluation period.

MLN2201 is a humanized monoclonal antibody directed toward the beta-2 subunit of integrins (cell surface proteins) found on the surface of all leukocytes, or white blood cells. In preclinical studies, MLN2201 inhibited inflammatory responses, apparently by blocking the attachment of beta-2 integrins to their adhesion molecules, limiting the recruitment of leukocytes from blood vessels to tissues and thereby reducing the inflammatory process. This could potentially be important for limiting the tissue damage that follows any obstruction of blood supply caused by thrombosis: much of this damage results from the inflammatory response triggered when blood flow is re-established. By reducing vascular inflammation, MLN2201 could be beneficial in the treatment of various conditions that involve the heart and blood vessels.

`We`re pleased to be moving into the clinic with MLN2201, which is another example of building our product pipeline through development collaborations,`said John L. Castello, XOMA`s chairman, president and chief executive officer. `Despite decades of research and significant advances in vascular treatment, there are still opportunities for innovative therapies that address the potential role inflammation plays in diseases affecting the heart and blood vessels.`

About the XOMA/Millennium Collaboration

XOMA and Millennium entered into an agreement in November 2001 to collaborate on the development of MLN2201and CAB-2, a recombinant protein that inhibits complement activation, for certain vascular inflammation indications. Under the terms of the agreement, XOMA is responsible for development activities and related costs for both products through the completion of phase II trials. After the successful completion of phase II studies, Millennium has the right to further develop and commercialize the products, with XOMA retaining the option to choose between further participation in the development program and eventual profit sharing, or alternatively being entitled to future royalty and milestone payments.

About XOMA

XOMA develops and manufactures antibody and other protein-based biopharmaceuticals for disease targets that include immunological and inflammatory disorders, cancer and infectious diseases. XOMA`s programs include collaborations with Genentech, Inc. on the Raptiva(TM) antibody for psoriasis (BLA submission), psoriatic arthritis (phase II) and other indications; with Baxter Healthcare Corporation to develop NEUPREX (R)(rBPI-21) for Crohn`s disease (phase II) and other indications; with Millennium Pharmaceuticals, Inc. on two biotherapeutic agents, CAB-2 and MLN2201, for cardiovascular inflammation indications (preclinical and phase I respectively); and with Onyx Pharmaceuticals, Inc. on its ONYX-015 product for various cancers (Onyx has announced that it is discontinuing its therapeutic virus program, which includes the ONYX-015 product). Earlier-stage programs focus on antibodies and BPI-derived compounds developed at XOMA for the treatment of cancer, retinopathies, and acne. For more information about XOMA`s pipeline and activities, please visit XOMA`s website at http://www.xoma.com/.

Statements made in this news release related to collaborative arrangements and current plans for product development, or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. These risks, including those related to changes in the status of the Company`s collaborative relationships, the timing or results of pending or future clinical trials, the ability of collaborators and other partners to meet their obligations, market demand for products, actions by the Food and Drug Administration or the US Patent and Trademark Office, and uncertainties regarding the status of biotechnology patents, are discussed in the Company`s most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in evaluating XOMA`s prospects.

SOURCE: XOMA Ltd.

XOMA Ltd. Laura Zobkiw, 510/204-7200

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


06/19/2003 (16:11 ET) Xoma initiates phase I clinical trial of vascular inflammation inhibitor MLN2201 - Datamonitor



06/19/2003 (09:12 ET) PREMARKET: XOMA Initiates Phase 1 Trial for MLN2201 - Knobias



06/19/2003 (07:31 ET) XOMA Initiates Phase I Clinical Trial of MLN2201, an Inhibitor of Vascular Inflammation - Business Wire



06/17/2003 (10:25 ET) SECTOR(HCR): WR Hambrecht Comments on Biotechs - Knobias



06/16/2003 (09:34 ET) SECTOR(HCR): JP Morgan Comments on Biotechs - Knobias



06/13/2003 (09:11 ET) SECTOR(HCR): Prudential Bullish on Biotech Industry - Knobias



06/12/2003 (10:02 ET) MORNING UPDATE: Man Securities Issues Alerts for PCS, CMCSA, MLNM, FCS, And POWI - PR Newswire



06/11/2003 (10:32 ET) CONF: MLNM To Present At Goldman Sachs Health Conference @ 13:20 ET - Knobias



06/11/2003 (09:25 ET) SECTOR(HCR): CSFB Biotech Target Price Changes - Knobias



06/11/2003 (09:12 ET) SECTOR(HCR): CSFB Raises Biotech Target Prices - Knobias



06/11/2003 (09:00 ET) SECTOR(HCR): Merrill Lynch Comments on Biotech Industry - Knobias



06/11/2003 (06:00 ET) Nadine Wong Highlights the Following Stocks: Targeted Genetics, Oxigene, ImClone Systems, ICOS, and Millennium Pharmaceutical - Business Wire



06/11/2003 (03:31 ET) Cambridge, Mass.-Based Vertex Pharmaceuticals Lays Off 111 Employees - Knight Ridder



06/10/2003 (05:26 ET) Rising nicely - The Australian Financial Review



06/09/2003 (13:53 ET) SECTOR(HCR): First Albany Comments on Biotech Industry - Knobias



06/09/2003 (12:03 ET) SECTOR(HCR): Biotechs Down; OXGN, ENMD, GERN, PPHM Up - Knobias



06/09/2003 (06:09 ET) MEDIA: Latest Barron`s Publication Mentions MLNM - Knobias



06/06/2003 (16:39 ET) Biotech advance stalls as Biogen closes lower - UPDATE 2 - AFX News Asia



06/06/2003 (16:39 ET) Biotech advance stalls as Biogen closes lower - UPDATE 2 - AFX News Europe



06/06/2003 (16:39 ET) Biotech advance stalls as Biogen closes lower - UPDATE 2 - AFX News UK



06/06/2003 (16:30 ET) New 8-K just released for MLNM - Edgar



06/06/2003 (15:11 ET) Biotech advance stalls as Biogen drops - UPDATE 1 - AFX News UK



06/06/2003 (15:10 ET) Biotech advance stalls as Biogen drops - UPDATE 1 - AFX News Asia



06/06/2003 (15:10 ET) Biotech advance stalls as Biogen drops - UPDATE 1 - AFX News Europe



06/06/2003 (11:53 ET) RATING(=): Deutsche Bank Reiterates MLNM Rating @ Hold - Knobias

JS200

[js200]

http://www.investtech.com/nasdaq/ana/mlnm.htm

JS200

[hawe1]

mal bei google übersetzt hab........

XOMA Ltd. (Nasdaq:XOMA) verkündeten heute die Einführung eines klinischen Versuches der Phase von I von MLN2201 (früher bekannt als MLN01), ein gevermenschlichter monoclonal Antikörper, der für sich entwickelt wurde die Bedingungen, die auf Entzündung das Herz und $blutgefässe bezogen wurden. MLN2201 ist eins von zwei Produkten z.Z. unter Entwicklung als Teil einer fortwährenden Zusammenarbeit mit Millennium Pharmaceuticals, Inc. (Nasdaq:MLNM). Die Phase, die ich studiere, ist ein open-label, Dosis-entwickelnder klinischer Versuch, der entworfen werden, um die Sicherheit auszuwerten, eine Erträglichkeit, Pharmacokinetics und Pharmacodynamics von MLN2201 in den gesunden Freiwilligern. Teilnehmer empfangen eine einzelne intravenöse Infusion von MLN2201, das bis zum einer Überwachungs- und Auswertungsperiode gefolgt wird. MLN2201 ist ein gevermenschlichter monoclonal Antikörper, der in Richtung zur Untereinheit beta-2 der integrins verwiesen werden (Zellenoberflächenproteine) gefunden auf der Oberfläche aller Leukozyten oder weiße Blutzellen. In den preclinical Studien hemmte MLN2201 entzündliche Antworten, anscheinend, indem es das Zubehör von integrins beta-2 zu ihren Adhäsionsmolekülen blockierte, die Verstärkung der Leukozyten von $blutgefässe zu Gewebe begrenzte und dadurch den entzündlichen Prozeß verringert. Dieses könnte für das Begrenzen der Gewebebeschädigung wichtig möglicherweise sein, die jedem möglichem Hindernis des Blut-Versorgungsmaterials verursacht durch Thrombosis folgt: viel dieser Beschädigung resultiert aus der entzündlichen ausgelösten Antwort, wenn Blutfluß wieder hergestellt wird. Indem man Gefäßentzündung verringerte, könnte MLN2201 Behandlung der verschiedenen Bedingungen vorteilhaft sein, die in der das Herz und $blutgefässe miteinbeziehen. ` We`re gefiel, in die Klinik mit MLN2201 zu bewegen, das ein anderes Beispiel des Errichtens unserer Produktrohrleitung durch Entwicklungscollaborations, `said John L. Castello, Vorsitzenden XOMA`s, Präsidenten und Generaldirektor ist. ` trotz der Dekaden Forschung und bedeutende Fortschritte in der Gefäßbehandlung, dort sind ruhige Gelegenheiten für erfinderische Therapien, die die möglichen Rollenentzündungspiele in den Krankheiten adressieren, die das Herz und Blut, vessels.` über die XOMA-/Millenniumzusammenarbeit von von XOMA und von von Jahrtausendfeier schlossen wird einen Vertrag im November 2001, auf der Entwicklung von MLN2201and Cab-2 zusammenzuarbeiten beeinflussen, ein recombinant Protein, das Ergänzungsaktivierung hemmt, für bestimmte Gefäßentzündunganzeigen. Unter den Bezeichnungen der Vereinbarung, ist XOMA für Entwicklungstätigkeiten und in Verbindung stehende Kosten für beide Produkte durch die Beendigung der Versuche der Phase II verantwortlich. Nach der erfolgreichen Beendigung der Studien der Phase II, hat Jahrtausendfeier das Recht, die Produkte weiter zu entwickeln und in den Handel zu bringen, wenn XOMA die Wahl behält, um zwischen weiterer Teilnahme an das Entwicklungsprogramm und etwaige Gewinnbeteiligung, oder zu wählen wechselweise, erlaubend zur zukünftigen Abgabe und zu den Meilensteinzahlungen. Über XOMA entwickelt XOMA und stellt Antikörper und andere proteinbasierte biopharmaceuticals für Krankheitziele her, die die immunologischen und entzündlichen Störungen, Krebs und ansteckende Krankheiten umfassen. Programme XOMA`s schließen collaborations mit Genentech, Inc. auf dem Antikörper Raptiva(TM) für psoriasis (BLA-Unterordnung), psoriatic Arthritis mit ein (Phase II) und andere Anzeigen; mit Baxter Healthcare Corporation zum Entwickeln von NEUPREX (R)(rBPI-21) für Krankheit Crohn`s (Phase II) und andere Anzeigen; mit Millennium Pharmaceuticals, Inc. auf zwei biotherapeutic Mitteln, Cab-2 und MLN2201, für die Herzgefäß- Entzündunganzeigen (preclinical und Phase I beziehungsweise); und mit Onyx Pharmaceuticals, Inc. auf seinem Produkt Onyx-015 für verschiedene Krebse (Onyx hat verkündet, daß es sein therapeutisches Virusprogramm einstellt, das das Produkt Onyx-015 miteinschließt). Früh-Stadiumsprogramme konzentrieren auf Antikörper und die BPI-abgeleiteten Mittel, die an XOMA für die Behandlung von Krebs, von retinopathies und von Akne entwickelt werden. Zu mehr Information über Vorwärts-schauen Rohrleitung XOMA`s und Tätigkeiten, bitte besuchen Sie website XOMA`s an http://www.xoma.com/. der Aussagen, das in dieser gebildet werden Nachrichtenfreigabe, die auf gemeinschaftliche Vorbereitungen und gegenwärtige Pläne für Produktentwicklung bezogen wird, oder das anders beziehen auf zukünftigen Perioden, Aussagen innerhalb der Bedeutung Abschnitt 27A der Sicherheitstat von 1933 und Abschnitt 21E des Börsengesetzes von 1934. Diese Aussagen basieren auf Annahmen, die möglicherweise nicht genaues prüfen können. Tatsächliche Resultate konnten von jenen vorweggenommenen wegen bestimmter Gefahren materiell sich unterscheiden, die in der Biotechnologieindustrie und für die Firmen zugehörig sind, die an der Entwicklung der neuen Produkte in einem regulierten Markt teilnahmen. Diese Gefahren, einschließlich deren, die auf Änderungen im Status von der gemeinschaftlichen Verhältnisse Company`s, von des TIMINGS oder von der Resultate der schwebenden oder zukünftigen klinischen Versuche, von der Fähigkeit Mitarbeiter und andere Partner, ihre Verpflichtungen nachzukommen, von der Marktnachfrage nach Produkten, von der Tätigkeiten durch die Nahrungsmittel- und Drogeleitung oder das US-Patent- und -warenzeichenbüro und von der Ungewißheiten betreffend sind den Status der Biotechnologiepatente bezogen werden, werden im Company`s der meiste neue jährliche Bericht über Form 10-K und in anderen sek-Archivierungen besprochen. Betrachten Sie solche Gefahren sorgfältig, wenn Sie Aussichten XOMA`s auswerten.

[hawe1]

sorry, ist vom Format her a bisserl verunglückt

[mountainbiker]

Fuck, was ist denn eigentlich mit der Aktie los???
Seit geraumer Zeit gehts nur noch runter. Bald sind wir wieder auf dem Niveau von vor der Velcade Zulassung!
Das ist doch wohl ein Witz,oder???

[bernimaus]

1. schlechter gesamtmarkt
2. gewinnmitnahmen
3. ausgelöste stoplose

wenn der markt wieder dreht, ist mill. wieder vorne mit dabei. so ist das wohl mit aktien, die immer den markt übertreiben...

cool bleiben,
bernimaus

[Nerven_wie_stahl]

ca. 70% + ist doch ganz net seit kauf
goog trade

[KMS]

war es das?
die letzten Tage ging der Kurs von MLNM ja ganz ordentlich in die Knie!
Aber heute plötzlich wieder top.
Nun einsteigen?

KMS

[schakal23]

--------------------------------------------------------------------------------

25.06. 21:59
Millennium Pharma wird übernommen?

--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)
Die Aktie von Millennium Pharma kann aktuell mit 4,9% deutlich gegen den Trend zulegen. Grund seien Übernahmegerüchte durch Amgen. Auch Johnson & Johnson soll an dem BioTech Unternehmen interessiert sein, so Spekulationen.


veleicht das wegen

[mountainbiker]

Wer hat denn da gerade auf Xetra seine Stücke für 12,40 hergegeben???
Leute gibts...

[mountainbiker]

Oh Mann, die technischen Indikatoren sprechen für einen schönen Anstieg in den nächsten Tagen.
Der Stochastic sieht bombastisch aus, der RSI hat gedreht und von der 50 Tagelinie sind wir auch einwandfrei abgeprallt.
War ne schöne Korrektur - und nun neuer Anlauf...

[js200]

Millennium and Xenova Initiate Phase I Clinical Trial Of MLN944 [INLINE] MILLENNIUM PHARMACEUTICALS LOGO Millennium Pharmaceuticals, Inc. logo. (PRNewsFoto)[JL] CAMBRIDGE, MA USA 02/07/2003
via CDS

July 3, 2003

[LINK] [LINK] [LINK]

CAMBRIDGE, Mass., and SLOUGH, U.K., July 3 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) and Xenova Group, plc (Nasda q: XNVA; London Stock Exchange: XEN), today announced the initiation of a phase I clinical trial of MLN944 (also known as XR5944). MLN944 is a novel DNA targeting agent under investigation for the treatment of advanced cancers. The phase I clinical trial is an open label, dose-escalation study in adult patients with advanced solid tumors to evaluate the safety and tolerability, as well as pharmacokinetic properties of MLN944. The study will be conducted at three centers in the United Kingdom and will include approximately 40 patients. (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

MLN944 is a novel DNA targeting agent that in preclinical studies has demonstrated a high level of anti-tumor activity, both in vitro and in vivo, against a number of human tumor models. In human tumor xenograft models, treatment with MLN944 caused both partial and complete regression of large established tumors. Recent data published in the Proceedings for the 2003 Annual Meeting of the American Association for Cancer Research, suggests that MLN944 acts through a novel mechanism of action distinct from other current cytotoxic agents. Further exploration into the mechanism of action is ongoing.

`MLN944 is an important compound in our oncology portfolio that we believe holds great potential and is based on the Millennium commitment to breakthrough science and breakthrough medicine,`said Barry Greene, general manager of oncology at Millennium. `With both the preclinical activity data and our growing understanding of the novel mechanism of action, we are optimistic that MLN944 may provide patients with an important new therapeutic option.`

`MLN944 has one of the best preclinical profiles we have seen both in vitro and in vivo,`said David Oxlade, Xenova`s Chief Executive Officer. `We are hopeful that the exciting MLN944 preclinical activity will translate into a clinical compound that helps address the clear and growing need in the marketplace for better, more efficacious cancer treatments.`

Millennium licensed MLN944 from Xenova Group plc in December 2001 as part of a larger collaboration including two other compounds MLN576 (XR11576) and MLN612 (XR11612). Millennium is currently funding Xenova to implement development activities associated with the program to the completion of phase II clinical trials, at which time Millennium has the right to assume development responsibility in North America. Xenova retains commercialization and development responsibility for the rest of the world. Enrollment for MLN576 is currently completing in its UK-based Phase I trials and the study data will then be reviewed to assess further development plans.

For more information about MLN944 clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at [phone], or for European calls, 1-510-740-1273.



The Millennium Oncology Franchise

Millennium is committed to pursuing oncology as a core franchise area, dedicating significant resources and capabilities in the areas of technology, scientific expertise, clinical development, and strategic business development. To this end, Millennium is focused on leveraging its expertise in kinases, the proteasome pathway, and targeting monoclonal antibodies, and has already produced a deep pipeline that ranges from multiple novel targets to commercialized therapeutic products including VELCADE(TM) (bortezomib) for Injection, an oncology product recently approved by the U.S. Food and Drug Administration. Among the Company`s most advanced clinical compounds are MLN518, MLN591RL, MLN2704 and MLN576 (XR11576).



About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in Cambridge, Mass., co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, markets VELCADE(TM) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is seeking to develop breakthrough personalized medicine products.



About Xenova Group


Xenova Group plc`s product pipeline focuses principally on the therapeutic areas of cancer and immune system disorders. Xenova has a broad pipeline of programmes in clinical development. The Group has a well-established track record in the identification, development and partnering of innovative products and technologies and has partnerships with significant pharmaceutical and biopharmaceutical companies including Lilly, Pfizer, Celltech, Genentech, QLT and Millennium Pharmaceuticals.



This press release contains `forward-looking statements,`including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause the Company`s actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN(R) (eptifibatide) Injection and VELCADE(TM) (bortezomib) for Injection; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Editors`Note:

This press release is also available under the Media section of the Company`s website at: http://www.millennium.com.

For further information about Xenova please visit the Xenova website at http://www.xenova.co.uk



Contacts:

Gina Nugent (investor) David Oxlade: Chief Executive Officer

[phone] Daniel Abrams: Finance Director

Kelly Lindenboom (media) Jon Davies: Corporate Communications

[phone] Tel: [phone]

Millennium Pharmaceuticals, Inc. Xenova Group plc

JS200

[js200]

.
http://www.investtech.com/nasdaq/ana/mlnm.htm

JS200

[js200]

07/09/2003 (16:23 ET) CLOSER(+): Last 90 Min, MLNM Jumps +1.82%; Vol +72% - Knobias
07/09/2003 (07:20 ET) TABLE: Unconfirmed Earnings Expected Tuesday, Jul 15 - Knobias
07/09/2003 (04:32 ET) MLNM CEO to Appear on Bloomberg TV Today @ 7:40 AM ET - Knobias
07/08/2003 (16:23 ET) CLOSER(+): Last 90 Min, MLNM Jumps +1.54%; Vol +59% - Knobias
07/08/2003 (12:23 ET) JP Morgan Affirms Strong Sales Growth for Cancer Drugs - Knobias


JS200

[js200]

Millennium Announces Changes in Senior Management [INLINE]
via CDS

July 10, 2003

CAMBRIDGE, Mass., July 10 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced new roles fo r senior executives at the Company. Effective immediately, Kenneth Bate, chief financial officer, has been appointed to the position of executive vice president, head of commercial operations and chief financial officer with responsibility for all commercial operations and the business functions of global corporate affairs, finance and corporate strategy. Vaughn Kailian, vice chairperson, has decided to leave the Company at year-end and has relinquished his daily responsibilities for commercial operations. Mr. Kailian will retain his position as vice chairperson of Millennium, continuing to serve as a member of the Company`s board of directors. For the balance of the year, he will work to ensure a smooth transition of his commercial responsibilities and will continue to be involved in corporate strategic activities.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The company also announced that Marsha Fanucci has been appointed to the newly-created position of vice president of finance and corporate strategy. Ms. Fanucci will have responsibility for treasury, strategic planning and financial planning and reporting.

`I want to personally thank Vaughn for his extraordinary commitment to Millennium, our employees and the patients we serve. He has helped to successfully transition the Company into a commercial enterprise and I am delighted he will continue to be strategically involved at Millennium,`said Mark Levin, chief executive officer and chairperson of Millennium. `Vaughn has played a key role in Millennium reaching a number of major milestones, including facilitating the integration of our merger with COR Therapeutics, Inc. and building the Company`s commercial organization that has driven the success of INTEGRILIN(R) (eptifibatide) Injection and the successful launch of VELCADE(TM) (bortezomib) for Injection.`

Mr. Bate will continue to report to Mr. Levin. A transition of responsibility for commercial operations will take place over several months with Mr. Kailian remaining in a strategic management role through December 2003.

`Ken`s broad and deep experience with multi-national companies and strong track record of building and leading commercial operations make him the ideal candidate to fill this critical role as we evolve our operating capabilities, advance our clinical pipeline and move towards profitability,`said Levin.

Mr. Bate joined Millennium as chief financial officer in December 2002. He has more than 25 years of business experience, including 12 years in the biotechnology sector in capacities ranging from finance to sales and marketing. He joined Biogen in 1990 as vice president-finance before becoming vice president-sales and marketing with responsibility for building the commercial organization that launched Avonex(R) (interferon beta-1a), one of the most successful biotechnology products in the history of the sector. Prior to joining Millennium, Ken was a partner at JSB Partners, LP, a firm that provides investment banking and transaction services to clients in the healthcare and life sciences industries.

Mr. Kailian joined Millennium through the merger of Millennium and COR announced in December 2001. During his tenure at Millennium, he was instrumental in building the Company`s commercial capabilities and launching a new oncology product, VELCADE(TM) (bortezomib) for Injection. Previously, Mr. Kailian served as president and chief executive officer of COR, where he was responsible for building the company into a fully-integrated biotechnology company and launching an innovative cardiology product, INTEGRILIN(R) (eptifibatide) Injection.

Ms. Fanucci joined Millennium in July 2000 as vice president, mergers and acquisitions. She has been instrumental in developing the Company`s overall business strategy and led the Company`s merger activity, including the merger with COR Therapeutics. Ms. Fanucci has more than 25 years of industry experience and previously served as vice president of corporate development and strategy at Genzyme Corporation and as a vice president and managing director at Arthur D. Little, Inc.



About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in Cambridge, Mass., co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, markets VELCADE(TM) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is seeking to develop breakthrough personalized medicine products.

Avonex(R) (interferon beta-1a) is a registered trademark of Biogen, Inc.



This press release contains `forward-looking statements,`including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause the Company`s actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN(R) (eptifibatide) Injection and VELCADE(TM) (bortezomib) for Injection; and the

requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editors`Note: This press release is also available under the Media section of the Company`s website at: http://www.millennium.com.



Contacts:

Adriana Jenkins (media) Gina Nugent (investor)

[phone] [phone]

JS200

[js200]

CONF: MLNM To Present At BIOCHIPS Conference @ 09:10 ET

Monday , July 14, 2003 07:32 ET

Company representatives of Millennium Pharmaceuticals, Inc. (NasdaqNM: MLNM) will be presenting at the BIOCHIPS: From Novel Technology to Latest Applications today. The Company`s presentation is scheduled to begin at 09:10 ET.

Expected Speaker(s):
Ron Blackman, Ph.D., Senior Scientist II, Functional Genomics


Misc Releated Info:
** Original Confirmation
** Conference Information:

BIOCHIPS: From Novel Technology to Latest Applications
The Conference will feature discussions regarding the latest developments and great diversities of microarray technology.

Leading scientists will present new applications utilizing these tools to create a successful impact on drug discovery and development.

Conference Dates: 07/14/2003-07/15/2003
Woodbridge Sheraton Place
Iselin, NJ

Phone: [phone] Email: [e-mail]

http://www.srinstitute.com/part_iter_site_page.cfm?iteration…

JS200

[js200]

SECTIONS INCLUDE:

Microarray Experimental Design & Data Analysis
System Biology/In Silico Approaches
Biomedical/Pharma Applications
Antibody Arrays/Protein Profiling
Protein Arrays/Phenotype Profiling


HEAR FROM PHARMACEUTICAL & BIOCHIP INDUSTRY LEADERS:

AFFYMETRIX INC.
AGILENT TECHNOLOGIES
AVENTIS PHARMACEUTICALS
CIPHERGEN BIOSYSTEMS
ELI LILLY & COMPANY
IBM T.J. WATSON RESEARCH CENTER
JOHNSON & JOHNSON PHARMACEUTICAL R & D, L.L.C.
MERCK RESEARCH LABORATORIES
MILLENNIUM PHARMACEUTICALS
PROCTER & GAMBLE
SCHERING PLOUGH
ZYOMYX INC.

AND OTHER EMERGING BIOARRAY COMPANIES:

ACCELRYS INC.
AVALON PHARMACEUTICALS
BIOLOG INC.
BIOMINERVA GROUP
CEA GRENOBLE FRANCE
GENWAY BIOTECH
LI-COR BIOSCIENCES
MATRIX TECHNOLOGIES
METRIGENIX
PARTEK INC.
PHOSPHOSOLUTIONS INC.
TELECHEM
UNIVERSITY OF COLORADO
UNIVERSITY OF HOUSTON
VENTANA MEDICAL SYSTEMS INC.
XEOTRON CORPORATION



SUPPORTING WORKSHOPS:

AMERSHAM BIOSCIENCES
MERGEN LTD.

KEYNOTE ADDRESS:

Microarray Technology Tailored to the Needs of the Pharmaceutical Research Community

Barney Saunders - AGILENT TECHNOLOGIES


JS200

[js200]

Millennium to Webcast Conference Call on Second Quarter 2003 Financial Results on July 22, 2003 [INLINE]
via CDS

July 16, 2003

CAMBRIDGE, Mass., July 16 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) will hold a live webcast of its conference call at 8:30 a.m. EDT on Tuesday, July 22, 2003. Mark Levin, chairperson and chief executive officer will host the call. He will discuss the Company`s second quarter results for 2003, as well as provide an overview of the Company and progress against 2003 goals. Millennium will announce its financial results for this period in a press release to be issued prior to market open on Tuesday, July 22, 2003.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The press release and the live webcast can be accessed by visiting the Company`s website, http://www.millennium.com, under the Investor section. F ollowing the webcast, an archived version of the call will be available at the same address until July 24, 2003.



About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in Cambridge, Mass., co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, markets VELCADE(TM) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is seeking to develop breakthrough personalized medicine products.



Editor`s Note: This release is also available on the Company`s website at: http://www.millennium.com



Contact:

Cynthia Clayton

Millennium Pharmaceuticals, Inc.

[phone]

JS200

[js200]

TransForm Awarded Contract to Develop Technology with Biological Focus
via CDS

July 17, 2003

TransForm Pharmaceuticals Inc. (TransForm) today announced that it has received a contract from the US Defense Advanced Research Projects Agency (DARPA) to develop a prototype system for the discovery of methods and compositions to control in vitro cell differentiation. This new initiative marks the first expansion of TransForm`s capabilities into a biological field and will leverage its distinctive capabilities in high-throughput form and formulation. The system, being developed as part of DARPA`s Engineered Tissue Constructs (ETC) Program, will enable micro-array based screening of complex mixtures that control and promote cell growth and differentiation. TransForm will conduct biological experimentation and apply its informatics and automation expertise to develop applications that will enable faster and more meaningful interpretation of the experimental results. `This initiative demonstrates that TransForm has developed a unique set of capabilities that are valuable to the analysis of biological systems,`commented Douglas Levinson, Ph.D., Vice President, Emerging Science and Technology for TransForm. `Through our work in the field of pharmaceutical form and formulation research, we have developed expertise in exploring complex experimental systems that are characterized by non-linear responses and non-obvious interactions. Biological systems behave in much the same way and therefore we are excited about extending our capabilities in this direction,`continued Levinson. TransForm will screen complex mixtures in hopes of defining conditions that control cell differentiation in vitro. `This is an exciting new approach that has the potential to increase our understanding of cell differentiation and lead to the development of more effective vaccines and therapeutics,`said George Daley, M.D., Ph.D., Research Scientist at the MIT-affiliated Whitehead Institute and faculty member in the Departments of Biological

Chemistry and Pediatrics at the Harvard Medical School and Children`s Hospital. `TransForm is introducing an empirical approach to a field dominated by low throughput and directed experimentation. I expect that this approach could become an important complement to current efforts aimed at understanding the complexities of cell differentiation,`concluded Daley. As TransForm grows, it is looking to expand its technologies and expertise to new areas beyond small molecule pharmaceuticals. The system TransForm is developing with DARPA will complement the company`s internal development efforts focused in the area of vaccines and therapeutics. About TransForm TransForm Pharmaceuticals is reinventing the pharmaceutical industry`s approach to form and formulation, with a novel set of high-throughput, automated platform technologies, powered by state-of-the-art informatics and a scientific and managerial team with deep experience in pharmaceuticals. It uses these capabilities to optimize drug form and/or formulations, and increase the clinical and commercial value of pharmaceutical products, across the entire pharmaceutical value chain. In research and development, TransForm is

working with partners such as Alza Corporation and Lilly, to help them make better candidate selection decisions, and reduce attrition and development time and cost. For later stage and marketed products, TransForm can help partners enhance product life cycle management by rapidly discovering novel forms and/or formulations to potentially improve bioavailability, broaden intellectual property protection and enable new dosage forms and/or combination products. TransForm is also using these capabilities to develop its own proprietary product portfolio. TransForm, founded in late 1999 with initial technology from Millennium Pharmaceuticals (NASDAQ:MLNM), is a privately held company located in Lexington, MA. For more information visit our website at www.transformpharma.com.



CONTACT: TransForm Pharmaceuticals, Inc.
Douglas Levinson, Ph.D., 781/674-7818
or
Noonan Russo Presence
Robert Stanislaro, 212/845-4268


JS200

[mountainbiker]

Steigen die auch mal wieder, oder haben sie Velcade bereits wieder vom Markt genommen?
Vor der Zulassung standen wir schon genau so hoch...
Drecks Amis...

[paulowitsch]

millennium hält sich über der 14$ marke !!!wenn sie es schafft drüber zu bleiben sieht es gut aus,leider befürchte ich aber das sie drunter fällt und dann gute nacht!soweit ich es deuten kann hat sich ein descending triangle gebildet was ein bearishes signal ist!!!!!so strong.....

[gerdiman]

Hi, weiß einer wie die Zahlen morgen ausfallen sollen?

Gruß
gerdiman

p.s.: Gehts jetzt eigentlich wieder gen süden? Die Amis tun ja so als hätte es velcade gar nicht gegeben.....tze!

[js200]

ERN/RLS(X): MLNM To Release Q2 Results Jul 22 [BMO]

Monday , July 21, 2003 13:00 ET

Millennium Pharmaceuticals, Inc. (NasdaqNM: MLNM) is scheduled to release its Q2 financial results on July 22, 2003, before the market opens (BMO).

CONSENSUS ESTIMATES:

Q2 Revenue: $107.53 million
Q2 EPS: $-0.17 per share

PREVIOUS PERIOD:

Prev Q2 Revenue: $91.85 million
Prev Q2 EPS: $-0.16 per share

ADDITIONAL INFORMATION

Original Confirmation

The Company will also hold a related conference call to discuss these results.

JS200

[js200]

07/21/2003 (13:00 ET) ERN/RLS(X): MLNM To Release Q2 Results Jul 22 [BMO] - Knobias
07/21/2003 (10:53 ET) BIOTECHNOLOGY: Lehman Keeps Positive View on Industry - Knobias
07/21/2003 (06:55 ET) TABLE: Confirmed Earnings Expected Tuesday, Jul 22 - Knobias
07/18/2003 (03:25 ET) Lobbying Increasingly Popular among Biotechnology Companies - Knight Ridder
07/16/2003 (16:02 ET) Millennium to Webcast Conference Call on Second Quarter 2003 Financial Results on July 22, 2003 - PR Newswire


JS200

[js200]

Vorsicht!!!!!!!!!!!!!!

http://www.investtech.com/nasdaq/ana/mlnm.htm

JS200

[mountainbiker]

Langsam reichts mit diesen blöden Amis!
Solche Vollidioten. Auf Zahlen kann man ja bei einem deratrigen Unternehmen eh nichts geben. Ob sie jetzt 310 oder 320 Mio $ Verlust machen, ist doch wirklich scheißegal. Wahrscheinlich haben einige erwartet, dass MLNM überrascht und einen Gewinn ausweist...
Nun stehen wir wirklich da, wo MLNM vor der Velcade Zulassung stand. Nur dass die Börsen mittlerweile auch kräftig angezogen haben. Das heißt hier wurde weder die Zulassung, noch der allgemeine Börsentrend eingepreist.
Ein absoluter Witz...

[LMeister7]

Hallo,
so isser nu mal, der Markt. Gepeilte 50 Mill. USD weniger Umsatz quittiert er mit c.a. 200 Mill.(bis jetzt) USD Kursverlust. Vielmehr beunruhigt mich, dass MLNM erst im 2 Quartal 2004 mit der Europa-Zulassung für Velcade rechnet.
Den heutigen Abschlag kann man natürlich wenn man einen etwas längeren Horizont hat ausnützen. Mit Sicherheit kommen auch wieder bessere Nachrichten,
MfG,
LM7

[mountainbiker]

Europa Rechte hat doch eh Johnson&Johnson soweit ich weiß...
Abgesehen davon waren ja die Quartalszahlen sehr gut ausgefallen!
Echter Schwachsinn, die Aktie so in den Keller zu schicken...

[7clever]

und ich wollte nicht mehr zocken
da sind ja schon wieder ein paar % drin

seven zockt doch wieder

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


07/22/2003 (15:21 ET) RATING(=): Ryan Beck Reiterates MLNM Rating @ Outperform - Knobias



07/22/2003 (15:06 ET) RATING(=): S&P Reiterates MLNM Rating @ 5 STARS (Buy) - Knobias



07/22/2003 (14:57 ET) Schaeffer`s Street Chatter Features Millennium Pharmaceuticals, Novellus Systems, and United Parcel Service: MLNM, NVLS, UPS - PR Newswire



07/22/2003 (14:49 ET) RATING(-): JMP Sec Cuts MLNM to Mkt Underperform from Mkt Perform - Knobias



07/22/2003 (14:17 ET) Schaeffer`s Midday Options Update Features BA, AOL, IP, VIA, TXN, UPS, MLNM, AMCC - PR Newswire



07/22/2003 (13:51 ET) 8-K: MLNM Files Jul-22 PR Regarding Q2 2003 Financial Results - Knobias



07/22/2003 (09:31 ET) MORNING UPDATE: Man Securities Issues Alerts for NVLS, ALTR, MLNM, BK, And SLAB - PR Newswire



07/22/2003 (08:09 ET) New 8-K just released for MLNM - Edgar



07/22/2003 (07:40 ET) ERN(+): MLNM/Q2 Adj (7c) vs (16c); Beats Q Est; Mixes Guidance - Knobias



07/22/2003 (07:30 ET) Millennium Reports Second Quarter 2003 Financial Results - PR Newswire



07/22/2003 (06:50 ET) TABLE: Confirmed Earnings Expected Tuesday, Jul 22 - Knobias



07/22/2003 (06:32 ET) ERN/CALL: MLNM To Hold Q2 Conf Call @ 08:30 ET Today - Knobias



07/21/2003 (13:00 ET) ERN/RLS(X): MLNM To Release Q2 Results Jul 22 [BMO] - Knobias



07/21/2003 (10:53 ET) BIOTECHNOLOGY: Lehman Keeps Positive View on Industry - Knobias



07/18/2003 (03:25 ET) Lobbying Increasingly Popular among Biotechnology Companies - Knight Ridder



07/16/2003 (16:02 ET) Millennium to Webcast Conference Call on Second Quarter 2003 Financial Results on July 22, 2003 - PR Newswire



07/14/2003 (11:38 ET) BIOTECHS: JMP Sec Previews Q2 Earnings for Industry - Knobias



07/14/2003 (07:32 ET) CONF: MLNM To Present At BIOCHIPS Conference @ 09:10 ET - Knobias



07/10/2003 (07:59 ET) Millennium Announces Changes in Senior Management - PR Newswire



07/09/2003 (16:23 ET) CLOSER(+): Last 90 Min, MLNM Jumps +1.82%; Vol +72% - Knobias



07/09/2003 (04:32 ET) MLNM CEO to Appear on Bloomberg TV Today @ 7:40 AM ET - Knobias



07/08/2003 (16:23 ET) CLOSER(+): Last 90 Min, MLNM Jumps +1.54%; Vol +59% - Knobias



07/08/2003 (12:23 ET) JP Morgan Affirms Strong Sales Growth for Cancer Drugs - Knobias



07/08/2003 (09:37 ET) BIOTECH (BTC): Piper Jaffray Covers Genomics Stks - Knobias



07/03/2003 (09:30 ET) Millennium and Xenova initiate phase I clinical trial of MLN944 - Datamonitor


JS200

[js200]

RATING(=): Ryan Beck Reiterates MLNM Rating @ Outperform

Tuesday , July 22, 2003 15:21 ET

Issuer: Millennium Pharmaceuticals, Inc. (NasdaqNM: MLNM)
Analyst Firm: Ryan Beck & Co.

Ratings Action: REITERATION
Current Rating: Outperform

Target Price Action: MAINTAIN
Target Price: $21.00

Additional Comments: Analyst states that while they believe each of these developments enhances the long-term potential of Millennium, 3Q03 does not appear to have the same quality or quantity of potential catalysts as 2Q03. In firm`s opinion, clinical news flow (particularly related to Velcade, which is being evaluated in over 40 ongoing trials) and Velcade’s commercial performance will be the most significant potential drivers of value. Analyst is reiterating their Outperform rating and 12-month target price of $21.

This rating information was reported by Ryan Beck & Co..


JS200

[js200]

http://www.investtech.com/nasdaq/ana/mlnm.htm

JS200

[mountainbiker]

Drecks-Amis! Warum kauf ich mir überhaupt eine Aktie von euch!

[mountainbiker]

Jetzt mal im Ernst: Wie weit wollen die eigentlich noch fallen???
Velcade wurde zu-ge-lassen. Vorher waren die wohl mehr wert, oder wie?
Unglaublich...

[7clever]

könnte morgen welche unter 10 EUR geben

seven es wird spannend

[HalfLife11]

Es wird halt immer übertrieben - aber bei Millennium ist das wirklich ein absoluter Witz - es war schon immer bekannt, dass erst 2005 die Gewinnzone erreicht wird -
auch sonst nichts Neues - außer das ein Medikament die Zulassung erhält ( ist ja nichts Besonderes! )
und die Pipeline prall gefüllt ist! - also ich bleib der Aktie treu und seh es als sehr lohnendes Langfristinvestment - es kann auch sehr schnell wieder nach oben gehen

[js200]

Die Unterstützung bei 12 Dollar wird halten

Hatte euch vorgewarnt

JS200

[mountainbiker]

Von wegen, die Drecks-Amis hält nichts mehr. Schaut euch mal die technischen Indikatoren an. So eine überverkaufte Aktie hab ich ja noch nie gesehen. Der Stochastik vor allem läuft schon seit langer Zeit am absoluten Tiefstpunkt dahin (im 3 und 6 Monats Chart).
Jeden Tag denk ich mir, jetzt müßte doch eigentlich mal ein gewaltiger Pullback erfolgen - aber Pustekuchen!
Verdammt, und das bei dem derzeitigen Marktumfeld.

[KMS]

MLNM würde die letzte Zeit ja heftig runtergeprügelt.

Gestern hat sich die Aktie allerdings vom Tagestief ja wieder deutlich erholt.
Kann man vielleicht sogar langsam wieder einsteigen?

Was meint ihr?

KMS

[kostoson]

Hi kms,

nun-ja, dass am freitag Abend nocheinmal zugegriffen wurde, läßt wohl darauf schließen das ein 50iger Retracement gerettet werden sollte. Der RSI liegt bei knapp 30, was ebenfalls für eine Erholung sprechen könnte und das Gap bei ca.13$ ist auch geschlossen worden(Di).
Bullish macht mich außerdem, dass nach den letzten Meldungen die Zittrigen zittern.
Da an der börse 2*2=5-1 ist und nicht 4, hoffe ich persönlich darauf, das der letzte kursrückgang von 17,50$ auf 12$ die -1 waren.

Aber: "Der Analytiker denkt und die Börse lenkt"

[7clever]

schön mal wieder auf der Gewinnerseite zu sein
Bald wieder 11 EUR

seven

[js200]

EquityOutlook.Com: EquityOutlook.Com announces Stock Evaluation Ratings for Millennium Pharmaceuticals, Globespanvirata , Amr Corporation, Clear Channel Comm Inc, Network Appliance

Tuesday , July 29, 2003 10:46 ET

SHREVEPORT, La., Jul 29, 2003 (M2 PRESSWIRE via COMTEX) -- EquityOutlook.Com makes these short-term stock recommendations:

Millennium Pharmaceuticals (NASDAQ:MLNM - News) - STRONG BUY Globespanvirata (NASDAQ:GSPN - News) - WEAK SELL Amr Corporation (NYSE:AMR - News) - SELL Clear Channel Comm Inc (NYSE:CCU - News) - BUY Network Appliance (NASDAQ:NTAP - News) - SELL

WHAT THESE RATINGS MEAN: EquityOutlook.Com ranks stocks with a proprietary unbiased system of technical analysis. These ratings do not indicate a "long term" view of any company listed. These are ratings that reflect our opinion of a stock`s potential price movement over the next five to ten trading sessions. The stock ratings range from +10 (which indicates our view that a stock has a great chance to move higher) to - 10 (which indicates our belief that a stock has a great chance to move lower).

These ratings may change based on daily market conditions.

ABOUT EquityOutlook.Com: EquityOutlook.Com is a stock research firm. Our daily commentary has regular, worldwide distribution. We are Registered Investment Advisors. We do not accept third-party compensation to make stock suggestions. We do not own shares of any stock we rate.

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.

EquityOutlook.Com`s goal is to provide stock research FREE from bias or conflicts. You can get your FREE trial to EquityOutlook.Com at http://www.equityoutlook.com.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].


(C)1994-2003 M2 COMMUNICATIONS LTD


-0-

JS200

[mountainbiker]

Mir reichts jetzt bald mit dieser Scheiß-Drecks-Aktie, was ist denn da los?
Nicht mal eine ordentliche technische Gegenreaktion bekommt die hin!!
Der absolute Underperformer in meinem Depot, bin echt am Überlegen, ob ich sie raushaue und in was lukrativeres investiere.
Manchmal muss man wohl auch Verluste realisieren...

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


07/30/2003 (09:49 ET) BIOTECHNOLOGY: Lehman Comments on Industry - Knobias



07/29/2003 (10:46 ET) EquityOutlook.Com: EquityOutlook.Com announces Stock Evaluation Ratings for Millennium Pharmaceuticals, Globespanvirata , Amr Corporation, Clear Channel Comm Inc, Network Appliance - M2 Communications



07/28/2003 (14:00 ET) BIOTECHS: Industry Rallies on OXGN, HGSI, XOMA, IMCL - Knobias



07/28/2003 (12:02 ET) CONF: MLNM To Present At Metabolic Disease Conference @ 14:45 ET - Knobias



07/28/2003 (06:42 ET) MEDIA: Latest Barron`s Publication Mentions MLNM - Knobias

JS200

[7clever]

sind doch mehr als 70Cent Gewinn/Aktie geworden...
Bis bald...

seven

[7clever]

und nochmal ein Zock?
Ich kann sie bald wieder günstig zurückkaufen---
wer zockt noch MLNM?
Halten ist doch out

seven

[mountainbiker]

DRECKS-AMIS!!!

[polenpaule]

he die aktie holt luft!!!ruhig bleiben bald schiesst sie durch die decke!!!!!!!!

[schakal23]

@polenpaule
da hast du nicht unrecht bis jetst heute 9% in plus

[js200]

08/14/2003 (11:43 ET) EquityOutlook.Com: EquityOutlook.Com announces Stock Evaluation Ratings for Redback Networks Inc., CENDANT CORP, SOLECTRON CORP, Millennium Pharmaceuticals, Inc., UTStarcom, Inc. - M2 Communications
08/14/2003 (07:32 ET) CONF: MLNM To Present At Drug Discovery World Conference @ 09:30 ET - Knobias
08/13/2003 (14:32 ET) CONF: MLNM To Present At Drug Discovery World Conference @ 17:05 ET - Knobias
08/12/2003 (16:42 ET) New 10-Q just released for MLNM - Edgar
08/12/2003 (08:32 ET) CONF: MLNM To Present At Drug Discovery World Conference @ 11:20 ET - Knobias

JS200

[js200]

EquityOutlook.Com: EquityOutlook.Com announces Stock Evaluation Ratings for Redback Networks Inc., CENDANT CORP, SOLECTRON CORP, Millennium Pharmaceuticals, Inc., UTStarcom, Inc.

Thursday , August 14, 2003 11:43 ET

SHREVEPORT, La., Aug 14, 2003 (M2 PRESSWIRE via COMTEX) -- EquityOutlook.Com makes these short-term stock recommendations:

Redback Networks Inc. (NASDAQ:RBAK) - BUY CENDANT CORP (NYSE:CD) - BUY SOLECTRON CORP (NYSE:SLR) - BUY Millennium Pharmaceuticals, Inc. (NASDAQ:MLNM) - BUY UTStarcom, Inc. (NASDAQ:UTSI) - SELL

WHAT THESE RATINGS MEAN: EquityOutlook.Com ranks stocks with a proprietary unbiased system of technical analysis. These ratings do not indicate a "long term" view of any company listed. These are ratings that reflect our opinion of a stock`s potential price movement over the next five to ten trading sessions. The stock ratings range from +10 (which indicates our view that a stock has a great chance to move higher) to - 10 (which indicates our belief that a stock has a great chance to move lower).

These ratings may change based on daily market conditions.

ABOUT EquityOutlook.Com: EquityOutlook.Com is a stock research firm. Our daily commentary has regular, worldwide distribution. We are Registered Investment Advisors. We do not accept third-party compensation to make stock suggestions. We do not own shares of any stock we rate.

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.

EquityOutlook.Com`s goal is to provide stock research FREE from bias or conflicts. You can get your FREE trial to EquityOutlook.Com at http://www.equityoutlook.com.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].


(C)1994-2003 M2 COMMUNICATIONS LTD


JS200

[mountainbiker]

Kann mir mal irgendjemand erklären, was hier gerade abgeht?
Warum steigt die Aktie vorbörslich so stark???

[lukoil007]

Neben den Halbleiterwerten wird auch die Aktie von Millennium Pharmaceuticals (NASDAQ: MLNM - Nachrichten) auf der Gewinnerseite erwartet. Morgan Stanley (NYSE: MWD - Nachrichten) hat die Aktie wegen des guten Verkaufsstarts des Medikaments Velcade auf "Equal-Weight" herauf genommen.

[lukoil007]

und Sie laufen weiter.....

[js200]

09/02/2003 (10:57 ET) New 4 just released for MLNM - Edgar
09/02/2003 (10:50 ET) EquityOutlook.Com: EquityOutlook.Com announces Stock Evaluation Ratings for Millennium Pharmaceuticals, Inc., Linear Technology Corporation, QWEST COMM INTL INC, CheckFree Corporation, StorageNetworks, Inc - M2 Communications
08/29/2003 (09:12 ET) HCR: Jyske Banks Starts Healthcare Sector at Neutral - Knobias
08/28/2003 (16:01 ET) Newsmakers in the Biotech Industry Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation - PR Newswire
08/28/2003 (13:05 ET) StreetInsider Alert for MLNM - StreetInsider


JS200

[js200]

StreetInsider Alert for MLNM

Thursday , August 28, 2003 13:05 ET

Aug 28, 2003 (streetinsider.com via COMTEX) -- Rumors resurface Millennium Pharmaceutical (Nasdaq: MLNM) is the target of a takeover bid. Rumored suitors include Johnson & Johnson (NYSE: JNJ) and Amgen (Nasdaq: AMGN). Speculators suggest progress with cancer treatment Velcade is the top reason potential suitors would be interested.


CONTACT: StreetInsider.com, Inc.
US Toll Free: 800-323-0153
[e-mail]
http://www.streetinsider.com

About StreetInsider.com:

StreetInsider.com is a premium financial news wire service covering the US
equity markets. StreetInsider.com provides its premium members with live, market
moving news reports for the pre-open, intra-day and after-hours trading
sessions. Areas of focus include: Trader Talk, Market Rumors, Broker Comments,
Upgrades/Downgrades, Earnings Releases, Corporate News, and General Market
News/Events.

For a 2-week free trial to StreetInsider.com Premium please visit the web site
at: http://www.streetinsider.com



(C) 2003 StreetInsider, Inc. All rights reserved.


-0-


SUBJECT CODE: Rumors

JS200

[js200]

.
http://www.investtech.com/nasdaq/ana/mlnm.htm

JS200

[js200]

09/09/2003 (11:07 ET) EquityOutlook.Com: EquityOutlook.Com Announces Stock Evaluation Ratings for Millennium Pharmaceuticals, Inc., Linear Technology Corporation, QWEST COMM INTL INC, CheckFree Corporation, StorageNetworks, Inc. - M2 Communications
09/09/2003 (09:17 ET) MORNING UPDATE: Man Securities Issues Alerts for RFMD, XLNX, AIG, MLNM, and GS - PR Newswire
09/08/2003 (14:37 ET) BTC: Biotechs Keep Momentum in Late-day Trading - Knobias
09/08/2003 (11:17 ET) New 4 just released for MLNM - Edgar
09/08/2003 (08:30 ET) New Treatment Options Featured in NCCN Multiple Myeloma Clinical Practice Guidelines - Business Wire


Last Trade: 16.010 Change: 0.260 (+1.651%)
Previous Close: 15.750 Volume: 4,216,600
Bid: 15.880 Ask: 15.950
Today`s Open: 15.570 # of Trades: 8,132


Seht euch diese Untertassenformation an, einfach zum kaufen

JS200

[js200]

Der Weg ist frei

http://www.investtech.com/nasdaq/ana/mlnm.htm

JS200

[js200]

New Data Show Early Use Of Anti-Platelet Therapy Reduced Combined Death Or Subsequent Heart Attacks In High-Risk Heart Attack Patients
via COMTEX

September 17, 2003

WASHINGTON, Sep 17, 2003 /PRNewswire-FirstCall via COMTEX/ --

Treating high-risk acute coronary syndrome (ACS) patients with an anti-platelet medicine, known as a glycoprotein (GP) IIb-IIIa inhibitor, before interventional procedures such as angioplasty significantly reduced the in-hospital incidence of combined death or subsequent heart attacks, according to research presented today at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C. The data were collected from CRUSADE, a national quality improvement initiative that retrospectively examines the treatment of high-risk chest pain disorder patients at hospitals in the United States. CRUSADE is led by the Duke Clinical Research Institute (DCRI) and funded by Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) And Schering-Plough Corporation (NYSE: SGP).

(Logo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Although the benefit of GP IIb-IIIa inhibitors has been recognized for several years, these new data refine the understanding of how the timing of treatment may have a significant impact on patient health.

`The data are significant because they suggest that earlier use of GP IIb- IIIa inhibitors -- before the patient is taken to the catheterization lab -- could directly improve patient outcomes,`said Matthew Roe, M.D., MHS, of the DCRI, a CRUSADE Principal Investigator and study co-author.

In this project, Dr. Adam Greenbaum, associate director, Cardiac Catheterization Laboratory at the Henry Ford Heart and Vascular Institute, and colleagues from nine other institutions analyzed the CRUSADE database for outcomes of patients admitted for high-risk chest pain disorders collectively known as non-ST-segment elevation acute coronary syndromes (NSTE ACS) based on the timing of GP IIb-IIIa inhibitor initiation. After adjusting for various risk factors, the authors concluded that using a GP IIb-IIIa inhibitor `upstream,`or before a patient is taken to the catheterization lab, reduced the risk of combined acute, in-hospital death or subsequent heart attack by approximately 14 percent (p<0.05).

Of the 40,979 patients in the CRUSADE database at the time of the project, 5,971 underwent PCI within 48 hours of admission. Of those patients, 2,191 (37 percent) were treated with a GP IIb-IIIa inhibitor before being taken to the catheterization lab, and 3,780 (63 percent) were given a GP IIb-IIIa inhibitor at the time of the procedure. The in-hospital incidence of death and combined death or reinfarction stratified by timing of GP IIb-IIIa inhibition was 1.32 percent for patients who received a GP IIb-IIIa inhibitor early `upstream` compared to 1.53 percent for patients receiving a GP IIb-IIIa inhibitor in the catheterization lab.

While the results of this analysis are consistent with previous results of randomized clinical trials, the use of a GP IIb-IIIa inhibitor before catheterization or PCI remains low. GP IIb-IIIa inhibitor use prior to catheterization or PCI has a I-A recommendation, signifying the highest level of supportive evidence, from the American College of Cardiology/America Heart Association (ACC/AHA) NSTE ACS Guidelines for use of GP IIb-IIIa inhibitors in patients for whom PCI is planned.

`These data suggest that earlier administration of GP IIb-IIIa inhibitors, prior to angiography, may reduce the risk of death or heart attack,`said Dr. Greenbaum. `This finding is consistent with what has been seen in other retrospective analyses of `upstream`GP IIb-IIIa use.`

About CRUSADE

CRUSADE (Can Rapid risk Stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) is a national quality improvement initiative designed to improve adherence to ACC/AHA guidelines for care of patients with NSTE ACS at up to 600 hospitals across the U.S. Aggregate data regarding the treatment, procedures, and medications received by patients with this diagnosis are retroactively collected and analyzed by DCRI, an academic research organization affiliated with Duke University Medical Center. Each CRUSADE site receives feedback and advice and tools for implementing changes to improve patient care.

CRUSADE is led by Drs. Eric Peterson and Matthew Roe at DCRI. The CRUSADE Executive Committee is co-chaired by W. Brian Gibler of the University of Cincinnati College of Medicine and E. Magnus Ohman of the University of North Carolina School of Medicine. CRUSADE is funded by Millennium Pharmaceuticals, Inc. and Schering-Plough Corporation. Millennium and Schering-Plough are worldwide marketing partners for INTEGRILIN(R) (eptifibatide) Injection, a GP IIb-IIIa inhibitor.

About INTEGRILIN

INTEGRILIN is indicated for the treatment of patients with acute coronary syndrome (unstable angina/non-ST-segment myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). It is also indicated in the United States for the treatment of patients at time of PCI, including in patients undergoing intracoronary stenting.

INTEGRILIN is contraindicated in patients with a history of bleeding diathesis, or evidence of abnormal bleeding within the previous 30 days; severe hypertension (systolic blood pressure greater than 200 mm Hg or diastolic blood pressure greater than 110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within the preceding six weeks; history of stroke within 30 days, or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb-IIIa inhibitor; dependency on renal dialysis; or known hypersensitivity to any component of the product.

Bleeding is the most common complication encountered during INTEGRILIN therapy. The majority of excess major bleeding events were localized at the femoral artery access site. Oropharyngeal, genitourinary, gastrointestinal and retroperitoneal bleeding were also seen more commonly with INTEGRILIN compared to placebo.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, markets VELCADE(TM) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three disease areas: cardiovascular, oncology and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is seeking to develop breakthrough personalized medicine products.

Millennium Forward Looking Statement

This press release contains `forward-looking statements,`including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various important risks may cause the Company`s actual results to differ materially from the results indicated by these forward- looking statements, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN(R) (eptifibatide) Injection and VELCADE(TM) (bortezomib) for Injection; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Schering-Plough Disclosure Notice: The information in this press release includes certain `forward-looking`statements concerning, among other things, the future prospects of Integrilin, which the reader of this release should understand are subject to substantial risks and uncertainties. The prospects of Integrilin and other products may be adversely affected by general market and economic factors, competitive product development, product availability, current and future branded, generic and OTC competition, market acceptance of new products, federal and state regulations and legislation, the regulatory review process in the United States and foreign countries for new products and indications, existing manufacturing issues and new manufacturing issues that may arise, timing of trade buying, patent positions, litigation and investigations, and instability or destruction in a geographic area important to Schering-Plough due to reasons such as war or SARS. For further details and a discussion of these and other risks and uncertainties, see Schering- Plough`s Securities and Exchange Commission filings, including Schering- Plough`s 8-K filed August 21, 2003.

About Schering-Plough

Schering-Plough is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.

Editors`Note: This press release is also available under the Media section of the Company`s website at: www.millennium.com.

Millennium Pharmaceuticals, Inc. Contacts: Todd Cooper (media) Cynthia Clayton (investor) [phone] [phone] Schering-Plough Corp. Contacts: Denise K. Foy (media) Geraldine U. Foster (investor) [phone] [phone] Lisa W. Debardine (investor) Janet Barth (investor) [phone] 908-298-7417
SOURCE Millennium Pharmaceuticals, Inc.

Todd Cooper (media), [phone], or Cynthia Clayton(investor), [phone], both of Millennium Pharmaceuticals, Inc.; orDenise K. Foy (media), [phone], or Geraldine U. Foster (investor), [phone], or Lisa W. Debardine (investor), [phone], or Janet Barth(investor), [phone], all of Schering-Plough Corp./Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, 888-776-6555 or 212-782-2840/Company News On-Call: http://www.prnewswire.com/comp/114562.html
http://www.millennium.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[mauserla]

18.09. 09:48
Millennium Pharma - positive Testergebnisse

--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)
Millennium Pharmaceuticals (WKN: 900625, US: MLNM) präsentierte am Mittwoch kurz vor Börsenschluss positive Ergebnisse aus den Teststudien des Wirkstoffes IIb-IIIa. Er hätte die Rate von neuen Herzattacken und die Todesanzahl bei Herzpatienten deutlich gemindert, hieß es. Zudem konnte mit dem Medikament die Verweildauer der Patienten in den Krankenhäusern verkürzt werden. Die Crusade Studie wird von Millenium und Schering-Plough finanziert.



sind doch gut die Aussichten

[js200]

UBS Global Life Sciences Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation
via COMTEX

September 22, 2003

CAMBRIDGE, Mass., Sep 22, 2003 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced today that its presentation at the UBS Global Life Sciences Conference will be webcast live and may be accessed by visiting the Investors section of the Company`s website, www.millennium.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Millennium management will provide an overview of the Company and progress against 2003 goals. The presentation will be delivered at 3:30 p.m. EDT on Thursday, September 25, 2003 from The Plaza Hotel in New York City. The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, markets VELCADE(TM) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three disease areas: cardiovascular, oncology and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is seeking to develop breakthrough personalized medicine products.

Editors`Note: This press release is also available under the Media section of the Company`s website at: www.millennium.com.

Contact: Cynthia Clayton, Investor Relations Millennium Pharmaceuticals, Inc. [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Cynthia Clayton, Investor Relations of MillenniumPharmaceuticals, Inc., [phone]/Company News On-Call: http://www.prnewswire.com/comp/114562.html/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, 888-776-6555 or 212-782-2840
http://www.millennium.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

EquityOutlook.Com: EquityOutlook.Com announces Stock Evaluation Ratings for The Gap Inc, Foundry Networks Inc, , Millennium Pharmaceuticals Inc, Boeing Company
via COMTEX

September 24, 2003

SHREVEPORT, La., Sep 24, 2003 (M2 PRESSWIRE via COMTEX) --

EquityOutlook.Com makes these short- term stock recommendations:

The Gap Inc (NYSE:GPS) - STRONG BUY Foundry Networks Inc (NASDAQ:FDRY) - STRONG SELL Millennium Pharmaceuticals Inc (NASDAQ:MLNM) - BUY Boeing Company (NYSE:BA) - WEAK SELL

WHAT THESE RATINGS MEAN: EquityOutlook.Com ranks stocks with a proprietary unbiased system of technical analysis. These ratings do not indicate a `long term`view of any company listed. These are ratings that reflect our opinion of a stock`s potential price movement over the next five to ten trading sessions. The stock ratings range from +10 (which indicates our view that a stock has a great chance to move higher) to - 10 (which indicates our belief that a stock has a great chance to move lower).

These ratings may change based on daily market conditions.

ABOUT EquityOutlook.Com: EquityOutlook.Com is a stock research firm. Our daily commentary has regular, worldwide distribution. We are Registered Investment Advisors. We do not accept third-party compensation to make stock suggestions. We do not own shares of any stock we rate.

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.

EquityOutlook.Com`s goal is to provide stock research FREE from bias or conflicts. You can get your FREE trial to EquityOutlook.Com at http://www.equityoutlook.com.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2003 M2 COMMUNICATIONS LTD


JS200

[js200]

Millennium Announces Assignment of Medicare Code for VELCADE(TM) (bortezomib) for Injection [INLINE]
via CDS

September 26, 2003

Received five months following launch --



CAMBRIDGE, Mass., Sept. 26 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that the Center for Medicare and Medicaid Services (CMS) has qualified VELCADE for pass-through status and assigned it to a Healthcare Common Procedure Coding System (HCPCS) whereby hospitals may obtain reimbursement for VELCADE under the hospital

outpatient prospective payment system (OPPS) effective October 1, 2003. Specific coding and payment instructions will be published January 1, 2004 and pass-through payment for VELCADE will be effective retroactive to services provided on or after October 1, 2003.

(Logo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

VELCADE was approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy.

`This is terrific news for the many Medicare patients with multiple myeloma,`said Kenneth Bate, executive vice president, chief financial officer and head of commercial operations at Millennium. `It has been our number one priority to work closely with our various partners throughout the development and launch process to help ensure broad access to patients in need, and this marks another important step in that process.`



About VELCADE(TM) (bortezomib) for Injection

VELCADE, the first of a new class of medicines called proteasome inhibitors, is the first treatment in more than a decade to be approved for patients with multiple myeloma - a cancer of the blood. Millennium received approval from the FDA on May 13, 2003 to market VELCADE for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. The effectiveness of VELCADE is based on response rates. There are no controlled trials demonstrating a clinical benefit such as an improvement in survival.

VELCADE has a generally predictable, manageable safety profile (with appropriate monitoring and, if necessary, dose modification). VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol.

In 228 patients who were treated with VELCADE(TM) (bortezomib) for Injection in two phase II studies of multiple myeloma, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise and weakness) (65 percent), nausea (64 percent), diarrhea (51 percent), appetite decreased (including anorexia) (43 percent), constipation (43 percent), thrombocytopenia (43 percent), peripheral neuropathy (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (37 percent), pyrexia (36 percent), vomiting (36 percent), and anemia (32 percent). Fourteen percent of patients experienced at least one episode of grade four toxicity, with the most common toxicity being thrombocytopenia (three percent) and neutropenia (three percent). A total of 113 (50 percent) of the 228 patients experienced serious adverse events (SAEs). The most commonly reported SAEs included pyrexia (seven percent), pneumonia (7 percent), diarrhea (6 percent), vomiting (5 percent), dehydration (5 percent) and nausea (4 percent).

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-(866) VELCADE.



About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, markets VELCADE(TM) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three disease areas: cardiovascular, oncology and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is seeking to develop breakthrough personalized medicine products.

This press release contains `forward-looking statements,`including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various important risks may cause the Company`s actual results to differ materially from the results indicated by these forward- looking statements, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN(R) (eptifibatide) Injection and VELCADE(TM) (bortezomib) for Injection; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Editors`Note: This press release is also available under the Media section of the Company`s website at: http://www.millennium.com



Contacts:

Kelly Lindenboom (media) Gina Price Nugent (investor)

[phone] [phone]

JS200

[js200]

EquityOutlook.Com: EquityOutlook.Com announces Stock Evaluation Ratings for The Gap, Foundry Networks, Sprint, Millennium Pharmaceuticals, Boeing
via COMTEX

October 1, 2003

SHREVEPORT, La., Oct 01, 2003 (M2 PRESSWIRE via COMTEX) --

EquityOutlook.Com makes these short-term stock recommendations:

The Gap (NYSE:GPS) - SELL Foundry Networks (NASDAQ:FDRY) - SELL Sprint (NYSE:SDE) - SELL Millennium Pharmaceuticals (NASDAQ:MLNM) - SELL Boeing (NYSE:BA) - STRONG BUY

WHAT THESE RATINGS MEAN: EquityOutlook.Com ranks stocks with a proprietary unbiased system of technical analysis. These ratings do not indicate a `long term`view of any company listed. These are ratings that reflect our opinion of a stock`s potential price movement over the next five to ten trading sessions. The stock ratings range from +10 (which indicates our view that a stock has a great chance to move higher) to - 10 (which indicates our belief that a stock has a great chance to move lower).

These ratings may change based on daily market conditions.

ABOUT EquityOutlook.Com: EquityOutlook.Com is a stock research firm. Our daily commentary has regular, worldwide distribution. We are Registered Investment Advisors. We do not accept third-party compensation to make stock suggestions. We do not own shares of any stock we rate.

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.

EquityOutlook.Com`s goal is to provide stock research FREE from bias or conflicts. You can get your FREE trial to EquityOutlook.Com at http://www.equityoutlook.com.

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2003 M2 COMMUNICATIONS LTD

Print story

Current Quote

NSD: MLNM
Biotech/Medical

Last: 15.900
Change: 0.450
Volume: 6,113,400
Day High: 16.230
Day Low: 15.700



First Alert News
Get real-time MLNM release alerts by entering your email address below.

JS200

[js200]

Inpharmatica Appoints Director of Chemistry and Recruits Chemistry Team; Appointments Address Needs of Rapidly Advancing Internal Drug Discovery
via COMTEX

October 2, 2003

LONDON &CAMBRIDGE, England, Oct 2, 2003 (BUSINESS WIRE) --

Inpharmatica Ltd, the selective drug discovery company, announces that Dr Andrew Ayscough has been appointed Director of Chemistry and that a team of seven experienced medicinal chemists have simultaneously been recruited from Millennium Pharmaceuticals Ltd.

Dr Ayscough, aged 40, was previously Director of Research at British Biotech Pharmaceuticals Ltd., where he was responsible for the direction of the company`s medicinal chemistry programmes. During his period at British Biotech, Dr Ayscough was responsible for the focus and strategy of Research in Cancer and Anti-infectives, directing successful projects to develop novel, orally active drugs that have now moved forward to clinical trials. He also managed a number of highly successful research collaborations with Pharma partners. Dr Ayscough is a graduate of the University of Bath and received his doctorate from the University of Oxford Dyson Perrins Laboratory.

The Company`s recruitment of a team of seven experienced medicinal chemists from Millennium Pharmaceuticals in Cambridge, UK follows that company`s announcement that it will be shortly closing its Cambridge site. The team was attracted against the backdrop of significant competition from other companies in the area and will be based at the Company`s recently acquired Cambridge facility.

Commenting on the announcement, Dr Malcolm Weir, Chief Executive of Inpharmatica, said: `I am extremely pleased to have attracted such a high calibre team of medicinal chemists within only a few months of establishing the Company`s chemistry facilities, following our acquisition of the former operations of ArQule UK Limited. Andrew and his new team will bring much experience to our rapidly advancing internal discovery programmes. Their recruitment fulfils a key milestone in the development of Inpharmatica`s internal drug discovery capability and is a further step in the Company`s drive to develop new drugs.`

Notes to Editors: Inpharmatica: (www.inpharmatica.com)

Inpharmatica Ltd, the selective drug discovery company, focuses its discovery efforts upon the selection of quality drug targets, quality leads that act against those targets and quality drug candidates, thereby reducing attrition in the drug discovery process. The Company`s flagship technology platform is PharmaCarta(TM), a computational chemogenomics system. It links genomic and proteomic space with chemistry and provides a unique approach to hit identification, lead generation and drug optimisation for druggable targets. Biopendium(TM) is an integral part of PharmaCarta(TM) that is also available to clients as a stand alone product. Inpharmatica`s platform utilises the massive computing power of the Company`s 2,500- processor compute farm, one of the largest in the world.

Founded in 1998, Inpharmatica`s technology is based on research from Professor Janet Thornton`s group at University College London. Employing approximately 100 staff, Inpharmatica is headquartered in London where it has its own in-house laboratory facilities. These laboratory facilities provide experimental validation of in silico discoveries, enabling Inpharmatica (and its strategic partners) to advance novel drug targets identified through its application of PharmaCarta(TM) and to develop novel drugs against those targets. The Company`s ADME and chemistry facilities are located on the Cambridge Science Park and provide support for its internal discovery programmes as well as contract ADME services.

Inpharmatica operates a hybrid business model with four distinct components:

i. Internal discovery programs for long-term value generation;

ii. Application of PharmaCarta(TM) to research programs of collaborators, generating mid-term value through research payments, milestone payments and royalties;

iii. Biopendium(TM) licensing to generate near-term revenues; and

iv. ADME Optimisation to generate near-term revenues and extend the capabilities of PharmaCarta(TM).

These components are outlined further below:

Internal Drug Discovery is focused upon discovering, validating and finding leads against highly druggable targets mined from the human genome, and has resulted in the Company filing patents over more than 200 novel proteins to date. The Company`s lead discovery program is focused upon the development of 16 novel Nuclear Receptors (`NR`s`). NR`s are a family of proteins widely considered to be both druggable and of high therapeutic interest. Drugs targeted against NR`s generate more than $10bn in sales annually. Inpharmatica`s novel NR`s represent a more than a 30% increase on those identified in the public domain.

PharmaCarta(TM) is the Company`s knowledge-based chemogenomics technology platform which drives the discovery process from gene to drug candidate. Inpharmatica applies PharmaCarta(TM) both in collaboration with third parties and for internal drug discovery. The Company concluded its first PharmaCarta(TM) collaboration, for the identification of novel protein therapeutics, with Serono in July 2001, a collaboration that was expanded in January 2003 and extended in August 2003. Since then, the Company has concluded further PharmaCarta(TM) collaborations with Chiron and Galapagos.

Biopendium(TM) is the Company`s proteome annotation resource, accessed by partners through commercial license. It is the world`s most comprehensive annotation resource; enabling rapid high throughput annotation of large datasets for target prioritisation, target mining and microarray analysis. Inpharmatica`s non-exclusive subscription collaborators include Pfizer, Genentech, Serono, Daiichi and Riken. Inpharmatica also has a joint venture with Celera to develop a special edition of the Biopendium(TM) that incorporates Celera`s proprietary genomic data (Celera Edition Biopendium(TM)).

ADME Optimisation is the latest offering from Inpharmatica, providing a further enhancement of PharmaCarta(TM), and so moving the Company`s drug discovery capabilities downstream. Inpharmatica makes the in silico, in vitro and Lead Optimisation experience of its experienced ADME team available to third parties, such as other biotechnology and pharmaceutical companies, on a fee for service basis. This team is based on the Cambridge Science Park and announced its first deals with Ionix and British Biotech in August 2003.

SOURCE: Inpharmatica

Inpharmatica Dr Malcolm Weir or Patrick Banks, [phone] www.inpharmatica.com or Buchanan Communications Lisa Baderoon, [phone]

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.


JS200

[Rambo0712]

Polarisiert ausgedrueckt, haengt der kurz und mittelfristige Er-
folg des Biotech/Pharmaunternehmens Millennium Pharma von der
Entwicklung des im Mai zugelassenen Krebsmedikamentes Velcade
ab. Dabei zeichnet sich ein ueberproportionaler Erfolg ab, denn
ungeachtet des natuerlich noch alles andere als repraesentativen
Zeitraums liegen die Velcade-Umsaetze bereits jetzt deutlich
ueber den Ewartungen.

In diesem Zusammenhang halten wir im laufenden Einfuehrungsjahr
Velcade-Umsaetze von ueber 40 Mio. $ fuer moeglich, was knapp
30% ueber der urspruenglichen Schaetzung liegt. Vor diesem Hin-
tergrund sehen wir bei Millennium noch erheblichen Spielraum bei
den EPS-Prognosen. Die ueber den Erwartungen liegende Entwi-
cklung von Velcade ist fuer Millennium sehr wichtig, denn auf
diese Weise ist das Biotechunternehmen in der Lage, die schwae-
chelnden Absaetze zweier anderer Medikamente zu kompensieren.

Entsprechend arbeitet das Unternehmen nun mit Hochdruck daran,
die Indikationsgebiete fuer Velcade zu erweitern um eine FDA-Zu-
lassung auch fuer weitere Krebsarten zu erhalten. Nochmals gilt
es zu betonen, dass Velcade fuer Millennium von entscheidender
Bedeutung ist, denn das Unternehmen verfuegt zwar ueber eine
quantitativ gut gefuellte Produktpipeline, allerdings befinden
sich die allermeisten Medikamentenkandidaten in sehr fruehen
Entwicklungsstadien, so dass mit den naechsten Zulassungen po-
tenziell signifikanter Umsatztraeger erst zwischen 2005/2007 zu
rechnen ist.

Vor diesem Hintergrund duerften sich konkretisierte Erfolgsmel-
dungen, die wir demnaechst erwarten, bezueglich Velcade fuer den
Aktienkurs als sehr relevant herausstellen. Entsprechend kann
der spekulativ ausgerichtete und risikobereite Trader die Ein-
nahme einer tradingorientierten Longposition erwaegen. Fuer
fundamentalorientierte Anleger kommt das Papier allerdings nicht
in Frage, da das Unternehmen zurzeit noch defizitaer ist, der
Breakeven ist erst 2006/07 zu erwarten.

Dessen ungeachtet deutet die Aktinonaersstruktur darauf hin,
dass einige grosse Unternehmen grosses Vertrauen in die Millen-
nium-Produktpipeline setzen, so sind bspw. Bayer, Abott Labora-
tories und Axa zu jeweils mehr als 5% an Millennium beteiligt.


MILLENNIUM PHARMACEUTIC. / ISIN: US5999021034, WKN: 900625

Marktkapitalisierung: 3,8 MRD

Kurs 02.10: 13,65 Euro
52-Wochen-Hoch: 14,50 Euro
52-Wochen-Tief: 6,00 Euro

empfohlenes Stopp-Loss: 11,90 Euro
Unser Anlage-Urteil: "Long Term Buy Speculative"

[js200]

10/07/2003 (07:50 ET) HCR: Smith Barney Highlights the Healthcare Sector - Knobias
10/06/2003 (16:57 ET) Mkt Wrap: MOT & RMBS Up Big; SOX Flat; Biotechs Down - Knobias
10/06/2003 (15:16 ET) Profit Taking Hits Equities in Late Trading - Knobias
10/06/2003 (10:41 ET) New 4 just released for MLNM - Edgar
10/02/2003 (16:42 ET) Internet, Biotech, Wireless Industries Drive Mkt Gains - Knobias

JS200

[Ramschbus]

.





moin.



----------------------------------------------------------------------------------------------------------------------



29.10. 10:29
Bayer verkauft Millenium-Beteiligung

--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)


Der Chemie- und Pharmakonzern Bayer AG hat seine Beteiligung an dem US-Biotechnologieunternehmen Millenium Pharmaceuticals verkauft. Wie bereits Anfang der Woche bekannt gegeben wurde, endet die 5-jährige Forschungskooperation zum 31. Oktober 2003. Im Rahmen dieser Zusammenarbeit hatte sich Bayer im Jahr 1998 mit rund 97 Mio. US-Dollar an einer Kapitalerhöhung von Millenium beteiligt. Das entsprach einer Beteiligungsquote von 6,6 %. Das Aktienpaket wurde von der Credit Suisse First Boston zur Weiterveräußerung übernommen.

Der Verkaufserlös in Höhe von mehr als 300 Mio. Euro wird zur Reduzierung der Verbindlichkeiten verwendet.





----------------------------------------------------------------------------------------------------------------------

[gerdiman]

Hi,

hat der Kursrückgang heute ausschließlich mit der Bayer-Meldung zu tun oder gibt es noch andere Gründe?

gruß
gerdiman

[perry2]

22Mio. Stücke wollen erst mal an den Mann gebracht werden. Das dürfte den Kurs noch eine Weile unter Druck setzen.
Perry

[LMeister7]

Hallo,
ich wollte nur mal feststellen, dass sich dass Managment von Bayer in 6 bis 8 Monaten sicherlich in den Allerwertesten beissen wird wenn sie denn den Kurs von Mille sehen. Danke Bayer!!! Ich habe Eure Schrottteile verkauft und kauf mir dafür noch mehr Millennium.
LM7

[BonMala]

Hi, bin seit einiger Zeit mit Millennium nicht auf dem Laufenden.
Bekomme aber immer noch die INFO-Mails und der steigende Kurs beruhigt ...

Ist diese INFO schon bekannt?

http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-…

[LMeister7]

@ Bon Mala
Scheint aber kein Schwein zu interessieren. Nu hab ich mir halt noch ein paar gekauft. Wollte im Februar eh welche steuerfrei verkaufen. Kurs war im Februar 2k3 5,9 Euro! ja ja kommt Zeit kommt Rad.
Tschüss,
LM7

[Mister NO]

hallo,

glaubt einer das die "mille" irgendwann den kurs von sagen wir mal 60€ erreicht???

über eure antworten würde ich mich freuen.

mfg
no

[perry2]

Warum nicht? Fragt sich nur, ob ich`s auch noch erlebe?
Heute kommen ja wieder nachbörslich Zahlen - das Ergebnis könnte die Richtung für die nächsten Wochen vorgeben.
Perry

[Mister NO]

@ perry,

wie alt biste denn

[schakal23]

27.01. 22:33
Millennium: Verlust ausgeweitet

--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)
Millennium Pharmaceuticals haben im abgelaufenen Quartal ihren Verlust deutlich auf 146,4 Millionen Dollar oder 49 Cents pro Aktie ausgeweitet. Im Vorjahreszeitraum lag das Minus bei 28 Cents pro Aktie. Ohne Restrukturierungskosten und Abschreibungen habe der Verlust bei 30 Cents pro Aktie gelegen.

Die Analysten waren im Vorfeld noch ein wenig pessimistischer und hatten laut Reuters Research ein Minus von 32 Cents pro Aktie erwartet. Die Titel, die heute im regulären Handel bereits um 3,06 Prozent auf 17,40 Dollar gefallen sind, verlieren nachbörslich dennoch weitere 0,8 Prozent auf 17,26 Dollar.





wann werden die endlich vernuftiegen zahlen bringen

[Mister NO]

was ist da los mit der "mille" ?

hab das gefühl das sie kein bock haben was besser zu machen.

[amorphis]

soweit ich das richtig behalten habe,plant mlnm ab 2006 den break even zu erreichen!wo ist also das prob?forschung kostet nunmal geld...

[Boersenkrieger]

So lange man genug Cash hat kann man sich teure Forschung leisten. Der Biotech-Markt ist eben hart umkämpft weil viele Firmen ähnliche Wirkstoffe produzieren. Der schnellste wird gewinnen und Zeit is eben Geld
Seh ich nicht so dramatisch vor allem weil sogar noch mehr Verlust erwartet wurde.

[perry2]

1,4 Millionen Umsatz in N.Y, 9000 in Frankfurt - entweder herrscht panische Angst in Deutschl. vor einer weiteren Schwächung des Dollar, oder das Interesse an MLNM hat hierzulande mächtig nachgelassen. Zu Unrecht, wie ich meine.
@ Mister N.O. - 42 (habe also, hoffentlich, noch jede Menge Zeit).
Perry

[Boersenkrieger]

das interesse hat ja schon längst nachgelassen seit 2 jahren... nur bei mir nicht. hab anfangs mille zu nem Kurs 99 € ins depot gelegt... danach immer verbilligt bei 45 € und massiv bei 7,5 €. inzwischen hab ich nur noch -10% performance und bin eigentlich recht zuversichtlich daß die 0 mal wieder steht nach 3 jahren LOL. Ich denke daß die Margen im Biotecbereich weiterhin hoch bleiben werden und wenn sich milles forschung mal auszahlt ist ein break even viellicht nichtmal so sehr weit entfernt. auch wenn das primäre ziel sein wird weiterhin stark in die forschung zu investieren um den langfristigen fortbestand und die stärke im markt zu sichern... man stelle sich vor mille schafft 2006 den break even. dann begintn auch wieder ein hype. werde auf jeden fall so lange investiert bleiben, auch wenn es sich bislang nicht wirklich gelohnt hat

[LMeister7]

Schleichfahrt Nordwärts - Kein "Schwein" inteessierts. Kennt jemand den Grund?
MfG,
LM7

[perry2]

Für nordwärts oder für Schleichfahrt?
P.

[LMeister7]

@ Perry
Aus welchem Kindergarten bist Du denn entsprungen? Müssteste nicht längst die Schäfchen zählen?
LM7

[perry2]

Wieso Kindergarten? Hauptschule - allerdings ohne Abschluss (Abgang 7.Klasse). Und Schäfchen zählen ist ohnehin verpönt. Ich dachte, du kennst dich eher bei Schweinen aus?
Sooo intelligent war deine Frage nun auch nicht, dass du hier gleich den Beleidigten heraushängen lassen musst.
Nebenbei habe ich unter der wahren Flut von gestrigen Infos zum Biotechbereich nichts auf den ersten Blick Milln. betreffendes gefunden. Auch keine aktuelle Hochstufung. Also entweder Trittbrettfahrerei oder es kommt noch was nach - die Umsätze sind o.k..
Nicht ausschließen kann man m.E., dass charttechnisch ausgerichtete Anleger sich mehr u. mehr für Mlnm. interessieren.
Perry

[Brettvormkopp]

Velcade wird an dt. Unikliniken bereits verabreicht.
(nicht kostenlos, versteht sich...)
Für mich ist Millennium eine Bank

[perry2]

Für mich auch; wäre nicht schlecht, wenn ein paar Leut` mehr so denken würden.
Ach so - wie bekommt den Probanten denn ihre Velcade-Dosis?
Sind sie Versuchspersonen der aktuellen Testphase oder ist die Einnahme auf eigene Gefahr sozusagen die letzte Hoffnung?! Schade, dass das Verabreichen eines Medikaments als Erfolgskriterium nicht ausreicht.
Perry

[Boersenkrieger]

Wenn man so sieht was bei CVTX, Vertex oder Seprator immer passiert ist... da ist man bei Millennium im sicheren Hafen. Kann man glaub ich getrost laufen lassen. In 2 Jahren steht´s deutlich höher. ...ist mir meine liebste Aktie im depot ... nur noch -6,67 % ...die 0 naht bei mir und dann steh ich vielleicht tatsächlich mal im plus mit mille... wird auch zeit

[blb]

An MLNM wir man noch viel Freude haben. Aubruch ist geglückt. Gruß allen Investierten!

@Börsenkrieger: Falls du Sepracor meinst. Die hab ich auch, und ich magse zur Zeit sogar noch lieber!
V.a., wenn die Zulassung von Estorra kommt!

[dr.gips]

mlnm war mal einer der am meisten besprochenen biotech-werte!!
bin ich hier der letzte der noch an die perspektiven dieser firma glaubt und weiterhin dabei ist?

[muschelsucher]

Habe ich eben im Vorübergehen bei Bloomberg gelesen, Millenium wird von Lyondell übernommen...
habe ich das was nicht richtig gelesen? Finde gar keine Kursreaktion??
ms

[muschelsucher]

Aha, deshalb keine Kursreaktion:
Zusammenschluß über Aktientausch.
Die Millenium-Aktionäre sollen 0,95 bis 1,05 Lyondell-Aktien je Millenium-Aktie erhalten.
ms

[leonide]

Falsche Baustelle!
Soweit ich sehe handelt es sich um Millennium Chemical, hat mit Millennium Pharmaceuicals nichts zu tun.
Den Aktien von Chemical tut es zwar gut, mir ist es aber recht so, was soll eine Chemiefirma wie Lyondell - kannte ich bisher gar nicht - denn mit "meiner" Millennium? Würd ich denen gar nicht geben.
Viele Grüße den Fans der einzig "echten" Millennium!

[Megapol]

Bei dem Zusammenschluss geht es aber um Millenium Chemicals (MCH) und nicht um Millenium Pharmaceuticals (MLNM), wie in diesem Thread

[muschelsucher]

Super, da bin ich aber froh....man sollte doch nicht nur am TV vorbeihuschen, wenn bloomberg läuft.
Danke für die Aufklärung
ms

[blb]

MLNM ist vom Chance/Riskioverhältnis her für mich DAS Basisinvestment im Biotechbereich schlechthin. Muss man langfristig haben.

Charttechnisch seh ich zur Zeit noch Abwärtspotenzial bis max 14,5$. Spätestens dann sollte man aber nachfassen oder neu einsteigen.

Viele Grüße an alle!
blb

PS: Zu meinem unteren Posting: SEPR hab ich mit 150% verkauft!

[KaderLoth]

Millennium Pharmaceuticals "buy"

Monday, March 29, 2004 2:38:30 PM ET
Banc of America

NEW YORK, March 29 (New Ratings) - In a research note published on March 26, analysts at Banc of America Securities maintain their "buy" rating on Millennium Pharmaceuticals Inc (MLNM). The target price is set to $24.

© 2004 New Ratings

[KaderLoth]

02.04.2004
Millennium Pharmaceuticals "in-line"
Goldman Sachs

Die Analysten der Investmentbank Goldman Sachs stufen die Aktie von Millennium Pharmaceuticals (ISIN US5999021034/ WKN 900625) unverändert mit "in-line" ein.

Anlässlich des Conference Calls habe sich Millennium hinsichtlich seines Krebs-Programms optimistisch gezeigt. Die Pipeline wachse angesichts von fünf Phase I Programmen und verschiedenen neuen Indikationen für Velcade.

Millennium erwarte dass die Übermittlung der APEX-Daten an die FDA die frühere Anwendung von Velcade unterstützen werde.

Die Anlageeinschätzung beruhe auf vermehrten Anwendungsgebieten für Velcade, einer breiten Pipeline, einer guten Finanzausstattung, einer fairen Bewertung und dem Erreichen der Profitabilität in 2006.

Vor diesem Hintergrund bewerten die Analysten von Goldman Sachs die Aktie von Millennium Pharmaceuticals weiterhin mit dem Votum "in-line".

[blb]

Scheint so, als ob sie zur Zeit eher nach oben durchstartet, Mir solls recht sein!

Grüße
blb

[KaderLoth]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[KaderLoth]

Millennium Pharmaceut. mit Potential
Biotech-Report

Für die Anlageexperten vom "Biotech-Report" hat die Aktie von Millennium Pharmaceuticals (ISIN US5999021034/ WKN 900625) Potential bis 35 USD.

Die Analysten von Prudential haben in ihrer Ersteinschätzung den Titel mit "neutral" bewertet und den fairen mit 20 USD angegeben. Das Biotechunternehmen sei gut positioniert, um die Markteinführung des Krebs-Präparates Velcade zu beschleunigen. Charttechnisch sehe der Wert recht vielversprechend aus. Überwinde die Aktie die Hürde von 20 USD, sei der Weg bis 35 USD frei.

Vor diesem Hintergrund halten die Wertpapierexperten vom "Biotech-Report" die Aktie von Millennium Pharmaceuticals für ein interessantes Investment.

[KaderLoth]

CAMBRIDGE, Mass., April 22 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. will hold a live webcast of its conference call at 8:30 a.m. EDT on Thursday, April 29, 2004. Mark Levin, chairperson and chief executive officer, will host the call. Senior management will discuss the Company``s first quarter financial results for 2004, progress against 2004 goals, and additional corporate activities. Millennium will announce its financial results for this period in a press release to be issued after market close on Wednesday, April 28, 2004.

The press release and the live webcast can be accessed by visiting the Investors section of the Company``s website, http://www.millennium.com/. Following the webcast, an archived version of the call will be available at the same address until 11:59 p.m. on Monday, May 3, 2004.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company``s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular, and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products.

Editors`` Note: This press release is also available under the Media section of the Company``s website at: http://www.millennium.com/.

Contact: Cynthia Clayton, Investor Relations Millennium Pharmaceuticals, Inc. [phone]

Logo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO AP Archive: http://photoarchive.ap.org PRN Photo Desk, 888-776-6555 or 212-782-2840

Millennium Pharmaceuticals, Inc.

© PR Newswire

[KaderLoth]

die zahlen kommen !!!!

[Hufeland]

wann und woher weißt Du das? Kannst Du eine Quellen nennen. Ein seit schon 4 Jahren in Millenium Investierter und endlich auf steigende Kurse Hoffender.
Die letzten Monate verlief die Kursentwicklung doch recht positiv.

[Hufeland]

Oh sorry, hab das vorhergehende Posting doch glatt übersehen, daher erübrigt sich meine Frage.

[ONYXLeader]

Hallo Leute !!

Interssiere mich vorallem für die Aktie ONYX WKN 900778.

Zu meiner Depotbeimischung würde mich aber Millenium reizen.

Welche Produkte haben die denn in den verschiedenen
Phasen, kann mir das einer sagen ??

Wie gehts denn euerer Meinung nach mit Millenium weiter !

Vielleicht könnt ihr mir ein paar OInfos weiter geben !!

Vielen Dank

ONYX

[amorphis]

@onyx...geh doch einfach mal auf die seite mlnm.com da findest du alle nötigen infos!kann aber ehrlich nicht verstehen warum du nen wert wie mlnm nur zur beimischung benutzen willst!mlnm ist auf jeden fall ein basisinvest im biotechbereich...als beimischung würde ich eher kleinere werte benutzen!

[ONYXLeader]

Hi !!

Vielen Dank, habe gerade rein geschaut.
Bei der Auswahl an Produnkten, müsste der Kurs doch
viel höher stehen ?
Meinst du, das dies eine ähnliche Amgen in 5 Jahren ist ??

mfg. ONYX

[KaderLoth]

Für die Anlageexperten vom "Biotech-Report" hat die Aktie von Millennium Pharmaceuticals (ISIN US5999021034/ WKN 900625) Potential bis 35 USD.

Die Analysten von Prudential haben in ihrer Ersteinschätzung den Titel mit "neutral" bewertet und den fairen mit 20 USD angegeben. Das Biotechunternehmen sei gut positioniert, um die Markteinführung des Krebs-Präparates Velcade zu beschleunigen. Charttechnisch sehe der Wert recht vielversprechend aus. Überwinde die Aktie die Hürde von 20 USD, sei der Weg bis 35 USD frei.

Vor diesem Hintergrund halten die Wertpapierexperten vom "Biotech-Report" die Aktie von Millennium Pharmaceuticals für ein interessantes Investment.

[ONYXLeader]

Hallo Leute !!

Vielen Dank für euere Mails, werde die
Aktie noch ein paar Tage verfolgen, um dann
eventuell zu zuschlagen.
Es schaut so aus, als hätte man mit der Aktie
die Risiken im Biotech Bereich doch einweinig gemnildert.
Im Gegensatz zu anderen kleinen Biotech Schmieden !
Jetzt einsteigen und ein halbes Jahr später die 35 Dollar
erreichen, das wäre halt super !

mfg. ONYX

[blb]

@onyx: Also 35$ sind totaler Schwachsinn. Wir ham es hier nicht mit ner kleinen Biotechschmiede zu tun. Ich kann mir für dieses Jahr maximal 25$ vorstellen. So richtig Schwung wird erst 2005 reinkommen.

Grüße
blb

[Boersenkrieger]

naja 35 $ ist hochgegriffen. Sehe aber relativ wenig risiko bei der aktie und bin schon lange investiert zu kursen von 45 $ bis runter zu 7... hab noch -8% im depot. aber bald kommt nach langer zeit mal das pluszeichen das fühl ich schon ..ein ruhiger anstieg bis jahresende auf 25 $ fänd ich prima... bei über 30 verkauf ich mal die hälfte aber das dauert sicher noch ne weile... nur runter geht´s glaub nicht mehr bei mille un wenn dann maximal auf 15 $. is ne gute altersvorsorge die mlnm

[blb]

Wie geschrieben, absolutes Basisinvestment. Würd zum Traden andere Bios nehmen.

Sehr gute Cashposition, mit Velcade möglichen Blockbuster in der Pipeline. Da macht man nicht viel falsch.

Aber man sollte auch nicht zu viel auf einmal wollen. Das ist ein Investment, kein Zock...

Bin übrigens auch schon länger dabei. Mischkurs ist so um die 14-15EUR!

Grüße
blb

Bios heute übrigens mega!!! Mein Depot ist auf Jahreshoch!

[KaderLoth]

[LMeister7]

European Commission Grants Marketing Authorization to Millennium for VELCADE(R) (Bortezomib) First new treatment to be approved in the European Union for patients with relapsed and refractory multiple myeloma in more than 10 years to be marketed by O


CAMBRIDGE, Mass., Apr 27, 2004 /PRNewswire-FirstCall via COMTEX/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that the European
Commission has granted marketing authorization for VELCADE for the treatment of
patients with multiple myeloma who have received at least two prior therapies
and have demonstrated disease progression on their last therapy. The Marketing
Authorization Application for VELCADE was submitted to the European Medicines
Evaluation Agency (EMEA) in January 2003 and accepted for review in February
2003.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Under this authorization, a single license is granted for marketing VELCADE in
the 15 member states of the European Union, plus Norway and Iceland. On May 1,
2004, VELCADE will also be approved when the 10 accession member countries
officially join the European union.

"The European approval of VELCADE represents another significant step toward the
Company`s global mission of developing and delivering to the marketplace
breakthrough medicines that make an important difference in patients` lives,"
said Mark Levin, chief executive officer and chairperson of Millennium. "Through
much hard work and collaboration with investigators, advocates, the European
regulatory authorities and our research and development collaborator, Johnson &
Johnson Pharmaceutical Research and Development, Millennium will be able to
expeditiously bring VELCADE to patients in need across Europe."

Under the terms of the co-development and commercialization agreement for
VELCADE, Ortho Biotech and its affiliate, Janssen-Cilag, divisions of Johnson &
Johnson, will commercialize VELCADE outside of the U.S., including Europe.
Millennium will receive royalties from Ortho Biotech and its affiliate
Janssen-Cilag on sales outside the U.S.

"The approval of VELCADE by the European Commission represents an important step
forward in the struggle against multiple myeloma," said Martine George, M.D.,
vice president, global clinical research and development for Johnson & Johnson
Pharmaceutical Research and Development, L.L.C. "With its new and unique
mechanism of action, VELCADE is different from traditional therapies and
represents a significant new treatment option for patients."

VELCADE was approved in the United States in May 2003 and is marketed by
Millennium in the U.S. for patients with multiple myeloma who have received at
least two prior therapies and have demonstrated disease progression on the last
therapy. Millennium and Johnson & Johnson Pharmaceutical Research and
Development continue to investigate the full potential of VELCADE in both
hematologic and solid tumors and in 2004 will have approximately 80 ongoing or
planned clinical trials.

About VELCADE(R) (bortezomib) for Injection

VELCADE is approved for the treatment of multiple myeloma patients who have
received at least two prior therapies and have demonstrated disease progression
on the last therapy. The effectiveness of VELCADE is based on response rates.
There are no controlled trials demonstrating a clinical benefit, such as
improvement in survival. VELCADE is contraindicated in patients with
hypersensitivity to bortezomib, boron, or mannitol.

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson &
Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible
for commercialization of VELCADE in the U.S. Ortho Biotech Products L.P. and the
Janssen-Cilag group of companies will be responsible for commercialization in
the EU and the rest of the world. Janssen Pharmaceutical K.K. will be
responsible for Japan.

Risks associated with VELCADE therapy include new or worsening peripheral
neuropathy, orthostatic hypotension, congestive heart failure, gastrointestinal
adverse events, thrombocytopenia, and tumor lysis syndrome. Women of
childbearing potential should avoid becoming pregnant while being treated with
VELCADE.

In 228 patients who were treated with VELCADE(R) (bortezomib) 1.3 mg/m2/dose in
phase II studies, the most commonly reported adverse events were asthenic
conditions (65%), nausea (64%), diarrhea (51%), decreased appetite including
anorexia (43%), constipation (43%), thrombocytopenia (43%), peripheral
neuropathy (37%), pyrexia (36%), vomiting (36%), and anemia (32%). Fourteen
percent of patients experienced at least one episode of Grade 4 toxicity, with
the most common toxicities being thrombocytopenia (3%) and neutropenia (3%). A
total of 113 (50%) of the 228 patients experienced Serious Adverse Events (SAEs)
during studies. The most commonly reported SAEs included pyrexia (7%), pneumonia
(7%), diarrhea (6%), vomiting (5%), dehydration (5%), and nausea (4%).

For more information about VELCADE clinical trials, patients and physicians can
contact the Millennium Medical Product Information Department at
1-(866)-VELCADE.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in
Cambridge, Mass., markets VELCADE, a novel cancer product, co- promotes
INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product,
and has a robust clinical development pipeline of product candidates. The
Company`s research, development and commercialization activities are focused in
three therapeutic areas: oncology, cardiovascular, and inflammation. By applying
its knowledge of the human genome, its understanding of disease mechanisms, and
its industrialized drug discovery platform, Millennium is seeking to develop
breakthrough products.

This press release contains "forward-looking statements," including statements
about our growth and future operating results, discovery and development of
products, potential acquisitions, strategic alliances and intellectual property.
Various important risks may cause the Company`s actual results to differ
materially from the results indicated by these forward- looking statements,
including: adverse results in our drug discovery and clinical development
programs; failure to obtain patent protection for our discoveries; commercial
limitations imposed by patents owned or controlled by third parties; our
dependence upon strategic alliance partners to develop and commercialize
products and services based on our work; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from our
development efforts; the commercial success of INTEGRILIN and VELCADE; and the
requirement for substantial funding to conduct research and development and to
expand commercialization activities. For a further list and description of the
risks and uncertainties we face, see the reports we have filed with the
Securities and Exchange Commission. We disclaim any intention or obligation to
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

Editor`s Note: This release is available under the Media section on the
Company`s website at www.millennium.com.

[LMeister7]

zur Erinnerung:

Das Abkommen mit dem Pharmakonzern hat am Markt zunächst enttäuscht.

Nach Schließung der Börsentore haben die Anleger den Stab über der Aktie von Millennium Pharmaceuticals gebrochen und den Wert in die Tiefe geschickt. Vom Schlusskurs bei 15,73 Dollar ging es abwärts auf 14,60 Dollar. Der Grund wird in der Vereinbarung der Gesellschaft mit dem Pharmariesen Johnson&Johnson gesehen, deren Bestimmungen für Enttäuschung gesorgt haben.

Gegenstand der Kooperation zwischen Millennium und J&J ist das jüngst in Rekordzeit zugelassene Krebsmedikament Velcade. Zunächst wird ein so genanntes Upfront Payment, eine Anfangszahlung, in Höhe von 15 Mio. Dollar fällig. Analyst Dennis Harb von der Deutsche Bank Securities sieht das als recht wenig an, denn Velcade ist bereits zugelassen.

Bis zu 125 Mio. Dollar werden in Form von Meilensteinzahlungen fällig, die sich auf Fortschritte bei Entwicklung und Zulassung von Velcade außerhalb der USA beziehen. Für weitere Indikationen, für die das Mittel entwickelt wird, erhält Millennium bis zu 330 Mio. Dollar, wenn bestimmte Ziele erreicht werden. J&J wird schließlich 40 Prozent der Entwicklungskosten für Velcade bis 2005 und 45 Prozent darüber hinaus bezahlen.

Hinsichtlich der Vermarktung des Medikamentes haben sich die beiden Gesellschaft darauf geeinigt, dass Millennium die Rechte für die USA behalten wird. Außerhalb der USA wird J&Js Ortho Biotech für die Vermarktung verantwortlich sein, wobei Millennium für diverse europäische Staaten die Option erhalten hat, als Co-Vermarkter aufzutreten. Das Unternehmen wird nach Aussage ihres CFO Ken Bate Tantiemen im zweistelligen Bereich erhalten.


Autor: 4investors.de (© 4investors.de),08:32 01.07.2003


Könnte morgen nachbörslich spannend werden. SR vom 15.4. ist 4,5! Verstehe zwar das die News verkauft werden, aber das die Shorties so "billig" raus kommen....
Naja der Markt hat immer Recht, hilft kein Lamento. Kauf ich mir halt noch welche. Ich weiss zwar nicht wie hoch der Kostenanteil von Velcade ist aber wenn mal von 100 Mill. USD pro Quartal ansetzt kommt noch ganz schön was zusammen.
MfG,
LM7

[KaderLoth]

...wird kurzfristig möglich.

Millennium Pharma (MLNM)

Kursstand : 18,71 $ (+4,2%)

Kurz-Kommentierung : Mit den heute festen Biotechsektor gehört die Aktie von Millennium Pharma derzeit zu den größten Gewinnern im Nasdaq100. Der Kurs bildete im Februar das bisherige Rally-Hoch bei 19,9$ und konsolidiert seitdem den Anstieg aus. Über dem EMA 200 (rot) bei derzeit 16,4$ besteht jetzt die Möglichkeit der Ausbildung eines Doppelbodens. Kann MLNM jetzt über die Triggerlinie bei 18,6$ auf Schlusskursbasis nach oben ausbrechen ist kurzfristig mit weiter steigenden Notierungen zu rechnen.





Chart erstellt mit Qcharts





© GodmodeTrader

[BonMala]

Der Bericht kam gestern Abend:

http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-…

Grüßle!

[Brettvormkopp]

Habe eben nochmal nachgekauft.
Mitte bis Ende Mai wird die dt. Zulassung von....
erwartet Na , Ihr wisst schon.
Es handelt sich um Medikament "B.. wie "Blockbuster, das
bereits heftige Umsätze abwirft. The "Killerdrug".
Ausserdem gibts nicht geringe Übernahmegerüchte...
Charttechnisch gibts jetzt Widerstand von unten.
Mich wunderts nicht. Bei 10 bis 12 Euros
wird nochmal nachgelegt.

[Brettvormkopp]

Vor ner halben Stunde 16,3 €.
Jetzt 16,75 €
Nicht schlecht Herr Specht
Wenns nochmal runter geht, kaufe ich bis der Arzt kommt.

Meine unmaßgebliche Einschätzung :
fundamental preiswert

[midgbridg]

Was ist los mit mlnm
Warum stürzen die so ab? Hab ich irgendwo etwas übersehen?
Wäre für Eure Meinungen dankbar!

[Brettvormkopp]

Nicht fragen.
Kaufen.
Die Yankees sind bekloppt.

[midgbridg]

Is leider nix mit kaufen derzeit
Also werde ich warten, das kann ich ja schon ganz gut, denn mit go away in May ist`s bei diesen Kursen wohl auch vorbay.

[Isabartels]

7.05. 23:17
Millennium: Erfolg an Krebs-Front
(©BörseGo - http://www.boerse-go.de)

Das Knochenkrebs-Medikament Velcade des Biotech-Unternehmens Millennium Pharmaceuticals hat in einer Studie erneut hervorragende Ergebnisse erzielt. Darin konnte gezeigt werden, dass das Präparat das Leben von Patienten mit Krebs in fortgeschrittenem Stadium signifikant verlängert. Auch die Überlebensrate unter den Probanden stieg an. Bisher war man davon ausgegangen, dass der Wirkstoff den wuchernden Krebs lediglich eindämmen könne.

Velcade wurde vergangenen Mai auf den US-Markt gebracht. Während Millennium die Vertriebsrechte für die USA besitzt, deckt der Pharmariese Johnson & Johnson den Rest der Welt ab. Die Aktie von Millennium Pharmaceuticals konnte sich im regulären Handel heute um 0,07 Prozent verbessern, und schoss nachbörslich dann um bislang 12,02 Prozent nach oben auf 15,19 Dollar.

[js200]

Guten Abend MLNM Freunde

Ich muss mich mal bei allen Bedanken die den Tread fortfahren, mir bleibt nicht all zu viel Zeit mich drum zu kümmern

Danke, an alle

JS200

[Wuscher]

New York: Millennium Pharma entdeckt
(Instock) Nach einem recht ruhigen Handel zur Wochenmitte nehmen die US-Indizes am Donnerstag wieder Fahrt auf. Rückenwind kam von Konjunkturseite: So revidierte das US-Handelsministerium die Wachstumsrate des Bruttoinlandsprodukts (BIP) im ersten Quartal von 4,1 auf 4,4 Prozent nach oben. Auch die weiter rückläufige Zahl der wöchentlichen Erstanträge auf Arbeitslosenunterstützung stimmt Investoren recht zuversichtlich.

Der Dow Jones-Index klettert gegen 16 Uhr rund 65 Zähler auf 10.175 Punkte. Der breiter gefasste S&P 500 legt indes 5 Zähler auf 1.120 Punkte zu. An der Technologiebörse Nasdaq gewinnt der Composite-Index 7 Zähler auf 1.984 Punkte.

Am Rentenmarkt notiert die Rendite der richtungsweisenden 10-jährigen Staatsanleihe mit 4,63 Prozent (- 4 Stellen), die der 30-jährigen Staatsanleihe mit 5,35 Prozent (- 3 Stellen). Am Devisenmarkt springt der Euro auf 1,2245 US-Dollar. Der Preis für eine Feinunze Gold klettert auf 393,30 Dollar.

Im Blickpunkt

Die Citigroup (+0,8 Prozent auf 46,90 Dollar) hat eine 20-Prozent-Beteiligung an der in Saudi-Arabien ansässigen Samba Financial Group veräußert. Im Zuge der Transaktion sei ein Buchgewinn von 760 Millionen Dollar erzielt worden, hieß es.

Dow-Kollege Home Depot erhöhte seine Quartalsdividende um 25 Prozent und weitete das Aktienrückkaufprogramm aus. Daher gewinnt die Baumarktkette 0,1 Prozent auf 35,51 Dollar

Im Technologiesektor wird EMC (+1,9 Prozent auf 11,41 Dollar) von Merrill Lynch mit "neutral" eingestuft. Die Experten rechnen mit einer zunehmenden Konkurrenz durch IBM (+0,5 Prozent auf 88,77 Dollar) und Hitachi, erwarten jedoch das der Speicherspezialist 2004 rund 34 Cents je Aktie verdient. 2005 geht man von 46 Cents Gewinn je Aktie aus.

Eine Kaufempfehlung der UBS beschert Coca-Cola einen Zugewinn von 1,6 Prozent auf 51 Dollar. Auch im Biotechsektor bewegen Analysten die Kurse: Die Deutsche Bank stufte Millennium Pharma (+6,1 Prozent auf 15,13 Dollar) auf "kaufen" herauf und nannte ein Kursziel von 19 Dollar. Die Experten erwarten positive Testergebnisse eines Lungenkrebspräparates.

Pharmariese Chiron hat eine US-Ausschreibung zur Entwicklung eines Impfstoffes gegen die Vogelgrippe gewonnen, worauf die Notierung 0,2 Prozent auf 45,18 Dollar zulegt.
[ Donnerstag, 27.

[Wuscher]

27.05.2004
Millennium Pharmaceuticals "buy"
Deutsche Securities

Rating-Update:

Die Analysten von Deutsche Securities stufen die Aktie von Millennium Pharmaceuticals (ISIN US5999021034/ WKN 900625) von "hold" auf "buy" herauf.

[Wuscher]

Giebt es dazu Meinungen ?

[Wuscher]

DELRAY BEACH, Fla., June 30 /PRNewswire-FirstCall/ -- At a press conference today, Office Depot , one of the world``s leading resellers of office supplies, unveiled a new concept in retailing called Millennium2 (M2).

To view the Multimedia News Release, complete with video and Hi-Res images, go to: http://www.prnewswire.com/mnr/officedepot/12470/" target="_blank" rel="nofollow ugc noopener">http://www.prnewswire.com/mnr/officedepot/12470/

M2 was developed from the ground-up by a cross-functional task force hand picked by Office Depot Chairman and CEO Bruce Nelson. The task force was given one mandate: Reinvent the retail model by creating a store that is less expensive to open, more efficient to operate and easier to shop.

"By building on the things we have learned from Office Depot``s Millennium pilot project and combining them with extensive market research and a healthy dose of home-spun ingenuity, we are able to offer our customers the most enjoyable and satisfying shopping experience in the industry," Nelson said. "M2 is intuitive, logical and designed specifically for the way people make purchase decisions."

For example, Nelson noted that products are grouped in highly visible, strategically located "pods," with core supplies at the outer perimeter of the store (signed for optimal visibility and easy purchase) and furniture and technology at the center (to better support consultative sales and the area in which the majority of staff will be located during peak buying hours).

According to Nelson, M2 plays a central role in the implementation of Office Depot``s seven corporate strategies, most notably addressing the company``s number one objective: Realigning the North American real estate portfolio.

"In 2004, Office Depot is embarking upon one of the most ambitious expansion plans in company history," Nelson said, while reiterating Office Depot``s intent to open between 80 and 100 new stores this year.

"We will leverage the M2 format along with our recent purchase of Kids ``R`` Us locations to enhance Office Depot``s presence in existing core markets and provide immediate access to large areas of the country in which we do not currently have a strong retail concentration, such as Massachusetts, New York, New Jersey and Pennsylvania," Nelson added.

"As we roll out these new stores, customers in the Northeast -- for the first time -- will have a choice, an alternative to the only place they``ve been able to purchase office supplies," Nelson continued. "And what they will find is an Office Depot store that represents a true ``destination experience`` -- one that is warm, colorful and exciting and reflects the latest thinking in everything from product layout and adjacencies to graphics, replenishment and service."

Overseeing the M2 launch on a daily basis is Rick Lepley, who was recently named Executive Vice President of North American Retail for Office Depot, and who was responsible for putting together the original M2 project team.

According to Lepley, the extensive research conducted for M2 indicated that customers want two specific things when shopping at an office supply superstore: "For basic supplies, they want convenience, including help in getting oriented, the ability to find everything on a shopping list and fast checkout. For technology and furniture, they want information and advice, including assistance and support from knowledgeable staff and the ability to touch and try out various product options. M2 executes beautifully on both of these fronts."

To ready the M2 concept for introduction, Nelson and Lepley teamed with Chuck Rubin, Executive Vice President and Chief Merchandising Officer for Office Depot. Together, the marketing and merchandising organizations, store operations unit and IT group, set forth to completely revamp existing processes and ways of doing business.

"We looked at M2 as a rare opportunity to begin with a clean slate," Rubin said, in noting that almost every aspect of the retail environment was scrutinized, analyzed and dissected. "The result is a series of innovations that make M2 unlike any other format in the retail industry."

According to Rubin, these advancements include: Graphics and Color Palette

* New color scheme is vibrant and cheerful, and incorporates a contemporary color palette featuring bright orange, lime green, aqua and purple

* New way-finding system (versus lifestyle graphics) improves the shopping experience by making it easier to navigate the store and find what you want

Store Layout * "Pod" structure assures easy navigation

* Modularity of format adapts to different store sizes/shapes, yet provides a consistent customer experience

* Low center fixtures offer clear sight lines

* Open format allows employees to find and assist customers more efficiently, while at the same time allowing customers to easily seek out employees for assistance

* Sales floor reduced by 10% without significantly sacrificing SKU count

* Combined check-out and copy areas with cross-trained front-end labor creates a unified service offering

* Redesigned copy area utilizes 50% less space while maintaining full functionality

Fixtures

* High steel at outer walls and increased shelf depth maximizes holding power at point of sale

* Holding power reduces perceived out-of-stocks and number of employee product "touches"

* Planogramming tech assortment into designated top-stock locations reduces replenishment time/labor

Bulks and Pegs

* High-velocity items are bulk-stacked to reduce labor and reinforce value statement

* Number of pallets on sales floor increased five fold

* Number of pegs reduced by 50% to improve labor allocation away from the products and towards the customer

Packaging * Move to "display ready" trays minimizes stocking and zone recovery labor

* Selective use of gravity-fed or spring-loaded shelving keeps products organized

Information Technology * Interlock scanners provide extra security

* All PCs are fully imaged to increase functionality and reduce number needed on sales floor

* Wireless (RF) technology on PCs increases flexibility

But, as Lepley noted, M2 is more than just an evolution in marketing and merchandising: "To make it a practical solution that Office Depot could roll out as our new store format or utilize as part of our remodel program, M2 had to demonstrate efficiencies of operation."

"To justify the launch, we needed to address the financial aspects that govern retail, including costs associated with opening, maintaining and staffing a store," he said. To that end, Lepley concluded by indicating that the company made significant progress in several areas, such as:

Costs

* Remodel costs are expected to be $250,000 to $300,000 as opposed to the $350,000 to $400,000 typically associated with Office Depot remodels

* New store build-out costs are expected to be less expensive * On average, M2 remodels will have a lower incremental sales hurdle

* M2 offers a broader roll-out opportunity for the portfolio of Office Depot stores

* The modularity of the M2 format dramatically reduces the number of unique planograms as well as overall store planning complexity

Information Technology

* IT setup costs are expected to be reduced by 40% with virtually no reduction in functionality

* Annual IT maintenance costs are expected to be reduced by 45% Labor

* Reallocation of labor to value-added selling activities can positively impact conversion, average order value and overall customer satisfaction

About Office Depot

With annual sales of more than $12 billion, no one sells more office supplies to more customers in more countries than Office Depot. Founded in 1986 and headquartered in Delray Beach, Fla., the company conducts business in 23 countries and employs nearly 50,000 people worldwide.

Office Depot is a leader in every distribution channel -- from retail stores and contract delivery to catalogs and e-commerce. The company is the world``s number three online retailer -- generating $2.6B in sales for FY``03. In North America, Office Depot has 900 retail stores in addition to a national business-to-business delivery network supported by 22 delivery centers, more than 60 local sales offices and 13 regional call centers. The company``s common stock is traded on the New York Stock Exchange under the symbol ODP and is included in the S&P 500 Index. Additional press information can be found at: http://mediarelations.officedepot.com/." target="_blank" rel="nofollow ugc noopener">http://mediarelations.officedepot.com/.

Website: http://mediarelations.officedepot.com

Video: http://www.prnewswire.com/mnr/officedepot/12470 Office Depot

[amorphis]

@wuscher....wo ist`n bitte die verbindung zu mlnm?

[midgbridg]

@all
und warum bitte, fällt mlnm jetzt so zurück?

[DMKE]

lohnt sich da jetzt ein einstieg, oder noch warten ..

[Isabartels]

Konnte bei 10,12€ jedenfalls nicht widerstehen!

[Isabartels]

#377
nicht alles wo Millenium draufsteht ist Millenium drin!!!

[midgbridg]

@dmke
ich denke, wir haben das tal jetzt durchwandert und es sollte wieder langsam aufwärts gehen. aber wie heisst`s so schön: alles ist möglich, aber nix is fix!

[DMKE]

sieht nicht danach aus... die scheint sich eher unter unter 10 € zu etablieren. oder gibt es schlechte news ? ich hab leider nichts in der richtung gefunden.

[midgbridg]

solltest dir mal den thread biotech-einzelwerte ansehen, da hat`s vor ein paar wochen eine diskussion hinsichtlich mlnm gegeben. schlecht daten gibt`s eigentlich nicht, obwohl zur euphorie ist gegenwärtig auch kein grund. ich glaube nicht, dass wir unter die usd 10 gehen, ich denke eher, dass einfach die bären auch hier zugeschlagen haben und es demnächst, spätestens anfang august wieder aufwärts gehen wird. aber bitte......schlage mich nicht an`s kreuz wegen dieser aussage!

[blb]

Ich vermute mal bei den nächsten Zahlen wirds ne negative Überraschung geben. Ohne Grund fällt das Teil nicht von 20$ auf 11$. Die Velcade-Umsätze letztes Quartal hatten enntäuscht...

Bleib hier aber weiterhin dabei...

[DMKE]

wann kommen die nächsten zahlen ?

[skaya]

Nächste Zahlen kommen am 22.07.

Grüße Skaya

[DMKE]

danke
da werde ich noch abwarten und wenn sie weiter fallen zuschlagen ... ich glaube kaum, dass man hier positiv überrascht sein wird.

[amorphis]

warum sollten so schlechte zahlen kommen?andere bios haben auch erheblich korrigiert...denke das ist eher ne ganz natürliche volatilität!

[nanekx]

hallo leute,
die mlnm sollte sich so langsam mal wieder erholen, seit geraumer zeit fällt sie wie ein stein...
laut " www.godmode-trader.de" ist sie jetzt aktuell bei einer unterstutzung, sollte diese durchbrochen werden, z.b.durch schlechte quartalszahlen geht der kursverfall bis zum bereich 9,3$- 10,3$ weiter....
Ich persönlich bin beim einsammeln um 1. mein durchschnittlichen einkaufspreis zu senken und 2. der ansicht bin das falls schlechte zahlen kommen sollten diese im kurs schon eingepreist sind...
Achja da fällt mir der alte kostalany ein... Nicht die Nachrichten machen Kurse sondern die Kurse machen Nachrichten

P.S. Hey urlauber bist du kräftig am einsammeln, nicht die ganze munition auf einmal verschießen

[Isabartels]

Zu 8,84€ nochmals nachgelegt!

[DMKE]

werde mir jetzt auch mal ein paar zulegen

[antonio22]

bei aktuellen 8,69€ hat die Aktie einen Nettowert von 6,70€ für 2004!! Das heißt wir haben hier 2 € Differenz für die Phantasie die in einem Weltunternehmen steckt. Kaufen und liegenlassen. Kosto würde sich freuen.
Oder???

[stiffmaster]

kommen heute nicht auch die zahlen???

wenn ja, wann werden diese veröffentlicht???


danke im voraus
stiff

[Isabartels]

Sind schon einige zeit draussen. Sind meiner Meinung nach gut!

[elimu]

Im zweiten Quartal 2004 beträgt der Nettoverlust 18 Cents je Aktie gegenüber dem Vorjahreszeitraum von 36 Cents.
Die Erlöse erhöhten sich von $121,7 Mio (Vj) auf $145,3 Mio.

Gruß elimu

[DMKE]

zahlen sind gut.
würde immer noch mit dem kaufen warten. der gesamtmarkt könnte noch einmal deftig abschmieren.

[midgbridg]

der umsatz ist auch gut und das gegen den strom. ob`s die nochmals günstiger geben wird?

[Isabartels]

Also ich glaube es ist jetzt gut. Immerhin hat sie in den letzten Wochen fast 50% verloren und steht jetzt auf einem Niveau als es z.B. velcade noch nicht gab. Ich werde nochmals kaufen und mich dann von kleineren eventzellen Rücksetzern nicht irritieren lassen. Mittelfristig ist ein jetziger Kauf auf alle Fälle ein Gewinn!!!

[DMKE]

keine frage, das ding ist mittelfristig ein kauf wert bei den kursen.

[blb]

Zahlen zwar nicht überragend, aber gut. Werd noch nicht nachkaufen, will erst mal abwarten was das Teil die nächsten Tage/Wochen so macht...
Mit dem Kaufen und Liegenlassen bei der Cashbasis macht man aber bestimmt nichts falsch...

[Isabartels]

Nochmal zu 9,0€ gekauft.

[Isabartels]

23.07. 15:29
Gene Logic kauft Technologie von Millennium
(©BörseGo - http://www.boerse-go.de)

Gene Logic vermeldet die Akquisition eines Technologieprogrammes zusammen mit einem zugehörigen Team von Wissenschaftlern von Millennium Pharmaceuticals. Gene Logic will die Technologie in die eigenen Kerntechnologien integrieren, um das eigene Angebot zu festigen. Gegen Gebühren, Meilensteinzahlungen und Lizenzgebühren wird Gene Logic für Millennium die neue Technologie einsetzen, um den Millennium-Wirkstoff MLN4760 zu ertesten. Sollten die Anstrengungen von Gene Logic von Erfolg gekrönt sein, so will Millennium den Wirkstoff wieder in seine Entwicklungspipeline aufnehmen, was zu einer Meilensteinzahlungen und weiteren Erlösen für Gene Logic führen würde. Über finanzielle Details vereinbarten die beiden Parteien Stillschweigen. Die Gene Logic Aktie verliert vorbörslich um 5.41% auf $3.50.

[Isabartels]

EW - BTK (Biotechs): Realistische Bodenbildungschance



Bislang wurden auf der Short-Seite bereits zwei Abwärtswellen ausgebildet. Es handelt sich jeweils um eine Impulswelle, so dass zusammengesetzt eine Zigzag-Korrektur unterstellt werden kann, zumal die Welle B (überschießendes Flat bis 525) unterhalb des 50%-Retracements geblieben ist.

Wenn man zudem sieht, dass die laufende Welle C das Idealziel 450 Punkte (100%-Ausdehnung) fast erreicht hat, steht für die nächsten Wochen und Monate eigentlich eine Aufwärtsbewegung bevor.

[jm78]

Mkt. Kap.
in Mrd. $ 3,36 Mittlerer Marktwert Mit einer Marktkapitalisierung zwischen $1 & $5 Mrd., ist MILLENNIUM PHARMACEUTICALS ein mittel kapitalisierter Titel.
revid. Gew.
Prognose



Analysten neutral, zuvor negativ (seit 14. September 2003) Die Gewinnprognosen pro Aktie haben sich in den letzten 7 Wochen nicht wesentlich verändert (Veränderungen zwischen +1% bis -1% werden als neutral betrachtet). Das letzte signifikante Analystensignal war negativ und hat am 14. September 2003 bei einem Kurs von USD 15,24 eingesetzt.
Bewert.

Stark überbewertet Auf Basis des Wachstumspotentials und anderer Messwerte erscheint der Kurs zur Zeit wesentlich zu hoch.
Wachstum
/ KGV -0,46 Unternehmen in Schwierigkeiten Ein negatives "Verhältnis zwischen Wachstum plus geschätzte Dividende und Kurs-Gewinn Zahl" zeigt an, dass sich entweder das vorhergesagte Wachstum verlangsamt (negatives jährliches Wachstum) oder die Finanzanalysten einen Verlust (negatives PE) erwarten.
KGV -778,09 Verlust vorhergesagt Der erwartete PE-Wert (Kurs-Gewinn-Verhältnis) ist negativ: Die Finanzanalysten erwarten einen Verlust.
langfrist.
Wachstum -357,9% Wachstum heute bis 2006 p.a.

Auszüge aus der Analyse von Consors.
Was meint Ihr dazu?

[jm78]

Liebe begeisterte hobbyanalysten und Millenniumaktionäre,ich habe seit Jahren die Millennium im Depot.
Ich habe sehr sehr viel Geld verloren weil ich total naiv war und mich für einen coolen Zocker gehalten habe.
Dieser Wert ist eine absolute Niete und nur Schwachköpfe glauben noch an die Story von VALCADE. Versucht mal mit diesem Unternehmen in Kontakt zu treten, dann seht ihr mit wem ihr es zu tun habt. Nehmt bitte euer Geld aus diesem Lügenunternehmen und haltet euch an deutsche Unternehmen wie Mohrphosys oder Medigene. Millennium Pharma gehöret seit fast 4 Jahren zu den top verlierern im gesamten biotechsektor, weil dieser Wert entgegen aller Beteuerungen und Empfehlungen ohne jede Substanz ist.

Ich möchte niemandem zu nahe treten oder miesmachen , ich möchte nur meine eigenen Erfahrungen weitergeben um vielleicht jemanden vor meinem großen Fehler zu bewahren.
Jüngste Nachrichten geben mir recht un die Aktie kann sehr leicht wieder bei 6 $ landen.
Gruß JM 78

[blb]

Du bist ein Schwafler. Is ja gut, ich hab Medigene auch, aber MLNM ist mindestens zwei Kaliber größer. Als stell hier nicht so blöde Vergleiche auf.

MLNM hat fett Cash, die können noch ein paar Jährchen rumforschen. Klar ist der Kursverlauf mehr als enttäuschend, aber in ein paar Jahren wird das Ding um einiges höher stehen...

[Isabartels]

Na ja, so fett cash haben die auch nicht mehr. Kann mich noch erinnern als die 1,9 Milliarden$ als Cash auswiesen. Beim letzten Quartalsbericht glaube ich waren es noch knapp 600 Millionen. Und wenn Du Dir den Cashverbrauch anschaust, dann sind das für mich noch 2-3 jahre ohne Kapitalerhöhung. Also wenn die nicht bald ordentliche Einnahmen machen werden die wohl zum wiederholten Male neue Aktien rausgeben müssen.
Isa

[blb]

@Isabartels: Die wollen ja 2006 die Gewinnzone erreichen. Mal schaun ,ob sies schaffen...

[Isabartels]

Jedenfalls wäre beim Kurs doch mal eine ordentliche technische Reaktion fällig oder?
isa

[jm78]

Wenn Sie aggresiv und arrogant und dumm auf ehrlich gemeinte Beiträge reagieren wird die Millennium auch nicht besser. Seit Jahren reden viele Leute ähnliches Zeug daher wie Sie. Nennen Sie mir einen Wert der in den letzten 3 Monate ähnlich stark verloren hat trotz so einer angeblich guten Story (Valcade) wie Millennium.
Ps
oder sollen hier nur blauäugige Beiträge (wie Ihre geschrieben werden)
MfG
JM78

[ipollit]

@jm78

ein bischen Objektivität täte gut... du kannst eine MLNM nicht mit MDG oder MOR vergleichen - wobei Medigene von 135 EUR und MOR von 440 EUR kommt...

MLNM macht noch Verluste anders als z.B. Amgen oder Genentech... daher brechen sie in eine für Biotechs schlechten Zeit auch stärker ein als diese. Der NBI hat in den letzten 3 Monaten 17,26% verloren... MLNM 25,75%

ich kann dir problemlos viele goße NBI-Werte nennen, die in den letzten Monaten trotz ausichtsreicher Medikamente in der Pipeline soviel oder mehr wie MLNM verloren haben:

ONXX -42,19%
LGND -40,20%
REGN -44,18%
PDLI -25,29%
NPSP -25,98%
NKTR -36,97%
NABI -47,46%

... so wie es runter geht, geht es auch wieder rauf... Velcade wird meines Wissens noch in vielen Indikationen getestet.

mfg ipollit

[Boersenkrieger]

@jm78

die fonds wollen uns abschütteln drum sinkt das teil... hab mille bei 99 € gekauft und bei 9 € massiv nachgekauft vor einiger zeit wo die milles runtergeprügelt wurden wie jetzt... ich erwarte noch so 8 $ rum dann bretzel ich nochmal volle kanne rein und bin bei 18 $ kurswert voll fett im gewinn... dann passt das schon !!! mille ist einfach ne kultige aktie da führt kein weg dran vorbei... du bruder der sonne du !!! ...spätestens 2006 wenn die gewinnzone erreicht wird brechen alle dämme un viele gläubige werden zu mille-millionäre ...ich bin dabei !!!! un du heisst klaus !!! oder kennste den nicht: Alle Kinder schauen zum brennenden Haus, nur Klaus schaut raus! ... oder wie wär´s mit Alle Kinder haben Mille nur jm78 braucht ne Brille muaaaaaaaaaaaaahahahahaaaaaaaaaa also hau dir die milles wieder rein un komm an bord, dann machen wir 2006 ne millionärsparty ey

[Boersenkrieger]

und wenn ihr´s noch nicht kapiert habt dann hilft nur noch:
Alle Kinder gehen über die Strasse, nur Rolf klebt am Golf!



Alle Kinder schauen zum brennenden Haus, nur Klaus schaut raus!



Alle Kinder tragen einen Badeanzug, ausser Simone, die geht oben ohne!



Allen Kindern steht das Wasser bis zum Hals ausser Reiner, der war kleiner!



Alle Kinder gehen zur Schule ausser Frank, der macht krank!



Alle Kinder springen über die Schlucht, nur nicht Peter, dem fehlt 1 Meter!



Alle Kinder gehen über die Wiese, nur nicht Hildegard, die klebt am Stacheldraht!



Alle Kinder habens begriffen ausser Sepp, der ist der Depp!



Alle Jungs lieben junge Mädchen ausser Thomas, der steht auf Omas!



Alle Kinder gehen neben dem Sarg ausser Hagen, der wird getragen!



Alle Kinder sind schon in der Berghütte, nur nicht Sabine, die steckt in einer Lawine!



Alle Kinder spielen im Wasser, nur nicht Kai, den jagt ein Hai!

[Rotrenner]

Ich dachte hier würden ernsthafte Gespräche über
Biotechaktien geführt,ich wußte nicht das wier hier
im Kindergarten sind.

[Boersenkrieger]

na also geht doch ! mille fett im plus ! die talfahrt ist zu ende... 20 $ bis jahresende

[blb]

Hab nir gestern nen Pack dazugekauft. Von mir aus kanns jetzt wieder hoch gehn!

[blb]

Na das sieht doch gut aus!

Grüße
blb

[Isabartels]

Da gehen sie dahin, die schönen Gewinne von heute!

[Boersenkrieger]

Mille macht Millionäre !!!
Der Abwärtstrend ist gebrochen... jetzt geht es schnell in Richtung 15 und dann 20... danach wäre der Weg nach oben endgültig frei und die Rakete kann abheben yippie ey joooooooooooooooo

[franke66]

börsenkrieger,
du hast recht!!! auch der widerstand bei 12,00-12,15 ist heute wohl gebrochen!! jetzt kann es wirklich bergauf gehen... gutes gelingen#

gruss
franke

[midgbridg]

Zacks.com Announces That Nadine Wong Highlights the Following Stock: Millenium Pharmaceuticals



CHICAGO--(BUSINESS WIRE)--Sept. 28, 2004--Nadine Wong is raising sales and earnings estimates for one cancer company, and explains why she expects 2005 to turn to profitability with upside from a massive pipeline. Read about Millenium Pharmaceuticals (NASDAQ:MLNM). Nadine Wong is editor of the Biotech Stock Report newsletter. Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84

Here are the highlights from the Featured Expert column:

Millennium (NASDAQ:MLNM)

We`ve revised Millennium`s target price from $15 to $17 based on Velcade sales reaccelerating in the late part of 2004 and low Integrilin expectations that are now priced into the stock. Millennium markets Velcade for the treatment of relapsed/refractory multiple myeloma, which represents 10% of all malignant blood cancers, and Integrilin, the leading GP IIb-IIIa inhibitor for patients with severe cardiovascular disease. The company also has a pipeline of 10 novel drug candidates in early stages of clinical development.

Velcade sales should be bolstered by increased second-line multiple myeloma penetration following the positive APEX data announced at the June 2004 ASCO. The trial was halted one year early after an independent data monitoring committee concluded in an interim analysis that Velcade showed a statistically significant improvement in time-to-disease progression compared to high-dose dexamethasone. Based on these results, Millennium is expected to file an sNDA with the FDA for an expanded label in second-line multiple myeloma shortly.

Millennium is developing Velcade for other indications including non-Hodgkin`s lymphoma (NHL), non-small cell lung cancer (NSCLC), and other solid tumors including ovarian, prostate and breast cancers. In total, the company expects to have 80 trials in progress by year-end. Although Velcade has the potential to become a broad-spectrum anticancer agent, Velcade`s strength lies in treating blood cancers. However, to expand Velcade use in other types of cancer, it needs to prove its full potential with additional data such as treating solid tumors. Potential other blood cancers include refractory follicular and mantle cell NHL. The company should decide to pursue a pivotal trial in NHL by early 2005 as well as a decision for a pivotal NSCLC trial by late 2004. While early efficacy signals in NHL and NSCLC were positive, results in colorectal cancer and chronic lymphocytic leukemia have been negative.

Read Nadine Wong`s commentary, along with review of Millenium`s entire product pipeline, by clicking: http://at.zacks.com/?id=85
SOURCE: Zacks.com

[7911793]

Hi Leute,

habe einen Artikel über diesen Wert gelesen und seit dem Interessiere ich mich für die Aktie. Eigentlich wollte ich Lufthansa kaufen, da ich auf einen fallenden Ölpreis spekulieren möchte, die sind aber heute um 3% gestiegen.
Wie seht ihr das aktuelle Niveau? Melden die demnächst Zahlen oder so?

Gruß

Timo

[midgbridg]

UPDATE: Millennium Seeks Approval For Earlier Velcade Use



By Hollister H. Hovey, Of DOW JONES NEWSWIRES

NEW YORK (Dow Jones)--If the Food and Drug Administration approves Millennium Pharmaceuticals Inc.`s (MLNM) cancer drug Velcade for use as a second treatment of a rare blood cancer, it would double the approved patient population, the company`s head of cancer research said.

The company said on Wednesday it filed for FDA approval of the drug as a second therapy of the condition known as multiple myeloma. The FDA approved Velcade last May as a last-ditch treatment for the disease. The label only recommended that patients who failed two prior treatments receive the drug.

Speaking in an interview with Dow Jones Newswires, Dr. David Schenkein, vice president, clinical oncology development at Millennium, said that with the current label, Velcade is approved to treat one-fourth of the patient population. Receiving approval as a second treatment would add another 20,000 to 25,000 patients to that group.

This application for an expanded approval is based on data from a large confirmatory trial, meant to show the drug can work earlier in the treatment process.

In the study, announced at a cancer meeting in June, Velcade far surpassed the company`s goal in delaying the time patients suffering from the late stages of this blood cancer got worse.

The good results weren`t a complete surprise when they were fully announced at that cancer meeting. The company stopped the late-stage trial a year early in December after the results were positive enough to make it immoral to keep the drug from the patients in the control arm. However, at the time, the company didn`t give the specific data.

That said, physicians have known about the data in this second-line setting for some time. Schenkein said the company has seen physicians prescribing Velcade "off label" to their patients in this earlier setting.

While the company isn`t allowed to promote in that setting and doesn`t, Schenkein said, about 10% to 20% of patients with multiple myeloma are receiving it as part of their second treatment. "There is some second line use . . . but this (approval) would significantly increase the pool of patients," he said.

Millennium expects the FDA to decide whether to accept this application within 60 days. Should the filing receive priority review status, a regulatory decision on the approval of the filing would be expected within six months. A regulatory decision would be expected within 10 months through a standard review.

Velcade, the first of a new class of medicines called proteasome inhibitors, is the first treatment in more than a decade to be approved for patients with multiple myeloma.

The company is conducting a number of early stage trials of Velcade as a first treatment for multiple myeloma. By the end of the fourth quarter or in the first quarter, the company plans to start multiple late-stage studies of the drug in the first-line setting.

Velcade is being co-developed by Millennium and Johnson & Johnson (JNJ). Millennium is responsible for commercialization of the drug in the U.S. and J&J are responsible for commercialization in Europe and the rest of the world.

-By Hollister H. Hovey, Dow Jones Newswires, 201-938-5287; hollister.hovey@ dowjones.com


Dow Jones Newswires
09-29-040950ET
Copyright (C) 2004 Dow Jones & Company, Inc. All Rights Reserved.

[js200]

10/01/2004 (11:01 ET) MLNM: Filed New Form 4 - Edgar
09/29/2004 (08:30 ET) StreetInsider Alert for MLNM - Street Insider
09/29/2004 (08:28 ET) MLNM: Files New Drug App to FDA for VELCADE® - Knobias
09/29/2004 (08:25 ET) Millennium Files Supplemental New Drug Application for VELCADE(R) (Bortezomib) for Injection for the Treatment of Patients with Second-Line Multiple Myeloma - PR Newswire
09/28/2004 (06:00 ET) Zacks.com Announces That Nadine Wong Highlights the Following Stock: Millenium Pharmaceuticals - Business Wire

JS200

[midgbridg]

Millennium Pharma, XOMA Restructure Collaboration Pact



CAMBRIDGE, Mass. (Dow Jones)--Millennium Pharmaceuticals Inc. (MLMN) and XOMA Ltd. (XOMA) have restructured their agreement related to the collaboration for the development of MLN2222, now being investigated in a phase I clinical trial for Coronary Artery Bypass Graft (CABG) surgery.

In a news release, Millennium and XOMA said the agreement supersedes the companies` previous development and investment agreements, established in November 2001.

Key elements of the new, restructured relationship include:

-XOMA will be responsible for development work and expenses related to MLN2222 through completion of the ongoing phase I clinical trial. Millennium will assume responsibility for all subsequent development work and expenses for MLN2222 at initiation of phase II testing. Under terms of the original agreement, XOMA was responsible for development work and expenses through phase II testing;

-XOMA will continue to provide quantities of bulk drug substance requested by Millennium at the expense of Millennium for phase II trials;

-XOMA will be entitled to receive an undisclosed royalty on future net sales of MLN2222, as well as payments related to the achievement of clinical and regulatory milestones. Under terms of the original agreement, XOMA had the option of either entering into a cost and profit-sharing arrangement through phase III clinical trials and commercialization or a milestone and royalty arrangement;

-The investment agreement between Millennium and XOMA is terminated and there will be no further issuance of XOMA common shares to Millennium.

Millennium and XOMA are biopharmaceutical companies.

Company Web Sites: http://www.mlmn.com and http://www.xoma.com

-Wendy Tsau, Dow Jones Newswires; 416-306-2100
Visit http://djnewswires.ar.wilink.com/?link=XOMA or call 1-888-301-0513
Dow Jones Newswires
10-12-040921ET
Copyright (C) 2004 Dow Jones & Company, Inc. All Rights Reserved.

[midgbridg]

Millennium Pharmaceuticals Uncovers Genetic Clues to Rheumatoid Arthritis



-- First data from one of the world`s largest genetic and clinical rheumatoid

arthritis patient registry reveal molecular markers for risk, severity and

treatment response --
CAMBRIDGE, Mass., Oct. 18 /PRNewswire-FirstCall/ -- Researchers at Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) and the Brigham and Women`s Hospital today presented results from seven studies in rheumatoid arthritis (RA) that could pave the way for the development of more effective, less toxic therapies that are custom-designed for each patient based on his or her genetic make-up. The research, which was shared during the American College of Rheumatology meeting in San Antonio, Texas, offers new insight into genetic clues to better understand RA risk, underlying disease mechanisms, and response to treatment.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"The research presented at ACR brings Millennium one step closer to fulfilling our goal of delivering personalized medicine for patients with rheumatoid arthritis," said Robert Tepper, M.D., president of research and development, Millennium. "The study findings, based on data from our significant patient registry, could one day help medical professionals predict who will develop RA, how severe their disease may become, which patients will respond best to which treatments, and how aggressively to treat them -- based on each patient`s unique genetic makeup."

"These are exciting discoveries that we can now put to use in our development and discovery efforts, such as incorporating newly-identified biomarkers for treatment response into clinical trials designed to identify the right medicine for the right patients," said Ronenn Roubenoff, M.D., M.H.S., senior director, molecular medicine, Millennium.

The studies are made possible by the rheumatoid arthritis patient registry Millennium established with Brigham and Women`s Hospital in Boston, Mass. in 2002. The registry, believed to be one of the world`s largest RA cohort for the evaluation of genetic and proteomic data, is profiling and prospectively following approximately 1,000 patients with RA for a period of five years. Designed to provide a full understanding of genetic backgrounds, treatment responses and outcomes of the patients, the data generated from the registry serve to identify molecular markers and clinical characteristics that will allow for better disease diagnosis and improved prediction of patients` responses to drug therapy and outcomes.

New Markers Predict Treatment Response, Disease Severity

In total, the research provides new insight into RA risk, disease severity and treatment response. Two of the studies were shared as oral presentations. In the first study, led by Elena Izmailova, Ph.D., scientist, inflammation discovery, Millennium, the researchers identified biomarkers that indicate whether treatment with disease modifying anti-rheumatic drugs (DMARD) is working. They found that elevated serum proteins MMP3 and TNFR1 correlated with physician global assessment scores (PGA) and the number of painful and swollen joints -- clinical criteria for response established by the American College of Rheumatology. The second study, led by Alex Parker, Ph.D., associate director of molecular medicine, Millennium, found that 15 of the 30 known risk and severity genes for RA work in aggregate to account for most or all or the total estimated genetic risk of developing RA.

Other findings from the research teams included:
* Development of a biomarker set including MMP2 and MMP3 levels, HLA
genotype, and the DQB1 mRNA expression profile which predicted RA
patients with higher disease activity;
* A combination of clinical and genetic variables which might predict
patients at risk for erosive disease;
* A combination of clinical and genetic variables which might distinguish
RA patients who have achieved remission; and
* Patients in remission and those with active disease have 28
differentially expressed genes when they are HLA-DRB1 SE negative, a
well-established genetic marker for RA.

"This research sheds light on many pieces of the genetic RA puzzle and will help us improve the diagnosis and treatment of the disease," said Michael E. Weinblatt, M.D., one of the lead investigators of the study and co-director of Clinical Rheumatology at Brigham and Women`s Hospital. "RA is a difficult disease to treat because without knowledge of genetic signatures, our current approach is one of trial and error to determine which patients will benefit most from available therapies."

About Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic, progressive inflammatory disease of the articular joints that results in significant pain, stiffness and swelling and leads to degradation of the joint tissue. RA can cause permanent damage and deformities to joints, resulting in loss of function and ultimately leading to joint replacement surgery in some cases. In addition, some RA patients develop extra-articular manifestations such as rheumatoid nodules, interstitial lung disease and vasculitis.

According to the Arthritis Foundation, RA affects 2.1 million Americans and is about three times more common in women than men. The disease has a significant socioeconomic impact with medical costs and indirect expenses due to lost wages for RA estimated to be over $3 billion per year. In addition, mortality rates for people with RA are double those of the general population. The cause of RA is not known. However, it is believed that RA is an autoimmune disease where the body`s natural immune system attacks healthy joint tissue causing inflammation and subsequent joint damage.

About The Company

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular, and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, the Company is seeking to develop breakthrough products.

This press release contains "forward-looking statements," including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various important risks may cause the Company`s actual results to differ materially from the results indicated by these forward- looking statements, including: adverse results in our drug discovery and clinical development programs; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of VELCADE(R) (bortezomib) for Injection and INTEGRILIN(R) (eptifibatide) Injection; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editor`s Note: This release is available on Media section of Millennium website at http://www.millennium.com


Contact:
Adriana Jenkins (media) Gina Price Nugent (investors)
[phone] [phone]


SOURCE Millennium Pharmaceuticals, Inc.
-0- 10/18/2004
/CONTACT: Adriana Jenkins, [phone], or Gina Price Nugent, +1-617-
551-3611 both of Millennium Pharmaceuticals, Inc./
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, [e-mail] /
/Company News On-Call: http://www.prnewswire.com/comp/114562.html/
/Web site: http://www.millennium.com/
(MLNM)

[js200]

New Data Reveal Clinical Differences Between INTEGRILIN (R) (Eptifibatide) Injection and Bivalirudin
via COMTEX

November 6, 2004

-- PROTECT Study Shows INTEGRILIN Achieved Significantly Better Flow to the
Heart Muscle Resulting in Better Clinical Outcomes --

NEW ORLEANS, Nov 6, 2004 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced results of the PROTECT trial, which was designed to compare the glycoprotein (GP) IIb-IIIa inhibitor INTEGRILIN with the direct thrombin inhibitor bivalirudin in high risk patients using clinical and physiologic endpoints. On the physiologic primary endpoint of coronary flow reserve (CFR), a measure of coronary artery flow, adjusted as pre-specified, the primary endpoint favored bivalirudin but was not statistically significant when imputed as pre-specified for abrupt closure, no reflow, and thrombotic bail-out during percutaneous coronary intervention (PCI) (p=0.036 by intent-to-treat; p=0.13 imputed, 1.43 bivalirudin versus 1.33 pooled INTEGRILIN, respectively). However, INTEGRILIN showed a statistically significant (p=0.048, adjusted for baseline as pre-specified) improvement in myocardial perfusion (a measure of blood flow to the heart muscle) compared to bivalirudin. Myocardial perfusion has been shown to correlate highly with improved survival.(1)

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"A key finding from this study is that better cardiac blood flow resulted in better clinical outcomes. While the overwhelming majority of patients (over 93%) left the cath lab with normal flow in the artery, INTEGRILIN significantly improved flow downstream into the heart muscle itself, as measured by TIMI Myocardial Perfusion Grade (TMPG)," said C. Michael Gibson, MS, MD, principal investigator in the PROTECT study and Associate Chief of Cardiology in the Cardiovascular Division of Beth Israel Hospital at Harvard Medical School. "This study adds to the growing body of scientific literature linking improved blood flow into the heart muscle with improved clinical outcomes. Further, this study highlights the importance of arriving to the cath lab with good flow to the muscle."

Previous studies have shown up to a seven-fold increase in 30-day mortality following heart attack in patients whose flow in the artery was normal but whose myocardial perfusion was rated TMPG 0 or 1, versus those who demonstrated normal TMPG 3.(2) TMPG measurement shows how effectively blood flow is restored to the heart muscle following therapeutic and mechanical intervention. In the PROTECT study, when compared to those acute coronary syndrome (ACS) patients who received bivalirudin, 13.8% more INTEGRILIN- treated patients achieved normal perfusion TMPG 3, a statistically significant benefit (p=0.048 adjusted for baseline as pre-specified).

In addition, in the PROTECT study, other endpoints showed that among patients with ischemia, INTEGRILIN(R) (eptifibatide) Injection showed a statistically significant reduction in median duration of ischemia in the first 24 hours post-PCI versus bivalirudin (36 minutes versus 169 minutes, p=0.013). Furthermore, measurement of troponin and CK-MB, important protein and enzymatic markers of cardiac damage, directionally showed lower peak rises among those patients who received INTEGRILIN. In the subset of the highest risk ACS patients, those with inadequate blood flow to the heart muscle upon arrival in the catheterization lab (TMPG 0, 1 or 2), high troponin levels at baseline correlated significantly with impaired blood flow. Post-PCI, patients who received INTEGRILIN in this sub-group had a significantly lower elevation in troponin and CK-MB post-PCI versus those who received bivalirudin (3.5 vs. 5.3, p=0.04, 2.7 vs. 10, p=0.009, respectively), signifying a possible reduction in heart muscle damage with use of INTEGRILIN.

Across all patient groups, only 18 of the 857 patients (2%), experienced any TIMI major or minor bleeding event. In the major safety endpoint for the trial there was no reported TIMI major bleeding in the INTEGRILIN arm with UFH or in the bivalirudin arm. There was a 1.5% incidence of TIMI major bleeding in the INTEGRILIN arm with enoxaparin. TIMI minor bleeding was 2.5% in the pooled INTEGRILIN arms compared to 0.4% in the bivalirudin arm (p=0.027).

"All clinical efficacy outcome measures in this trial favored INTEGRILIN over bivalirudin," said Nancy Simonian, MD, senior vice president, clinical development at Millennium Pharmaceuticals, Inc. "This study reinforces the need for early and aggressive use of INTEGRILIN in ACS patients to preserve the heart muscle and protect against future cardiac events."

About PROTECT

(Randomized Trial to Evaluate the Relative PROTECTion Against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia Among Anti-Platelet and Anti-Thrombotic Agents) PROTECT was a multi-center, open-label, randomized trial involving 857 high-risk patients in over 100 sites in North America. The primary objective of the PROTECT-TIMI 30 trial was to compare the efficacy and safety of the glycoprotein IIb-IIIa inhibitor INTEGRILIN (with either unfractionated heparin, UFH, or enoxaparin) to the direct thrombin inhibitor, bivalirudin alone in patients undergoing PCI with unstable angina (UA) or non- ST-segment elevation myocardial infarction (NSTEMI), also known as acute coronary syndromes (ACS). These agents were assessed for efficacy in the trial by examining the delivery of blood flow both through the artery, as measured by coronary flow reserve (CFR), and directly to the heart muscle, as measured by TIMI myocardial perfusion grade (TMPG), as well as for safety measured by bleeding events.

PROTECT results were announced during the Texas Heart Institute Symposium on Saturday, November 6, in conjunction with the American Heart Association Scientific Sessions Symposium 2004. This event is not part of the official Scientific Sessions 2004 as planned by the AHA Committee on Scientific Sessions Program.

About INTEGRILIN(R) (eptifibatide) Injection

INTEGRILIN is indicated for the treatment of patients with acute coronary syndrome (unstable angina/non-ST-segment myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). It is also indicated in the United States for the treatment of patients at time of PCI, including in patients undergoing intracoronary stenting.

INTEGRILIN is contraindicated in patients with a history of bleeding diathesis, or evidence of abnormal bleeding within the previous 30 days; severe hypertension (systolic blood pressure greater than 200 mm Hg or diastolic blood pressure greater than 110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within the preceding six weeks; history of stroke within 30 days, or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb-IIIa inhibitor; dependency on renal dialysis; or known hypersensitivity to any component of the product.

Bleeding is the most common complication encountered during INTEGRILIN therapy. In the registration trials, the majority of excess major bleeding events were localized at the femoral artery access site. Oropharyngeal, genitourinary, gastrointestinal and retroperitoneal bleeding were also seen more commonly with INTEGRILIN compared to placebo.

For inquiries about INTEGRILIN, patients and physicians can call 1-(888)-267-4MED.

INTEGRILIN is co-promoted and co-developed by Millennium Pharmaceuticals, Inc. and Schering-Plough Corporation in the U.S.

About The Company

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular, and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, the Company is seeking to develop breakthrough products.

This press release contains "forward-looking statements," including statements about the Company`s growth and discovery and development of products. Various important risks may cause the Company`s actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company`s dependence upon strategic alliance partners to develop and commercialize products and services based on the Company`s work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from the Company`s development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company`s products; government and third party reimbursement rates; the commercial success of INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

(1) Gibson et.al. Circulation 2000;101:125-130 (2) Gibson et.al. Circulation 2004;109:3096-3105 Contacts: Lisa Adler (media) [phone] Gina Price Nugent (investor) [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Media - Lisa Adler, [phone], or Investors - Gina Price Nugent, [phone], both for Millennium Pharmaceuticals, Inc. /Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO /Company News On-Call: http://www.prnewswire.com/comp/114562.html http://www.millennium.com

Copyright (C) 2004 PR Newswire. All rights reserved.

[grafbibi]

Heute geht es nach Norden
vor Börse 13,35$

[midgbridg]

New Clinical Trial Data Showed the Addition of INTEGRILIN(R) (Eptifibatide) Injection Achieved Superior Platelet Inhibition and Less Heart Muscle Damage When Compared to a Commonly Used Antiplatelet Regimen Alone



NEW ORLEANS, Nov. 8 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) has announced that in the CLEAR Platelets (Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets) trial, the addition of INTEGRILIN, a potent glycoprotein (GP) IIb-IIIa inhibitor, to a commonly used antiplatelet regimen provided superior platelet inhibition and prevention of heart muscle damage associated with elective coronary stenting in the low-to-moderate risk study patients. Damage to heart muscle has been linked to mortality.(1) Results from CLEAR Platelets were presented on Sunday, November 7, 2004 at the 2004 American Heart Association Scientific Sessions meeting in New Orleans.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"The CLEAR Platelets study supports the use of INTEGRILIN as a critical component in acute cardiovascular care. The patients in this study are representative of a real-world population that is often not pretreated with clopidogrel or other agents. Their underlying conditions include risk factors such as hypertension, smoking and diabetes," said Paul Gurbel, MD, principal investigator in the CLEAR Platelets study, director of Sinai Center for Thrombosis Research at Sinai Hospital of Baltimore and associate professor at Johns Hopkins University, Baltimore. "Our findings show that the addition of INTEGRILIN with either a high or standard dose of clopidogrel provided an optimal platelet inhibition strategy, and were associated with the lowest incidence of heart muscle damage, also known as myocardial necrosis."

In the study, patients receiving the combination of INTEGRILIN and clopidogrel had the lowest platelet reactivity over 24 hours compared to patients receiving clopidogrel alone (p<0.001). The combined INTEGRILIN and clopidogrel group also had the lowest release of cardiac markers (p<0.05). The incremental increases in cardiac marker release in patients with higher levels of post-treatment platelet reactivity lend strong support to the concept that reactive platelets play a central role in the development of post-percutaneous coronary intervention (PCI) heart muscle damage. Additionally, no significant differences in bleeding were observed among groups.

"Compelling new data in the CLEAR Platelets study, presented in conjunction with data from the PROTECT study at the AHA meeting, add to the cumulative evidence that potent early platelet inhibition with INTEGRILIN and appropriate doses of other anticoagulants plays a critical role in the aggressive management of patients to prevent long-term cardiac damage," said Arthur Hiller, senior vice president, sales and marketing at Millennium.

CLEAR Platelets, a randomized, open-label trial was designed to evaluate whether the addition of INTEGRILIN to a strategy of high (600mg) or standard (300mg) dosages of clopidogrel-based regimens in patients undergoing elective coronary stenting was superior to the administration of clopidogrel alone in achieving adequate platelet inhibition and preventing heart muscle damage. CLEAR Platelets is the first prospective study ever conducted to investigate the effect of adding INTEGRILIN to varying clopidogrel-dosing regimens, as well as, the relation of platelet inhibition to heart muscle damage associated with elective coronary stenting. All patients (n=120) received daily aspirin (325mg) and heparin administered in the catheterization laboratory.

About INTEGRILIN(R) (eptifibatide) Injection

INTEGRILIN is indicated for the treatment of patients with acute coronary syndrome (unstable angina/non-ST-segment myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). It is also indicated in the United States for the treatment of patients at time of PCI, including in patients undergoing intracoronary stenting.

INTEGRILIN is contraindicated in patients with a history of bleeding diathesis, or evidence of abnormal bleeding within the previous 30 days; severe hypertension (systolic blood pressure greater than 200 mm Hg or diastolic blood pressure greater than 110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within the preceding six weeks; history of stroke within 30 days, or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb-IIIa inhibitor; dependency on renal dialysis; or known hypersensitivity to any component of the product.

Bleeding is the most common complication encountered during INTEGRILIN therapy. In the registration trials, the majority of excess major bleeding events were localized at the femoral artery access site. Oropharyngeal, genitourinary, gastrointestinal and retroperitoneal bleeding were also seen more commonly with INTEGRILIN compared to placebo.

For inquiries about INTEGRILIN, patients and physicians can call 1-(888)-267-4MED.

INTEGRILIN is co-promoted and co-developed by Millennium Pharmaceuticals, Inc. and Schering-Plough Corporation in the U.S.

About The Company

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibatide) INJECTION, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular, and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, the Company is seeking to develop breakthrough products.

This press release contains "forward-looking statements," including statements about the Company`s growth and discovery and development of products. Various important risks may cause the Company`s actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company`s dependence upon strategic alliance partners to develop and commercialize products and services based on the Company`s work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from the Company`s development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company`s products; government and third party reimbursement rates; the commercial success of INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

(1) Newby LK et. al. Circulation 1998, 98: 1853-1859.

Contacts:
Lisa Adler (media)
[phone]
Gina Price Nugent (investor)
[phone]

SOURCE Millennium Pharmaceuticals
-0- 11/08/2004
/NOTE TO EDITORS: This release is available under the Media section on the
Company`s website at http://www.millennium.com/" target="_blank" rel="nofollow ugc noopener">http://www.millennium.com/
/CONTACT: Media: Lisa Adler, [phone], or Investor: Gina Price
Nugent, [phone], both of Millennium Pharmaceuticals/
/Company News On-Call: http://www.prnewswire.com/comp/114562.html" target="_blank" rel="nofollow ugc noopener">http://www.prnewswire.com/comp/114562.html /
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, [e-mail] /
/Web site: http://www.millennium.com /
(MLNM)

CO: Millennium Pharmaceuticals
ST: Louisiana
IN: HEA MTC BIO
SU: SVY

MC
-- NYM076 --
3623 11/08/200408:01 ESThttp://www.prnewswire.com

[js200]

11/19/2004 (15:54 ET) Schaeffer`s Street Chatter Highlights the Following Stocks: Millennium Pharmaceuticals, NVIDIA and Advanced Micro Devices - Business Wire
11/17/2004 (13:01 ET) Xenova shares fall on Millennium back-out - Datamonitor
11/16/2004 (09:25 ET) StreetInsider Alert for XNVA - Street Insider
11/16/2004 (08:39 ET) Xenova says Millennium to stop funding early trials on DNA targeting agent - AFX News - Europe
11/16/2004 (08:39 ET) Xenova says Millennium to stop funding early trials on DNA targeting agent - AFX News - UK

[metallix]

ich gehe bei 9,55 Eu wider rein
dann denke ich geht es wider aufwärts:

[jm78]

Hallo, ich lese in diesem Forum immer nur hoffnungsvolle oder positive Kommentare. Wieviele Leute hat dieses Papier schon in den Ruin getrieben? Hier melden sich wohl nur die kleveren Jungs zu Wort oder macht Ihr euch vieleicht was vor? Eine etwas kritischere Haltung wäre manchmal glaubhafter und hilfreicher. Wir müssen hier doch keine Werbung machen.

Gruß

JM78

[Boersenkrieger]

naja Ruin wohl nicht... da gibt´s wirklich "bessere kandidaten" meinereiner gurkt im depot bei -35% dumm rum... war mal bis auf -1% rangekommen ...rühre grad nichts an und hab das teil schon jahre... nachkaufen is nicht, da fundamental zu teuer... verkaufen auch nicht da fundamental zu aussichtsreich ...verkaufe vielleicht mal bei 20 oder so....

[blb]

@jm78: Du bist mir einer! Klar könnte das Papier besser laufen, aber in den Ruin??!! Ich lach gleich! 2006 schreiben die Gewinne, Velcade wird ein Blockbuster! Also geh mit deinen Sprüchen ins Nanotechforum!

MLNM ist und bleibt ein Basisinvestment...

Grüße
blb

[jm78]

bib, eine etwas kritischere Haltung wäre vielleicht gut. Schon seit 99 habe ich die Mille im Depot und habe seither einiges mitgemacht. Immer wieder gab es in den letzten Jahren Leute wie dich die diese SCHEISS AKTIE gut geredet haben. Ich habe 80% meines Geldes verloren weil ich mich oft von solchen Sprüchen wie deinen beeinflussen lassen habe.(BLOCKBUSTER BASISINVESTMENT) Wer sagt das? Die letzten Zahlen von Valcade sehen nicht so gut aus. Damals wollte Mille in 04 schwarze Zahlen schreiben,schon vergessen oder nie gelesen oder ? Nimmst du denn die Realität nicht war? Erzähle doch nicht immer so einen Schwachsinn und geh doch ins Träumer Forum.

[leonide]

Ich seh das persönlich nicht so kritisch, es geht doch schön voran. Könnte schneller gehen, weniger Kursrückschläge, etc. Aber wem es zu heiß ist, soll es lassen.


FDA Accepts sNDA Filing with Priority Review for VELCADE(R) (bortezomib) for Injection to Treat Second-Line Multiple Myeloma

-- Submission includes favorable survival data relative to standard therapy --

CAMBRIDGE, Mass., Dec. 1 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the U.S. Food and Drug Administration (FDA) accepted for review the Company`s supplemental New Drug Application (sNDA) and granted Priority Review designation for VELCADE for the treatment of patients with multiple myeloma who have received at least one prior therapy. The submission was based on data from the phase III APEX study that compared VELCADE to a traditional myeloma therapy, high-dose dexamethasone, which demonstrated a statistically significant survival in patients receiving VELCADE. A patient population of approximately 22,000 in the U.S. could potentially benefit from a new second-line treatment option.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Priority Review of a sNDA is granted by the FDA for a treatment that addresses an unmet medical need. The FDA expedites the approval process for such a sNDA by reducing the standard review period for the application from ten months to six months. Acceptance of the filing means the FDA has made a threshold determination that the sNDA is sufficiently complete to permit a substantive review.

"We are excited that more patients may soon have access to VELCADE earlier in their treatment where VELCADE has shown a significant improvement over a standard therapy in delaying disease progression and improved survival," said David Schenkein, M.D., vice president, clinical oncology development, Millennium. "Millennium is committed to making a difference in patients` lives, and will continue in partnership with Johnson & Johnson Pharmaceutical Research and Development L.L.C., to extensively research the benefits of VELCADE extensively across the multiple myeloma treatment paradigms as well as in other hematologic and solid tumors."

The acceptance of this supplementary filing comes approximately eighteen months after the FDA approval of VELCADE for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. VELCADE, the first of a new class of medicines called proteasome inhibitors, is the first treatment in more than a decade to be approved for patients with multiple myeloma, a cancer of the blood.

APEX Results

The sNDA submission was based primarily upon the results of the phase III APEX confirmatory study that compared VELCADE to high-dose dexamethasone. The APEX trial was halted one year early after an independent data monitoring committee concluded the findings of a pre-specified interim analysis showed a statistically significant improvement in time-to-disease progression in favor of VELCADE.

The APEX trial enrolled 669 patients with relapsed or refractory multiple myeloma (patients had received one to three prior therapies) at 93 centers in North America, Europe and Israel. Preliminary results presented at ASCO 2004 included:

* A statistically significant survival advantage (p<.01) in patients
treated in the VELCADE alone arm. Importantly, statistical significance
was maintained even though approximately 50 percent of patients crossed
over to receive VELCADE after experiencing progressive disease on the
dexamethasone arm;
-- During the first year, there was an estimated 30 percent reduction in
risk of death in patients receiving VELCADE compared to those
receiving dexamethasone.
* Data from the interim analysis showed a 58 percent improvement in time
to progression (p<.0001) in patients receiving VELCADE (5.7 months)
compared to high-dose dexamethasone (3.6 months).
-- The incidence of adverse events was similar between the two groups.
Importantly, the overall grade 4 adverse events rates were 11
percent in the VELCADE arm and 13 percent in the dexamethasone arm.

The final APEX data, including updated survival data, response rates and time-to-progression data, will be presented at the American Society of Hematology (ASH) 46th annual meeting in San Diego, Calif. on December 6, 2004.

Millennium and Johnson & Johnson Pharmaceutical Research and Development, L. L. C., continue to investigate VELCADE globally in both hematologic and solid tumors and currently have approximately 80 ongoing clinical trials.

VELCADE is currently approved in the United States, 27 European Union states, Argentina, Israel, and South Korea. VELCADE is being co-developed by Millennium and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Ortho Biotech and Janssen-Cilag are responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for Japan.

[leonide]

Zusätzlicher Kommentar zu den "encouraging results":


VELCADE(R) (Bortezomib) for Injection Studies Results Indicate Potential Utility Across the Multiple Myeloma Treatment Paradigm

- Frontline studies with VELCADE alone and in combination with other therapies

indicate impressive activity; in relapsed disease, VELCADE alone achieved a

survival benefit over a conventional therapy -

ASH Abstract #: 333, 1478, 1490, 3462, 210, 336, 336.5

SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced encouraging results from several studies exploring the use of VELCADE in treating all stages of multiple myeloma (MM). These data were presented at the 46th Annual Meeting of the American Society of Hematology (ASH) taking place this week in San Diego, CA.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Overall response rates from ongoing investigator-initiated studies evaluating VELCADE in combination with other commonly used agents in untreated multiple myeloma ranged from 95 percent to 73 percent; complete and near-complete responses were observed. Also presented were the final data analysis of the APEX trial, a phase III randomized study of patients who had relapsed after one or more lines of prior therapy. VELCADE was significantly superior to high-dose dexamethasone based on time to progression, survival, overall response rates and complete response rates.

"The unprecedented survival advantage reported with VELCADE in the relapsed setting, coupled with the preliminary response rates with VELCADE in these ongoing, front-line, investigator-initiated studies are very encouraging," said David Schenkein, M.D., vice president, clinical oncology development, Millennium. "We believe these data may signal a significant step forward for patients with multiple myeloma. As a result, we and our development and commercialization collaborator, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., are looking forward to the initiation of three phase III trials in the next six months to further evaluate the safety and efficacy of VELCADE in previously untreated multiple myeloma patients."

VELCADE(R) (bortezomib) for Injection as a front-line treatment

In an ongoing multi-center phase II trial conducted by Sundar Jagannath, M.D., St. Vincent`s Comprehensive Cancer Center, New York, and investigators in the Salick Health Care Research Network, VELCADE was studied alone and in combination with dexamethasone in patients with previously untreated, symptomatic MM. The trial enrolled 42 patients with 32 evaluable for response.

* The overall response rate was 88 percent with a complete and near
complete response rate of 25 percent;
* Six of eight patients achieved complete or near complete responses on
VELCADE alone;
* In addition, stem cell harvesting and engraftment was successful in 100
percent of patients (eight out of eight) with all transplant patients
making complete hematologic recoveries; and,
* Adverse events were similar to those observed in other clinical trials
with VELCADE and included gastrointestinal events, neuropathy, fatigue,
and hematologic toxicities.

"Our findings indicate VELCADE could be a promising drug for front-line use in previously untreated patients with myeloma," said Dr. Jagannath. "Additionally, it was encouraging to find that stem cell harvest and engraftment were not adversely affected by treatment with VELCADE. We look forward to the results of the future randomized phase III studies."

Three additional studies evaluated the safety and activity of VELCADE in combination with other therapies in previously untreated patients. An ongoing phase II study, led by James Cavenagh, M.D., St. Bartholomew`s Hospital in London, explored the combination of VELCADE (formerly PS-341), dexamethasone and doxorubicin (PAD) in patients with previously untreated MM. Data from 21 patients showed:

* The overall response rate was 95 percent with a complete and near
complete response rate of 29 percent prior to stem cell
transplantation;
* Twenty of 21 evaluable patients underwent successful stem cell
mobilization for transplantation; and,
* The major adverse event reported was neuropathy which was found to be
generally mild and improving in all patients upon completion of
therapy.

A second ongoing phase II study, led by Jean-Luc Harousseau, M.D., University Hospital of Nantes in Nantes, France, explored the combination of VELCADE and dexamethasone in patients with previously untreated MM. Data from 30 evaluable patients showed:

* An overall response rate of 73 percent with a complete response and
near complete response rate of 17 percent; and,
* Adverse events were similar to those observed in other clinical trials
with VELCADE and included gastrointestinal events, fatigue, neuropathy,
pyrexia and thrombocytopenia.

A third ongoing phase II study, led by M. Victoria Mateos, M.D., Hematology Grupo Espanol de Multiple Myeloma, Spain, explored the combination of VELCADE and melphalan and prednisone in elderly untreated MM patients. Data from 11 evaluable patients showed:

* An overall response rate of 91 percent with a complete and near
complete response rate of 18 percent; and,
* Adverse events were similar to those observed in other clinical trials
with VELCADE(R) (bortezomib) for Injection and included anemia,
neutropenia, gastrointestinal events and thrombocytopenia.

In a single institutional experience reported by Raymond Alexanian, M.D., of The University of Texas M.D. Anderson Cancer Center the combination of VELCADE with thalidomide and dexamethasone was evaluated in untreated MM patients. Data from 30 evaluable patients showed:

* The overall response rate was 80 percent; and,
* Most common adverse events included infection, hypotension, deep vein
thrombosis, neutropenia and thrombocytopenia.

A separate ongoing phase II trial evaluated the safety and activity of VELCADE as a single agent in previously untreated MM patients. Led by Paul Richardson, M.D., of the Dana Farber Comprehensive Cancer Center in Boston, the preliminary study data from 27 evaluable patients showed:

* The overall single agent response rate was 45 percent with a complete
response rate of four percent; and,
* Adverse events were similar to those observed in other clinical trials
with VELCADE and included neuropathy, gastrointestinal events and
fatigue.

APEX final results in relapsed patients

APEX, a phase III, multi-center trial with 669 patients, was the first and largest randomized study to achieve a survival advantage in relapsed MM. VELCADE was superior to high-dose dexamethasone based on time to progression (p<.0001), survival (p<.0013) and response rate (p<.0001). Additional findings include:

* Overall response rate of 38 percent with VELCADE, with a duration of
response of eight months; compared with a response rate of 18 percent,
with a duration of response of 5.6 months for dexamethasone;
* The VELCADE arm had a complete response or near complete response rate
of 13 percent, versus dexamethasone of two percent;
* Improvement in median time to progression was 78 percent in the VELCADE
arm; and,
* During the first year, there was an estimated 41 percent reduction in
risk of death in patients receiving VELCADE compared to those receiving
dexamethasone.

A subset analysis from this same study in 251 patients who had only one prior therapy also showed the VELCADE arm was superior based on time to progression (p<.0021), response rate (p<.0035) and one-year survival (p<.0098).

* Overall response rate with VELCADE was 45 percent (duration of response
was 8.1 months) compared with 26 percent for dexamethasone (duration of
response 6.2 months);
* The VELCADE arm had a complete response and near complete response rate
of 13 percent, versus dexamethasone of four percent;
* Statistically significant time-to-progression benefit of seven months
versus 5.6 months for dexamethasone; and,
* One-year survival was improved significantly from 89 percent in the
VELCADE arm compared with 72 percent for dexamethasone.

The safety profiles of VELCADE and dexamethasone were predictable and toxicities were manageable with VELCADE having a favorable risk-to-benefit ratio. The most common side effects reported with VELCADE were diarrhea, nausea, fatigue, peripheral neuropathy, thrombocytopenia and anemia.

"Our sNDA submission for second-line treatment with VELCADE was based on data from the APEX study, which achieved a statistically significant survival benefit in patients receiving VELCADE versus standard therapy, and we are pleased the agency has granted priority review for the submission," said Schenkein.

[blb]

@jm78: Da kann ich doch nichts dafür, wenn du das Teil für 80$ gekauft hast! Schonmal was von Stoppkursen gehört? Klar lief da nicht alles rund, aber 2006 ist mittlerweile ein realistisches Ziel für den Break-Even. Selbst wenns erst 2007 klappt, wär noch genug Luft, da immer noch ein großes Cashpolster vorliegt. Also lass deinen Frust an anderen Personen aus. Anstatt rumzujammern, kauf nach und hau sie bei 20$ raus, dann haste ein schönes Plus! Auf die 80$ kannste mämlich vorerst lange warten...

Grüße
blb

[Isabartels]

Gestern mal zu 9,04€ gekauft!

[Isabartels]

Und noch einml zu 8,96€. irgendwann muss die doch mal steigen!

[jm78]

Mkt. Kap.
in Mrd. $ 3,62 Mittlerer Marktwert Mit einer Marktkapitalisierung zwischen $1 & $5 Mrd., ist MILLENNIUM PHARMACEUTICALS ein mittel kapitalisierter Titel.
revid. Gew.
Prognose



Analysten neutral, zuvor negativ (seit 30. November 2003) Die Gewinnprognosen pro Aktie haben sich in den letzten 7 Wochen nicht wesentlich verändert (Veränderungen zwischen +1% bis -1% werden als neutral betrachtet). Das letzte signifikante Analystensignal war negativ und hat am 30. November 2003 bei einem Kurs von USD 15,83 eingesetzt.
Bewert.

Stark überbewertet Auf Basis des Wachstumspotentials und anderer Messwerte erscheint der Kurs zur Zeit wesentlich zu hoch.
Wachstum
/ KGV 0,53 >50% Premium relativ zur Wachstumserwartung Liegt das "Verhältnis zwischen Wachstum plus geschätzte Dividende und Kurs-Gewinn Zahl" unter 0.6, so beinhaltet der Kurs bereits einen starken Aufschlag gegenüber dem normalen Preis für das Wachstumspotential. Hier: 50% Aufschlag.
KGV 1.143,55 Erwartetes PE für 2006 Der erwartete PE-Wert (Kurs-Gewinn-Verhältnis) gilt für das Jahr 2006.
langfrist.
Wachstum 606,2% Wachstum heute bis 2006 p.a. Die durchschnittlichen jährlichen Wachstumsraten gelten für die Gewinne von heute bis 2006
Anzahl der
Analysten 11 Bei den Analysten von mittlerem Interesse In den zurückliegenden sieben Wochen haben durchschnittlich 11 Analysten eine Schätzung des Gewinns pro Aktie für diesen Titel abgegeben.
mittelfrist.
Mkt. Trend

Negativer Markttrend seit dem 19. November 2004 Der mittelfristige technische 40-Tage Trend ist seit dem 19. November 2004 negativ. Der bestätigte technische Trendwendepunkt (Tech Reverse + 1.75%) liegt bei USD 12,91.
rel. 4 Wo.
Perform. -9,7% Unter Druck (vs. SP500) Die relative "Underperformance" der letzten vier Wochen im Vergleich zum SP500 beträgt -9,7%.
Dividenden
Rendite 0% Keine Dividende Die Gesellschaft bezahlt keine Dividende.

[Isabartels]

Groundbreaking Research Identifies Potential Biomarkers of Rheumatoid Arthritis Disease Severity

-- Research published in Arthritis & Rheumatism; biomarkers associated with signaling and inflammation processes --

CAMBRIDGE, Mass., Dec. 14 /PRNewswire-FirstCall/ -- Researchers at Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the discovery of a panel of protein biomarkers that could play a role in the early detection, prognosis and monitoring of rheumatoid arthritis (RA). The research, published in this month`s Arthritis & Rheumatism in conjunction with an accompanying editorial, represents an important potential advance in the ability for clinicians to predict disease severity for patients with rheumatoid arthritis.

"The clinical application of these biomarkers could -- for the first time -- allow clinicians to identify patients who would benefit from aggressive treatment early enough in the disease course to prevent unnecessary joint destruction and disability," said Ronenn Roubenoff, M.D., senior director, Molecular Medicine, Millennium and a co-author of the study.

This study was conducted as part of a collaborative research alliance between Millennium and Roche Diagnostics. The researchers have selected 33 of these potential biomarkers for further validation in the serum of patients with RA as well as healthy volunteers.

To identify the biomarkers, researchers used a proteomic technique called mass spectrometry to generate and compare protein profiles of synovial fluids (joint fluids) from patients with erosive and non-erosive RA. The differences in the protein profiles revealed a distinct set of protein biomarkers that were elevated in the joint fluid of patients with erosive disease, but not in patients with non-erosive RA. Among the set of proteins more abundant in patients with erosive RA was C-reactive protein (CRP) and six members of the S100 protein family of calcium binding proteins. Many of the marker candidates discovered are directly or indirectly involved in cell signaling and inflammation.

Joint erosion is a standard clinical indication of future disability in RA. The identification of biomarkers that would predict erosion would allow physicians to identify patients who should receive aggressive anti-rheumatic treatment early in the hopes of preventing erosion and resulting disability.

"These are exciting discoveries that we are currently utilizing in our development and discovery efforts, such as incorporating the newly-identified biomarkers for treatment response into clinical studies designed to identify the right medicine for the right patients," said Roubenoff.

About Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic, progressive inflammatory disease of the articular (rotating) joints that results in significant pain, stiffness and swelling and leads to degradation of the joint tissue. RA can cause permanent damage and deformities to joints, resulting in loss of function and ultimately leading to joint replacement surgery in some cases. In addition, some RA patients develop extra-articular manifestations such as rheumatoid nodules, interstitial lung disease and vasculitis.

According to the Arthritis Foundation, RA affects 2.1 million Americans and is about three times more common in women than men. The disease has a significant socioeconomic impact with medical costs and indirect expenses due to lost wages for RA estimated to be over $3 billion per year. In addition, mortality rates for people with RA are double those of the general population. The cause of RA is not known. However, it is believed that RA is an autoimmune disease where the body`s natural immune system attacks healthy joint tissue causing inflammation and subsequent joint damage.

[Isabartels]

Millennium Receives Top Industry Awards

-- Recognized by Red Herring, MedAd News and Science magazine

as an industry leader in leadership, innovation and employee culture --

CAMBRIDGE, Mass., Dec. 15 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the Company has received three significant awards from leading business and pharmaceutical publications: the "Top 100 Innovators" from Red Herring magazine, "Most Admired Healthcare Companies" from Med Ad News, and "Top Employers" from Science magazine.

(Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"We are honored to receive these three awards from such highly respected publications for our industry leadership in innovation, strategy, and environment of excellence," said Mark Levin, chief executive officer, Millennium. "These awards Millennium has received reflect the creativity, dedication, and passion which fuel the culture of our Company and allow us to deliver breakthrough medicines to patients."

Red Herring Top 100 Innovator Awards

Following rigorous evaluation of more than 1,200 entries from over 900 companies, the Red Herring editorial team selected Millennium as a "Top 100 Innovator." The award recognizes innovation and individual achievement in a number of categories including: leadership, business strategy, marketing, sales and service. The editors conducted an analysis of financial data as well as subjective criteria, including quality of management, execution of strategy, and dedication to research and development. The "Top 100 Innovators" were announced at Red Herring`s Fall 2004 Conference December 6th in Monterey, CA and will be published in the December 13th issue of Red Herring. The mission of Red Herring is to report on innovation, technology, financing, and entrepreneurial activity.

Med Ad News Most Admired Healthcare Companies

Millennium was also listed as fifth in the list of the 10 most admired biotechnology companies in the fourth annual "Most Admired Healthcare Companies" from Med Ad News, a leading pharmaceutical trade magazine. In their selection process of the most admired pharmaceutical, biotechnology, and specialty companies, the editors of Med Ad News polled readers through an electronic ballot on the magazine`s Website, http://www.pharmalive.com. The invitation to vote was sent via e-mail broadcast to approximately 15,000 people. Participants could vote for three choices from among the top 25 publicly traded companies based on published revenue in each category: pharmaceutical, biotechnology, and specialty. The list was published in the October 2004 issue of Med Ad News.

Science Magazine Top Employers

In recognition of the breakthrough science and culture Millennium sustains, Science magazine recognized Millennium as one of 20 "Top Employers" for scientists in a ranking of the world`s most respected biotechnology and pharmaceutical companies. Millennium was characterized as offering a respectful environment for employees, being socially responsible, and having a clear vision toward the future. The honor is the result of a survey of 1,162 Science readers worldwide who work in the pharmaceutical, biotechnology, and biopharmaceutical industries sponsored by Science magazine, along with the American Association for the Advancement of Science, and conducted by Senn- Delaney Culture Diagnostics and Measurement (SDCDM). Companies were evaluated on 42 specific attributes including being an innovative leader in the industry, treating employees with respect, and carrying out quality research. The list was published in a supplement included with the November 25th issue of Science magazine.

[Isabartels]

Echt zum ko....

[jm78]

Rating-Update:

Die Analysten von Lehman Brothers stufen die Aktie von Millennium Pharmaceuticals (ISIN US5999021034/ WKN 900625) unverändert mit "equal weight" ein. Es sei zweifelhaft, ob das Unternehmen mit Velcade ein Umsatzniveau von 400 Mio. USD erzielen könne, um die angepeilte Profitabilität zu erreichen.

[leonide]

Hallo liebe Leidensgenossen, liebe Nichtinvestierte,

zur Weihnachtszeit bin ich in besinnlicher Stimmung und schreibe mal ganz persönlich: Die Entwicklung dieser, "meiner" Aktie habe ich falsch eingeschätzt, wohl verursacht durch die in meinen Augen recht positiven News zu Velcade. Die Entwicklung der Quartalszahlen fand und finde ich auch nicht schlecht, ob das Verlassen der Verlustzone nun ein Quartal früher oder später kommt, ist mir als Langzeitanleger eigentlich wurscht. Eigentlich heißt, es nervt natürlich schon.

Soweit so schlecht. Mein persönliches Fazit: Ich werde wissentlich einen Anfängerfehler machen und verlorenem Geld weiteres nachschmeißen und mir noch ein paar Milles unter den Weihnachtsbaum legen.
Eben bereits zu 8,50 nachgekauft.
Habe offensichtlich eine masochistische Ader.

Wer es nachmacht: selbst Schuld.
Wer es läßt: auch selbst Schuld.

leonide

[DMKE]

ich warte lieber noch etwas ab, bis sie weiter runtergeht ... bei 8,- euro schlage ich zu

[blb]

Das ist doch Schwachsinn, leonide! Natürlich kann man nachkaufen. Hab damals bei 10$ zugelangt, danach gings auf 14$ rauf ,also fast das Tiefv erwischt. Aktuell einfach Bodenbildung abwarten. Es war/ist Druck drauf, weil MLNM mit die schlechteste Aktie dieses Jahr im Nasdaq100 war. Für Velcade bleib ich weiterhin positiv. Allerdings sollte man bedenken, dass MLNM nicht grad ein kleines Unternehmen ist und deshalb die großen Gewinn hier nicht zu machen sind. Aber 20$ sind sicher mal wieder drin!

Grüße und frohe Weihnachten!
blb

[Isabartels]

Millennium Announces Changes in Commercial Management and Board of Directors

CAMBRIDGE, Mass., Dec 20, 2004 /PRNewswire-FirstCall via COMTEX/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced Kenneth Bate, executive vice president and head of commercial operations, has decided to leave the company in January 2005. Millennium is actively recruiting a successor to lead the Company`s commercial organization. Upon Mr. Bate`s departure, oversight of the commercial organization will immediately transition to Mark Levin, chief executive officer and chairperson of Millennium.



Mr. Bate joined Millennium as chief financial officer in 2002 and assumed the additional role of head of commercial operations in 2003.

"I want to thank Ken for his commitment to Millennium, our employees and the patients we serve. He has been instrumental in the implementation of our plan to reach profitability and in the successes of the Company`s commercial organization during the past two years. We greatly appreciate his significant contributions," said Levin. "We will continue to seek extraordinary executives with deep commercial biopharmaceutical experience as we are moving into the next phase of our development."

Separately, Millennium also announced the departure of three Board members. Ginger Graham, the president and chief executive officer of Amylin Pharmaceuticals, Vaughn Kailian, the managing partner of Deerhaven Partners and Edward Miller, M.D., the chief executive officer and dean of the Johns Hopkins University School of Medicine will all be leaving the Board effective January 2005. During 2005, Mr. Kailian will continue to provide services to the Company through a consulting agreement. Shaun Coughlin, M.D., Ph.D., Grant Heidrich, Charles Homcy, M.D., Raju Kucherlapati, Ph.D., Eric Lander, Ph.D., Mark Levin, Norman Selby and Kenneth Weg will continue to serve on the Board.

"The Company has benefited greatly from the contributions and guidance Ginger and Vaughn, who joined us in connection with the COR merger, and Ed, who joined us in 2000, have all provided. We wish them all the best as they focus on their own demanding endeavors," said Levin. "Our Board Governance Committee is currently in discussions with prospective independent directors who would bring the strong financial, biopharmaceutical and public policy backgrounds that Millennium needs in the next phase of its evolution into a leading biopharmaceutical company."

About The Company

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular, and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, the Company is seeking to develop breakthrough products.

Editor`s Note: This release is available on Media section of Millennium website at http://www.millennium.com

Contact:

Adriana Jenkins (media) Kyle Kuvalanka (investors)

[phone] [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Adriana Jenkins (media), [phone] or Kyle Kuvalanka (investors),
[phone], both of Millennium

http://www.prnewswire.com

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Millennium Pharmaceuticals`s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company`s Annual Report or Form 10-K for the most recently ended fiscal year.

© 2004 Millennium Pharmaceuticals, Inc.Update Notice | Usage Terms |

[Boersenkrieger]

nachkaufen würde ich bleiben lassen... wir haben hier keinen kgv-10-wert vor uns... da kann´s noch ganz schön knallen ...trotzdem mille steht super da aber seit merck und pfizer kotzt die börse über pharma-werte

[Isabartels]

ich glaube, dass wir uns in der Nähe des Bodens befinden. gestern wurde nochmals das 52-Wochen tief getestet. eigentlich solte es jetzt langsam drehen!

[blb]

@Boersenkrieger: Mit KGVs komst da nicht weit. Es zählt Cash und Pipeline bei Bios...

@Isabartels: Bodenbildung abwarten!

Grüße
blb

[Isabartels]

blb
ich glaube der Boden ist nah!

[Isabartels]

Jetzt schon fast 7 Millioen Aktien gehandelt. Solche umsätze sind aber auch schon einige zeit her!!

[Isabartels]

Was mich positiv stimmt, ist das der gestrige Anstieg diesmal nicht wieder vor Handelsende verkauft wurde!

[Isabartels]

Sieht doch super aus, heute!(Gestern auch)

[Boersenkrieger]

@blb

+454

jep, da haste recht... ztotzdem ist mille vergleichsweise hoch bewertet... aber auch zurecht. gerade bei bios hab ich das gefühl man ist bei stärkeren unternehmen wie celgene und millennium besser aufgehoben als bei den kleineren... die schwirren meist mal richtung süden ab

[DMKE]

weiss jemand, warum es abwärts geht .. ??

[Isabartels]

VELCADE® (bortezomib) for Injection Phase III Clinical Trial Initiated In Patients With Newly Diagnosed Multiple Myeloma
SAN FRANCISCO, Jan 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced, in collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC, the initiation of VISTA (VELCADE as Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone), a multicenter, international phase III clinical trial of VELCADE in combination with melphalan and prednisone versus melphalan and prednisone in patients with newly diagnosed multiple myeloma (MM) who are not transplant candidates. This large, international randomized study will assess efficacy, overall safety and tolerability of the combination versus melphalan and prednisone alone.

The VISTA trial was reviewed by the U.S. Food and Drug Administration (FDA) through the special protocol assessment (SPA) process. An SPA is a binding agreement between the FDA and the sponsor of a clinical trial requiring that the study design meets the scientific and regulatory requirements of the FDA to support a New Drug Application (NDA) or supplemental New Drug Application (sNDA).

VELCADE is currently approved in the United States and Europe for the treatment of patients with relapsed and refractory MM. The FDA is currently reviewing the Company`s supplemental sNDA, under Priority Review designation, for VELCADE as a treatment for patients with MM who have received at least one prior therapy.

"Millennium, and our partner Johnson and Johnson, are committed to strategically and expeditiously developing VELCADE as the cornerstone of care across the multiple myeloma treatment paradigm," said David Schenkein, M.D., vice president, clinical oncology development, Millennium. "The frontline data seen to date have been very promising, and we are eager to explore the potential of VELCADE in combination with other therapies so that we may be able to offer new options for patients in need."

Millennium and Johnson & Johnson are also planning to support two additional large, multi-national phase III frontline MM trials scheduled to be initiated in the first half of this year. These trials will be for patients who plan to undergo stem cell transplantation. In these trials, which are planned to be conducted by major European hematology cooperative groups, VELCADE will be integrated into the induction regimen.

Millennium supported the presentation of encouraging data at the 2004 46th Annual Meeting of the American Society of Hematology (ASH) meeting exploring the use of VELCADE in treating newly diagnosed MM. Overall response rates from ongoing investigator-initiated studies evaluating VELCADE in combination with other commonly used agents in untreated MM ranged from 95 percent to 73 percent with complete and near-complete response rates ranging from 25 to 17 percent. Adverse events were similar to those observed in other clinical trials with VELCADE and included gastrointestinal events, neuropathy, fatigue, and hematologic toxicities.

Millennium and Johnson & Johnson continue to investigate VELCADE globally in both hematologic and solid tumors and are currently supporting more than 100 ongoing or planned clinical trials.

About Multiple Myeloma (MM)

Multiple myeloma is a cancer of the bone marrow in which white blood cells called plasma cells, normally responsible for the production of antibodies (proteins that fight infection and disease), are overproduced. The proliferation of these abnormal plasma cells, known as myeloma cells, causes decreased production of normal red and white blood cells, and of normal disease-fighting antibodies, as well as the growth of tumors that spread to multiple sites -- hence the term multiple myeloma. The decreased white blood cell production damages the immune system while the myeloma tumors cause bone destruction that manifests as pain and fractures.

MM is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and younger age of onset. In the United States, more than 40,000 individuals have MM and over 14,000 new cases of the disease are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths due to multiple myeloma each year.

[midgbridg]

Millennium to Highlight 2004 Accomplishments and 2005 Outlook at JPMorgan 23rd Annual Healthcare Conference



2004: Year of accomplishments and focus

2005: Resolute commitment to 2006 non-GAAP profitability(1) goal

SAN FRANCISCO, Jan. 10 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM), today announced 2004 accomplishments and 2005 Company goals and financial outlook. In conjunction with this news release, Millennium will host a live webcast of its conference call today, Monday, January 10, 2005 at 8:30 AM EST (5:30 AM PST). The live webcast can be accessed by visiting the Investors section of the Company`s website, http://www.millennium.com. Following the webcast, an archived version of the call will be available at the same address until 11:59 p.m. (EST) on Monday, February 9, 2005. Mark Levin, chairperson and chief executive officer of Millennium, will present additional detail January 12, 2005 at the JPMorgan 23rd Annual Healthcare Conference. The presentation will be webcast live at 3:00 p.m. PDT (6:00 p.m. EDT) and may be accessed by visiting the Investors section of the Company`s website, http://www.millennium.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"Millennium had a remarkable year in 2004, as hundreds of thousands of patients around the world benefited from our two market-leading products VELCADE and INTEGRILIN," said Levin. "We are resolute in our commitment to meet our 2006 non-GAAP profitability goal, and believe we are entering 2005 in a very strong position financially and operationally to ensure our short- and long-term success."

Millennium achieved a number of corporate objectives in 2004, as outlined below, and provided forward-looking guidance about the Company`s financial outlook and critical goals for 2005.

Financial:
In 2004, Millennium:

-- Realized VELCADE U.S. net product sales of approximately $143 million,
meeting sales guidance;

-- Expects to realize INTEGRILIN(R) (eptifibatide) Injection U.S.
ex-factory sales of approximately $300 million; which is below the
Company`s original sales guidance provided in January 2004 of
$320-$335 million. INTEGRILIN demand sales are estimated to be
$355 million as reported by a third-party source;

-- On track to achieve a non-GAAP net loss within the guidance range of
$175-200 million, and GAAP net loss within the guidance range of
$255-285 million; and

-- On track to achieve a year-end cash balance of greater than
$700 million, meeting guidance.

Final 2004 audited financial results will be reported on January 27, 2005.
In 2005, Millennium has set goals to:

-- Achieve VELCADE U.S. net product sales of $185 million to $195 million;

-- Achieve INTEGRILIN U.S. ex-factory sales of $315 million to
$330 million;

-- Achieve net loss on a GAAP basis of better than $155 million and on a
non-GAAP basis of better than $100 million with the difference between
the GAAP and non-GAAP net loss attributable primarily to amortization
and restructuring charges(2); and

-- Achieve a cash balance at the end of 2005 of greater than $500 million
with approximately $105 million in debt.

VELCADE(R) (bortezomib) for Injection:

Multiple Myeloma
In 2004, Millennium:

-- Achieved market leadership in the approved indication;

-- Submitted a sNDA for an expanded label for multiple myeloma second line
treatment based on the phase III APEX data, which was accepted by the
Food and Drug Administration (FDA) under priority review;

-- Supported a number of front line studies presented at the 2004 46th
Annual Meeting of the American Society of Hematology (ASH) in which
overall response rates ranged from 95 percent to 73 percent with
complete and near-complete response rates ranging from 25 to
17 percent. Adverse events were similar to those observed in other
clinical trials with VELCADE and included gastrointestinal events,
neuropathy, fatigue, and hematologic toxicities.

-- With our development collaborator, Johnson & Johnson Pharmaceutical
Research & Development, L.L.C.:

- Secured approval and launched VELCADE in more than 30 countries
for multiple myeloma patients who have received at least two
prior treatments and relapsed on the last treatment; and

- Initiated VISTA, a large, international phase III registration
enabling clinical trial of multiple myeloma in the front line
setting.

In 2005, Millennium will strive to:

-- Secure FDA approval in second line multiple myeloma in the second
quarter of 2005;

-- Support presentation and publication of data evaluating VELCADE in the
treatment of front line multiple myeloma and support compendia listings
as appropriate; and

-- In collaboration with Johnson & Johnson, continue aggressive evaluation
of VELCADE, including:

- Supporting two additional large, European cooperative group-led
phase III multiple myeloma front line clinical trials anticipated
to initiate in the first half of 2005; and

- Initiating a phase IV clinical trial evaluating VELCADE(R)
(bortezomib) for Injection for multiple myeloma retreatment.

Non-Hodgkin`s Lymphoma
In 2004, Millennium:

-- Received fast track status by the FDA for VELCADE in mantle cell
lymphoma;

-- Initiated a phase II clinical trial in combination with rituximab in
non-Hodgkin`s lymphoma;

-- Received a recommendation by the National Comprehensive Cancer Network
to include VELCADE in its guidelines for the treatment of second line
mantle cell lymphoma; and

-- Supported three separate ongoing phase II clinical trials presented at
ASH, in which the overall response rates with single-agent VELCADE in
follicular lymphoma ranged from 60 percent to 17 percent, and in mantle
cell lymphoma, from 50 to 39 percent. Adverse events observed were
thrombocytopenia, fatigue, anemia and peripheral neuropathy.

In 2005, Millennium will:
-- Support presentation and publication of data evaluating VELCADE in the
treatment of mantle cell and follicular lymphoma and support further
development activities and compendia listings as appropriate.

Lung Cancer
In 2004, Millennium:

-- Presented interim data analysis from the company-sponsored ongoing
phase II clinical trial (048) of VELCADE in non-small cell lung
cancer (NSCLC) which found VELCADE showed promising activity both as a
single agent and in combination with docetaxel; and

-- Concluded, following further evaluation of this trial and based on
investigator-assessed response rate and survival data, VELCADE shows
promising single agent activity and is comparable to commonly-used
drugs in the second line treatment setting of NSCLC. However, the
preliminary data from the combination arm of the trial does not warrant
moving forward with the tested dose and schedule of VELCADE and
docetaxel. The Company will move forward with an expanded set of
clinical trials in 2005 to evaluate VELCADE as both a single agent and
in combination with other agents consistent with the evolving NSCLC
landscape, as described below.

In 2005, Millennium will strive to:

-- Initiate an expanded set of phase II company sponsored clinical trials
and support investigator initiated studies to evaluate VELCADE in NSCLC
as a single agent and in combination with other commonly used agents
including pemetrexed, docetaxel, epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKI);

-- Initiate a phase II clinical trial evaluating VELCADE in
bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC-like
features during the first half of 2005; and

-- Support presentation of phase II 048 data evaluating VELCADE in the
treatment of NSCLC.

INTEGRILIN(R) (eptifibatide) Injection:

Early Acute Coronary Syndrome (ACS)
In 2004, Millennium maintained its market leadership within the GP IIb- IIIa class and:

-- Initiated key strategies to maintain and expand leadership in the
catheterization laboratory and ACS setting, including the EARLY ACS
clinical trial; and

-- Continued to build awareness of GP IIb-IIIa use in early ACS setting
through CRUSADE, with 120,000 patients enrolled, 22 abstracts at
medical conferences and nine publications.

In 2005, Millennium will strive to:

-- Educate health care professionals about the benefit of early,
appropriate GP IIb-IIIa use and adherence to current ACC and AHA
guidelines through CRUSADE publications and the clinical cardiologist
sales force;

-- Educate physicians on appropriate risk stratification and immediate
initiation of treatment through publications, clinical data and the
sales force; and

-- Continue accrual in the EARLY ACS clinical trial and CRUSADE quality
initiative.

Percutaneous Coronary Intervention
In 2004, Millennium:

-- Initiated key strategies to maintain and expand leadership in the
catheterization laboratory including the initiation of the EVENT
registry; and

-- Presented favorable clinical outcome data from PROTECT and positive
data from the CLEAR Platelets study.

In 2005, Millennium will strive to:

-- Reinforce INTEGRILIN(R) (eptifibatide) Injection use in current
treatment paradigms through the communication of clinical data and the
initiation of new trials; and

-- Educate physicians about risk stratification and undertreated
populations through symposia, publications and the sales force.

Clinical development pipeline:
In 2004, Millennium:

-- Presented data on several key phase II programs including MLN1202,
MLN2704 and MLN518.

In 2005, Millennium will strive to:

-- Continue to employ aggressive portfolio management strategies to
increase the long term value of the Company and succeed in making
potential pipeline advancement decisions, which may include advancing:

- MLN1202 (an antibody designed to block CCR2) to phase IIb clinical
trials in rheumatoid arthritis and phase II clinical trials in
multiple sclerosis, scleroderma and/or secondary atherosclerosis;

- MLN3897 (a small molecule CCR1 inhibitor) to phase II clinical
trials in rheumatoid arthritis, multiple sclerosis, and/or
psoriasis;

- MLN3701 (a small molecule CCR1 inhibitor) to phase I clinical
trials;

- MLN2704 (anti-PSMA antibody) advancing to phase III clinical
trials;

- MLN518 (small molecule RTK inhibitor) to combination phase I
clinical trials in acute myeloid leukemia and glioma;

- MLN8054 (a small molecule aurora kinase inhibitor) to phase I
clinical trials for the treatment of solid tumors; and

- New molecular entities into phase I clinical trials.

Strategic business relationships:
In 2004, Millennium:

-- Restructured our INTEGRILIN European marketing relationship in which
GlaxoSmithKline plc is now exclusively marketing INTEGRILIN in Europe;
and

-- Initiated and advanced academic collaborations, renegotiated
development alliances and outlicensed and monetized lower priority
assets.

In 2005, Millennium will strive to:

-- Form value creating collaborations with strategic assets;

-- Balance the Company`s internal pipeline with in-licensing
opportunities; and

-- Out-license and monetize lower priority molecules and assets.

About VELCADE(R) (bortezomib) for Injection
VELCADE is approved for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. The effectiveness of VELCADE is based on response rates. There are no controlled trials demonstrating a clinical benefit, such as improvement in survival. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol.

VELCADE is being co-developed by Millennium and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Ortho Biotech and Janssen-Cilag are responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for Japan.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, orthostatic hypotension, congestive heart failure, gastrointestinal adverse events, thrombocytopenia, and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE.

In 228 patients who were treated with VELCADE 1.3 mg/m2/dose in phase II studies, the most commonly reported adverse events were asthenic conditions (65%), nausea (64%), diarrhea (51%), decreased appetite including anorexia (43%), constipation (43%), thrombocytopenia (43%), peripheral neuropathy (37%), pyrexia (36%), vomiting (36%), and anemia (32%). Fourteen percent of patients experienced at least one episode of Grade 4 toxicity, with the most common toxicities being thrombocytopenia (3%) and neutropenia (3%). A total of 113 (50%) of the 228 patients experienced Serious Adverse Events (SAEs) during studies. The most commonly reported SAEs included pyrexia (7%), pneumonia (7%), diarrhea (6%), vomiting (5%), dehydration (5%), and nausea (4%).

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-(866)-VELCADE.

About INTEGRILIN(R) (eptifibatide) Injection

INTEGRILIN is indicated for the treatment of patients with acute coronary syndrome (unstable angina/non-ST-segment myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). It is also indicated in the United States for the treatment of patients at time of PCI, including in patients undergoing intracoronary stenting.

INTEGRILIN is contraindicated in patients with a history of bleeding diathesis, or evidence of abnormal bleeding within the previous 30 days; severe hypertension (systolic blood pressure greater than 200 mm Hg or diastolic blood pressure greater than 110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within the preceding six weeks; history of stroke within 30 days, or any history of hemorrhagic stroke; current or planned administration of another parenteral glycoprotein (GP) IIb- IIIa inhibitor; dependency on renal dialysis; or known hypersensitivity to any component of the product.

Bleeding is the most common complication encountered during INTEGRILIN(R) (eptifibatide) Injection therapy. The majority of excess major bleeding events were localized at the femoral artery access site. Oropharyngeal, genitourinary, gastrointestinal and retroperitoneal bleeding were also seen more commonly with INTEGRILIN compared to placebo.

INTEGRILIN is co-promoted and co-developed by Millennium Pharmaceuticals, Inc. and Schering-Plough Corporation.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular, and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products.

This press release contains "forward-looking statements," including statements about the Company`s growth, future operating results, discovery and development of product and strategic alliances. Various important risks may cause the Company`s actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company`s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company`s products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editors` Note: This press release is also available under the Media section of the Company`s website at: http://www.millennium.com.

Contacts: Media: Adriana Jenkins [phone]

Investors: Gina Nugent [phone]
Kyle Kuvalanka [phone]

(1) Non-GAAP net loss and non-GAAP profitability are non-GAAP financial
measures. With respect to forward-looking information presented on a
non-GAAP basis, other than amortization expenses of approximately
$34.0 million in each of the next two years and costs associated with
the Company`s 2003 restructuring effort of between $5.0 million and
$20.0 million in 2005, the Company is unable to provide a quantitative
reconciliation because the items that would be excluded (which include
the types of items reflected in the reconciliation of historic results
and starting in 2005, stock-based compensation expense) are difficult
to predict and estimate and are primarily dependent on future events.
Please see the Form 8-K furnished on January 10, 2005 by the Company
to the Securities and Exchange Commission for a discussion of why the
Company believes these non-GAAP measures are useful to investors and
the additional purposes for which management uses these measures.

(2) As previously described in our non-GAAP measures, the Company
currently is unable to quantify the 2005 expense related to stock-
based compensation and does not provide guidance on this charge,
therefore all GAAP and non-GAAP measures exclude this charge.

SOURCE Millennium Pharmaceuticals, Inc.
-0- 01/10/2005
/CONTACT: Media - Adriana Jenkins, [phone], or Investors - Gina
Nugent, [phone], or Kyle Kuvalanka, [phone], all of Millennium
Pharmaceuticals, Inc./
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, [e-mail] /
/Company News On-Call: http://www.prnewswire.com/comp/114562.html" target="_blank" rel="nofollow ugc noopener">http://www.prnewswire.com/comp/114562.html /
/Web site: http://www.millennium.com /
(MLNM)

CO: Millennium Pharmaceuticals, Inc.
ST: California
IN: HEA MTC
SU: TDS CCA

WR
-- NYM091 --
2566 01/10/200508:09 ESThttp://www.prnewswire.com

[Isabartels]

Man könnte ja meinen die hätten Konkurs angemeldet. Der Kursverlauf ist ja eine Katastrophe!

[Isabartels]

11.01.2005 11:38:56 (PRUDENTIAL FINANCIAL) versenden drucken > vor
44 Datensätze gefunden.
Millennium Pharmaceuticals neutral



Die Analysten von Prudential Financial bewerten die Aktie des US-amerikanischen Unternehmens Millennium Pharmaceuticals (ISIN US5999021034/ WKN 900625) mit "neutral". Gestern habe das Unternehmen die vorläufigen Geschäftszahlen für das Jahr 2004 veröffentlicht und zugleich einen Ausblick für das kommende Jahr gegeben. Die US-Verkaufszahlen der Medikamente Velcade und Integrilin seien mit 143 Mio. USD bzw. 300 Mio. USD leicht schwächer als erwartet ausgefallen. Die Prognose der Experten habe auf 145 Mio. USD bzw. 308 Mio. USD gelautet. Der voraussichtliche Nettoverlust von 175-200 Mio. USD liege im Rahmen der Erwartungen. Für das Geschäftsjahr 2005 rechne Millennium Pharmaceuticals mit Velcade-Umsätzen in Höhe von 185-195 Mio. USD. Die Analysten seien bislang von 217,5 Mio. USD ausgegangen. Die Unternehmensprognose für das Medikament Integrilin liege hingegen mit 315-330 Mio. USD auf Höhe der Expertenschätzung von 325 Mio. USD. Die endgültigen Geschäftszahlen für das abgelaufene Jahr 2004 werde das Unternehmen am 27. Januar bekannt geben. Die EPS-Schätzung für das Geschäftsjahr 2005 betrage -0,33 USD. Das Kursziel habe man von bislang 15 USD auf aktuell 14 USD reduziert. Vor diesem Hintergrund bewerten die Experten von Prudential Financial die Aktie des Unternehmens Millennium Pharmaceuticals mit "neutral".
Quelle: AKTIENCHECK.DE

[DMKE]

da dürfte es noch weiter runter gehen !!!

[Boersenkrieger]

ist ja fast noch positiv... ich denke da wissen manche mehr... geht wohl noch deutlich tiefer 5 USD oder so

[leonide]

Ach, Weltuntergangsstimmung!?
Vielleicht berechtigt, vielleicht nicht.
Vor Wochen hätt ich zu den Kursen kräftig zugelangt.
Allein deswegen riskier ich was und leg weiter nach zu 7,70 E.
Wenn es weiter fällt, leg ich noch mal nach. Dann kauf ich mir die Klitsche halt ( in dem Tempo so in 2-300 Jahren ).
Bitte nicht nachmachen, sonst krieg ich nicht die Aktienmehrheit.

[DMKE]

na das wäre aber nochmal ein gewaltiger rutsch ...

[Boersenkrieger]

naja bei der bewertung kann einem auch schlecht werden... da kann´s auch noch auf 1-2 $ runtergehen...

[blb]

Naja wie sooft kommen die Analysten nach dem Kursrutsch jetzt mit Downgrades... Sollte bald aufwärts gehen!

Grüße
blb

[jm78]

12.01.2005 14:12:
Update Millennium Pharmaceuticals Inc.: Underweigh

Die Aktie des Unternehmens Millennium Pharmaceuticals (Nachrichten) wurde in einer Kurzanalyse vom Mittwoch, 12. Januar 2005 von den Analysten der Lehman Brothers von "Equal-weight" auf "Underweight" herabgestuft. Das Kursziel für die Aktie liegt momentan bei 8 $.


und erneut 8 monate mit mille horrornachrichten überstanden

gut das es bib gibi sonst hätte ich schon einen strick benutzt

lieben gruß
jm78

[jm78]

12.01.2005 12:58:
Millennium - Lehman sieht weiter Verlust
eine interessante horrormeldung hab ich noch gefunden

Millennium Pharmaceuticals (Nachrichten) wird von Lehman Brothers (Nachrichten) von „equal-weight“ auf „underweight“ und einem 12-Monats-Kursziel von $8 herabgestuft. In Anbetracht zu erwartender enttäuschender Umsätze zu dem Medikament Velcade mit voraussichtlich weniger als $200 Mio in 2005 und offensichtlich wenig überzeugenden klinischen Daten zur Bekämpfung von Lungenkrebs sehen sich die Experten in Zweifel, dass Millennium im kommenden Jahr die Profitabilität erreichen wird. Nach Ansicht der Broker ist für Millennium das Ziel der Profitabilität nur mit Hilfe von starken Partnern durch Zahlungen auf Produkterlöse zu erzielen. Zur Zeit sehe sich das Unternehmen mit einem nicht aufrecht zu erhaltenen Modell konfrontiert.

[Isabartels]

die lehmänner waren oft ein guter kontra indikator!!
Hatten glaube ich vor über einem jahr milnm mit kursziel 9$ angegeben. Lief nachgher fast auf 20!!

[blb]

Zumindest technische Reaktion sollte bald einsetzten, allerdings sind wir von einer Bodenbildung wie letztes Jahr um die 10$ noch weit entfernt...

Grüße
blb

[Isabartels]

wie weit könnte die techn. Gegenreaktion denn gehen?
gruss
Isa

[blb]

Ich schätze, 10-15% sollten drin sein! Vielleicht bildet sich auf aktuellem Niveau dann auch ein nachhaltiger Boden. Wer einsteigen will, und das auf längere Sicht, sollte aktuell allerdings noch warten!

Grüße
blb

[Isabartels]

Danke.
Ist wirklich unglaublich was hier abläuft. Wenn die jetzt jeden Tag 5% verliert, ich kann es kaum glauben.

[Boersenkrieger]

laßt das messer mal fallen...
die bewertung ist extrem hoch... bei guten bios so üblich.. nachteil: das potential nach unten ist enorm.. celgene entwickelt sich wesentlich besser.
bei mille sind bei bad news auch schnell mal kurse von 3-5 $ drin

[Boersenkrieger]

das 5-jahrestief war bei knapp über 6... evtl. der boden.

[blb]

3-5$? So ein Grampf! Das hamse doch schon fast als Cash!

Grüße
blb

[therman]

13.01.2005 - 17:13

MILLENNIUM Pharma bricht nach unten weg...

(©GodmodeTrader - http://www.godmode-trader.de/)


MILLENNIUM Pharma (MLNM) : 9,67$ (-4,25%)

Wochenchart (log) seit Dezember 2001 (1 Kerze = 1 Woche)

Diagnose: Unter Druck steht auch heute wieder die Aktie von Millennium Pharma und gehört damit zu den größten Verlierern im Nasdaq 100. Oberhalb des Key-Levels bei 9,69$ konnte sich der Kurs während der Korrektur Mitte 2004 fangen und erholte sich bis an den Widerstand bei 13,70$. Bereits in der Vorwoche fiel die Aktie wieder nachhaltig unter die Unterstützung bei 11,47$ und damit unter den mittelfristigen Sell-Trigger zurück, der Abverkauf setzt sich jetzt bis auf den Support bei 9,69$ fort.

Prognose: Hier bietet sich nochmals die Möglichkeit einer Gegenbewegung, kurzfristig ist MLNM bereits klar überverkauft. Kann sich die Aktie auf diesem Niveau aber nicht nachhaltig nach oben lösen drohen mittelfristig weiter fallende Notierungen bis zum Tief aus 2003 bei 6,24$.

[blb]

Also wenn es wirklich Richtung 6$ geht, werd ich nochmal hübsch nachlegen! Aktuell sollte man aber sein Pulver trocken halten. Will hier auch nicht dauernd als Oberbulle rüberkommen, die Ankündigungen dieser Woche werden wohl als Umsatz und evtl. Gewinnwarnung gesehen, die letzten Zahlen waren auch nicht berauschend (hab sie mir nochmal durchgelesen)! Trotzdem sollte man nicht vergessen, dass sie ab 2006 an der Gewinnschwelle dransein werden und selbst da dann noch einige hundert Millionen $ Cash haben dürften.

Aktuell gibts aber sicher aussichtsreichere Werte...

Grüße und schönen Abend!
blb

[Boersenkrieger]

naja rechne fast mit 6,x ...und danach ein schnller upmove über 10... alo bei 6,x sollte man nachlegen, denke daß das tief halten sollte für´s erste... davon abgesehen vielleicht gibt´s ja auch schon morgen nen upmove

[Isabartels]

Scheint wohl doch mehr zu seinls nur eine technische Gegenbewegung. Die Tiefs haben wir jetzt hoffentlich gesehen!?

[Isabartels]

so, da waren gerade die 10$!!

[Isabartels]

Millennium Pharmaceuticals to Webcast Conference Call on Fourth Quarter and Full-Year 2004 Financial Results

CAMBRIDGE, Mass., Jan 20, 2005 /PRNewswire-FirstCall via COMTEX/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) will hold a live webcast of its conference call at 8:30 a.m. EST on Thursday, January 27, 2005. Mark Levin, chairperson and chief executive officer, will host the call. Senior management will discuss the Company`s fourth quarter and full-year financial results for 2004 and additional corporate activities. The Company will announce its financial results for this period in a press release to be issued before market open on Thursday, January 27, 2005.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The press release and the live webcast can be accessed by visiting the Investors section of the Company`s website, http://www.millennium.com. Following the webcast, an archived version of the call will be available at the same address until 11:59 p.m. on Thursday, February 10, 2005.

[Isabartels]

Hat denn niemand mehr Mlnm??

[Boersenkrieger]

@Isabertels

doch, aber ich gebe es nicht gerne zu hier in der anonymen öffentlichkeit, da mein ruf darunter leidet

[Isabartels]

ich dachte Dein ruf wäre eh schon ruiniert!

[jm78]

Was soll ich sagen Jungs? Den wechselkursverlust eingerechnet bin ich bei 50 $ wieder im Plus.

Aber keine Panik , ich brauche die knete erst in 20 Jahren und 11 Monaten

[Isabartels]

Na, dann brauchst Du aber viel Geduld! langsam könnte das Teil wenigstens mal den Ansatz einer Erholung zeigen!

[blb]

@Isabartels: Klar bin ich noch drin. Zur Zeit gibts nicht viel zu sagen, es ist noch kein Boden in Sicht!

@jm78: Falls du noch Kohle zum Nachkaufen hast, würd ich dir dazu raten. Der Zeitpunkt ist jedoch noch nicht gekommen. Bin mir aber ziemlich sicher, dass du mit nem Kaufkurs um die 20$ deine Kohle wieder sehen wirst!

Grüße an alle und Kopf hoch!
blb

[Isabartels]

Danke für die aufmunternden Worte in diesen schweren zeiten!

[Boersenkrieger]

#489 von Isabartels

na ich sehe du kennst einige meiner postings ...naja egal wie heißt es so schön ist der ruf mal ruiniert lebt sich´s gänzlich ungeniert

[Boersenkrieger]

naja ich hoffe mal es gibt bald ne gegenbewegung ..der haken an der sache ist, wenn mlnm kein großes wachstum mehr zugetraut werden sollte über längere zeit kann es wirklich noch sehr steil bergab gehen... gemessen an den umsätzen und der bewertung... drum neige ich auch seit einiger zeit dazu nur noch in werte zu investieren wo auch traditionelle bewertungsmethoden eine unterbewertung in einigen bereichen zumindest aufweisen. da ist man zumindest nach unten um einiges abgesichert... weil kein wachstumsunternehmen ein kgv von 5 aufgetischt bekommt ..gilt für werte wie rofin, steiner&leisure, orascom, secunet, eckert&ziegler und einige andere die sich noch in meiner watchlist oder im depot befinden. bei MLNM hab ich einfach ein sehr beschissenes gefühl, ehrlich gesagt....

[blb]

@Boersenkrieger: Dann wirst du auch kaum in Biotechnologie investieren können, weil da KUVs von ca. 8 und KGVs <20 an der Tagesordnung sind. Man sollte mal die Kirche im Dorf lassen. MLNM wächst und reduziert die Verluste stark. Wir haben es also hier mit keiner Kutsche zu tun, die kurz vor der Pleite steht oder nur ein Medikament in der Pipeline hat. Wird Velcade auch für andere Indikationen zugelassen, besteht weiterhin Potenzial. Dass die Firma mit einer Marketcap von 2,5 Milliarden kein Ten-Bagger wird ist klar. Trotzdem ist die Bewertung an Biotech-Maßstäben gemessen derzeit wirklich nicht zu hoch! Zur Zeit sind halt auch die Shorties auf den Plan gerückt, zudem das schlechte Marktumfeld.

Ich schätze, wir könnten vielleicht den finalen Rutsch nach den nächsten Quartalszahlen sehen. Dann sollte das Schlimmste überstanden sein!

Grüße
blb

PS: Nochmal: Es gibt sicher bessere Bios zur Zeit! Für die die drin sind gibt es aber wenig Grund auf dem niedrigen Niveau zu verkaufen, wenngleich der Chart angeschlagen bleibt!

[Isabartels]

Millennium and UCB Pharma Enter Into Agreement to Collaborate on Two Biotherapeutic Inflammation Programs
- UCB Pharma to Develop through Phase II; Millennium Retains Development and Commercialization Options -

BRUSSELS, Belgium and CAMBRIDGE, Mass., Jan 25, 2005 /PRNewswire-FirstCall via COMTEX/ -- UCB Pharma`s Celltech Antibody Research Centre of Excellence and Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced they have entered into an agreement in which they will collaborate to research, develop and commercialize new antibody therapeutics generated from two validated Millennium targets: a co-stimulatory molecule and a chemokine receptor.

The co-stimulatory molecule is a CD28 homologue and has been implicated in the regulation and activation of T cells. The chemokine receptor is expressed on peripheral T cells and has been implicated in multiple inflammatory diseases, including psoriasis, ulcerative colitis and graft rejection. Millennium controls broad patent estates relating to therapeutics directed to these targets.

Under the terms of the agreement, UCB Pharma will be responsible for development activities and related costs through phase II studies, including generating antibody candidates, and the preclinical and early stage clinical evaluation of antibodies. Upon the agreement of the parties, Millennium retains the option to co-develop and co-commercialize products with UCB Pharma, under a cost- and profit-sharing arrangement. UCB Pharma will make payments to Millennium upon achievement of certain clinical milestones. Additional financial details were not disclosed.

"Our highest priority is to develop a balanced and comprehensive portfolio. By working with UCB Pharma, we are able to accelerate development of these two exciting programs while concentrating more of our internal resources to maximize development of our later stage pipeline programs," said Joseph Bolen, Ph.D, senior vice president, discovery research at Millennium. "With UCB Pharma`s world-leading antibody expertise, gained through its recent acquisition of Celltech, along with its extensive global commercial reach, we believe it is the ideal partner to rapidly progress these exciting programs into clinical trials."

Dr. Melanie Lee, Director of Research and Development for UCB Pharma commented: "We believe this new collaboration adds two interesting novel targets to our research pipeline, creating a formidable partnership to bring the next wave of innovation to sufferers of inflammatory disorders."

[Isabartels]

stelle mal eine Info zu UCB rein.


20.10.2004 14:49:31 (BOERSEGO) versenden drucken > vor
2 Datensätze gefunden.
UCB Einstiegsgelegenheit



Die Experten von "BoerseGo" sind in ihrem aktuellen "Tec-Report" der Meinung, dass die Aktie von UCB (ISIN BE0003739530/ WKN 852738) eine Einstiegsgelegenheit bietet. Hierzulande bislang kaum bekannt, habe der belgische UCB-Konzern in den letzten Monaten mehrfach für Schlagzeilen gesorgt. Nach der Übernahme von Celltech sei nun der Verkauf des Chemiegeschäfts gefolgt. Nach der Neuausrichtung stünden die Chancen gut, dass die günstig bewertete Aktie ihren Aufwärtstrend fortsetze. Belgien gelte nun nicht gerade als Metropole der Weltwirtschaft. Aber auch der Kurszettel der international wenig beachteten Börse in Brüssel habe interessante Unternehmen zu bieten. Das Unternehmen, das seinen Firmensitz in der Hauptstadt Brüssel habe, habe mit 12.000 Mitarbeitern im vergangenen Jahr einen Umsatz von rund drei Milliarden Euro erzielt. Bekannt sei UCB vor allem durch sein Antiallergikum Zyrtec, das gemeinsam mit Claritin von Schering-Plough und Allegra von Aventis den schnell wachsenden Weltmarkt - die Zahl der Allergiker nehme pro Jahr um circa 15 Prozent zu - beherrsche. In Europa, wo man mit Zyrtec sogar die unangefochtene Nummer eins gewesen sei, sei der Patentschutz jedoch mittlerweile abgelaufen. Auf den Patentablauf von Zyrtec, das zeitweise mehr als die Hälfte der Erlöse in der Pharmasparte generiert habe, habe man längst reagiert und mit Xyzal ein verbessertes Nachfolgepräparat auf den Markt gebracht. Zudem laufe in den USA der Patentschutz für Zyrtec noch bis 2007. Ein weiteres erfolgreiches Produkt sei Keppra, ein Anti-Epilepsie-Präparat, das laut Vorstandschef George Jacobs bis 2007 mehr als eine Milliarde Euro Umsatz einfahren solle. Zudem habe man sich mit dem Kauf des britischen Biotech-Unternehmen Celltech im Mai dieses Jahres einige zukunftsträchtige Arzneimittel gesichert. Der größte Hoffnungsträger sei das Arthritis-Mittel CDP 870: Experten würden dem Medikament, das voraussichtlich 2007 zugelassen werden solle, Blockbuster-Potenzial bescheinigen. Zudem habe Celltech fünf weitere Präparate in früheren Entwicklungsphasen. Die Pharmasparte sei bei UCB für knapp 60 Prozent des Gesamtumsatzes verantwortlich. Rund 25 beziehungsweise 15 Prozent würden auf die Bereiche Chemie und Folien entfallen. Diese margenschwächeren Bereiche seien bislang auch dafür verantwortlich gewesen, dass UCB auf Grund seiner Mischstruktur von den Börsianern im Vergleich zu reinrassigen Pharmakonzernen eine niedrigere Bewertung zugebilligt worden sei. Dies könnte sich nun ändern. Kurz hintereinander habe UCB den Verkauf der beiden Bereiche gemeldet. Ende September habe man den Verkauf des Foliengeschäfts für 320 Millionen Euro an ein Konsortium um Candover Partners unter Dach und Fach gebracht. Nur wenige Tage später habe man einen Käufer für das Chemiesegment präsentiert. Die US-Firma Cytec übernehme die Sparte für 1,5 Milliarden Euro, davon 1,275 Milliarden Euro in bar und 225 Millionen Euro in Cytec-Aktien. Somit präsentiere sich der belgische UCB-Konzern nunmehr als reinrassiger Pharmakonzern mit einer gehörigen Portion Biotechfantasie. Das KGV liege mit 16 deutlich unter dem vergleichbarer Pharmatitel. Es spreche viel dafür, dass sich der im März 2003 eingeleitete Aufwärtstrend fortsetze. Nach Ansicht der Experten von "BoerseGo" sollte sich ein Einstieg in die Aktie von UCB auszahlen.
Quelle: AKTIENCHECK.DE
20.10.2004 14:49:31 (BOERSEGO)
UCB Einstiegsgelegenheit
20.05.2004 11:42:09 (N.A.)
ANALYSE: ING stuft UCB von "Hold" auf "Buy" hoch - Celltech-Übernahme

[Isabartels]

Und jeder Anstieg wird wieder gnadenlos verkauft.Es ko... mich an!!!!!!!!!!!!